CA2540459C - Benzimidazole compounds and uses in treating proliferative disorders - Google Patents
Benzimidazole compounds and uses in treating proliferative disorders Download PDFInfo
- Publication number
- CA2540459C CA2540459C CA2540459A CA2540459A CA2540459C CA 2540459 C CA2540459 C CA 2540459C CA 2540459 A CA2540459 A CA 2540459A CA 2540459 A CA2540459 A CA 2540459A CA 2540459 C CA2540459 C CA 2540459C
- Authority
- CA
- Canada
- Prior art keywords
- group
- hydroxy
- acrylamide
- benzoimidazol
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002062 proliferating effect Effects 0.000 title claims abstract description 22
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 337
- 238000002360 preparation method Methods 0.000 claims abstract description 123
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 62
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 50
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 50
- 230000000694 effects Effects 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 21
- -1 alkoxyheteroaryl Chemical group 0.000 claims description 109
- 125000000217 alkyl group Chemical group 0.000 claims description 83
- 206010028980 Neoplasm Diseases 0.000 claims description 49
- 125000003342 alkenyl group Chemical group 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 125000002252 acyl group Chemical group 0.000 claims description 36
- 125000000304 alkynyl group Chemical group 0.000 claims description 35
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 33
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 31
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 31
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 28
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 125000001188 haloalkyl group Chemical group 0.000 claims description 21
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 16
- 125000003282 alkyl amino group Chemical group 0.000 claims description 15
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 15
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 13
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 13
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000004442 acylamino group Chemical group 0.000 claims description 12
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 12
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 12
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 12
- 125000001769 aryl amino group Chemical group 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 11
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 11
- 125000004104 aryloxy group Chemical group 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 11
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 8
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 7
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 7
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- ZQUSYVORYNBGLG-FQEVSTJZSA-N (2s)-2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]-4-methylpentanoic acid Chemical compound COC1=CC=CC(OC)=C1C1=CC(C(=O)N[C@@H](CC(C)C)C(O)=O)=NN1C1=CC=NC2=CC(Cl)=CC=C12 ZQUSYVORYNBGLG-FQEVSTJZSA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 102100039996 Histone deacetylase 1 Human genes 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 claims description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 140
- 201000010099 disease Diseases 0.000 abstract description 22
- 239000003112 inhibitor Substances 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 143
- 238000004128 high performance liquid chromatography Methods 0.000 description 124
- 239000007858 starting material Substances 0.000 description 112
- 238000005160 1H NMR spectroscopy Methods 0.000 description 107
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 94
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- 239000000203 mixture Substances 0.000 description 53
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 51
- BONVROUPOZRCDU-UHFFFAOYSA-N 2-hydroxyprop-2-enamide Chemical compound NC(=O)C(O)=C BONVROUPOZRCDU-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 43
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 36
- 208000035475 disorder Diseases 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- 239000002904 solvent Substances 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000002253 acid Substances 0.000 description 19
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 16
- 108010033040 Histones Proteins 0.000 description 14
- 229910017912 NH2OH Inorganic materials 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 14
- 208000026278 immune system disease Diseases 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 208000027866 inflammatory disease Diseases 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 14
- 150000004702 methyl esters Chemical class 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 208000015122 neurodegenerative disease Diseases 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- HQVFKSDWNYVAQD-UHFFFAOYSA-N n-hydroxyprop-2-enamide Chemical compound ONC(=O)C=C HQVFKSDWNYVAQD-UHFFFAOYSA-N 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 description 11
- 102000006947 Histones Human genes 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000005605 benzo group Chemical group 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 102220389089 c.33G>T Human genes 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 229940086542 triethylamine Drugs 0.000 description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 208000023105 Huntington disease Diseases 0.000 description 7
- 230000021736 acetylation Effects 0.000 description 7
- 238000006640 acetylation reaction Methods 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000006268 reductive amination reaction Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 235000017550 sodium carbonate Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 125000005251 aryl acyl group Chemical group 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 235000011150 stannous chloride Nutrition 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
- 208000010412 Glaucoma Diseases 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 4
- QBDALTIMHOITIU-DUXPYHPUSA-N 20797-48-2 Chemical compound OC(=O)\C=C\C1=CC=C(Cl)C([N+]([O-])=O)=C1 QBDALTIMHOITIU-DUXPYHPUSA-N 0.000 description 4
- 208000003120 Angiofibroma Diseases 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012901 Milli-Q water Substances 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 206010011005 corneal dystrophy Diseases 0.000 description 4
- 238000005100 correlation spectroscopy Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 125000004663 dialkyl amino group Chemical group 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 201000007737 Retinal degeneration Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 229910008066 SnC12 Inorganic materials 0.000 description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006195 histone acetylation Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052740 iodine Chemical group 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 108010040003 polyglutamine Proteins 0.000 description 3
- 229920000155 polyglutamine Polymers 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 230000004258 retinal degeneration Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 3
- 229960000237 vorinostat Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- LLOKIGWPNVSDGJ-AFBVCZJXSA-N (3s,6s,9s,12r)-3,6-dibenzyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 LLOKIGWPNVSDGJ-AFBVCZJXSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- LTNUSYNQZJZUSY-UHFFFAOYSA-N 3,3-dimethylbutanal Chemical compound CC(C)(C)CC=O LTNUSYNQZJZUSY-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 206010059199 Anterior chamber cleavage syndrome Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 229920000298 Cellophane Polymers 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 208000003495 Coccidiosis Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 description 2
- 208000001351 Epiretinal Membrane Diseases 0.000 description 2
- 206010016212 Familial tremor Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 2
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010065630 Iris neovascularisation Diseases 0.000 description 2
- 206010023076 Isosporiasis Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010023335 Keratitis interstitial Diseases 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 102220517591 Methyl-CpG-binding domain protein 3-like 2B_R11C_mutation Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
- 206010037075 Protozoal infections Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000002367 Retinal Perforations Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 208000006045 Spondylarthropathies Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010044074 Torticollis Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- LLOKIGWPNVSDGJ-UHFFFAOYSA-N Trapoxin B Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 LLOKIGWPNVSDGJ-UHFFFAOYSA-N 0.000 description 2
- 241000223105 Trypanosoma brucei Species 0.000 description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 150000001805 chlorine compounds Chemical group 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000004340 degenerative myopia Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 201000006517 essential tremor Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 201000006904 interstitial keratitis Diseases 0.000 description 2
- 239000011630 iodine Chemical group 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 208000029233 macular holes Diseases 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- HQVWYUZVGLAMBS-HWKANZROSA-N methyl (e)-3-(4-chloro-3-nitrophenyl)prop-2-enoate Chemical compound COC(=O)\C=C\C1=CC=C(Cl)C([N+]([O-])=O)=C1 HQVWYUZVGLAMBS-HWKANZROSA-N 0.000 description 2
- HQVWYUZVGLAMBS-UHFFFAOYSA-N methyl 3-(4-chloro-3-nitrophenyl)prop-2-enoate Chemical compound COC(=O)C=CC1=CC=C(Cl)C([N+]([O-])=O)=C1 HQVWYUZVGLAMBS-UHFFFAOYSA-N 0.000 description 2
- WSGPZALOOZJTHJ-UHFFFAOYSA-N methyl 3-[3-amino-4-[2-(diethylamino)ethylamino]phenyl]prop-2-enoate Chemical compound CCN(CC)CCNC1=CC=C(C=CC(=O)OC)C=C1N WSGPZALOOZJTHJ-UHFFFAOYSA-N 0.000 description 2
- LMQHJAAMPCCITR-UHFFFAOYSA-N methyl 3-[4-[2-(methylamino)ethylamino]-3-nitrophenyl]prop-2-enoate Chemical compound CNCCNC1=CC=C(C=CC(=O)OC)C=C1[N+]([O-])=O LMQHJAAMPCCITR-UHFFFAOYSA-N 0.000 description 2
- AYWAAIHTLQTNMB-UHFFFAOYSA-N methyl 3-[4-[2-[di(propan-2-yl)amino]ethylamino]-3-nitrophenyl]prop-2-enoate Chemical compound COC(=O)C=CC1=CC=C(NCCN(C(C)C)C(C)C)C([N+]([O-])=O)=C1 AYWAAIHTLQTNMB-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000004344 phenylpropyl group Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 230000014493 regulation of gene expression Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000003755 striatonigral degeneration Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000018724 torsion dystonia Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108010060596 trapoxin B Proteins 0.000 description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000013298 xenograft nude mouse model Methods 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical class C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 125000001847 2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- WTPYRCJDOZVZON-UHFFFAOYSA-N 3,5,5-Trimethylhexanal Chemical compound O=CCC(C)CC(C)(C)C WTPYRCJDOZVZON-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010049678 Endometrial dysplasia Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 201000000016 Peters anomaly Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 206010046905 Vaginal dysplasia Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 208000021096 adenomatous colon polyp Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 208000028183 atypical endometrial hyperplasia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- CYKIHIBNSFRKQP-UHFFFAOYSA-N benzo[f][1]benzothiole Chemical compound C1=CC=C2C=C(SC=C3)C3=CC2=C1 CYKIHIBNSFRKQP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 150000002244 furazanes Chemical class 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- FXHGMKSSBGDXIY-UHFFFAOYSA-N heptanal Chemical compound CCCCCCC=O FXHGMKSSBGDXIY-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 102000045898 human HDAC1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- ULDIVZQLPBUHAG-UHFFFAOYSA-N n',n',2,2-tetramethylpropane-1,3-diamine Chemical compound CN(C)CC(C)(C)CN ULDIVZQLPBUHAG-UHFFFAOYSA-N 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000002262 penten-4-yl group Chemical group C=CCC(C)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003899 tartaric acid esters Chemical class 0.000 description 1
- CMIBWIAICVBURI-UHFFFAOYSA-N tert-butyl 3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)C1 CMIBWIAICVBURI-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000004435 urinary system cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention relates to compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to heterocyclic compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase (HDAC) activities.
Description
=
BENZIMIDAZOLE COMPOUNDS AND USES IN TREATING PROLIFERATIVE DISORDERS
FIELD OF THE INVENTION
[0001] The present invention relates to hydroxamate compounds that are inhibitors of histone deacetylase (HDAC). More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase (HDAC) activities.
BACKGROUND OF THE INVENTION
BENZIMIDAZOLE COMPOUNDS AND USES IN TREATING PROLIFERATIVE DISORDERS
FIELD OF THE INVENTION
[0001] The present invention relates to hydroxamate compounds that are inhibitors of histone deacetylase (HDAC). More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase (HDAC) activities.
BACKGROUND OF THE INVENTION
[0002] Local chromatin architecture is generally recognized as an important factor in the regulation of gene expression. The architecture of chromatin, a protein-DNA
complex, is strongly influenced by post-translational modifications of the histones which are the protein components. Reversible acetylation of histones is a key component in the regulation of gene expression by altering the accessibility of transcription factors to DNA. In general, increased levels of histone acetylation are associated with increased transcriptional activity, whereas decreased levels of acetylation are associated with repression of gene expression [Wadem P.A. Hum. Mol. Genet. 10, 693-698 (2001), De Ruijter A.J.M. et al, Biochem. J., 370, 737-749 (2003)]. In normal cells, histone deacetylases (HDACs) and histone acetyltransferase together control the level of acetylation of histones to maintain a balance. Inhibition of HDACs results in the accumulation of acetylated histones, which results in a variety of cell type dependent cellular responses, such as apoptosis, necrosis, differentiation, cell survival, inhibition of proliferation and cytostasis.
complex, is strongly influenced by post-translational modifications of the histones which are the protein components. Reversible acetylation of histones is a key component in the regulation of gene expression by altering the accessibility of transcription factors to DNA. In general, increased levels of histone acetylation are associated with increased transcriptional activity, whereas decreased levels of acetylation are associated with repression of gene expression [Wadem P.A. Hum. Mol. Genet. 10, 693-698 (2001), De Ruijter A.J.M. et al, Biochem. J., 370, 737-749 (2003)]. In normal cells, histone deacetylases (HDACs) and histone acetyltransferase together control the level of acetylation of histones to maintain a balance. Inhibition of HDACs results in the accumulation of acetylated histones, which results in a variety of cell type dependent cellular responses, such as apoptosis, necrosis, differentiation, cell survival, inhibition of proliferation and cytostasis.
[0003] Inhibitors of HDAC have been studied for their therapeutic effects on cancer cells. For example, suberoylanilide hydroxamic acid (SAHA) is a potent inducer of differentiation and/or apoptosis in murine erythroleukemia, bladder, and myeloma cell lines [Richon V.M. et al, Proc. Natl. Acad. Sci. USA, 93: 5705-5708 (1996), Richon V.M. et al, Proc. Natl. Acad. Sci. USA, 95: 3003-3007 (1998)]. SAHA has been shown to suppress the growth of prostate cancer cells in vitro and in vivo [Butler L.M. et al, Cancer Res. 60, 51 65-51 70 (2000)]. Other inhibitors of HDAC that have been widely studied for their anti-cancer activities are trichostatin A (TSA) and trapoxin B [Yoshida M. et al, J. Biol. Chem., 265, 17174 (1990), Kijima M. et al, J. Biol. Chem., 268, 22429 (1993)]. Trichostatin A is a reversible inhibitor of mammalian HDAC. Trapoxin B is a cyclic tetrapeptide, which is an irreversible inhibitor of mammalian HDAC.
However, due to the in vivo instability of these compounds they are less desirable as anti-cancer drugs. Recently, other small molecule HDAC inhibitors have become available for clinical evaluation [US6,552,065]. Additional HDAC inhibiting compounds have been reported in the literature [Bouchain G. et al, J. Med. Chem., 46, 820-830 (2003)] and patents [WO 03/066579A2]. The in vivo activity of such inhibitors can be directly monitored by their ability to increase the amount of acetylated histones in the biological sample. HDAC inhibitors have been reported to interfere with neurodegenerative processes, for instance, HDAC inhibitors arrest polyglutamine-dependent neurodegeneration [Nature, 413(6857): 739-43, 18 October, 2001]. In addition, HDAC
inhibitors have also been known to inhibit production of cytokines such as TNF, IFN, IL-1 which are known to be implicated in inflammatory diseases and/or immune system disorders. [J. Biol. Chem. 1990; 265(18): 10230-10237; Science, 1998; 281:
1005; Dinarello C.A. and Moldawer L.L. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis, A primer for clinicians, 2rid Edition, Amergen Inc., 2000].
However, due to the in vivo instability of these compounds they are less desirable as anti-cancer drugs. Recently, other small molecule HDAC inhibitors have become available for clinical evaluation [US6,552,065]. Additional HDAC inhibiting compounds have been reported in the literature [Bouchain G. et al, J. Med. Chem., 46, 820-830 (2003)] and patents [WO 03/066579A2]. The in vivo activity of such inhibitors can be directly monitored by their ability to increase the amount of acetylated histones in the biological sample. HDAC inhibitors have been reported to interfere with neurodegenerative processes, for instance, HDAC inhibitors arrest polyglutamine-dependent neurodegeneration [Nature, 413(6857): 739-43, 18 October, 2001]. In addition, HDAC
inhibitors have also been known to inhibit production of cytokines such as TNF, IFN, IL-1 which are known to be implicated in inflammatory diseases and/or immune system disorders. [J. Biol. Chem. 1990; 265(18): 10230-10237; Science, 1998; 281:
1005; Dinarello C.A. and Moldawer L.L. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis, A primer for clinicians, 2rid Edition, Amergen Inc., 2000].
[0004] Nevertheless, there is still a need to provide further HDAC inhibitors that would be expected to have useful, improved pharmaceutical properties in the treatment of diseases such as cancer, neurodegenerative diseases, disorders involving angiogenesis and inflammatory and/or immune system disorders. With a view to meeting this need a number of small organic moiety scaffolds have been investigated including a number of heterocyclic systems, especially bicyclic heterocyclic ring systems. One heterocyclic system that has been investigated has been the benzimidazole ring system. We have now found that judicious selection of the substituents on the 5 membered ring of the benzimidazole ring system leads to the production of a family of compounds with improved pharmacokinetic properties when compared with the compounds of the prior art. The compounds within the family exhibit microsomal stability and thereby demonstrate improved half lives in the plasma when compared to the compounds of the prior art. The compounds within the family typically provide a longer duration of action due to the increased in vivo exposure (i.e., area under the curve, AUCo_last) thereby yielding improved tumor growth inhibition profiles in the xenograft models.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0005] In one aspect the present invention provides a compound of the formula (I):
N N/
Formula (I) wherein
N N/
Formula (I) wherein
[0006] R1 is an optionally substituted heteroaryl group, an optionally substituted heterocycloalkyl group or a group of formula:
-(CR20R21)m_(c R22 R23)._( c R24 R25)._ N R26 R27;
-(CR20R21)m_(c R22 R23)._( c R24 R25)._ N R26 R27;
[0007] R2 is selected from the group consisting of: H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, alkoxyalkyl, R11S(0)R13-, R11S(0)2R13-, R11C(0)N(R12)R13-, R11S02N(R12)R13-, R11N(R12)C(0)R13-, R11N(R12)S02R13-, R11N(R12)C(0)N(R12)R13- and acyl, each of which may be optionally substituted;
[0008] R3 is selected from the group consisting of H, C1 -C6 alkyl, and acyl, each of which may be optionally substituted;
[0009] X and Y are the same or different and are independently selected from the group consisting of: H, halogen, -CN, -NO2, -CF3, -0CF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, arylalkyloxy, -amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, aminoalkyl, alkoxyalky, -C001-1 -C(0)0R5, -COR5, -SH, -SR6, -OW acyl and -NR7R5, each of which may be optionally substituted;
[0010] each R4 is selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
[0011] each R5 is independently selected from the group consisting of: alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
[0012] each R6 is independently selected from the group consisting of: alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl;
each of which may be optionally substituted;
each of which may be optionally substituted;
[0013] each R7 and R5 is independently selected from the group consisting of:
H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
[0014] each R11 and R12 is independently selected from the group consisting of H, alkyl, alkenyl, and alkynyl, each of which may be optionally substituted;
[0015] each R13 is a bond or is independently selected from the group consisting of:
alkyl, alkenyl, and alkynyl, each of which may be optionally substituted;
alkyl, alkenyl, and alkynyl, each of which may be optionally substituted;
[0016] each R20, R21, R22, R23, R24 and R25 is independently selected from the group consisting of: H, halogen, -CN, -NO2, -CF3, -0CF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy heteroaryloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, aminosulfonyl, arylsulfonyl, arylsulfinyl -COON, -C(0)0R5, -COR5, -SH, -SR6, -OW and acyl, each of which may be optionally substituted; or R2 and R21 when taken together may form a group of formula =0 or =S, and/or R22 and R23 when taken together may form a group of formula =0 or =S, and/or R24 and R25 when taken together may form a group of formula =0 or =S;
[0017] each R26 and R27 is independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, 5 heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, aryl heteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino,' phenoxy, benzyloxy, COOH, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR5 and acyl, each of which may be optionally substituted, or R26 and R27 when taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycloalkyl group;
[0018] Z is a bond or is selected from the group consisting of -CH2-, -CH2CH2-, -CH=CH-, C3-C6 alkylene, C3-C6 alkenylene, C3-C6 alkynylene, C3-C6 cycloalkyl, unsubstituted or substituted with one or more substituents independently selected from the group consisting of C1-C4 alkyl;
[0019] m, n and o are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
[0020] or a pharmaceutically acceptable salt or prodrug thereof.
[0021] In one embodiment of the invention R4 is H and the compounds are those of formula (la):
OH
Formula (la)
OH
Formula (la)
[0022] or a pharmaceutically acceptable salt or prodrug thereof
[0023] wherein R1, R2, R3, X, Y and Z are as defined for compounds of formula (I).
[0024] In another embodiment R3 and R4 are H and the compounds are of formula (lb):
R2-- 3 I 4 5 ¨Z OH
., 61 Formula (lb)
R2-- 3 I 4 5 ¨Z OH
., 61 Formula (lb)
[0025] or a pharmaceutically acceptable salt or prodrug thereof
[0026] wherein Ize, R2, R3, X, Y and Z are as defined for compounds of formula (I).
[0027] As with any group of structurally related compounds which possess a particular utility, certain groups are preferred for the compounds of the Formula (I), (la) and (lb) in their end use application.
[0028] In one embodiment the group R1 is a group of formula -(CR20R21)m-(cR22R23)n..(c R24R25)04NR26R27;
[0029] in which m, n and o are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
[0030] Accordingly in one embodiment the compounds of the invention are compounds of formula (lc):
X 0 ,R3 R2-- 31 I 4 5j-Z 0-R4 NN
Formula (lc) wherein R1 is a group of formula _(cRR),,r(cR22R23),r( 2021 cR24R25)0_NR26R27
X 0 ,R3 R2-- 31 I 4 5j-Z 0-R4 NN
Formula (lc) wherein R1 is a group of formula _(cRR),,r(cR22R23),r( 2021 cR24R25)0_NR26R27
[0031] and R2, R3, R4, X, Y, Z, R20, R21, R22, R23, R24, R25, R26, K m, n and o are as defined for compounds of formula (I).
[0032] As the values of m, n and o are integers ranging from 0 to 4 the sum of m+n+o is an integer selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12. In one embodiment the sum of m+n+o is an integer selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7 and 8. In another embodiment the sum of m+n+o is an integer selected from the group consisting of 0, 1, 2, 3 and 4. In another embodiment that the sum of m+n+o is an integer selected from the group consisting of 2 and 3.
[0033] In one specific embodiment the sum of m+n+o is 2. When this occurs R1 is selected from the group consisting of:
c R20 R21 )2_N R26R27;
c R22 R23 )2_ NR26R27;
R24R25)2_NR26R27;
.(cR20R21 )-(cR22R23)_NR26R27;
_(cR20R21)-(cR24R25)_NR26R27;
R22R23xc R24R25)-NR26R27;
c R20 R21 )2_N R26R27;
c R22 R23 )2_ NR26R27;
R24R25)2_NR26R27;
.(cR20R21 )-(cR22R23)_NR26R27;
_(cR20R21)-(cR24R25)_NR26R27;
R22R23xc R24R25)-NR26R27;
[0034] In one form of this embodiment R1 is the group:
_(cR20R21 )-(cR22R23)_NR26R27;
_(cR20R21 )-(cR22R23)_NR26R27;
[0035] This provides compounds of the formula (II):
N' R2o R21 <
Formula (II)
N' R2o R21 <
Formula (II)
[0036] wherein X, Y, Z, R2, R3, R4, R20, R21, R22, R23, R26 and K.-.27 are as defined in =
formula (I).
formula (I).
[0037] In a specific form of this embodiment R4 is H which provides compounds of formula (11a):
X
NI/
R24 3Z O¨H
7<><R22 R26-"N\ R23 .Formula (11a)
X
NI/
R24 3Z O¨H
7<><R22 R26-"N\ R23 .Formula (11a)
[0038] wherein X, Y, Z, R2, R3, R20, R21, R22, R23, R26 and 11.-.27 are as defined in formula (I).
[0039] In another specific form R3 is H leading to compounds of formula (11b):
X
N
R2-- 31 I 4 56-hZ 0¨H
y 1R2o7 oR N R23 Formula (11b)
X
N
R2-- 31 I 4 56-hZ 0¨H
y 1R2o7 oR N R23 Formula (11b)
[0040] wherein X, Y, Z, R2, R20, R21, R22, R23, R26 and 11 are as defined in formula (I).
[0041] In an even more specific form of this embodiment R20, R21, R22 and R23 are H
providing compounds of formula (11c):
X 0\\
31 7 -1--Z O¨H
pj R26,-N\
Formula (11c)
providing compounds of formula (11c):
X 0\\
31 7 -1--Z O¨H
pj R26,-N\
Formula (11c)
[0042] wherein X, Y, Z, R2, R26 and R27 are as defined in formula (I).
[0043] In another embodiment the sum of m+n+o is 3. When this occurs R1 is selected from the group consisting of:
..(cR2oR21)3_NR26R27;
_(cR22R23)3_NR26R27;
_(cR2.4R25)3_NR26R27;
-(CR2 R21)2-(CR22R23)-NR26R27 -(CR2 R21)2_(cR24R25).NR26R27 4cR'20R21xcR22R23)2_NR26R27 -(C R22R23)2-(CR24R25)-NR26 R27 _(cR20R21 )-(cR24R25)2-N R261:127 4cR22R23)..(c R24R25)2_NR26R27 -(CR20R21 )-(cR22R23)_(c R24R25)_NR2eR27;
..(cR2oR21)3_NR26R27;
_(cR22R23)3_NR26R27;
_(cR2.4R25)3_NR26R27;
-(CR2 R21)2-(CR22R23)-NR26R27 -(CR2 R21)2_(cR24R25).NR26R27 4cR'20R21xcR22R23)2_NR26R27 -(C R22R23)2-(CR24R25)-NR26 R27 _(cR20R21 )-(cR24R25)2-N R261:127 4cR22R23)..(c R24R25)2_NR26R27 -(CR20R21 )-(cR22R23)_(c R24R25)_NR2eR27;
[0044] In one form of this embodiment R1 is a group of the formula:
-(CR20R21)_(c R22R23)-(c R24R25yNR26R27.
-(CR20R21)_(c R22R23)-(c R24R25yNR26R27.
[0045] This provides compounds of the formula (III):
Formula (III)
Formula (III)
[0046] wherein X,Y, Z, R2, R3, R4, R20, R21, R22, R231R24, R25, -26 K and R27 are as defined in formula (I).
[0047] In a specific form of this embodiment R4 is H which provides compounds of formula (111a).
N/
AT-Z O¨H
7 ,`:,1 N' R2o Formula (111a)
N/
AT-Z O¨H
7 ,`:,1 N' R2o Formula (111a)
[0048] wherein X,Y, Z, R2, R3, Ra, R20, R21, R22, R231R24, R25, R26 and K.-.27 are as 5 defined in formula (1).
[0049] In another specific form R3 is H leading to compounds of formula (111b):
-Z O¨H
Formula (111b) 10 [0050] wherein X,Y, Z, R2, R3, Fe, R20, R21, R22, R23,R24, R25, K.-.26 and R27 are as defined in formula (I).
[0051] In an even more specific form of this embodiment R20, R21, R24, R25 are H, and R22 and R23 are methyl providing compounds of formula (111c).
N
R2-- 3Dt1 I 4 5 -2> NO¨H
7 ,9 N
Formula (111c) [0052] wherein X,Y, Z, R2, R3, R4, R20, R21, R22, R23, R24, R25, R26 and 11 are as defined in formula (I).
[0053] In each of the above embodiments of the invention R2 and R21 may represent a number of different variables. In one embodiment R2 and R21 are independently selected from the group consisting of H, alkyl, alkenyl and alkynyl. In another embodiment R2 and R21 are independently selected from the group consisting of H and alkyl. In a specific embodiment R2 and R21 are both H.
[0054] In each of the above embodiments of the invention R22 and R23 may represent a number of different variables. In one embodiment R22 and R23 are independently selected from the group consisting of H, alkyl, alkenyl and alkynyl. In another embodiment R22 and R23 are independently selected from the group consisting of H and alkyl. In a further embodiment R22 and R23 are independently selected from the group consisting of alkyl. In a most specific embodiment R22 and R23 are both methyl.
[0055] In each of the above embodiments of the invention R24 and R25 may represent a number of different variables. In one embodiment R24 and R25 are preferably independently selected from the group consisting of H, alkyl, alkenyl and alkynyl. In another embodiment R24 and R25 are independently selected from the group consisting of H and alkyl. In a specific embodiment R24 and R25 are both H.
[0056] In each of the above embodiments there are a number of values for R26 and R27. In one embodiment R26 and R27 are independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, alkoxyalkyl, and acyl. In another embodiment R26 and R27 are independently selected from the group consisting of: H, alkyl and acyl.
In a further embodiment R26 and R27 are independently selected from the group . consisting of H, methyl, ethyl, isopropyl, propyl, 2-ethyl-propyl, 3,3-dimethyl-propyl, butyl, isobutyl, 3,3-dimethyl-butyl, 2-ethyl-butyl, pentyl, 2-methyl, pentyl, pent-4-enyl, hexyl, heptyl, octyl, acetyl and 2-methoxy-ethyl.
[0057] In another embodiment R1 is a heterocycloalkyl group which may optionally be substituted.
[0058] In one form of this embodiment the heterocycloalkyl group is selected from the group consisting of:
N/
R28 "R28 [0059] wherein R28 is selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, alkoxycarbonyl, alkylaminocarbonyl, arylacyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR5 and acyl, each of which may be optionally substituted.
[0060] In one embodiment R28 is selected from the group consisting of H, alkyl, alkenyl, arylalkyl and arylacyl. Specific values of R28 are H, methyl; ethyl;
propyl; 2-methyl-propyl, 2-2-dimethyl-propyl; isopropyl; 3,3,3-triflouro-propyl; butyl;
isobutyl; 3,3-, dimethyl-butyl; pentyl; 2,4,4-trimethyl-pentyl; penten-4-yl, hexyl;
heptyl, octyl, nonyl, 2-methoxy nonyl, benzyl, 2-phenyl-ethyl, 2-phenyl-acetyl, 3-phenyl-propyl, [0061] In another embodiment the heterocycloalkyl group is pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, and 1,4-oxathiapane. It is particularly preferred that R1 is selected from the group consisting of piperidine-3-yl, piperidine-4-y1 and pyrollidin-3-y.
[0062] In another embodiment R1 is a heteroaryl group.
[0063] In another embodiment R1 is a group selected from the group consisting of:
(32.4.N
N
(32.2 N N
N La?7- N N
NH
,CNH
N
NH
N
N
N N N
NH
N
N
[0064] In one specific embodiment R1 is a group of formula:
'Z'etNH2 [0065] In another specific embodiment R1 is a group of formula:
[0066] In another specific embodiment R1 is a group of formula:
[0067] In yet another specific embodiment R1 is a group of formula:
[0068] In another specific embodiment R1 is a group of formula:
N/
[0069] In another specific embodiment R1 is a group of formula:
N/
[0070] In another specific embodiment R1 is a group of formula:
[0071] In another specific embodiment R1 is a group of formula:
[0072] In another specific embodiment R1 is a group of formula:
Lh2,N
[0073] In one embodiment R2 is selected from the group consisting of H, alkyl, cycloalkyl, heteroalkyl, alkenyl, alkynyl, alkoxyalkyl and cycloalkylalkyl.
[0074] In one form of this embodiment R2 is alkyl. In one embodiment the alkyl is a C1-C10 alkyl. In anotherform of this embodiment the alkyl is a C,-C6 alkyl group. In another form of this embodiment R2 is selected from the group consisting of:
methyl;
ethyl; propyl; 2-methyl-propyl, 2-2-dimethyl-propyl; isopropyl; 3,3,3-triflouro-propyl;
butyl; isobutyl; 3,3-dimethyl-butyl; pentyl; 2,4,4-trimethyl-pentyl; hexyl;
heptyl, octyl, nonyl, and 2-methoxy nonyl.
[0075] In one form of this embodiment R2 is alkenyl. In one form of this embodiment the alkenyl is y a Ci-Cio alkeny. In another form of this embodiment the alkenyl is a C1-C6 alkenyl group. In another form of this embodiment R2 is selected from the group consisting of: ethenyl, prop-1-enyl, prop-2-enyl, but-l-enyl, but-2-enyl but-3-enyl, pent-1-enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl and hex-5-enyl.
[0076] In another embodiment R2 is selected from the group consisting of R11S(0)R13-, R11S(0)2R13-, R11c(o)N(R12)R13-, R11S02N(R12)R13-, R11N(R12)C(0)R13-, R11N(R12)S02R13-, and RN(R12)C(0)N(R12)R13-. In one form of this embodiment R2 is a group of the formula R11C(0)N(R12)R13-. In one form of this embodiment R13 is a Cr 06 alkyl. In a specific form of this embodiment R13 is methyl or ethyl. In one form of thsi embodiment R12 is H or C1-C6alkyl. A specific value for R12 is H. In one form of thsi embodiment R11 is 01-06 alkyl group. Specific values for R11 include t-butyl and propyl.
. Specific examples of groups of this type include: (CH3)3CCH2CONH(CH2)2-;
(CH3)3CCONH(CH2)2-; (CH3)3CCONH(CH2)- and CH3(CH2)2CONH(CH2)-=
[0077] Specific values of R2 are Selected from the group consisting of: H;
methyl;
ethoxymethyl; [Bicylco[2.2.1]2-ylmethyl; Adamantan-2-ylmethyl; 2-methansulfanyl-ethyl; 2,2,2-triflouro-ethyl; propyl; 2-2-dimethyl-propyl; isopropyl; 3,3,3-trifiouro-propyl;
butyl; isobutyl; 3,3-dimethyl-butyl; but-3-enyl; but-3-yny; pentyl; 2,4,4-trimethyl-pentyl;
Bicyclo[2.2.1]hept-5-en-2y1; hexyl; hex-3-enyl; octyl; non-3-enyl; non-6-enyl;
methoxy-nonyl, 2-phenyl-cyclopropyl; cyclohexyl; (CH3)3CCH2CONH(CH2)2-;
(CH3)3CCONH(CH2)2-; (CF13)3CCONH(CH2)- and CH3(0H2)2CONH(CH2)-=
[0078] In one embodiment X and Y may be the same or different and are selected from the group consisting of H, halogen, 01-04 alkyl, -CF3, -NO2, -C(0)R5, -SR6, -ON and NR7R8.
[0079] In one embodiment X is H;
[0080] In one embodiment Y is H;
[0081] In one embodiment X and Y (if present) are at the 4 and 7 positions of the aromatic ring.
[0082] In one embodiment R3 is H, C1-C6 alkyl, or acyl. In another embodiment R3 is H or C1-C4 alkyl. A specific value for R3 is H;
[0083] In one embodiment R4 is H or C1-C4 alkyl. A specific value for R4 is H;
[0084] In one embodiment R5 is C1-C4 alkyl, heteroalkyl, or acyl. A specific value for R5 is methyl;
[0085] In one embodiment R5 is C1-C4 alkyl, heteroalkyl or acyl. A specific value for R5 is 01-04 alkyl;
10086] In one embodinnentR7 and R5 are selected from the group consisting of H, C1-C6 alkyl, C4-C9cycloalkyl, C4-C9heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl [0087] Many if not all of the variables discussed above may be optionally substituted.
If the variable is optionally substituted then in one embodiment the optional substituent is selected from the group consisting of: halogen, =0, =S, -CN, -NO2, -CF3, -0CF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, arylalkyloxy, -amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, aminoalkyl, alkoxyalky, -COOH, -COR5, -C(0)0R5, -SH, -SR5, -0R6and acyl;
[0088] In a further embodiment the optional substituents are selected from the group consisting of: halogen, =0, =S, -CN, -NO2, alkyl, alkenyl, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylsulfonyl, arylsulfonyl, aminosulfonyl, -C(0)0R5, COOH, SH, and acyl.
[0089] In one embodiment the Z moiety is at the 5 or 6 position. In a specific embodiment the Z moiety is at the 5 position. In one embodiment the Z moiety is a group of formula -CH=CH-. If the Z moiety is a group of this type it is preferably in the "E" configuration.
[0090] In addition to compounds of Formula (I), the embodiments disclosed are also directed to pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of such compounds, and pharmaceutically acceptable salts of such metabolites. Such compounds, salts, prodrugs and metabolites are at times collectively referred to herein as "HDAC inhibiting agents" or "HDAC inhibitors".
[0091] The invention also relates to pharmaceutical compositions including a compound of the invention with a pharmaceutically acceptable carrier, diluent or excipient.
[0092] In yet a further aspect the present invention provides a method of treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis including administration of a therapeutically effective 5 amount of a compound of formula (I). The embodiments disclosed also relate to pharmaceutical compositions each comprising a therapeutically effective amount of a HDAC inhibiting agent of the embodiments described with a pharmaceutically acceptable carrier or diluent for treating cellular proliferative ailments, e.g., inhibition of proliferation of malignant cancer cells, benign tumor cells or other proliferative cells.
[0093] In one embodiment the method includes administration of a compound of formula (la) or (lb) as described herein.
[0094] In one embodiment the disorder is selected from the group consisting of but not limited to cancer (e.g. breast cancer, colon cancer, prostate cancer, pancreatic cancer, leukemias, lymphomas, ovarian cancers, neuroblastomas, melanoma, inflammatory diseases/immune system disorders, angiofibroma, cardiovascular diseases (e.g. restenosis, arteriosclerosis), fibrotic diseases (e.g. liver fibrosis), diabetes, autoimmune -diseases, chronic and acute neurodegenerative disease like .
disruptions of nerval tissue, Huntington's disease and infectious diseases like fungal, bacterial and viral infections. In another embodiment the disorder is a proliferative disorder. In one embodiment the proliferative disorder is cancer. The cancer can include solid tumors or hematologic malignancies.
[0095] The invention also provides agents for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis including a compound of formula (1) as disclosed herein. In one embodiment the agent is an anti-cancer agent. In another embodiment the agent is an anti-angiogenesis agent.
[0096] In one embodiment the agent contains a compound of formula (la) or (lb).
[0097] The invention also relates to the use of compounds of formula (I) in the preparation of a medicament for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis. In one embodiment the disorder is a proliferative disorder. In a specific embodiment the disorder is a cancer.
[0098] The compounds of the present invention surprisingly show low toxicity, together with a potent anti-proliferative activity.
[0099] In yet a further embodiment the invention provides a method of treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase including administration of a therapeutically effective amount of a compound of formula (I).
[0100] In one embodiment the method includes administration of a compound of formula (la) or (lb) as described herein.
[0101] In one embodiment the disorder is selected from the group consisting of but not limited to Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesis, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Pick's disease, Intracerebral haemorrhage Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, macular myopic degeneration, Rubeotic glaucoma, Interstitial keratitis, Diabetic retinopathy, Peters anomaly retinal degeneration, Cellophane Retinopathy; Cogan's Dystrophy;
Corneal Dystrophy; Iris Neovascularization (Rubeosis); Neovascularization of the Cornea;
Retinopathy of Prematurity; Macular Edema; Macular Hole; Macular Pucker;
Marginal Blepharitis, Myopia, nonmalignant growth of the conjunctiva; Inflammatory diseases and/or Immune system disorders including Rheumatoid Arthritis (RA), Osteoarthritis, Juvenile chronic arthritis, Graft versus Host disease, Psoriasis, Asthma, Spondyloarthropathy, Crohn's Disease, inflammatory bowel disease, Colitis Ulcerosa, Alcoholic hepatitis, Diabetes, Sjoegrens's syndrome, Multiple Sclerosis, Ankylosing spondylitis, Membranous glomerulopathy, Discogenic pain, Systemic Lupus Erythematosus, allergic contact dermatitis; Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease, schizophrenia, depression and dementia; Cardiovascular Diseases including Heart failure, restenosis, cardiac hypertrophy and arteriosclerosis; Fibrotic diseases including liver fibrosis, lung fibrosis, cystic fibrosis and angiofibroma;
Infectious diseases including Fungal infections, such as Candida Albicans, Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis, and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
[0102] The invention also provides agents for the treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase including a compound of formula (I) as disclosed herein. In one embodiment the agent is an anti-cancer agent.
[0103] The invention also relates to the use of compounds of formula (I) in the preparation of a medicament for the treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase.
[0104] The invention also provides a method for inhibiting cell proliferation including administration of an effective amount of a compound according to formula (I).
[0105] In yet an even further aspect the invention provides a method of treatment of a neurodegenerative disorder in a patient including administration of a therapeutically effective amount of a compound of formula (I). In one embodiment the method includes administration of a compound of formula (la) or (lb) as described herein. In one embodiment the neurodegenerative disorder is Huntington's Disease.
[0106] The invention also provides agents for the treatment of neurodegenerative disorder including a compound of formula (I) as disclosed herein. In one embodiment the agent is preferably anti-Huntington's disease agent.
[0107] The invention also relates to the use of compounds of formula (I) in the preparation of a medicament for the treatment of a neurodegenerative disorder.
In one embodiment the neurodegenerative disorder is Huntington's Disease.
[0108] In yet an even further aspect the invention provides a method of treatment of an inflammatory disease and/or immune system disorder in a patient including administration of a therapeutically effective amount of a compound of formula (1). In one embodiment the method includes administration of a compound of formula (la) or (lb) as described herein. In one embodiment the inflammatory disease and/or immune system disorder is rheumatoid arthritis. In another embodiment the inflammatory disease and/or immune system disorder is Systemic Lupus Erythematosus.
[0109] The invention also provides agents for the treatment of inflammatory disease 5 and/or immune system disorder including a compound of formula (I) as disclosed herein.
[0110] The invention also provides agents for the treatment of eye disease mediated by HDAC inhibition including a compound of formula (I) as disclosed herein. In one 10 embodiment, the eye disease is macular degeneration. In another embodiment, the eye disease is glaucoma. In another embodiment, the eye disease is retinal degeneration.
[0111] The invention also relates to the use of compounds of formula (I) in the 15 preparation of a medicament for the treatment of inflammatory disease and/or immunesystem disorder. In one embodiment the inflammatory disease and/or immune system disorder is rheumatoid arthritis. In another embodiment the inflammatory disease and/or immune system disorder is Systemic Lupus Erythematosus.
[0111a] In accordance with an aspect of the present invention there is provided a compound of the formula (I):
X
R2 ___________________ < 0-R4 N
Formula I
wherein R1 is a group of formula:
_( CR20-R 21 )õ,-( cR22R2),-(CR24R25 )0_NR26R27;
R2 is selected from the group consisting of: alkyl and heteroalkyl, each of which may be optionally substituted with one or more optional substituents wherein 23a each optional substituent is selected from the group consisting of halogen, =0, -CN, alkenyl, alkynyl and alkoxy;
R3 is H;
X and Y are H;
R4 is H;
each R5 is independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
each R6 is independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl;
each of which may be optionally substituted;
each R20, R21, R22, R23, R24 and R25 is independently selected from the group consisting of: H, halogen, -ON, -NO2, -CF3, -0CF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy heteroaryloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, aminosulfonyl, arylsulfonyl, arylsulfinyl -COOH, -C(0)0R5, -COR5, -SH, -SR6, -0R6 and acyl, each of which may be optionally substituted;
or R2 and R21 when taken together may form a group of formula =0 or =S, and/or R22 and R23 when taken together may form a group of formula =0 or =S, and/or R24 and R25 when taken together may form a group of formula =0 or =S;
23b each R26 and R27 is independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR5, and acyl, each of which may be optionally substituted, or R26 and R27 when taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycloalkyl group;
m, n and o are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
Z is ¨CH=CH- and is attached at ring position 5;
or a pharmaceutically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0112] In this specification a number of terms are used which are well known to a skilled addressee. Nevertheless for the purposes of clarity a number of terms will be defined.
[0113] As used herein, the term unsubstituted means that there is no substituent or that the only substituents are hydrogen.
[0114] The term "optionally substituted" as used throughout the specification denotes that the group may or may not be further substituted or fused (so as to form a condensed polycyclic system), with one or more substituent groups. Preferably the substituent groups are one or more groups independently selected from the group consisting of halogen, =0, =S, -CN, -NO2, -CF3, -0CF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, arylalkenyl, heteroarylalkenyl, cycloalkylheteroalkyl, heterocycloalkyiheteroalkyl, arylheteroalkyl, heteroarylheteroalkyl, hydroxy, 23c sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR5, and acyl, each of which may be optionally substituted, or R26 and R27 when taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycloalkyl group;
m, n and o are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
or a pharmaceutically acceptable salt or prod rug thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0112] In this specification a number of terms are used which are well known to a skilled addressee. Nevertheless for the purposes of clarity a number of terms will be defined.
[0113] As used herein, the term unsubstituted means that there is no substituent or that the only substituents are hydrogen.
[0114] The term "optionally substituted" as used throughout the specification denotes that the group may or may not be further substituted or fused (so as to form a condensed polycyclic system), with one or more substituent groups. Preferably the substituent groups are one or more groups independently selected from the group consisting of halogen, =0, =S, -CN, -NO2, -CF3, -0CF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, arylalkenyl, heteroarylalkenyl, cycloalkylheteroalkyl, heterocycloalkyiheteroalkyl, arylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycycloalkyl, alkoxyheterocycloalkyl, alkoxyaryl, alkoxyheteroaryl, alkoxycarbonyl, alkylaminocarbonyl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, phenoxy, benzyloxy, heteroaryloxy, arylalkyloxy, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, alkylsulfinyl, arylsulfinyl, aminosulfinylaminoalkyl, -COOH, -COR5, -C(0)0R5, CONHR5, NHCOR5, NHCOOR5, NHCONHR5, C(=NOH)R5, -SH, -SR5, -0R5 and acyl.
[0115] "Alkyl" as a group or part of a group refers to a straight or branched aliphatic hydrocarbon group, preferably a C1¨C14 alkyl, more preferably C1-C10 alkyl, most preferably C1-C6 unless otherwise noted. Examples of suitable straight and branched C1-C6 alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl, hexyl, and the like.
[0116] "Alkylamino" includes both monoalkylamino and dialkylamino, unless specified. "Monoalkylamino" means a ¨NH-Alkyl group, in which alkyl is as defined above. "Dialkylamino" means a ¨N(alkyl)2 group, in which each alkyl may be the same or different and are each as defined herein for alkyl. The alkyl group is preferably a C1-C6 alkyl group.
[0117] "Alkylamino" includes both monoalkylamino and dialkylamino, unless specified. "Monoalkylamino" means a ¨NH-Alkyl group in which alkyl is as defined above. "Dialkylamino" means a ¨N(alkyl)2 group in which each alkyl may be the same or different and are each as defined herein for alkyl. The alkyl group is preferably a C6 alkyl group.
[0118] "Arylamino" includes both mono-arylamino and di-arylamino unless specified.
Mono-arylamino means a group of formula aryl NH-, in which aryl is as defined herein.
di-arylamino means a group of formula (ary12) N- where each aryl may be the same or different and are each as defined herein for aryl.
[0119] "Acyl" means an alkyl-CO- group in which the alkyl group is as described herein. Examples of acyl include acetyl and benzoyl. The alkyl group is preferably a Cr C6 alkyl group.
[0120] "Alkenyl" as a group or part of a group denotes an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched preferably having 2-14 carbon atoms, more preferably 2-12 carbon atoms, most preferably 2-6 carbon atoms, in the normal chain. The group may contain a 5 plurality of double bonds in the normal chain and the orientation about each is independently E or Z. Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl and nonenyl.
[0121] "Alkoxy" refers to an ¨0-alkyl group in which alkyl is defined herein.
10 Preferably the alkoxy is a C1-C6alkoxy. Examples include, but are not limited to, nnethoxy and ethoxy.
[0122] "Alkenyloxy" refers to an -0- alkenyl group in which alkenyl is as defined herein. Preferred alkenyloxy groups are C1-C6alkenyloxy groups.
[0123] "Alkynyloxy" refers to an ¨0-alkynyl group in which alkynyl is as defined herein. Preferred alkynyloxy groups are C1-C6alkynyloxy groups.
[0124] "Alkoxycarbonyl" refers to an ¨C(0)-0-alkyl group in which alkyl is as defined herein. The alkyl group is preferably a C1-C6 alkyl group. Examples include, but not limited to, methoxycarbonyl and ethoxycarbonyl.
[0125] "Akylsulfinyl" means a ¨S(0)-alkyl group in which alkyl is as defined above.
The alkyl group is preferably a C1-C6 alkyl group. Exemplary alkylsulfinyl groups include, but not limited to, methylsulfinyl and ethylsulfinyl.
[0126] "Alkylsulfonyl" refers to a ¨S(0)2-alkyl group in which alkyl is as defined above. The alkyl group is preferably a C1-C6 alkyl group. Examples include, but not limited to methylsulfonyl and ethylsulfonyl.
[0127] "Alkynyl as a group or part of a group means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched preferably having from 2-14 carbon atoms, more preferably 2-12 carbon atoms, more preferably 2-6 carbon atoms in the normal chain. Exemplary structures include, but are not limited to, ethynyl and propynyl.
[0128] "Alkylaminocarbonyl" refers to an alkylamino-carbonyl group in which alkylamino is as defined above.
[0129] "Cycloalkyl" refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle preferably containing from 3 to 9 carbons per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, unless otherwise specified.
It includes monocyclic systems such as cyclopropyl and cyclohexyl, bicyclic systems such as decalin, and polycyclic systems such as adamantane.
[0130] "Cycloalkenyl" means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and preferably having from 5-carbon atoms per ring. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl. The cycloalkenyl group may be substituted by one or more substituent groups.
[0131] The above discussion of alkyl and cycloalkyl substituents also applies to the alkyl portions of other substituents, such as without limitation, alkoxy, alkyl amines, alkyl ketones, arylalkyl, heteroarylalkyl, alkylsulfonyl and alkyl ester substituents and the like.
[0132] "Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.
[0133] "Halogen" represents chlorine, fluorine, bromine or iodine.
[0134] "Heterocycloalkyl" refers to a saturated or partially saturated monocycli, bicyclic, or polycyclic ring containing at least one heteroatom selected from nitrogen, sulfur, oxygen, preferably from 1 to 3 heteroatoms in at least one ring. Each ring is preferably from 3 to 10 membered, more preferably 4 to 7 membered. Examples of suitable heterocycloalkyl substituents include pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, and 1,4-oxathiapane.
[0135] "Heterocycloalkenyl" refers to a heterocycloalkyl as described above but containing at least one double bond.
[0136] "Heterocycloalkylalkyl" refers to a heterocycloalkyl-alkyl group in which the heterocycloalkyl and alkyl moieties are as previously described. Exemplary heterocycloalkylalkyl groups include (2-tetrahydrofuryl)methyl, (2-tetra hydrothiofura nyl)methyl.
[0137] "Heteroalkyl" refers to a straight- or branched-chain alkyl group preferably having from 2 to 14 atoms, more preferably 2 to 10 atoms in the chain, one or more of which is a heteroatom selected from S, 0, and N. Exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl ainines, alkyl sulfides, and the like.
[0138] "Aryl" as a group or part of a group denotes (i) an optionally substituted monocyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) preferably having from 5 to 12 atoms per ring. Examples of aryl groups include phenyl, naphthyl, and the like; (ii) an optionally substituted partially saturated bicyclic aromatic carbocyclic moiety in which a phenyl and a C5_7 cycloalkyl or C5_7 cycloalkenyl group are fused together to form a cyclic structure, such as tetrahydronaphthyl, indenyl or indanyl.
[0139] "Arylalkenyl" means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described. Exemplary arylalkenyl groups include phenylallyl.
[0140] "Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C1.-5 alkyl moiety.
Exemplary arylalkyl groups include benzyl, phenethyl and naphthelenemethyl.
[0141] "Arylacyl" means an aryl-acyl- group in which the aryl and acyl moieties are as previously described. In general the aryl moiety is attached to the alkyl portion of the acyl moiety, typically to the terminal carbon of the alkyl portion of the acyl moiety.
Preferred arylacyl groups contain a C1..5 alkyl moiety in the acyl moiety.
Exemplary arylacyl groups include 2-phenyl-acetyl.
[0142] "Heteroaryl" either alone or part of a group refers to groups containing an aomatic ring (preferably a 5 or 6 membererd aromatic ring) having one or more heteroatoms as ring atoms in the aromatic ring with the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include nitrogen, oxygen and sulphur.
Examples of hetreoaryl include thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, isoindolizine, xantholene, phenoxatine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1H-indazole, purine, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, cinnoline, carbazole, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, oxazole, isooxazole, furazane, phenoxazine, 2-,3- or4- pyridyl, 2-, 3-, 4-, 5-, or 8-quinolyl, 1-, 3-, 4-, or 5- isoquinoliny11-, 2-, or 3- indolyl, and 2-, or 3-thienyl.
[0143] "Heteroarylalkyl" means a heteroaryl-alkyl group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a lower alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.
[0144] "Lower alkyl" as a group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having 1 to 6 carbon atoms in the chain, more preferably 1 to 4 carbons such as methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n-butyl, isobutyl or tertiary-butyl).
[0145] In Formula (I), as well as in Formulae (la) ¨ (lb) defining sub-sets of compounds within Formula (I), there is shown a benzimidazole ring system.
Within this ring system, there are substitutable positions at the 4-,5-, 6-, and 7-ring positions. In each of Formulae (I), (la), and (lb), there is a requirement for attachment of an acidic moiety at one of the ring positions. This acidic moiety may be provided by but is not limited to groups containing, a hydroxamic acid or salt derivatives of such acid which when hydrolyzed would provide the acidic moiety. In some embodiments the acidic moiety may be attached to the ring position through an alkylene group such as ¨CH2-or ¨CH2CH2-, or an alkenylene group such as -CH=CH-. Preferred positions for attachment of the acidic moiety are the 5¨ and 6¨ring positions.
[0146] It is understood that included in the family of compounds of Formula (I) are isomeric forms including diastereoisomers, enantiomers, tautomers, and geometrical isomers in "E" or "Z" configurational isomer or a mixture of E and Z isomers.
It is also understood that some isomeric forms such as diastereomers, enantiomers, and geometrical isomers can be separated by physical and/or chemical methods and by those skilled in the art.
[0147] Some of the compounds of the disclosed embodiments may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and /or diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the subject matter described and claimed.
[0148] Additionally, Formula (1) is intended to cover, where applicable, solvated as well as unsolvated forms of the compounds. Thus, each formula includes compounds having the indicated structure, including the hydrated as well as the non-hydrated forms.
[0149] In addition to compounds of the Formula (I), the HDAC inhibiting agents of the various embodiments include pharmaceutically acceptable salts, prodrugs, and active metabolites of such compounds, and pharmaceutically acceptable salts of such metabolites.
[0150] The term "Pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the above-identified compounds, and include pharmaceutically acceptable acid addition salts and base addition salts.
Suitable pharmaceutically acceptable acid addition salts of compounds of Formula (1) may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, sulfuric, and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, mak, tartaric, citric, fumaric, maleic, alkyl sulfonic, arylsulfonic. Suitable pharmaceutically acceptable base addition salts of compounds of Formula (1) include metallic salts made from lithium, sodium, potassium, magnesium, calcium, aluminium, and zinc, and organic salts made from organic bases such as choline, diethanolamine, morpholine. Other examples of organic salts are:
ammonium salts, quatemary salts such as tetramethylammonium salt; amino acid addition salts such as salts with glycine and arginine. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Co., Easton, PA 1995. In the case of agents that are solids, it is understood by those skilled in the art that the inventive compounds, agents and salts may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulae.
[0151] "Prodrug" means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of formula (I). For example an ester prodrug of a compound of formula (I) containing a hydroxyl group . 30 may be convertible by hydrolysis in vivo to the parent molecule. Suitable esters of compounds of formula (I) containing a hydroxyl group, are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-f3-hydroxynaphthoates, gestisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates. As another example an ester prodrug of a compound of formula (1) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule. (Examples of ester prodrugs are those described by F. J. Leinweber, Drug Metab. Res.,18:379, 1987).
[0152] Preferred HDAC inhibiting agents include those having an IC50 value of 10 0.4 or less.
[0153] Specific compounds of the invention include the following:
341-(3-Dimethylamino-2,2-dimethyl-propy1)-2-( (2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-N
hydroxy-acrylamide <
341-(3-Dimethylamino-2,2-dimethyl-propy1)-2-isopropy1-1H-benzoimidazol-5-y1]-N-hydroxy--/ acrylamide 312-Buty1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide 3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-(2-io11 nnethylsulfanyl-ethyl)-1H-benzoimidazol-5-A-N-- ________________________________ hydroxy-acrylamide OH
3-[1-(3-Dimethylamino-2,2-dimethyl-propy1)-2-ethoxyrnethy1-1H-benzoimidazol-5-y1]-N-N hydroxy-acrylamide /N
3-[1-(3-Dimethylamino-2,2-dimethyl-propy1)-2-( N.
isobuty1-1H-benzoimidazol-5-y1]-N-hydroxy-N
a cryla m ide 3-[1-(2-Diethylamino-ethyl)-2-isobuty1-1H-( __ c" 40 benzoimidazol-5-y1]-N-hydroxy-acrylamide r-N) 342-Buty1-1-(2-diethylamino-ethyl)-1H-\ 10 N
benzoimidazol-5-y1FN-hydroxy-acrylamide r-N) 312-But-3-yny1-1-(3-dimethylamino-2,2-dimethyl-\ 40 propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-N
acrylamide H OH 342-But-3-eny1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-.
hydroxy-acrylamide N OH 3-[2-But-3-eny1-1-(2-diethylamino-ethyl)-1H-iobenzoimidazol-5-y1]-N-hydroxy-acrylamide r-N) 342-But-3-yny1-1-(2-diethylamino-ethyl)-1H-- ______ 10 0E1 benzoimidazol-5-y11-N-hydroxy-acrylamide r-N) HNcm 341-(3-Dimethylamino-2,2-d imethyl-propy1)-2-\ (3,3,3-trifluoro-propy1)-1H-benzoirnidazol-5-y1]-N-hydroxy-acrylamide HN
F 3-[1-(2-Diethylaminc-ethyl)-2-(3,3,3-trifluoro-F F o propyl)-1 H-benzoimidazol-5-y1]-N-hydroxy-N acrylamide õN H 341-(2-Diethylamino-ethyl)-2-ethoxymethy1-1 H-\ _____ o<
N
40 benzoimidazol-5-y1FN-hydroxy-acrylamide HN/ H 3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-0 methyl-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (6, 341-(2-Diethylamino-ethyl)-2-(2,2-dimethyl-NH
,CH propyI)-1 H-benzoimidazol-5-y1]-N-hydroxy-N
acrylamide r) N! N-Hydroxy-311-(3-isopropylamino-propy1)-2-(3,3, 3-trifluoro-propy1)-1 H-benzoimidazo1-5-y1]-N acrylamide o 3-[2-(2,2-Dimethyl-propyI)-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-N
acrylamide / NH
341-(2-Diisopropylamino-ethyl)-2-(2,2-dimethyl-propy1)-1H-benzoimidazol-5-A-N-hydroxy-N
acrylamide 341-(2-Diisopropylamino-ethyl)-2-isobuty1-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide 311-(3-Dimethylamino-2,2-dimethyl-propy1)-2-/ <
hex-3-eny1-1H-benzoimidazol-5-A-N-hydroxy-acrylamide 3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-io(2,4,4-trimethyl-penty1)-1H-benzoimidazol-5-y11-7& ( N-hydroxy-acrylamide /N
o 312-Cyclohexy1-1-(3-dimethylamino-2,2-(JRNN = dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-\N-- hydroxy-acrylamide 342-Bicyclo[2.2.1]hept-5-en-2-y1-1-(3-; dimethylamino-2,2-dimethyl-propyI)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide 341-(2-Diethylamino-ethyl)-2-hex-3-eny1-1 H-/ 40 benzoimidazol-5-y9-N-hydroxy-acrylamide rN) 341-(2-Diisopropylamino-ethyl)-2-hex-3-eny1-1 / ___ NN IP IHN benzoimidazol-5-y1FN-hydroxy-acrylamide N)"
342-Hex-3-eny1-1-(2-isopropylamino-ethyl)-1 N
= benzoimidazol-5-y1FN-hydroxy-acrylamide 342-Hex-3-eny1-1-(3-isopropylamino-propy1)-1 benzoimidazol-5-y1]-N-hydroxy-acrylamide 3-[1-(2-Ethylamino-ethyl)-2-hex-3-eny1-1H-/ NN benzoimidazol-5-y1]-N-hydroxy-acrylamide 3-[1-(2-Diethylamino-ethyl)-2-hexyl-1 H-benzoimidazol-5-yll-N-hydroxy-acrylamide N-Hydroxy-3-[1-(3-isopropylamino-propyI)-2-(2,4,4-trimethyl-penty1)-1H-benzoimidazol-5-y1]-N acrylamide 3-[2-(2,2-Dimethyl-propyI)-1-(3-isopropylamino-propyI)-1 H-benzoimidazol-5-y1FN-hydroxy-N
acrylamide ,11 1" 341-(2-Diisopropylamino-ethyl)-2-(3,3,3-trifluoro-propyI)-1 H-benzoimidazol-5-y1]-N-hydroxy-F 111 acrylamide F
N-Hydroxy-3[2-isobuty1-1 -(2-isopropylamino-K a r ethyl)-1 H-benzoimidazol-5-y1]-acrylamide N ''Illre-/ NH
342-(2,2-Dimethyl-propy1)-1 -(2-ethylamino-)( 0 ethyl)-1H-benzoimidazol-5-y11-N-hydroxy-. 'P
\-- , acrylamide 341 -(2-Ethylami no-ethyl)-2-isobuty1-1 H-K a TH benzoimidazol-5-y1]-N-hydroxy-acrylamide HN
) 341 -(2-Diisopropylamino-ethyl)-2-(2,4,4-( <
r HO trimethyl-pentyI)-1 H-benzoi midazol-5-yll-N-hydroxy-acrylamide )N)--.
N-Hydroxy-341-(2-isopropylamino-ethyl)-2-( < 10 : (2,4,4-trimethyl-pentyI)-1 H-benzoimidazol-5-y1J-N
)---- acrylamide N
3-[1-(2-Ethylamino-ethyl)-2-(2,4,4-trimethyl-. (I\ pentyI)-1 H-benzoimidazol-5-y1]-N-hydroxy-NH--- .1" acrylamide 341 -(2-Diethylamino-ethyl)-2-(2,4,4-trimethyl-(N 41 \ pentyI)-1 H-benzoimidazo1-5-y1]-N-hydroxy-/) H''' acrylamide 341 -(2-Diethylamino-ethyl)-2-propy1-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide , 1"7,y" 40 \ -,,,,, /'---312-Buty1-1-(2-diisopropylamino-ethyl)-1H-[.
= benzoimidazol-5-y1J-N-hydroxy-acrylamide HO
gp-(2-ethylamino-ethyl)-1 benzoimidazol-5-A-N-hydroxy-acrylamide H
f, 311 -(2-Diethylam ino-ethyl)-2-(2-methylsulfanyl-ethyl)-1H-benzoimidazol-5-y1FN-hydroxy-/ acrylamide o 3[2-Buty1-1-(2-isopropylamino-ethyl)-1 benzoimidazol-5-y1FN-hydroxy-acrylamide / NH
OF1 342-Buty1-1-(3-isopropylamino-propy1)-1H-\
benzoimidazol-5-y1]-N-hydroxy-acrylamide 341-(1-Benzyl-piperidin-4-y1)-2-buty1-1 H-\ 40 benzoimidazol-5-A-N-hydroxy-acrylamide 44, 342-But-3-eny1-1-(2-ethylamino-ethyl)-1 / 40 benzoimidazol-5-y1]-N-hydroxy-acrylamide rNH
3[2-Hexy1-1-(2-isopropylamino-ethyl)-1 H-\
benzoimidazol-5-A-N-hydroxy-acrylamide / NH
)(' 0 341-(2-Dimethylamino-ethyl)-2-(2,4,4-trimethyl-(pentyI)-1 H-benzoimidazol-5-y1]-N-hydroxy-rj acrylamide 341-(2-Ethylamino-ethyl)-2-hexyl-1 H-40 NIH benzoimidazol-5-y11-N-hydroxy-acrylamide N-Hydroxy-3-[1-(2-isopropylamino-ethyl)-2-' I \
(3,3,3-trifluoro-propyI)-1 H-benzoimidazol-5-y1]-N
acrylamide HN\
3-[1-(2-Dimethylamino-ethyl)-2-hex-3-eny1-1 H-/ __ <
ip benzoinnidazol-5-yll-N-hydroxy-acrylamide 3-[1-(2-Amino-ethy1)-2-(2,4,4-trimethyl-penty1)-< 40 OH 1 H-benzoimidazol-5-y1J-N-hydroxy-acrylamide (-7( 112,4 3-[1-(2-Amino-ethyl)-2-(2-methoxy-nony1)-1H-OH /
benzoimidazol-5-y1]-N-hydroxy-acrylamide Hp õAN 342-Buty1-1-(2-dimethylamino-ethyl)-1H-\ vi benzoimidazol-5-y1]-N-hydroxy-acrylamide o 311-(2-Dimethylamino-ethyl)-2-hexy1-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide N-{2-[1-(2-Diethylamino-ethyl)-5-(2-"" OH
hydroxycarbamoyl-vinyI)-1 H-benzoimidazol-2-ylj-ethyl)-3,3-dimethyl-butyramide o 3-{1-(2-Diethylamino-ethyl)-242-(2,2-dimethyl-HN¨\ propionylamino)-ethy1]-1 H-benzoimidazol-5-y1}-N
N-hydroxy-acrylamide \
3-{1 -(2-Diethylam ino-ethyl)-2-[(2, 2-dimethyl-r propionylamino)-methy1]-1 H-benzoimidazol-5-y1}-N-hydroxy-acrylamide rN) N-E1-(2-Diethylamino-ethyl)-5-(2-hydroxycarbamoyl-viny1)-1 H-benzoimidazol-2-N
ylmethyli-butyramide 3-[1-(2-ethylamino-ethyl) -2-(3,3-dimethyl-butyI)-____ (N
1 H-benzoimidazol-5-yli-N-hydroxy-acrylamide OH
NH
3-[2-(3,3-Dimethyl-butyI)-1-(2-Dimethylamino-)\ __ ethyl)-1 H-benzoimidazol-5-y1]-N-hydroxy-N
acrylamide ¨4\
341-(2-Dimethylamino-ethyl)-2-penty1-1 H-. 411 \ 0 benzoimidazol-5-y1]-N-hydroxy-acrylamide F ___________ F
3-[1-(2-Dimethylamino-ethyl)-2-(2,2,2-trifluoro-ethyl)-1H-benzoimidazol-5-yli-N-hydroxy-N
4100 \0 acrylamide HN-OH
=
N-Hydroxy-341-(5-methy1-1H-pyrazol-3-y1)-2-õ
( 10 : (2,4,4-trimethyl-penty1)-1H-benzoimidazol-5-y9-acrylamide 341-(2-Ethylamino-ethyl)-2-penty1-I H-2 isbenzoimidazol-5-y9-N-hydroxy-acrylamide HN\
342-Butyl-I -pyrrolidin-3-y1-1 H-benzoimidazol-5-ioyI)-N-hydroxy-acrylamide NH
3-(2-Buty1-1-piperidin-4-y1-1H-benzoimidazol-5-yI)-N-hydroxy-acrylamide N
N-Hydroxy-311-(2-isopropylamino-ethyl)-2-, / OH penty1-1H-benzoimidazol-5-y1Facrylamide HN
0 N-Hydroxy-341-(2-methylamino-ethyl)-2-non-, eny1-1H-benzoimidazol-5-y1]-acrylamide __________________ 401 _---NH
N-Hydroxy-341-(2-methylamino-ethyl)-2-non-6-10 eny1-1H-benzoinnidazol-5-y1]-acrylamide io[r H 342-Hexy1-1-(2-methylannino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide N-Hydroxy-3-[1-(2-methylamino-ethyl)-2-pentyl-/ __ <
ioOH
1H-benzoimidazol-5-A-acrylamide "N\
N-Hydroxy-3-[1-(2-methylamino-ethy1)-2-octyl-11101 1H-benzoimidazol-5-y1Facrylamide FIN \
341-(2-Amino-ethyl)-2-octy1-1H-benzoimidazol-TH 5-y11-N-hydroxy-acrylannide 3-{2-Buty1-142-(isopropyl-methyl-amino)-ethy1]-OH / <
1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide 3-{112-(Ethyl-methyl-amino)-ethy1]-2-penty1-1 r(H-ON
benzoimidazol-5-y1}-N-hydroxy-acrylamide r-N\
0,4 3-(2-Hexy1-1-pyrrolidin-3-y1-1H-benzoimidazol-5-yI)-N-hydroxy-acrylamide OH 3[2-Buty1-1-(1-methyl-pyrrolidin-3-y1)-1 H-a N '"W"' benzoimidazol-5-yli-N-hydroxy-acrylamide N\
OH
3-(2-Butyl-1 -piperidin-3-y1-1 H-benzoimidazol-5-a N
yI)-N-hydroxy-acrylamide 0.4 3-(2-Hexy1-1-piperidin-3-y1-1H-benzoimidazol-5-) yI)-N-hydroxy-acrylamide 0 3-(1-{2-[Ethyl-(2-methoxy-ethyl)-amino]-ethyl}-2-N
11101 N-0H penty1-1H-benzoimidazol-5-y1)-N-hydroxy-H
acrylamide 0 3-{2-Butyl-1 42-(ethyl-methyl-amino)-ethy1]-1H-N
H benzoimidazol-5-y1}-N-hydroxy-acrylamide r 0 N-Hydroxy-341-(1-methyl-piperidin-3-y1)-2-OH
r/1 401 penty1-1H-benzoimidazol-5-y1]-acrylamide 0 3-{142-(Ethyl-hexyl-amino)-ethy11-1 benzoimidazol-5-y1}-N-hydroxy-acrylamide 0 3-{142-(Ethyl-pentyl-amino)-ethy1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide o 3-{142-(Ethyl-heptyl-amino)-ethy1]-1H-"N N,OH
benzoimidazol-5-y1}-N-hydroxy-acrylamide jj-j-(E)-3-(2-hexy1-1-(1-(2-hydroxyethyl)piperidin-3-NH
\oH yl )- 1 H-benzo[d]imidazol-5-y1)-N-hydroxyacrylamide 3-(2-Buty1-1-{24ethyl-(3-hydroxy-propyl)-amino]-\NOH ethy11-1H-benzoimidazol-5-y1)-N-hydroxy-. acrylamide 3-(1-{2-[Ethyl-(3-hydroxy-propy1)-amino]-ethyll-/
/ ____ < S 2-penty1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide o (E)-N-hydroxy-3-(1 -(1 -phenethylpyrrolidin-3-y1)-1 H-benzo[d]imidazol-5-yl)acrylamide o =(E)-N-hydroxy-3-(1 -(1 -pentylpiperidin-3-y1)-1 N--\N benzo[d]imidazol-5-yl)acrylamide 3-{1-[2-(Butyl-ethyl-amino)-ethy1]-1H-benzoimidazol-5-yll-N-hydroxy-acrylarnide rrN) (E)-N-hydroxy-3-(1-(1-phenethylpiperidin-3-y1)-c,, 1 H-benzo[d]imidazol-5-ypacrylamide o = (E)-N-hydroxy-3-(1-(1-(3-phenylpropyppiperidin-Nc'H
H 3-y1)-1 H-benzo[d]imidazol-5-yl)acrylamide 41, (E)-N-hydroxy-3-(1-(1-(3-phenylpropyl)pyrrolidin-3-y1)-1 H-benzo[d]imidazol-5-yl)acrylamide o 3-{141-(3,3-Dimethyl-buty1)-pyrrolidin-3-y1]-1 H-N = voH
benzoimidazol-5-y1)-N-hydroxy-acrylamide =
0 (E)-3-(1-(2-(diethylamino)ethyl)-1H-N
benzo[djimidazol-5-y1)-N-hydroxyacrylamide rN) - ___________________ õõ 3-[2-(4-Cyano-butyl)-1-(2-diethylamino-ethyl)-\
C'El 1 H-benzoimidazol-5-y1FN-hydroxy-acrylamide o (E)-3-(1-(1-butylpiperidin-3-y1)-1 H-N
benzo[d]imidazol-5-y1)-N-hydroxyacrylamide NH
OH
0 (E)-N-hydroxy-3-(1-(1-(pent-4-enyl)piperidin-3-OH y1)-1 H-benzo[d]imidazol-5-yl)acrylamide (E)-3-(1-(1-(3,3-dimethylbutyl)piperidin-4-y1)-1H-benzo[d]imidazol-5-y1)-N-hydroxyacrylamide tr,ori 3-[1-(2-Diethylamino-ethy1)-2-propylamino-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide O (E)-N-hydroxy-3-(1 -(2-(isopropyl(propyl)amino)ethyl)-1 H-N benzo[d]imidazol-5-ypacrylamide Ny o 3-{142-(Butyl-isopropyl-amino)-ethy1]-1 benzoimidazol-5-y11-N-hydroxy-acrylamide 0 N-Hyd roxy-3-{1 -[2-(isopropyl-pentyl-amino)-OH
ethyI]-1 H-benzoimidazol-5-y1}-acrylamide \\r-N
3-[2-(5-Cyano-penty1)-1-(2-diethylamino-ethyl)-\ 1 H-benzoimidazol-5-y11-N-hydroxy-acrylamide 1:
0 3-(1-{2-[(3,3-Dimethyl-buty1)-ethyl-aminoFethyl}-401 ( H1 H-benzoimidazol-5-y1)-N-hydroxy-acrylamide 0 3-{1-[2-(Ethyl-propyl-am ino)-ethy1]-1 OH
110 benzoimidazol-5-y1}-N-hydroxy-acrylamide 0 N-Hyd roxy-3-(1 -{24isopropyl-(2-methyl-penty1)-OH
amino]-ethyl}-1 H-benzoimidazol-5-y1)-acrylamide o "\r¨N
(E)-N-hydroxy-3-(1-(2-(isopropy1(4,4,4-40, V trifluorobutypamino)ethyl)-1 H-benzo[d]imidazol-N 5-yl)acrylamide F F
3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-OH
1101 propylamino-1 H-benzoinnidazol-5-y1]-N-hydroxy-N acrylamide o 3-{142-(Ethyl-hexyl-amino)-ethy11-2-methyl-1H-i) OH benzoimidazol-5-y1}-N-hydroxy-acrylamide rN
o 3-{142-(Butyl-ethyl-amino)-ethy1]-2-F __ N trifluoromethy1-1H-benzoimidazol-5-y1}-N-NH
hydroxy-acrylamide FrJ
3-{142-(Ethyl-hexyl-amino)-ethy1]-2-F N OH
F __ trifluoromethy1-1H-benzoimidazol-5-y1}-N-FriN hydroxy-acrylamide rN
o (E)-3-(1-(2-(dibutylamino)ethyl)-2-propy1-1H-/,, benzo[d]imidazol-5-y1)-N-hydroxyacrylamide 0 341-(2-Dipropylamino-ethyl)-1H-benzoimidazol-OH
N
5-y1]-N-hydroxy-acrylamide o N-Hydroxy-3-(1-{2-psopropyl-(3-methyl-butyl)-amino]-ethyl}-1 H-benzoimidazol-5-y1)-acrylamide O 3-(1-{2-[(3,3-Dimethyl-buty1)-methyl-amino]-(OH
ethyl}-1 H-benzoimidazol-5-y1)-N-hydroxy-acrylamide N
O 3-(1-{2-[(2-Ethyl-butyl)-methyl-amino]-ethyl}-1 40/ ( H
\N benzoimidazo1-5-y1)-N-hydroxy-acrylamide (E)-3-(1-(2-(bis(3,3-dimethylbutyl)amino)ethyly N,,OH
1 H-benzo[d]imidazol-5-y1)-N-hydroxyacrylamide 0 (E)-3-(1-(2-(diisobutylamino)ethyl)-1H-NVOH benzo[d]imidazol-5-y1)-N-hydroxyacrylamide 0 3-{14243,3-Dimethyl-butylamino)-ethy1]-1 H-N
N/OH
benzoimidazol-5-y1}-N-hydroxy-acrylamide HN
0 N-Hydroxy-3-{1-[2-(methyl-pent-4-enyl-amino)-N SI N/OH
ethyl]-1H-benzoimidazol-5-y1}-acrylamide N
N
, 0 3-(1-{2-[(3,3-Dimethyl-buty1)-propyl-amino]-/) 40 õ, Nõ..õ...OH
N
ethyl}-1 H-benzoimidazol-5-y1)-N-hydroxy-acrylamide 0 3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-OH
\ 110 rr methylsulfanyl-1 H-benzoimidazol-5-y1]-N-N hydroxy-acrylamide N"----/ o 3-{142-(3,3-Dimethyl-butylamino)-ethy1]-2-õ.
propyl-1 H-benzoimidazo1-5-y1}-N-hydroxy-acrylamide \---- 0 34142-(3,3-Dimethyl-butylamino)-ethyl]-2-(2,2-dimethyl-propy1)-1 H-benzoimidazo1-5-y1]-N-7( hydroxy-acrylamide HN
k [1-{2-[Bis-(3,3-dimethyl-butyl)-amino]-ethyl)-2-7( < =
(2,2-dimethyl-propy1)-1H-benzoimidazol-5-A-N-. hydroxy-acrylamide 0 3-{1-[2-(2,2-Dimethyl-propylam ino)-ethyl]-1H-OH
benzoimidazol-511}-N-hydroxy-acrylamide 3-(1-{2-[(2,2-Dimethyl-propyI)-propyl-amino]-ethyll-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide 3-{1 42-(3,3-Dimethyl-butylamino)-ethyl]-2-ethyl-N OH
1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide NH
[0154] The compounds disclosed are hydroxamate compounds containing a hydroxamic acid type moiety in one of the substituents that may be inhibitors of deacetylases, including but not limited to inhibitors of histone deacetylases.
The 5 hydroxamate compounds may be suitable for prevention or treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis when used either alone or together with a pharmaceutically acceptable carrier, diluent or excipient. An example of such a disorder is cancer. .
[0155] Administration of compounds within Formula (I) to humans can be by any of the accepted modes for enteral administration such as oral or rectal, or by parenteral administration such as subcutaneous, intramuscular, intravenous and intradermal routes. Injection can be bolus or via constant or intermittent infusion. The active compound is typically included in a pharmaceutically acceptable carrier or diluent and in an amount sufficient to deliver to the patient a therapeutically effective dose. In various embodiments the inhibitor compound may be selectively toxic or more toxic to rapidly proliferating cells, e.g. cancerous tumors, than to normal cells.
[0156] As used herein the term 'cancer' is a general term intended to encompass the vast number of conditions that are characterised by uncontrolled abnormal growth of cells.
[0157] It is anticipated that the compounds of the invention will be useful in treating various cancers including but not limited to bone cancers including Ewing's sarcoma, osteosarcoma, chondrosarcoma and the like, brain and CNS tumours including acoustic neuronia, neuroblastomas, glioma and other brain tumours, spinal cord tumours, breast cancers, colorectal cancers, advanced colorectal adenocarcinomas, colon cancers, endocrine cancers including adenocortical carcinoma, pancreatic cancer, pituitary cancer, thyroid cancer, parathyroid cancer, thymus cancer, multiple endocrine neoplasma, gastrointestinal cancers including stomach cancer, esophageal cancer, small intestine cancer, Liver cancer, extra hepatic bile duct cancer, gastrointestinal carcinoid tumour, gall bladder cancer, genitourinary cancers including testicular cancer, penile cancer, prostate cancer, gynaecological cancers including cervical cancer, ovarian cancer, vaginal cancer, uterus/endometrium cancer, vulva cancer, gestational trophoblastic cancer, fallopian tube cancer, uterine sarcoma, head and neck cancers including oral cavity cancer, lip cancer, salivary gland cancer, larynx cancer, hypopharynx cancer, orthopharynx cancer, nasal cancer, paranasal cancer, nasopharynx cancer, leukemias including childhood leukemia, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, acute promyelocytic leukemia, plasma cell leukemia, myelomas, haematological disorders including myelodysplastic syndromes, myeloproliferative disorders, aplastic anemia, Fanconi anemia, Waldenstroms Macroglobulinemia, lung cancers including small cell lung cancer, non-small cell lung cancer, lymphomas including Hodgkin's disease, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, AIDS related Lymphoma, B-cell lymphoma, Burkitt's lymphomaõ eye cancers including retinoblastoma, intraocular melanoma, skin cancers including melanoma, non-melanoma skin cancer, merkel cell cancer, soft tissue sarcomas such as childhood soft tissue sarcoma, adult soft tissue sarcoma, Kaposi's sarcoma, urinary system cancers including kidney cancer, Wilms tumour, bladder cancer, urethral cancer, and transitional cell cancer.
[0158] Exemplary cancers that may be treated by the compounds of the present invention are breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer (e.g. renal cell carcinoma), gastric cancer, colon cancer, colon cancer, colorectal cancer and brain cancer.
[0159] Exemplary cancers that may be treated by compounds of the present inventions include but are not limited to B-cell lymphoma (e.g. Burkitt's lymphoma), leukemias (e.g. acute promyeiocytiC leukemia), cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma.
[0160] Exemplary cancers that may be treated by compounds of the present invention include solid tumors and hematologic malignancies. In another embodiment, preferred cancers that may be treated the compounds of the present invention are colon cancer, prostate cancer, hepatoma and ovarian cancer.
[0161] The compounds may also be used in the treatment of a disorder involving, relating to or, associated with dysregulation of histone deacetylase (HDAC).
[0162] There are a number of disorders that have been implicated by or known to be mediated at least in part by HDAC activity, where HDAC activity is known to play a role in triggering disease onset, or whose symptoms are known or have been shown to be alleviated by HDAC inhibitors. Disorders of this type that would be expected to be amenable to treatment with the compounds of the invention include the following but not limited to: Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesis, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Pick's disease, Intracerebral haemorrhage Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, macular myopic degeneration, Rubeotic glaucoma, Interstitial keratitis, Diabetic retinopathy, Peter's anomaly, retinal degeneration, Cellophane Retinopathy; Cogan's Dystrophy;
Corneal Dystrophy; Iris Neovascularization (Rubeosis); Neovascularization of the Cornea;
Retinopathy of Prematurity; Macular Edema; Macular Hole; Macular Pucker;
Marginal Blepharitis, Myopia, nonmalignant growth of the conjunctiva; Inflammatory diseases and/or Immune system disorders including Rheumatoid Arthritis (RA), Osteoarthritis, Juvenile chronic arthritis, Graft versus Host disease, Psoriasis, Asthma, Spondyloarthropathy, Crohn's Disease, inflammatory bowel disease, Colitis Ulcerosa, Alcoholic hepatitis, Diabetes, Sjoegrens's syndrome, Multiple Sclerosis, Ankylosing spondylitis, Membranous glomerulopathy, Discogenic pain, Systemic Lupus Erythematosus, allergic contact dermatitis; Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease, schizophrenia, depression and dementia; Cardiovascular Diseases including Heart failure, restenosis, cardiac hypertrophy and arteriosclerosis; Fibrotic diseases including liver fibrosis, lung fibrosis, cystic fibrosis and angiofibroma;
Infectious diseases including Fungal infections, such as Candida Albicans, Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis, and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
[0163] In using the compounds of the invention they can be administered in any form or mode which makes the compound bioavailable. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the condition to be treated, the stage of the condition to be treated and other relevant circumstances. We refer the reader to Remingtons Pharmaceutical Sciences, 19th edition, Mack Publishing Co. (1995) for further information.
[0164] The compounds of the present invention can be administered alone or in the form of a pharmaceutical composition in combination with a pharmaceutically acceptable carrier, diluent or excipient. The compounds of the invention, while effective themselves, are typically formulated and administered in the form of their pharmaceutically acceptable salts as these forms are typically more stable, more easily crystallised and have increased solubility.
[0165]The compounds are, however, typically used in the form of pharmaceutical compositions which are formulated depending on the desired mode of administration.
As such in a further embodiment the present invention provides a pharmaceutical composition including a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent or excipient. The compositions are prepared in manners well known in the art.
[0166] The invention in other embodiments provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. In such a pack or kit can be found a container having a unit dosage of the agent (s). The kits can include a composition comprising an effective agent either as concentrates (including lyophilized compositions), which can be diluted further prior to use or they can be provided at the concentration of use, where the vials may include one or more dosages.
Conveniently, in the kits, single dosages can be provided in sterile vials so that the physician can employ the vials directly, where the vials will have the desired amount and concentration of agent(s). Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
[0167] The compounds of the invention may be used or administered in combination with one or more additional drug (s) that are chemotherapeutic drugs or HDAC
inhibitor drugs and/or procedures (e.g. surgery, radiotherapy) for the treatment of the disorder/diseases mentioned. The components can be administered in the same formulation or in separate formulations. If administered in separate formulations the compounds of the invention may be administered sequentially or simultaneously with the other drug (s).
[0168] In addition to being able to be administered in combination with one or more additional drugs that include chemotherapeutic drugs or HDAC inhibitor drugs the compounds of the invention may be used in a combination therapy. When this is done the compounds are typically administered in combination with each other. Thus one or more of the compounds of the invention may be administered either simultaneously (as ' a combined preparation) or sequentially in order to achieve a desired effect. This is especially desirable where the therapeutic profile of each compound is different such that the combined effect of the two drugs provides an improved therapeutic result [0169] Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), 5 and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0170] These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like.
It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the 15 like.
Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminium monostearate and gelatin.
[0171] If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
[0172] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile 25 solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
[0173] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with 30 at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium 35 carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[0174] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0175] The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
Examples of embedding compositions which can be used include polymeric substances and waxes.
[0176] If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
[0177] The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
[0178] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
[0179] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0180] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-s agar, and tragacanth, and mixtures thereof.
[0181] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[0182] Dosage forms for topical administration of a compound of this invention include powders, patches, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required.
[0183] The term "therapeutically effective amount" or "effective amount" is an amount sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations. An effective amount is typically sufficient to palliate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state. A therapeutically effective amount can be readily determined by an attending diagnostician by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective amount a number of factors are to be considered including but not limited to, the species of animal, its size, age and general health, the specific condition involved, the severity of the condition, the response of the patient to treatment, the particular compound administered, the mode of administration, the bioavailability of the preparation administered, the dose regime selected, the use of other medications and other relevant circumstances.
[0184] A preferred dosage will be a range from about 0.01 to 300 mg per kilogram of body weight per day. A more preferred dosage will be in the range from 0.1 to 100 mg per kilogram of body weight per day, more preferably from 0.2 to 80 mg per kilogram of body weight per day, even more preferably 0.2 to 50 mg per kilogram of body weight per day. A suitable dose can be administered in multiple sub-doses per day.
[0185] As discussed above, the compounds of the embodiments disclosed inhibit histone deacetylases. The enzymatic activity of a histone deacetylase can be measured using known methodologies [Yoshida M. et al, J. Biol. Chem., 265, (1990), J. Taunton et al, Science 1996 272: 408]. In certain embodiments, the histone deacetylase inhibitor interacts with and/or reduces the activity of more than one known histone deacetylase in the cell, which can either be from the same class of histone deacetylase or different class of histone deacetylase. In some other embodiments, the histone deacetylase inhibitor interacts and reduces the activity of predominantly one histone deacetylase, for example HDAC-1, HDAC-2, HDAC-3 or HDAC-8 which belongs to Class I HDAC enzymes [De Ruijter A.J.M. et al, Biochem. J., 370, (2003)]. HDACs can also target non-histone substrates to regulate a variety of biological functions implicated in disease pathogenesis. These non-histone substrates include Hsp90, a-tubulin, p53, NFkb and HIF1a [Drummond et al., Annu. Rev.
Pharmacol. Toxicol. 45:495 (2004)]. Certain preferred histone deacetylase inhibitors are those that interact with, and/or reduce the activity of a histone deacetylase which is involved in tumorigenesis, and these compounds may be useful for treating proliferative diseases. Examples of such cell proliferative diseases or conditions include cancer (include any metastases), psoriasis, and smooth muscle cell proliferative disorders such as restenosis. The inventive compounds may be particularly useful for treating tumors such as breast cancer, colon cancer, lung cancer, ovarian cancer, prostate cancer, head and/or neck cancer, or renal, gastric, pancreatic cancer and brain cancer as well as hematologic malignancies such as lymphomas and leukemias. In addition, the inventive compounds may be useful for treating a proliferative disease that is refractory to the treatment with other chemotherapeutics; and for treating hyperproliferative condition such as leukemias, psoriasis and restenosis. In other embodiments, compounds of this invention can be used to treat pre-cancer conditions or hyperplasia including familial adenomatous polyposis, colonic adenomatous polyps, myeloid dysplasia, endometrial dysplasia, endometrial hyperplasia with atypia, cervical dysplasia, vaginal intraepithelial neoplasia, benign prostatic hyperplasia, papillomas of the larynx, actinic and solar keratosis, seborrheic keratosis and keratoacanthoma.
[0186] Additionally compounds of the various embodiments disclosed herein may be useful for treating neurodegenerative diseases, and inflammatory diseases and/or immune system disorders.
[0187] In one embodiment the disorder is selected from the group consisting of cancer, inflammatory diseases and/or immune system disorders (e.g. rheumatoid arthritis, systemic lupus erythematosus), angiofibroma, cardiovascular diseases, fibrotic diseases, diabetes, autoimmune diseases, chronic and acute neurodegenerative disease like Huntington's disease, Parkinson's disease, disruptions of nerval tissue and infectious diseases like fungal, bacterial and viral infections. In another embodiment the disorder is a proliferative disorder.
[0188] The histone deacetylase inhibitors of the invention have significant antiproliferative effects and promote differentiation, cell cycle arrest in the G1 or G2 phase, and induce apoptosis.
SYNTHESIS OF DEACETYLASE INHIBITORS
[0189] The agents of the various embodiments may be prepared using the reaction routes and synthesis schemes as described below, employing the techniques available in the art using starting materials that are readily available. The preparation of particular compounds of the embodiments is described in detail in the following examples, but the artisan will recognize that the chemical reactions described may be readily adapted to prepare a number of other agents of the various embodiments. For example, the synthesis of non-exemplified compounds may be successfully performed by modifications apparent to those skilled in the art, e.g. by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions. A list of suitable protecting groups in organic synthesis can be found in T.W. Greene's Protective Groups in Organic Synthesis, Td Edition, John Wiley & Sons, 1999. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the various embodiments.
[0190] Reagents useful for synthesizing compounds may be obtained or prepared according to techniques known in the art.
[0191] In the examples described below, unless otherwise indicated, all temperatures in the following description are in degrees Celsius and all parts and percentages are by weight, unless indicated otherwise.
[0192] Various starting materials and other reagents were purchased from commercial suppliers, such as Aldrich Chemical Company or Lancaster Synthesis Ltd., and used without further purification, unless otherwise indicated.
Tetrahydrofuran (THE) and N,N-dimethylformamide (DMF) were purchased from Aldrich in SureSeal bottles and used as received. All solvents were purified by using standard methods in the art, unless otherwise indicated.
[0193] The reactions set forth below were performed under a positive pressure of 5 nitrogen, argon or with a drying tube, at ambient temperature (unless otherwise stated), in anhydrous solvents, and the reaction flasks are fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven-dried and/or heat-dried. Analytical thin-layer chromatography was performed on glass-backed silica gel 60 F 254 plates (E Merck (0.25 mm)) and eluted with the appropriate solvent ratios 10 (v/v). The reactions were assayed by TLC and terminated as judged by the consumption of starting material.
[0194] The TLC plates were visualized by UV absorption or with a p-anisaldehyde spray reagent or a phosphomolybdic acid reagent (Aldrich Chemical, 20wt% in ethanol) 15 which was activated with heat, or by staining in iodine chamber. Work-ups were typically done by doubling the reaction volume with the reaction solvent or extraction solvent and then washing with the indicated aqueous solutions using 25% by volume of the extraction volume (unless otherwise indicated). Product solutions were dried over anhydrous sodium sulfate prior to filtration, and evaporation of the solvents was under 20 reduced pressure on a rotary evaporator and noted as solvents removed in vacuo.
Flash column chromatography [Still et al, J. Org. Chem., 43, 2923 (1978)] was conducted using Silica gel 60 (Merck KGaA, 0.040-0.063 mm, 230-400 mesh ASTM) and a silica gel:crude material ratio of about 20:1 to 50:1, unless otherwise stated.
Hydrogenolysis was done at the pressure indicated or at ambient pressure.
[0195] NMR spectra were recorded on a Bruker AVANCE 400 spectrometer operating at 400 MHz for 11-I NMR and 100 MHz for 13C-NMR. NMR spectra are obtained as CDCI3 solutions (reported in ppm), using chloroform as the reference standard (7.26 ppm and 77.14 ppm) or CD3OD (3.3 and 49.3 ppm), or DMSO-d6 (2.50 and 39.5 ppm) or an internal tetramethylsilane standard (0.00 ppm) when appropriate.
Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, q =
quartet, m =
multiplet, br = broadened, dd = doublet of doublets, dt = doublet of triplets.
Coupling constants, when given, are reported in Hertz.
[0196] Mass spectra were obtained using LC/MS either in ESI or APCI. All melting points are uncorrected.
[0197] All final products had greater than 90% purity (by HPLC at wavelengths of 254 nm and/or 220 nm). Analytical HPLC conditions for purity check: Xterra RP18 3.5 gm 4.6 x 20mm IS column; 2.0 ml/min, gradient 5-65% B over 4 min, then 65-95%b over 1 min and 95%6 for additional 0.1 min; Solvent A: H20 with 0.1% TFA;
Solvent B:
acetonitrile with 0.1% TFA.
[0198] The following examples are intended to illustrate the embodiments disclosed and are not to be construed as being limitations thereto. Additional compounds, other than those described below, may be prepared using the following described reaction scheme or appropriate variations or modifications thereof.
SYNTHESIS
[0199] Scheme I and ll illustrates the procedure used for preparing compounds of formula lb, wherein X and Y are hydrogens, compounds (VII) of formula la can be prepared by analogous procedure, for example, by the choice of appropriate starting material. For example, in the case of Z is ¨CH=CH- and attached to C5-position in Formula lb, such compound(s) can be synthesized by analogous method illustrated in Scheme I and ll starting with a substituted cinnamic acid (e.g. trans-3-nitro-4-chloro-cinnamic acid), appropriate amine component (R1NF12), carboxylic acid component (R2CO2H, Scheme I) or aldehyde (R2CHO, Scheme II), and appropriate hydroxylamine or N-alkyl hydroxylamine (NHR3OH where R3 is defined as above in Formula la).
[0200] Specifically, the hydroxamate compounds Formula lb can be synthesized by the synthetic route shown in Scheme I. The reaction of trans-4-chloro-3-nitrocinnamic acid (I) with an amine R1NH2 in the present of a base (e.g. triethylamine) in an appropriate solvent (e.g. dioxane) gave (II). Treatment of (II) in methanol under acid catalysis (e.g. sulfuric acid) resulted in esterification providing (III).
Alternatively, the carboxylic acid (I) may be esterified to the methyl ester (la) and then the chloride was replaced by the appropriate amine component R1NH2 to give compound (III). The nitro group of (III) can be reduced by appropriate reducing agent (e.g. tin (II) chloride) and , the resulting phenylenediamine (IV) was coupled with an acid R2CO2H to give amide (V) which was subsequently cyclized in an appropriate solvent (e.g. acetic acid) to give benzimidazole (VI) (J. Med. Chem. 2001, 44, 1516-1529). The hydroxamate compounds (VI) were obtained from methyl ester (VI) by a known synthesis method (J.
Med. Chem., 2002, 45, 753-757).
Scheme I
02N la 02N
OH Base la OH Me0H 02N lb 0v pp.
CI IW dioxane WN H2SO4 H ii H iii Me0H o, RiNH2,/
H+ Base CI IW dioxane la SnCl2 H2N R2CO2H
AcOH/MedHN coupling reagent IV
n RV and/orO' .,R2 R' W
V
ItpLILs.... R44 40 , NH2OH.H.C1 R2 -\N pl N.OH
NaOCH3 R' VI vii [0201] Alternatively, as depicted in Scheme II, compound (VI) was prepared by reacting with an appropriate aldehyde component R2CHO in the presence of a reducing agent of nitro group (e.g. tin (II) chloride or zinc powder) in one-pot (Tetrahedron Letters, 2000, 41, 9871-9874). Formic acid was used to prepare compound (VI) when R2= H.
Scheme II
SnCl2 or Zn N
02N AcOH/Me0H N
R' WN Ilirvi H Ill HCO2H, SnCl2 __________________________________________ )1,- VI (R2 = H) Me0H
[0202] in both Schemes I & II, the benzimidazole ring may be constructed by a cyclization step involving either an aldehyde or a carboxylic acid. The following reaction steps 1-4 refer to the use of carboxylic acid for the cyclization of (IV) via (V) to form benzimidazole derivatives (VI), followed by the conversion of ester (VI) to the hydroxamate (VII). For one-pot cycylization of (III) to (VI), see the procedures under Example 1.
Step 1: Reduction of nitro group [0203] To a pre-stirred solution of starting material (III, 1.0 mmol) in 50 mL
of co-solvent (glacial acetic acid: methanol= 2:8), Tin chloride was added (5.0 mmol). The resulting solution was heated to 55 C overnight and then cooled to room temperature.
The solvent was removed and the mixture was neutralized with sodium bicarbonate to pH 8. The crude product was extracted with dichloromethane (20 mL) for three times.
The organic extracts were combined and washed with water (15 mL) twice and brine (15 mL) once and further dried over Na2SO4 for 1 hour. It was filtered and concentrated; the diamino product (IV) was purified by flash chromatography.
Step 2: Amide formation [0204] To a pre-stirred solution of carboxylic acid (1.1 mmol), diamino product (IV, 1.0 mmol) and PyBOP (1.1 mmol) in 10 mL of dried dichloromethane, was added DIEA
(3.0 mmol) via a syringe. The resulting mixture was stirred at room temperature for 4 hours. The amide product (V) was purified by silica gel column chromatography.
Step 3: Cyclization [0205] The amide product (V), obtained in Step 2, was treated with 5 mL of glacial acetic acid, the resulting solution was heated to 75 C for 24 hours. After cooling down to it, the solvent was removed under vacuum to give product (VI) near quantitatively.
Step 4: Hydroxamic acid formation [0206] To a stirred solution of ester (VI) and NH2OH=FICI (10 equiv.) in Me0H
(0.5 M) was added Na0Me solution (20 equiv.) at - 78 C. The reaction mixture was then allowed to warm up slowly to room temperature. The reaction was monitored by LC/MS
and was completed in around 15-60 min. IN HCI was then added slowly into the reaction mixture at 0 C. The desired product was separated by reverse-phase preparative HPLC and the fractions containing the desired product were freeze-dried.
The hydroxamate product (VI) was obtained as TEA salt (isolated yield varies between 40 - 70%).
[0207] Scheme III illustrates another alternative procedure used for preparing , compounds of formula lb, where X and Y are hydrogens and R2 is selected from the group R11S(0)R13-, R11S(0)2R13-, R11c(0)N(R12)R13_, R11S02N(R12)R13-, R11N(R12)c(0)R13_, R11N(Ri2)so2R13_, R11N(R12)C(0)N(R12)R13- and heteroalkyl.
For example, in the case of Z is -CH=CH- and attached to C5-position in Formula lb, such compound(s) (XIII) can be synthesized by analogous method illustrated in Schemes I &
starting with appropriate (III), appropriate Fmoc protected amino acids, appropriate acid chlorides or aldehydes, and hydroxylamine.
Scheme III
o o OMe SnC12/H+ H2N lei OMe I.
R1-N Me0H HN
i H III R1 IV , - -H 0 A Fmoc-HN-0-14 i 0 Fmoc-N n n OH 0 H2N 0 and/or 0 OMe __________________ N. 40 ', I
- HN Fmoc-HN n R1 Me0H/H+
OMe 20% Piperidine N
nN 4g _________ if/ _____ 1 40 OMe n H2N 1 Fmoc-HN rj Ri XI R1 x NaBH(OAc)3 R12-COCI [or R12-S02C1]
CH3COOH 0 Triethyl amine z 1 Iµl 0 OMe 0 z __ i 40 m -N1--i n FJ e i-NH 1 n r1 R12 R1 XII
R"12 Ri XiV [R12-S02] NH2OH.HCI
NH2OH.HCI
N
N Na0Me 0 a0Me 0 n 11101 1 )1\ii i <N OH
.
rN1-1 n ri RI 1 n=1, 2 n=1, 2 [0208] More specifically, for example, the hydroxamate compounds Formula lb, where X and Y are hydrogens, R2 is selected from the group R11S(0)R13-, R11S(0)2R13-, R"C(0)N(R12)R13-, Fe1s02N(R12)R13_, R11N(R12)C(0)R13-, R11N(R12)S02R13-, R11N(R12)C(0)N(R12)R13- and heteroalkyl; and Z is attached to C5-position, can be synthesized by the synthetic route shown in Scheme Ill. Appropriate intermediate (Ill) was reduced with tin chloride to the corresponding diamines (IV). The coupling reaction with appropriate Fmoc protected amino acids in the presence of PyBOP gave coupling product(s) (VIII) and/or (IX). Without further separation, (VIII) and/or (IX) were subjected to cyclization under acid conditions and yielded benzimdiazole (X).
The key intermediate (XI) can be obtained by treating (X) with 20% piperidine.
Treatment of (XI) with an appropriate acid chloride or an appropriate sulfonyl chloride gave (XII) and the target compounds (XIII) were obtained by using similar method described in Scheme I.
[0209] When (XI) was reacted with an appropriate aldehyde under reduction 5 conditions (NaBH(OAc)3 /CH3CO2H), (XIV) was obtained and can be transformed to corresponding hydroxamate derivatives (XV) by the same methods described above.
[0210] Scheme IV illustrates some reactions to further modify R1 side chain.
If the R1 side chain contained a protecting group such as Boc in compound (Vial), it could be 10 removed before converting to the final hydroxamic acid (Vila). The intermediate (Via) could be modified by acylation, reductive alkylation, alkylation or sulfonylation to form new analogs (VIlb, Vlic, Viid and Vile) through new intermediates (Vib, Vic, Vid and Vie). The above described methods were also applied to R1 = heterocycles, e.g., R1 =
N-Boc-piperidin-3-yl, N-Boc-piperidin-4-y1 and N-Boc-pyrrolidin-3-yl.
Scheme IV
o o 0 R2-N SI OMe H4*
--).- R2-<' N fa `- OMe NH OKHCI N 0 NH
2 ,... R2_</
N N W-P N OH
Vial H
NaOCH3 -.. Vla L.i Vila BOCN .Ri 1 HN..R11 H14..
N
OMe NH2OH.HCI R2_.N fa 0 R12CO2H or R2-<' 0 N NOH.
(Rump ______,...
N iqP H
v. L----. Vlb NaOCH3 H VIlb . ' Y. Ri 1 12 R N. u 0 it R
o o o OMe 0 R CHO R2--N liffl N id N,OH
R2- 1101 OMe NH2OH.HCI R2_.
ip. .
N
Reductive H Vic NaOCH3 H
L-1 via VlIc amination Ri2 NRi 1, ---....õ--HN,Ri 1 0.12 m rl 1'1' R11 N N-OH
R12X N NH2OH.HCI R2_<, 0 H
N
H Vld NaOCH3 (X = halide) R12____N, H I/11d R1 2._ pd, 0 '' \ 0 OMe N-OH
H
N
R12S0201 Vie NaOCH3 1:3 IfIle R124-N,Ril 8 R12_g-N-Ril II
[0211] Scheme V illustrates some alternative method to prepared (Via) and (Vic).
The primary amine (II1a2) was prepared either from (la) or via (Mai). The derivertization of the amino group (e.g., reductive amination) could be performed either from (111a2) or (VIa2). The products, i.e., (111a2-1) and (VIa2-1), could be further derivertized (e.g., reductive amination of the secondary amine).
Scheme V
H2N''-'NHBoc 02N
02N io o, ________ HN H+ 02N
CI H 111a1 HN
la NHBoc HNH2 111 a2 H2N, ¨ NH2 02N n R2CHO or HCO2H R24 al 1 R12CH0 __ R241 SCI2 or Zn N 11W
HN
11182 V1a2 reductive amination Vla2-1 reductive amination R2CHO or HCO2H R12 SnCl2 or Zn N
(y"
02N = 0.- 0 fa 2N
N
HN HN IWP
Vla2-2 111a2-1 \¨N
R1`2,..¨ NH
[0212] The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the subject matter hereof. They should not be considered as limiting the scope of the disclosure, but merely as being illustrative and representative thereof.
Preparation of intermediates III
[0213] Compound (III) was prepared either from (I) via (II) or from (I) via (la) (Scheme I and V). The following are examples of (III).
Intermediate 1 3-[4-(2-Dimethylamino-ethylamino)-3-nitro-phenyn-acrylic acid methyl ester [0214] A mixture of 3-(4-chloro-3-nitro-phenyl)acrylic acid methyl ester (la, 0.658 g, 2.72 mmol), N,N-dimethylethylenediamine (0.90 mL, 8.20 mmol) and triethylamine (1.2 mL, 8.6 mmol) in dioxane (20 mL) was heated at 80 C for 5h. The solution was evaporated and the residue was added DCM and aqueous Na2CO3. The DCM (x3) , extracts were concentrated and the residue was added Et0Ac-hexane. The resulting red solid was filtered to give the titled compound (0.672 g, 84.2%). HPLC
purity at 254 nm: 99.2%, tR = 1.59 min. LCMS (ESI) m/z: 294 ([M Fi]). 1H NMR (CDCI3 CD30D) 8 8.21 (1H, d, J = 2.1 Hz), 7.56 (1H, dd, J = 9.0, 2.1 Hz), 7.48 (1H, d, J =
16.0 Hz), 6.81 (1H, d, J = 9.0 Hz), 6.20 (1H, d, J = 15.9 Hz), 3.70 (3H, s), 3.34 (2H, t, J =
6.5 Hz), 2.56 68 =
(2H, t, J = 6.4 Hz), 2.23 (6H, s); 13C NMR (CDCI3 + CD30D) 8 167.3, 145.4, 142.6, 134.0, 131.1, 127.1, 121.3, 114.8, 114.0, 56.7, 51.1, 44.6,40.1.
Intermediate 2 344-(2-Diethylamino-ethylamino)-3-nitro-phenylFacrylic acid methyl ester.
[0215] Yellow solid. LCMS (ESI) m/z: 322 ([M + HIP). 1H NMR (CDCI3) 8 8.73 (1H, t-like, J = 4.3 Hz), 8.32 (1H, d, J = 2.0 Hz), 7.62 (1H, dd, J = 9.2, 2.0 Hz), 7.58 (1H, d, J
= 15.9 Hz), 6.85 (1H, d, J = 9.0 Hz), 6.29 (1H, d, J = 15.9 Hz), 3.80 (3H, s), 3.35 (2H, td, J = 5.4, 6.0 Hz), 2.77 (2H, t, J = 6.2 Hz), 2.59 (4H, q, J = 7.1 Hz), 1.07 (6H, t, J = 7.1 Hz).
Intermediate 3 344-(2-Ethylamino-ethylamino)-3-nitro-phenylFacrylic acid methyl ester [0216] Red solid. LCMS (ESI) m/z: 294 ([kl H]). 1H NMR (DMSO-d6) 58.49 (1H, t, J = 6.1 Hz), 8.35 (1H, d, J = 2.0 Hz), 7.96 (1H, dd, J = 9.1, 1.9 Hz), 7.62 (1H, d, J =
16.0 Hz), 7.20 (1H, d, J = 9.1 Hz), 6.52 (1H, d, J = 16.0 Hz), 3.75 (2H, td, J
= 6.5, 6.2 Hz), 3.70 (3H, s), 3.08 (2H, t, J = 6.5 Hz), 2.93 (4H, q, J = 7.2 Hz), 1.17 (6H, t, J = 7.2 Hz).
Intermediate 4 344-(2-lsopropylamino-ethylamino)-3-nitro-phenylFacrylic acid methyl ester [0217] Red solid. LCMS (ESI) m/z: 308 ([M H]+). 1H NMR (DMSO-d6) 8 8.58 (1H, t, J = 5.6 Hz), 8.33 (1H, d, J = 2.0 Hz), 7.94 (1H, dd, J = 9.1, 1.9 Hz), 7.60 (1H, d, J =
16.0 Hz), 7.14 (1H, d, J = 9.2 Hz), 6.49 (1H, d, J = 16.0 Hz), 3.70 (3H, s), 3.56 (2H, masked by water peak, identified by COSY), 3.10 (1H, septet, J = 6.4 Hz), 2.94 (2H, t, J = 6.2 Hz), 1.10 (6H, d, J = 6.4 Hz).
Intermediate 5 344-(3-Dimethylamino-2,2-dimethyl-propylamino)-3-nitro-phenylFacrylic acid methyl ester.
[0218] Red solid. LCMS (ESI) m/z: 336 ([M + Hr.). 1H NMR (CDCI3) 8 9.73 (1H, br s or t), 8.33 (1H, d, J = 2.0 Hz), 7.60 (1H, dd, J = 8.9, 2.0 Hz), 7.59 (1H, d, J = 16.1 Hz), 6.88 (1H, d, J = 9.1 Hz), 6.28 (1H, d, J = 15.9 Hz), 3.80 (3H, s), 3.21 (2H, d, J = 4.6 Hz), 2.36 (2H, s), 2.34 (6H, s), 1.04 (6H, s).
Intermediate 6 3-[4-(2-Diisopropylamino-ethylamino)-3-nitro-phenyl]acrylic acid methyl ester [0219] Yellow solid. LCMS (ESI) m/z: 350 UM + Hr). 1H NMR (CDCI3) 8 8.76 (1H, t-like, J = 4.3 Hz), 8.32 (1H, d, J = 2.0 Hz), 7.61 (1H, dd, J = 8.3, 2.7 Hz), 7.58 (1H, d, J
= 15.8 Hz), 6.85 (1H, d, J = 9.0 Hz), 6.29 (1H, d, J = 15.9 Hz), 3.79 (3H, s), 3.31 (2H, td, J = 5.3, 6.1 Hz), 3.08 (2H, septet, J = 6.6 Hz), 2.84 (2H, t, J = 6.2 Hz), 1.07 (12H, d, J = 6.6 Hz).
Intermediate 7 3-[4-(2-Methylamino-ethylamino)-3-nitro-phenyl]-acrylic acid methyl ester [0220] Red solid. LCMS (ESI) m/z: 280 ([M + H]4). 1H NMR (CDCI3) 8 8.54 (1H, t-like, J = 4.2 Hz), 8.33 (1H, d, J = 2.1 Hz), 7.63 (1H, dd, J = 9.0, 2.2 Hz). 7.59 (1H, d, J =
16.0 Hz), 6.90 (1H, d, J = 9.0 Hz), 6.31 (1H, d, J = 15.9 Hz), 3.80 (3H, s), 3.45 (2H, td, J = 5.8, 5.6 Hz), 2.96 (2H, t, J = 6.2 Hz), 2.50 (3H, s).
Intermediate 8 314-(2-tert-Butoxycarbonylamino-ethylamino)-3-nitro-pheny1]-acrylic acid methyl ester (111a1) Step 1:
[0221] A suspension of trans-4-chloro-3-nitrocinnamic acid (1, 5.057 g, 22.22 mmol) in Me0H (40 mL) and DCM (20 mL) was stirred and cooled in a dry-ice/acetone bath.
SOCl2 (1.0 mL, 13.8 mmol) was added to the above mixture. Dry-ice bath was removed, then the mixture was warmed to room temperature and stirred at 40 C
till the reaction completed. The solution was evaporated to dryness to a pale yellow solid (5.364 g, 99.9%). HPLC purity at 254 nm: 99.5%; tR = 2.96 min. LCMS (ESI) m/z:
and 212 (very weak signal, [M+H-Me0H]+).
Step 2:
[0222] A mixture of 3-(4-chloro-3-nitro-phenyl)acrylic acid methyl ester (la, 0.243 g, 1.00 mmol), N-Boc-ethylenediamine (0.316 mL, 2.0 mmol) and triethylamine (0.50 mL, 3.59 mmoL) in dioxane (7 mL) was heated at 80 C for about 80 h. The solution was evaporated and the residue was added Me0H. The resulting solid was filtered and washed with Me0H. 344-(2-tert-Butoxycarbonylamino-ethylamino)-3-nitro-pheny1]-, acrylic acid methyl ester (111a1) was obtained as bright yellow solid (9.193 g, 52.6%).
HPLC purity at 254 nm: 96.0-98.1%; tR = 3.27 min. LCMS (ESI) m/z: 366 (DM +
HIE), 310 (M+H-56), 266 (M+H-Boc). 1H NMR (CDCI3) 68.41 (1H, br t like, NHAr), 8.31 (1H, d, J = 1.8 Hz), 7.63 (1H, dd, J = 9.0, 1.7 Hz), 7.57 (1H, d, J = 16.0 Hz), 6.98 (1H, d, J =
8.9 Hz), 6.30 (1H, d, J = 15.9 Hz), 3.80 (3H, s), 3.52 (2H, m), 3.45 (2H, m), 1.45 (9H, s); 13C NMR (CDCI3) 8 166.9, 155.7, 145.8, 142.3, 134.1, 131.5, 127.1, 121.8, 115.4, 113.9, 79.5, 51.2, 42.7, 39.1, 27.9.
Intermediate 9 5 3-(4-(2-Amino-ethylamino)4-nitro-phenylFacrylic acid methyl ester (111a2) [0223] Method 1:
Remove Boc protecting group from (111a1) under acidic condition: 1) HCl/Me0H;
2) TFA/DCM.
[0224] Method 2:
10 To the ester (la, 2.47 g, 10.2 mmol) in dioxane (102 mL, 0.1 M) was added ethylenediamine (Merck. Product no. 8.00947, 2.04 mL, 30.6 mmol) followed by triethylamine (2.8 mL, 20.47 mmol). The resulting mixture was heated to 90 C
and stirred for 20 hours. The completion of reaction was confirmed by using HPLC
(where the product 111a2 tR = 1.6 min, starting material la tR = 3.1 min). Upon completion, 15 solvent was removed and the crude was dissolved in DCM. The solution was washed with water, brine, dried over Na2SO4 and filtered. The filtrate after removal of the solvent gave the titled compound 111a2. Yield =98 %, LCMS m/z: 266 ([M+H]).
Example 1 20 Preparation of 311 -(3-Dimethylamino-2,2-dimethyl-propy1)-2-(2,2-dimethyl-propy1)-1H-benzoimidazol-5-A-N-hydroxy-acrylamide (1) [0225] The titled compound (1) was prepared according to Scheme 1 and 11, by using appropriate starting materials.
Step 1:
25 [0226]
To a pre-stirred solution of trans-4-chloro-3-nitrocinnamic acid (1, 11g, 48 ' mmol) in dioxane (200 mL) was added triethylamine (20 mL, 126 mmol), followed by 3-dimethylamino-2,2-dimethyl-propylamine (20 mL, 143 mmol). The reaction mixture was allowed to stir at 100 C for 1-2 days till all starting material was fully converted. Then, the solvent was removed under vacuum followed by the addition of H20 (250 mL) to 30 dissolve the residue. Conc. HCI was added till pH 1 with orange precipitation. The suspension was filtered and residue was washed with H20 several times to obtain (11) as orange solid (13 g, 84%). LCMS (ESI) m/z: 322 ([M+H]).
Step 2:
[0227] Compound (11,13 g, 40.5 mmol) was dissolved in Me0H (250 mL) followed by the addition of conc. H2SO4(5 mL). The reaction mixture was allowed to stir at 80 C for 18 h. Solvent was removed under vacuum and H20 (250 mL) was added to dissolve the residue. Na2CO3 was added till pH 8-9, subsequently, Me0H was added and stirred for 1 hour. Then, the suspension was filtered under vacuo and the residue was washed with H20 several times to obtain ester (III) as orange solid (10 g, 74%). LCMS
(ESI) m/z: 336 ([M+H]).
Step 3:
[0228] To a stirred solution of ester (III, 1 equiv) and SnC12=2H20 (5 equiv) in AcOH
and Me0H (0.2 M, 1:9 mixture) was added 3,3-dimethyl butyraldehyde (1.5 equiv). The resulting mixture was heated to 45 C with stirring. The progress of the reaction was monitor by LC/MS. When the reaction was completed, solvent was removed under reduced pressure at 30-35 C. To the resulting residue, 20 mL of water and 20 mL of ethyl acetate were added at room temperature, the pH value of the mixture was carefully adjusted to 9-10 by addition of conc. NH3=H20. The mixture was stirred for half an hour, followed by centrifuge if necessary to separate the organic layer. The organic layer was collected. The aqueous phase and residue (oily-solid precipitate) were extracted another 3 times more with ethyl acetate as described above. The combined organic contents were dried over sodium sulphate, filtered and evaporated to dryness. The resulting oily residue was purified by flash column chromatography (isolated yield of cyclized product (VI) varies between 50-90%). LCMS (ESI) m/z: 386 ([M+H]).
Step 4:
[0229] To a stirred solution of ester (VI) and NH2OH.HCI (10 equiv.) in Me0H
(0.5M) was added Na0Me (20 equiv.) at ¨ 78 C. The reaction mixture was then allowed to warm up slowly to room temperature. The reaction was monitored by LC/MS and was completed in around 15 min. 1N HCI was then added slowly into the reaction mixture at 0 C. The desired product was separated by prep-HPLC and the fractions containing the desired product were freeze-dried. Product (VII) was obtained as di-TFA
salt (isolated yield varies between 40 ¨ 70%). HPLC purity at 254 nm: 100%, tR =
0.78 min.
LCMS (ESI) m/z: 387 ([M+H]). 1H NMR (DMSO-d6) 8 0.99 (15H, s), 2.91 (6H, s), 2.92 (2H, s), 3.32 (2H, bs), 4.30 (2H, s), 6.49 (1H, d, J = 15.8 Hz), 7.56 (1H, d, J = 9.0 Hz), 7.61 (1H, d, J = 15.76 Hz), 7.83 (1H, d, J = 9.0 Hz), 7.85 (1H, s), 9.22 (1H, bs), 10.72 (1H, bs); 13C NMR (DMSO-d6) 8 162.6, 154.2, 138.0, 135.3 (br), 134.7, 131.5, 122.8, 119.2, 115.2, 114.0,66.5, 51.1, 46.7, 38.4, 38.3, 33.6, 29.1, 22.8.
Example 2 Preparation of 3-[1-(3-Dimethylamino-2,2-dimethyl-propy1)-2-isopropyl-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (2) [0230] The titled compound (2) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm:
100%, tR
= 0.54 min. LCMS (ES!) miz: 359 ([M+H]+). 1H NMR (DMSO-d6) 6 1.05 (6H, s), 1.40 (6H, d, J = 6.36 Hz), 2.92 (6H, s), 3.36 (2H, s), 3.58 (1H, m, J = 6.4 Hz), 4.44 (2H, s), 6.55 (1H, d, J = 15.8 Hz), 7.63 (1H, d, J = 15.8 Hz), 7.66 (1H, d, J = 8.7 Hz), 7.95 (1H, d, J = 8.7 Hz), 7.90 (1H, s), 9.71 (1H, bs), 10.80 (1H, bs).
Example 3 Preparation of 3-[2-Butyl-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide (3) [0231] The titled compound (3) was prepared according to the procedures described in Example 1, by using appropriate starting materials. Yield: 74 mg as TFA
salt. HPLC
purity at 254 nm: 99.0%, tR = 0.89 min. LCMS (ES!) m/z: 373 ([M + 1H
NMR
(CD30D) 8 7.99 (1H, d, J = 8.8 Hz), 7.84 (1H, s), 7.72 (1H, d, J = 8.7 Hz), 7.55 (1H, d, J
= 15.8 Hz), 6.53 (1H, d, J = 15.7 Hz), 4.55 (2H, s), 3.43 (2H, s), 3.24 (2H, overlapped with CD2HOD), 3.00 (6H, s), 1.90 (2H, pentet, J = 7.2 Hz), 1.49 (2H, m), 1.21 (6H, s), 0.98 (3H, t, J = 7.3 Hz); 13C NMR (CD30D) 5 165.5 (br), 158.2, 139.8, 135.3, 135.1, 132.4, 126.4, 120.6 (br), 115.6, 114.3, 68.7, 53.5, 47.8 (Mex2), 39.5, 29.9, 27.2, 23.6 (Mex2), 23.3, 13.9.
Example 4 Preparation of 341-(3-D imethylamino-2,2-di methyl-propyI)-2-(2-methylsu Ifanyl-ethyl)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (4) [0232] The titled compound (4) was prepared according to the procedures described in Example 1, by using appropriate starting materials. Yield: 17 mg as TFA
salt. HPLC
purity at 254 nm: 96.2%, tR = 0.75 min. LCMS (ES!) miz: 391 UM + 1H
NMR
(CD30D) 8 8.02 (1H, d, J = 8.3 Hz), 7.92 (1H, s), 7.80 (1H, d, J = 8.7 Hz), 7.69 (1H, d, J
= 15.8 Hz), 6.60 (1H, d, J = 15.8 Hz), 4.49 (2H, s), 3.50 (2H, t, J = 7.2 Hz), 3.37 (21-I, s), 3.03 (2H, t, J = 7.2 Hz), 2.95 (6H, s), 2.18 (3H, s), 1.25 (6H, s); 13C NMR
(CD30D) 8 163.7, 154.6, 138.2, 133.9, 132.8, 132.5, 124.1, 118.2, 113.3, 113.2, 66.7, 51.5, 45.9 (Mex2), 37.6, 29.9, 26.2, 21.7 (Mex2), 13.7.
Example 5 Preparation of 3-[1-(3-Dimethylamino-2,2-dimethyl-propy1)-2-isobutyl-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide (6) [0233] The titled compound (6) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm:
96.2%, tR
= 0.82 min. LCMS (ESI) m/z: 373 ([M+H]+). 1H NMR (DMSO-d6): 8 10.80 (1H, s), 9.47 (1H, s), 7.93 (1H, s), 7.90 (1H, d, J=6.6 Hz), 7.64 (1H, d, J= 7.4 Hz), 7.62 (1H, d, J=
15.5 Hz), 6.54 (1H, d, J= 15.8 Hz), 4.39 (2H, s), 3.33 (2H, s), 2.97 (2H, d, J
= 7.26 Hz), 2.92 (6H, s), 2.35 (1H, qn), 1.09 (6H; s), 0.97 (6H, d, J = 6.6 Hz).
Example 6 Preparation of 341-(2-Diethylamino-ethyl)-2-isobuty1-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (7) [0234] The titled compound (7) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm:
99.0%, tR
= 0.56 min. LCMS (ESI) m/z: 359 ([M+H]). 1H NMR (DMSO-d6): 8 10.81 (1H, s), 10.13 (1H, s), 7.90 (1H, s), 7.81 (1H, d, J= 8.5 Hz), 7.66 (1H, d, J= 8.6 Hz), 7.61 (1H, d, J=
15.8 Hz), 6.53 (1H, d, J= 15.8 Hz), 4.72 (2H, t, J = 7.8 Hz), 3.30 (2H, d), 2.93 (2H, d, J
= 7.2 Hz), 2.27 (1H, m), 1.24 (6H, t, J = 7.2 Hz), 0.97 (6H, d, J= 6.6 Hz) 13C
NMR
(DMSO-d6) 8 162.7, 158.5, 158.2, 155.2, 138.4, 133.9, 131.0, 123.0, 118.6, 116.0, 111.6, 48.8, 46.8, 34.1, 27.1, 22.2, 8.5.
Example 7 Preparation of 342-Buty1-1-(2-diethylamino-ethyl)-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (8) [0235] The titled compound (8) was prepared according to the procedures described in Example 1, by using appropriate starting materials. Yield: 61 mg (20% in two steps) as TFA salt. HPLC purity at 254 nm: 98.1%, tR = 0.59 min. LCMS (ESI) m/z: 359 (EM +
Hr). 1H NMR (CD30D) 67.89 (1H, d, J = 8.6 Hz), 7.80 (1H, s), 7.71 (1H, d, J =
8.5 Hz), 7.45 (1H, d, J = 15.7 Hz), 6.44 (1H, d, J = 15.7 Hz), 4.90 (2H, overlapped with DHO, identified by COSY), 3.64 (2H, t-like, J = 7.6 Hz), 3.39 (4H, q, J = 7.6 Hz), 3.21 (2H, t, J
= 7.9 Hz), 1.89 (2H, pentet, J = 7.5 Hz), 1.52 (2H, m), 1.35 (6H, t, J. = 7.2 Hz), 1.00 (3H, t, J = 7.3 Hz); 13C NMR (CD30D) 8 163.6, 155.7, 138.1, 132.8, 132.1, 131.9, 124.6, 118.0, 113.2, 111.7, 48.3, 46.8 (2C), 38.6, 27.5, 24.7, 21.4, 12.0, 7.0 (2C) Example 8 Preparation of 342-But-3-yny1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (9) [0236] The titled compound (9) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm:
98.3 %;
tR = 0.52 min; LCMS (ESI) rn/z: 369 ([K4 +Fi]). 1H NMR (DMSO-d6) 8 9.49 (brs, 1H), 7.88 ¨ 7.85 (m, 2H), 7.63 ¨ 7.59 (m, 2H), 6.52 (d, J = 15.79 Hz, 1H), 4.37 (s, 1H), 3.33 (s, 2H), 3.26 (t, J = 7.24 Hz, 2H), 2.92 (s, 6H), 2.88 (t, J = 2.54 Hz, 1H), 2.81 (dt, J =
2.48, 7.70 Hz, 2H), 1.09 (s, 6H); 13C NMR (DMSO-d6) 5 162.8, 155.3, 138.4, 138.0, 135.9, 130.5, 122.3, 118.4, 117.8, 116.4, 114.9, 112.9, 111.9, 82.8, 72.3, 66.9, 50.9, 46.7, 25.8, 22.8, 16.2.
Example 9 Preparation of 342-But-3-eny1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (10) [0237] The titled compound (10) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99 %; tR = 0.80 min; LCMS (ESI) rn/z: 371 ([M + H].). 1H NMR (CD30D) 8 7.95 (d, J = 8.8 Hz, 1H), 7.85 (s, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 15.8 Hz, 1H), 6.54 (d, J = 15.8 Hz, 1H), 5.94 ¨ 5.84 (m, 1H), 5.10 (dd, J = 1.4, 17.1 Hz, 1H), 5.03 (dd, J =
1.1, 10.2 Hz, 1H), 4.51 (s, 2H), 3.40 (s, 2H), 3.32 (t, J = 7.6 Hz, 2H), 2.99 (s, 6H), 2.66 (q, J = 7.5 Hz, 2H), 1.19 (s, 6H); 13C NMR (CD30D) 8 165.7, 157.6, 140.2, 136.3, 135.9, 134.7, 134.5, 125.9, 120.2, 117.9, 115.2, 103.6, 68.8, 53.4, 39.6, 32.0, 27.2, 23.7.
Example 10 Preparation of 342-But-3-eny1-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (11) [0238] The titled compound (11) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.4 CYO tR =
0.52 min; LCMS (ESI) m/z: 357 ([M+H]+1). 1H NMR (CD30D) 5 7.94 (d, J = 8.7 Hz, 1H), 7.81 (s, 1H), 7.73 (d, J = 8.3 Hz, 1H), 7.50 (d, J = 15.87 Hz, 1H), 6.46 (d, 1= 15.8 Hz, 1H), 5.96 ¨ 5.86 (m, 1H), 5.13 (dd, J = 1.4, 17.1 Hz, 1H), 5.05 (dd, J = 1.1, 10.2 Hz, 1H), 4.93 (t, J = 7.9 Hz, 2H), 3.62 ¨ 3.58 (m, 2H), 3.38 ¨ 3.31 (m, 6H), 2.65 (q, J = 7.6 Hz, 2H), 1.35 ¨ 1.32 (m, 6H); 13C NMR (CD30D) 8 165.8, 157.0, 140.5, 136.6, 135.9, 134.6, 134.2, 126.1, 119.5, 117.7, 116.0, 113.3, 50.4, 40.4, 31.7, 26.7, 9.1.
Example 11 Preparation of 3-[2-But-3-yny1-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-y1]-N-' hydroxy-acrylamide (12) [0239] The titled compound (12) was prepared according to the procedures 5 described in Example 1, by using appropriate starting materials. HPLC:
99.6 %; tiR =
0.37 min; LCMS (ESI) m/z: 355 ([M+H]). 1H NMR (CD300) 8 7.82 (d, J = 8.7 Hz, 1H), 7.68 (s, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 15.8 Hz, 1H), 6.31 (d, J
= 15.8 Hz, 1H), 4.87 ¨ 4.79 (masked peaks), 3.54 ¨ 3.50 (m, 2H), 3.37 (t, J = 7.1 Hz, 2H), 3.24 (q, J = 7.2 Hz, 4H), 2.73 (dt, J = 2.4, 6.0 Hz, 2H), 2.30 (t, J = 2.5 Hz, 1H), 1.21 (t, J = 7.2 10 Hz, 6H); 13C NMR (CD30D) 8 165.9, 156.1, 140.9, 138.1, 135.2, 133.4, 125.6, 118.8, 117.0, 112.8, 82.4, 72.1, 50.6, 40.2, 26.7, 26.4, 17.3, 9.1.
Example 12 Preparation of 341-(3-Dimethylamino-2,2-dimethyl-propy1)-2-(3,3,3-trifluoro-15 propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (13) [0240] The titled compound (13) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 96.5 %; tR = 0.80 min; LCMS (ESI) m/z: 413 ([M+H]).
20 Example 13 Preparation of 341-(2-Diethylamino-ethyl)-2-(3,3,3-trifluoro-propy1)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (14) [0241] The titled compound (14) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity:
96.4%; tR
25 = 1.37 min; LCMS (ESI) m/z: 399 ([M+H]). 1H NMR (DMSO-d6) 8 1.25 (6H, t), 2.96 (2H, m), 3.31 (6H, m), 3.44 (2H, m), 4.72 (2H, m), 6.51 (1H, m), 7.51 (2H, m), 7.65 (1H, m), 7.83 (1H, m), 10.45 (1H, bs) .
Example 14 30 Preparation of 341-(2-Diethylamino-ethyl)-2-ethoxymethy1-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (15) , [0242] The titled compound (15) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity:
98.1%; tR
= 0.48 min; LCMS (ESI) m/z: 361([M+H]).
Example 15 Preparation of 341-(3-Dimethylamino-2,2-dimethyl-propy1)-2-methy1-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (16) [0243] The titled compound (16) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity:
99.5%; tR
= 0.30 min; LCMS (ESI) m/z: 331 ([M+H]). 1H NMR (DMSO-d6) 8 1.13 (6H, s), 2.78 (2H, m), 2.89 (6H, s), 3.33 (2H, m), 4.42 (3H, s), 6.57 (1H, m), 7.57-7.69 (2H, m), 7.95 (2H, m), 9.68 (1H, bs), 10.81 (1H, bs) Example 16 Preparation of 3-[1-(2-Diethylamino-ethyl)-2-(2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (17) [0244] The titled compound (17) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%, tR = 0.95 min. LCMS (ESI) m/z: 373 ([M+Hr). 1H NMR (CD30D) 8 7.85 (2H, t, J = 8.3 Hz), 7.75 (1H, d, J = 8.8 Hz), 7.61 (1H, d, J = 15.8 Hz), 6.51 (1H, d, J =
15.8 Hz), 4.93 (2H, t, J = 6.1 Hz), 3.54 (2H, t, J = 8.1 Hz), 3.31 (4H, qt, J
= 7.3 Hz), 3.10 (2H, s), 1.27 (6H, t, J = 7.3 Hz), 1.06 (9H, s); 13C NMR (CD30D) 8 163.7, 153.3, 138.3, 133.1, 131.9, 124.5, 118.3, 117.1, 113.5, 111.8, 48.1, 39.1, 37.5, 32.9, 27.8, 7.1.
Example 17 Preparation of N-Hydroxy-3-[1-(3-isopropylamino-propy1)-2-(3,3,3-trifluoro-propy1)-1H-benzoimidazol-5-y11-acrylamide (18) [0245] The titled compound (18) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity:
96.8%; tR
= 0.72 min. LCMS (ESI) m/z: 399 ([M+H]). 1H NMR (DMSO-d6) 8 1.18 (6H, d), 2.07 (2H, m), 2.95 (4H, m), 3.27 (3H, m), 4.43 (2H, m), 6.52 (1H, m), 7.55 (2H, m), 7.61 (1H, m), 7.84 (1H, m), 8.65 (2H, bs).
Example 18 Preparation of 342-(2,2-Dimethyl-propy1)-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (19) [0246] The titled compound (19) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.1%, tR = 0.86 min. LCMS (ESI) m/z: 359 ([M+H]+). 1H NMR (CD30D) 8 7.86 (1H, d, J = 8.6 Hz), 7.78 (1H, s), 7.73 (1H, d, J = 8.5 Hz), 7.44 (1H, d, J =
15.8 Hz), 6.45 (1H, d, J = 15.4 Hz), 4.83 (2H, t, J = 6.42 Hz), 3.52 (2H, t, J = 6.6 Hz), 3.36 (1H, 77 =
qt, J = 6.5 Hz), 3.13 (2H, s), 1.26 (6H, d, J = 6.2 Hz), 1.04 (9H, s); 13C NMR
(CD30D) 161.2, 153.4, 138.3, 133.0, 124.4, 113.6, 112.0, 51.1, 41.8, 41.1, 37.3, 33.1,27.8, 17.2.
Example 19 Preparation of 341-(2-Diisopropylamino-ethyl)-2-(2,2-dimethyl-propyl)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (20) [0247] The titled compound (20) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 96.8%, tR = 0.94 min. LCMS (ESI) rn/z: 400 ([M+1-11+). 1H NMR (CD30D) 8 7.86 (1H, s), 7.80 (1H, d, J = 8.7 Hz), 7.76 (1H, d, J = 8.6 Hz), 7.62 (1H, d, J =
15.8 Hz), 6.52 (1H, d, J = 16.0 Hz), 4.96 (2H, t, J = 5.2 Hz), 3.84 (2H, m), 3.53 (2H, t, J = 8.3 Hz), 3.06 (2H, s), 1.38 (12H, d, J = 6.5 Hz), 1.05 (9H, s); 13C NMR (CD30D) 8 160.2, 153.1, 138.2, 133.2, 131.9, 124.6, 113.5, 111.8, 54.9, 423.0, 40.5, 37.7, 33.0, 27.8, 16.3.
Example 20 Preparation of 3-[1-(2-Dilsopropylamino-ethyl)-2-isobuty1-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (21) [0248] The titled compound (21) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 95.3%, tR = 0.76 min. LCMS (ESI) m/z: 387 aM+Hr). 1H NMR (CD30D) 8 7.85 (1H, s), 7.71 (2H, s), 7.66 (1H, d, J = 15.8 Hz), 6.51 (1H, d, J= 15.8 Hz), 4.75 (2H, t, J
= 7.2 Hz), 3.86 (2H, t, J = 6.5 Hz), 3.50 (2H, t, J = 8.6 Hz), 2.98 (2H, d, J
= 7.4 Hz), 2.26 (1H, m) 1.41 (12H, d, J = 6.3 Hz), 1.06 (6H, d, J = 6.6 Hz).
Example 21 Preparation of 3-[1-(3-Dimethylami no-2,2-d i methyl-propy1)-2-hex-3-eny1-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (22) [0249] The titled compound (22) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%; tR = 1.24 min; LCMS (ESI) m/z: 399 ([M+Hr). 1H NMR (CD30D) 8 8.22 (d, J = 8.7 Hz, 1H), 8.11 (s, 1H), 7.96 (d, J = 8.6 Hz, 1H), 7.81 (d, J = 15.8 Hz, 1H), 6.68 (d, J = 15.8 Hz, 1H), 5.69 ¨ 5.59 (m, 2H), 4.79 (s, 2H), 3.66 (s, 2H), 3.55 (t, J = 7.3 Hz, 2H), 3.24 (s, 6H), 2.91 (q, J = 6.8 Hz, 2H), 2.21 ¨2.11 (m, 2H), 1.44 (s, 6H), 1.02 (t, J =
7.5 Hz, 3H); 13C NMR (CD30D) 8 165.7, 157.9, 140.2, 135.8, 134.6, 134.5, 126.1, 125.9, 120.1, 115.2, 114.6, 68.7, 533, 47.9, 39.6, 27.6, 25.9, 23.7, 21.4, 14.4.
Example 22 Preparation of 3-0-(3-Dimethylamino-2,2-dimethyl-propy1)-2-(2,4,4-trimethyl-pentyl)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (23) [0250] The titled compound (23) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.6%; tR = 1.61 min; LCMS (ESI) m/z: 429 ([M+H]). 1H NMR (CD30D) 8 8.19 (d, J = 8.8 Hz, 1H), 8.08 (s, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 15.7 Hz, 1H), 6.75 (d, J = 15.8 Hz, 1H), 4.79 (s, 2H), 3.62 (s, 2H), 3.35 ¨ 3.29 (m, 1H), 3.23 (s, 6H), 2.52 (brs, 2H), 1.50¨ 1.45 (m, 2H), 1.36 (d, J = 3.8 Hz, 6H), 1.12 (d, J = 5.5 Hz, 3H), 1.02 (s, 6H); 13C NMR (CD300) 8 165.6, 157.4, 139.9, 135.2, 135.1, 132.9, 126.4, 120.6, 115.7, 114.6, 68.6, 53.3, 51.4, 47.9, 39.7, 36.3, 31.9, 31.3, 30.2, 23.8, 22.3.
Example 23 Preparation of 342-Cyclohexy1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (24) [0251] The titled compound (24) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%; tR = 0.96 min; LCMS (ESI) m/z: 399([M+Hr). 1F1 NMR (CD300): 8 8.21 (d, J = 8.8 Hz, 1H), 8.06 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.83 (d, J = 15.8 Hz, 1H), 6.76 (d, J = 15.8 Hz, 1H), 4.79 (s, 2H), 3.65 (s, 2H), 3.60 ¨ 3.51 (m, 1H), 3.22 (s, 6H), 3.29 ¨
3.26 (m, 2H), 2.12 ¨ 2.09 (m, 2H), 2.03 ¨ 1.92 (m, 3H), 1.78 ¨ 1.59 (m, 3H), 1.41 (s, 6H); 13C NMR (CD30D) 8 165.7, 161.3, 140.1, 135.4, 134.8, 134.0, 126.1, 120.3, 119.6, 116.7, 115.5, 114.9, 68.7, 53.1, 47.9, 39.2, 37.0, 32.4, 26.5, 26.3, 23.6.
Example 24 Preparation of 342-Bicyclo[2.2.1]hept-5-en-2-y1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-ylj-N-hydroxy-acrylamide (25) [0252] The titled compound (25) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%; tR = 0.91 min; LCMS (ESI) m/z: 409 ([M+H]+).
Example 25 Preparation of 3-[1-(2-Diethylamino-ethyl)-2-hex-3-eny1-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (26) [0253] The titled compound (26) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.9%;
tR
1.14 min; LCMS (ESI) m/z: 385 ([M+H]). 1H NMR (CD30D) 87.95 (d, J = 8.6 Hz, 1H), 7.87 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.52 (d, J = 15.8 Hz, 1H), 6.50 (d, J
= 15.8 Hz, 1H), 5.57 - 5.44 (m, 2H), 3.72 - 3.68 (m, 2H), 3.44 (q, J = 7.2 Hz, 4H), 3.35 -3.30 (masked peaks), 2.73 (q, J = 7.1 Hz, 2H), 2.07 - 1.99 (m, 2H), 1.41 (t, J =
7.2 Hz, 6H), 0.88 (t, J = 7.5 Hz, 3H); 13C NMR (CD30D) 6 165.6, 157.2, 140.2, 135.9, 134.8, 134.6, 134.2, 126.4, 126.1, 119.8, 115.6, 113.5, 50.4, 40.5, 26.9, 25.4, 21.4, 14.4, 8.9.
Example 26 Preparation of 341 -(2-Diisopropylamino-ethyl)-2-hex-3-eny1-1 H-benzoimidazol-yli-N-hydroxy-acrylamide (27) [0254] The titled compound (27) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.9%;
tR =
1.22 min; LCMS (ESI) m/z: 413 ([M+H]). 1H NMR (CD30D) 8 7.94- 7.89 (m, 2H), 7.78 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 15.8 Hz, 1H), 6.50 (d, J = 15.8 Hz, 1H), 5.63 -5.44 (m, 2H), 3.99 - 3.91 (m, 2H), 3.69 - 3.64 (m, 2H), 3.36 - 3.26 (masked peaks), 2.72 (q, J = 7.2 Hz, 2H), 2.08 - 2.01 (m, 2H), 1.50 (d, J = 6.5 Hz, 12H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR (CD30D) 8 165.6, 157.0, 140.2, 135.9, 135.4, 134.5, 134.3, 126.6, 126.3,126.2, 119.8, 115.8, 113.3, 56.9, 45.3, 41.9, 27.2, 25.5, 21.4, 18.2, 14.4.
Example 27 Preparation of 342-Hex-3-eny1-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (28) [0255] The titled compound (28) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%; = 1.12 min; LCMS (ESI) m/z: 371 (EM+Hl+). 1H NMR (CD30D) 68.00 (d, J = 9.1 Hz, 1H), 7.77 - 7.75 (m, 2H), 7.17 (d, J = 15.7 Hz, 1H), 6.34 (d, J =
15.7 Hz, 1H), 5.57 - 5.42 (m, 2H), 4.92 (t, J = 5.9 Hz, 2H), 3.72 (t, J = 5.7 Hz, 2H), 3.54 - 3.48 (m, 1H), 3.39 (t, J = 7.5 Hz, 2H), 2.72 (q, J = 7.3 Hz, 2H), 2.06 - 1.99 (m, 2H), 1.39 (d, J = 6.5 Hz, 6H),0.87 (t, J = 7.5 Hz, 3H).
Example 28 Preparation of 341-(2-Ethylamino-ethyl)-2-hex-3-eny1-1H-benzoimidazol-5-y1FN-, hydroxy-acrylamide (29) [0256] The titled compound (29) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%; tR = 1.23 min; LCMS (ESI) m/z: 385 ([M+H]+). 1H NMR (CD300) 6 7.94 (d, J = 8.6 Hz, 1H), 7.89 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 15.8 Hz, 1H), 6.55 (d, J = 15.7 Hz, 1H), 5.57 - 5.42 (m, 2H), 4.62 (t, J = 7.5 Hz, 2H), 3.42 -3.33 (m, 1H), 3.32 ¨ 3.30 (masked peaks), 3.28 ¨ 3.24 (m, 2H), 2.71 (q, J = 7.2 Hz, 2H), 2.33 (brs, 2H), 2.03 ¨ 1.94 (m, 2H), 1.36 (d, J = 6.5 Hz, 6H), 0.84 (t, J = 7.5 Hz, 3H);
(CD30D) 6 165.6, 156.3, 139.9, 136.8, 136.2, 135.2, 133.8, 132.8, 126.7, 125.8, 120.4, 114.6, 114.1, 52.2, 43.5, 42.9, 27.2, 26.5, 25.5, 21.4, 19.2, 14.4.
Example 29 Preparation of 342-Hex-3-eny1-1-(3-isopropylamino-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (30) [0257] The titled compound (30) was prepared according to the procedures 10 described in Example 1, by using appropriate starting materials. HPLC
purity at 254 nm: 99.9%; tR = 1.04 min; LCMS (ESI) m/z: 357([M+H]+). 1H NMR (CD30D) 8 7.93 (d, J
= 8.4 Hz, 1H), 7.77 ¨ 7.73 (m, 2H), 7.23 (d, J= 15.7 Hz, 1H), 6.34(d, J = 15.7 Hz, 1H), 5.57 ¨ 5.42 (m, 2H), 4.87 (masked peaks), 3.68 (brs, 2H), 3.35 ¨ 3.30 (masked peaks), 3.22 ¨ 3.17 (m, 2H), 2.72 (q, J = 7.1 Hz, 2H), 1.35 (t, J = 7.2 Hz, 3H), 0.88 (t, J = 7.6 15 Hz, 3H); 13C NMR (CD30D) 5 165.6, 157.3, 140.5, 135.8, 134.9, 134.6, 134.2, 126.2, 126.1, 118.7, 115.9, 113.7, 113.6, 46.5, 45.0, 42.7, 26.4, 25.4, 21.4, 14.4, 11.4.
Example 30 Preparation of 3-[1-(2-Diethylam i no-ethyl)-2-hexy1-1H-benzoimidazol-5-y1]-N-20 hydroxy-acrylamide (31) [0258] The titled compound (31) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 100%, tR = 1.31 min. LC-MS m/z: 387 ([M+H]+). 1H NMR (DMSO-d6) 8 0.88 (3H, t, J = 7.0 Hz), 1.26 (6H, t, J = 7.2 Hz), 1.34 (4H, m), 1.44 (2H, m), 1.85 (2H, m), 3.12 25 (2H, t, J = 7.7 Hz), 3.31 (4H, m), 3.52 (2H, t, J = 7.7 Hz), 4.81 (2H, t, J = 7.7 Hz), 6.59 (1H, d, J = 15.8 Hz), 7.63 (1H, d, J = 15.8 Hz), 7.73 (1H, d, J = 8.8 Hz), 7.93 (1H, d, J =
8.8 Hz), 7.94 (1H, s) Example 31 30 Preparation of 3-[1-(3-isopropylamino-propy1)-2-(2,4,4-trimethyl-penty1)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (32) [0259] The titled compound (32) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: HPLC: 97.5%, tR = 1.68 min. LC-MS m/z: 415 ([M+H]+). 1H NMR (DMSO-d6) 5 0.89 35 (9H, s), 0.98 (3H, d, J = 6.6 Hz), 1.23 (6H, d, J = 6.5 Hz), 2.08-2.29 (4H, m), 2.27 (1H, m), 2.98-3.12 (4H, m), 3.29 (1H, m), 4.53 (2H, t, J = 7.4 Hz), 6.60 (1H, d, J
= 15.8 Hz), 7.65 (1H, d, J = 15.8 Hz), 7.75 (1H, d, J = 9.0 Hz), 7.96 (1H, d, J = 9.0 Hz), 7.98 (1H, s), 8.75 (2H, bs).
Example 32 Preparation of 342-(2,2-Dimethyl-propy1)-1-(3-isopropylamino-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (33) [0260] The titled compound (33) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99%, tR = 1.01 min. LC-MS m/z: 375 ([M+Hr). 1H NMR (DMSO-d6) 80.98 (9H, s), 1.24 (6H, bs), 2.17 (2H, bs), 3.14 (4H, m), 3.28 (1H, bs), 4.53 (2H, bs), 6.65 (1H, d, J =
15.5 Hz), 7.65 (1H, d, J = 15.5 Hz), 7.81 (1H, d, J = 7.4 Hz), 8.02 (1H, s), 8.03 (1H, d, J
= 7.4 Hz), 8.85 (2H, bs).
Example 33 Preparation of 3-[1-(2-Diisopropylamino-ethyl)-2-(3,3,3-trifluoro-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (34) [0261] The titled compound (34) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 97.5%;
tR =
0.93 min. LCMS (ESI) m/z: 427 ([M+H]). 1H NMR (DMSO-d6) 81.35 (12H, m), 2.94 (2H, m), 3.24 (2H, m), 3.45 (2H, t), 3.80 (211, m), 4.68 (2H, t), 6.48 (1H, m), 7.55 (3H, m), 7.85 (1H, m), 9.48 (1H, bs).
Example 34 Preparation of N-Hydroxy-342-isobuty1-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-y1]-acrylamide (35) [0262] The titled compound (35) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.3%, tR = 0.51 min. LCMS (ESI) m/z: 345 ([M-I-H]). 1H NMR (CD30D) 8 7.78 (1H, d, J = 8.7 Hz), 7.76 (1H, s), 7.68 (1H, d, J = 8.6 Hz), 7.46 (1H, d, J =
15.8 Hz), 6.42 (1H, d, J = 15.9 Hz), 4.70 (2H, t, J = 7.4 Hz), 3.48 (2H, t, J = 6.9 Hz), 3.37 (1H, m), 3.01 (2H, d, J = 7.4 Hz), 2.21 (1H, m), 1.27 (6H, d, J = 6.5 Hz), 1.00 (6H, d, J = 6.6 Hz);
13C NMR (CD30D) 5 160.3, 155.3, 138.5, 134.1, 131.5, 124.2, 113.9, 111.4, 51.1, 42.0, 40.3, 33.4, 27.3, 20.6, 17.2.
Example 35 Preparation of 342-(2,2-Dimethyl-propy1)-1-(2-ethylamino-ethyl)-benzoimidazol-5-*N-hydroxy-acrylamide (36) [0263] The titled compound (36) was prepared according to the procedures described in Example 1, by using appropriate starting materials. Yield: 74%.
HPLC
purity at 254 nm: 99.9%, tR = 0.71 min. LCMS (ESI) m/z: 345 ([M+H]+). 1H NMR
(CD30D) 5 7.81 (1H, d, J = 8.6 Hz), 7.75 (1H, s), 7.69 (1H, d, J = 8.5 Hz), 7.36 (1H, d, J
= 15.7 Hz), 6.40 (1H, d, J = 15.3 Hz), 4.81 (2H, t, J = 6.4 Hz), 3.51 (2H, t, J = 6.3 Hz), 3.10 (2H, s), 3.06 (2H, qt, J = 7.3 Hz), 1.23 (3H, t, J = 7.2 Hz), 1.04 (9H, s); 13C NMR
(CD30D) 5 161.0, 153.3, 138.5, 132.7, 132.2, 124.2, 117.5, 113.9, 111.9, 44.2, 43.0, 41.0, 37.4, 33.0, 27.9, 9.5.
Example 36 Preparation of 3-[1-(2-Ethylami no-ethyl)-2-isobuty1-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide (37) [0264] The titled compound (37) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%, tR = 0.40 min. LCMS (ESI) m/z: 331 ([M+1-1]+). 1H NMR (CD30D) 6 7.81 (1H, d, J = 8.6 Hz), 7.73 (1H, s), 7.67 (1H, d, J = 8.2 Hz), 7.34 (1H, d, J =
15.7 Hz), 6.36 (1H, d, J = 15.7 Hz), 4.74 (2H, t, J= 6.7 Hz), 3.54 (2H, t, J= 6.5 Hz), 3.10 (211, d, J = 7.4 Hz), 3.06 (2H, d, J = 9.5 Hz), 2.21 (1H, m), 1.23 (3H, t, J = 7.3 Hz), 1.04 (6H, d, J = 6.6 Hz); 13C NMR (CD30D) 8 163.7, 161.1, 154.8, 138.6, 133.2, 132.6, 132.4, 124.2, 117.2, 113.9, 111.6, 44.4, 43.0, 40.5, 33.4, 27.3, 20.6, 9.5.
Example 37 Preparation of 341-(2-Diisopropylamino-ethyl)-2-(2,4,4-trimethyl-penty1)-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (38) [0265] The titled compound (38) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.0 %;
tR
1.62 min; LCMS (ESI) m/z: 443 ([M4-Hr). 1H NMR (CD30D) 6 7.96 ¨ 7.94 (m, 2H), 7.82 (d, J = 8.7 Hz, 1H), 7.55 (d, J = 15.8 Hz, 1H), 6.54 (d, J = 15.8 Hz, 1H), 5.13 ¨
5.06 (masked peaks), 4.01 ¨ 3.92 (m, 2H), 3.71 ¨ 3.67 (m, 2H), 3.33 ¨ 3,24 (masked peaks), 3.18 ¨ 3.12 (m, 1H), 2.38 ¨ 2.36 (m, 1H), 1.52 (s, 6H), 1.51 (s, 6H), 1.41 ¨ 1.40 (m, 2H), 1.09 (d, J = 6.6 Hz, 3H), 0.94 (s, 9H); 13C NMR (CD30D) 8 165.5, 156.5, 140.1, 134.8, 134.7, 134.0, 126.5, 120.0, 114.6, 113.6, 56.9, 51.7, 45.2, 42.0, 35.9, 31.9, 30.6, 30.2, 22.6, 18.3.
Example 38 Preparation of N-Hydroxy-311-(2-isopropylamino-ethyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzoimidazol-5-yl]-acrylamide (39) [0266] The titled compound (39) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 97.9 %; tR = 1.49 min; LCMS (ESI) m/z: 401 ([M+H]+). 1H NMR (CD30D) 8 7.98 (d, J = 8.7 Hz, 1H), 7.79 - 7.76 (m, 2H), 7.24 (d, J = 15.7 Hz, 1H), 6.39 (d, J =
15.7 Hz, , 1H), 4.97 - 4.89 (masked peaks), 3.70 - 3.66 (m, 2H), 3.53 - 3.47 (m, 1H), 3.34 - 3.28 (masked peaks), 3.22 - 3.15 (m, 1H), 2.31 - 2.29 (m, 1H), 1.39- 1.38(m, 9H), 1.07(d, J = 6.6 Hz, 3H), 0.9 (s, 9H); 13C NMR (CD30D) 8 165.5, 156.9, 140.5, 134.7, 134.4, 126.3, 118.9, 115.9, 113.8, 53.2, 51..5, 44.2, 42.8, 35.7, 31.9, 30.9, 30.2, 29.6, 19.1, 18.8.
Example 39 Preparation of 341-(2-Ethylamino-ethyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzoimidazol-5111-N-hydroxy-acrylamide (40) [0267] The titled compound (40) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 100.0%; tR = 1.57 min; LCMS (ESI) miz: 387 ([M+H]+). 1H NMR (CD30D) 8 7.96 (d, J = 8.6 Hz, 1H), 7.79 (s, 1H), 7.78 - 7.75 (d, J = 8.7 Hz, 1H), 7.23 (d, J =
15.7 Hz, 1H), 6.37 (d, J = 15.7 Hz, 1H), 4.96 - 4.89 (masked peaks), 3.70 - 3.68 (m, 2H), 3.36 - 3.28 (masked peaks), 3.26 - 3.14 (m, 3H), 2.31 - 2.30 (m, 1H), 1.40 - 1.32 (m, 5H), 1.07(d, J = 6.6 Hz, 3H), 0.92 (s, 9H); 13C NMR (CD30D) 8 165.6, 156.9, 140.6, 134.9, 134.5, 134.2, 126.2, 118.7, 116.0, 113.7, 51.6, 46.5, 45.0, 42.7, 35.8, 31.9, 30.8, 30.2, 22.6, 11.4.
Example 40 Preparation of 3-E1 -(2-D iethylam ino-ethyl)-2-(2,4,4-trimethyl-penty1)-1 H-benzoim idazol-5-yll-N-hydroxy-acrylam i de (41) [0268] The titled compound (41) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 85.6%, tR = 1.55 min. LC-MS m/z: 415 ([M+H]). 1H NMR (CD30D) a 7.91 (d, 2H, ,J
= 6.0 Hz), 7.80 (br, d, 1H, J = 8.9 Hz), 7.68 (d, 2H, J = 15.8 Hz), 6.58 (d, 1H, J = 15.8 Hz), 4.96 (br, q, 2H), 3.64 (br, q, 2H), 3.43 (q, 4H, J = 7.3 Hz), 1.40 (t, 8H), 1.09 (br, d, 4H, J = 6.6 Hz), 0.94 (br, s, 10H); 13C NMR (CD30D) 8 156.8, 140.4, 135.8, 134.4, 134.3, 126.1, 115.8, 113.2, 119.7, 119.2, 51.6, 50.3, 40.3, 35.8, 31.9, 22.6, 9Ø
Example 41 Preparation of 341-(2-Diethylamino-ethyl)-2-propy1-1H-benzoimidazol-5-yll-N-hydroxy-acrylamide (42) [0269] The titled compound (42) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254nm:
99.0%, tR = 0.68 min. LC-MS (ESI) miz: 345 ([M+H]). 1H NMR (CD30D) 8 8.15 (d, 2H, J= 8.7 Hz), 7.68 (d, 1H, J = 15.8 Hz), 6.63 (d, 1H, J = 15.8 Hz), 5.08 (br, t, 2H), 3.70 (br, t, 2H), 3.44 (br, m, 4H), 3.35 (t, 2H), 2.03 (br, m, 2H), 1.44 (t, 6H, J
= 7.2 Hz), 1.20 (t, 3H); 13C NMR (CD30D) 8 165.5,157.4, 139.8, 135.5, 133.5, 132.3, 120.7, 120.7, 114.5, 114.3, 40.8, 28.5, 21.0, 13.9, 9.1.
Example 42 Preparation of 3-[1-(2-Diethylamino-ethyl)-2-(2-methylsulfanyl-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (45) [0270] The titled compound (45) was prepared according to the procedures described in Example 1, by using appropriate starting materials. Yield:17 mg (in two steps) as TFA salt. HPLC purity at 254 nm: 80%, tR = 0.50 min. LCMS (ESI) miz:
+ Hr). 1H NMR (CD300) 8 7.79 (1H, s), 7.77 (1H, d), 7.66 (1H, d, J = 8.6 Hz), 7.54 (1H, d, J = '15.8 Hz), 6.44 (1H, d, J = 15.8 Hz), 4.83 (2H, masked by DHO, identified by COSY), 3.57 (2H, m), 3.41 (2H, t, J = 7.1 Hz), 3.32 (4H), 3.01 (2H, t, J = 7.1 Hz), 2.89 (3H, s), 1.30 ¨1.25 (9H, overlapped t).
Example 43 Preparation of 342-Buty1-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (46) [0271] The titled compound (46) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.4%; tR = 1.56 min. LCMS m/z: 345 ([M+Hr). 1H NMR (DMSO-d6) 60.95 (3H, t), 1.22 (6H, m), 1.42 (2H, m), 1.80 (2H, m), 3.13 (2H, m), 3.41 (3H, t), 4.69 (2H, t), 6.58 (1H, m), 7.56 (1H, m), 7.73 (1H, m), 7.90 (2H, m), 9.14 (2H, bs).
Preapration of the freebase of the titled compound:
[0272] To a pre-stirred solution of the methyl ester (1 eq) in dried methanol, NH2OH.HCI (12 eq.) was added. The mixture was stirred in ice-water bath for about 10 min, followed by adding sodium methoxide solution (20 eq.). HPLC showed the reaction completed after 20 min, less than 1% of the acid was observed.
[0273] The above crude was treated with 1M of HCI until all the precipitate was dissolved (pH around 1-2). The pH value was carefully adjusted to around 7-8 using NaOH or NaHCO3, the precipitate which was formed was collected by filtration.
The solid was washed with water once. The above solid was suspended in methanol and 5 water again and was treated with 6N HCI until all dissolved, the pH value was carefully adjusted to around 7-8 using NaOH and NaHCO3. The precipitate, which was formed, was again collected by filtration; the freebase compound was obtained by drying in vacuo, the yield was around 80%-85%.
10 Preapration of the hydrochloric acid salt of the titled compound:
[0274] The above freebase compound was suspended in methanol and water and was treated with 6N HCI (2.8 eq.). The solution became clear. After removing the methanol on a Rotary Evaporator, the hydrochloric acid salt was obtained by freeze-drying. It was further recrystallized from methanol (HPLC purity at 254 nm: >
99%).
Example 44 Preparation of 342-Butyl-1-(3-isopropylamino-propy1)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (47) [0275] The titled compound (47) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.2%; tR = 1.72 min. LCMS (ESI) m/z: 359 ([MH]+). 1H NMR (DMSO-d6) 8 0.95 (3H, t), 1.22 (6H, m), 1.45 (2H, m), 1.82 (2H, m), 2.14 (2H, m), 3.17 (4H, m), 3.28 (1H, m), 4.52 (2H, t), 6.62 (1H, m), 7.57 (1H, m), 7.72 (1H, m), 7.89 (2H, m), 8.80 (2H, bs).
=
Example 45 Preparation of 341-(1-Benzyl-piperidin-4-y1)-2-butyl-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (48) [0276] The titled compound (48) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 96.7%, tR = 1.35 min. LC-MS m/z: 433 ([M+H]). 1H NMR (DMSO-d6) 6 0.94 (3H, s), 1.41 (2H, m), 1.77 (2H, m), 2.19 (2H, m), 2.99-3.10 (2H, m), 3.24 (4H, m), 3.68 (2H, m), 4.38 (2H, s), 5.01 (1H, m), 6.65 (1H, d, J = 15.8 Hz), 7.47-7.49 (3H, m), 7.61 (1H, d, J = 15.8 Hz), 7.69 (3H, m), 7.97 (1H, s), 8.60 (1H, d, J = 8.8 Hz), 10.35 (2H, s), 11.95 (1H, s).
Example 46 Preparation of 342-B utyl-1-(2-ethylam no-ethyl)-1H-benzoimidazol-5-yll-N-hydroxy-acrylamide (44) [0277] The titled compound (44) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm:
98%;
LC-MS m/z: 331 ([M+H]). 1H NMR (DMSO-d6) 6 10.88 (br s, 1H), 9.12 (br s, 2H), 7.93 (s, 1H), 7.87 (d, 1H, J = 8.4 Hz), 7.71 (d, 1H, J = 8.3 Hz), 7.62 (d, 1H, J =
15.7 Hz), 6.59 (d, 1H, J = 15.6 Hz), 4.67 (t-like, 2H), 3.42 (br s, 2H), 3.08 (q, 2H, J
= 7.7 Hz, Pr-CH2), 3.05 (br s, 2H), 1.81 (m, 2H), 1.45 (m, 2H), 1.18 (t, 3H, J = 7.1 Hz), 0.95(t, 3H, J
= 7.0 Hz); 130 NMR (DMSO-d6) 5 162.6, 156.2, 138.0, 135.0, 133.5, 131.6, 123.5, 119.2, 114.8, 112.1, 44.5, 42.4, 40.6, 28.2, 25.2, 21.7, 13.5, 10.8.
Example 47 Preparation of 342-But-3-eny1-1-(2-ethylamino-ethyl)-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (49) [0278] The titled compound (49) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.0 %;
tR =-1.61 min; LCMS m/z: 329 ([M+H]). 1H NMR (CD30D) 8 7.85 (d, J = 8.5 Hz, 1H), 7.78 (s, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 15.7 Hz, 1H), 6.40 (d, J =
15.5 Hz, 1H), 6.02 ¨ 5.92 (m, 1H), 5.19 (dd, J = 17.1, 1.3 Hz, 1H), 5.12 (dd, J = 10.2, 0.9 Hz, 1H), 4.80 (t, J = 6.4 Hz, 2H), 3.62 (t, J = 6.2 Hz, 2H), 3.22 ¨ 3.16 (m, 2H), 2.71 (q, J = 7.2 Hz, 2H), 1.35 (t, J = 7.2 Hz, 3H); 130 NMR (CD30D) 8 178.3, 157.1, 140.7, 136.5, 133.9, 125.9, 118.8, 117.6, 116.2, 113.2, 101.5, 67.6, 46.4, 44.9, 42.4, 31.6, 26.7, 20.7, 11.4.
Example 48 Preparation of 342-Hexy1-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (50) [0279] The titled compound (50) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 94.4%, tR = 1.32 min. LCMS (ESI) m/z: 373 ([M+H]). 1H NMR (CD30D) 5 7.80 (1H, d, J = 8.5 Hz), 7.74 (1H, s), 7.64 (1H, d, J = 9.0 Hz), 7.50 (1H, d, J =
13. 6 Hz), 6.42 (1H, d, J = 15.8 Hz), 4.65 (2H, d, J = 6.6 Hz), 3.48 (2H, d, J = 6.6 Hz), 3.38 (1H, qt, J = 6.5 Hz), 3.13 (2H, t, J = 5.9 Hz) 1.82 (2H, t, J = 6.7 Hz), 1.44 (2H, t, J = 7.0 Hz) 1.29 (7H, m) 0.84 (6H, d, J = 7.0 Hz).
Example 49 Preparation of 3-[1-(2-Dimethylamino-ethyl)-2-(2,4,4-trimethyl-penty1)--1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (51) [0280] The titled compound (51) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 100%, tR = 1.49 min. LC-MS m/z: 331 ([M+H]). 1H NMR (DMSO-d6) 60.85 (9H, s), 1.03 (2H, d, J = 6.4 Hz), 1.34 (2H, m), 2.27 (1H, m), 3.00 (6H, s), 3.24-3.27 (4H, m), 4.79 (3H, m), 6.53 (1H, d, J = 15.72 Hz), 7.62 (1H, d, J = 15.7 Hz), 7.75 (1H, d, J = 8.4 Hz), 7.86 (1H, s), 7.87 (1H, d, J = 8.4 Hz).
Example 50 Preparation of 341-(2-Ethylamino-ethyl)-2-hexy1-1H-benzoimidazol-5-y13-N-hydroxy-acrylamide (52) [0281] The titled compound (52) was prepared according to the procedures described in Example 1, by using appropriate starting materials. The modified or detailed procedures were described as below.
Step 3:
[0282] To a stirred solution of 344-(2-ethylamino-ethylamino)-3-nitro-phenylFacrylic acid methyl ester (8.174 g, 27.87 mmol) and heptaldehyde (4.85 g, 42.47 mmol, 1.52 eq) in AcOH and Me0H (1:9 v/v, 300mL) was added SnC122H20 (31.45 g, 139.4 mmol, 5 eq) in portions. The resulting mixture was heated to 40 C with stirring.
The progress of the reaction was monitor by LC/MS. When the reaction was completed, solvent was removed under reduced pressure below 40 C. The resultant residue was diluted with Et0Ac (50 mL) then basified (pH >10) with saturated aqueous Na2CO3 and extracted with dichloromethane (x3). Filtration may be needed to remove the white precipitates or suspension derived from Tin in order to get clearly separated layers. The organic extracts were combined, dried (Na2SO4), filtered, and evaporated to dryness.
The resulting oily residue was purified by flash column chromatography (silica, 4)67 x 65 mm, solvent Me0H/DCM gradient from 0 to 10%). 341-(2-ethylamino-ethyl)-2-hexyl-1H-benzoimidazol-5-y11-acrylic acid methyl ester was obtained as yellow solid (4.445 g, 44.6%). HPLC purity at 254 nm: 98.8%, tR = 1.71 min. LCMS (ESI) m/z: 358 (RA +
Hr).
1H NMR (CDCI3) 8 7.88 (1H, d, J = 1.2 Hz), 7.83 (1H, d, J = 16.0 Hz), 7.43 (1H, dd, J =
8.4, 1.4 Hz), 7.33 (1H, d, J = 8.4 Hz), 6.43 (1H, d, J = 15.9 Hz), 4.22 (1H, t, J = 6.6 Hz), 3.80 (3H, s), 3.01 (2H, t, J = 6.6 Hz), 2.89 (2H, t, J = 7.9 Hz), 2.65 (2H, q, J = 7.1 Hz), 1.91 (2H, pentet, J = 7.8 Hz), 1.46 (2H, m), 1.35 (4H, m), 1.07 (3H, t, J =
7.1 Hz), 0.90 (3H, t, J = 7.0 Hz). The solid could be recrystallized from Hexanes-ether to give a white or pale yellow solid with HPLC purity at 254 nm: 99.2%.
[0283] In another experiment starting with 2.725 g of 3-[4-(2-ethylamino-ethylamino)-3-nitro-pheny1]-acrylic acid methyl ester, the titled compound was obtained in 52.8%
yield (1.753 g).
Step 4:
[0284] To a solution of 341-(2-ethylamino-ethyl)-2-hexy1-1H-benzoimidazol-5-y1]-acrylic acid methyl ester (4.428 g, 12.39 mmol) and NH201-11-1C1 (8.66 g, 124.7 mmol) in dry Me0H (50 mL) which was stirred and cooled in a dry-ice acetone bath, added Na0Me solution in Me0H (25%, 4.37 M, 55 mL, 240 mmol). The reaction mixture was then stirred at room temperature. The progress of reaction was monitored by LC/MS
(usually reaction completed within 30-90 min) and quenched by adding 6N HCI
(40 mL). The mixture (HPLC purity at 254 nm = 94.6%) was added Milli-Q water, adjusted pH -8 by 1N NaOH and evaporated to remove the organic solvent. The resultant residue was washed with Milli-Q water (x3) and re-dissolved in Me0H-DCM, the solution was filtered and diluted with Milli-Q water. The suspension was evaporated to remove the organic solvent and the resultant residue was washed with Milli-Q
water (x2). The free base of the titled compound was obtained (HPLC purity at 254 nm =
98%). The free base could be recrystallized from Me0H-Ethyl acetate to give a white or pale yellow solid.
Step 5: hydrochloric acid salt formation.
[0285] The above freebase was dissolved in Me0H and excess 6N HCI (final pH
<2) and the clear solution was evaporated to dryness and then diluted with Me0H, co-evaporated with PhMe (x1) and Et0Ac (x2). The solid was recrystallized from Me0H-Et0Ac to give a white or pale yellow solid (3.298 g, 61.7%). HPLC purity at 254 nm:
98.4-99.6%, tR = 1.23 min. LCMS (ESI) m/z: 359 ([M + H]+). 1H NMR (CD30D) 5 9.33 (residual NH), 8.03 (1H, d, J = 8.3 Hz), 7.77 (1H, s), 7.73 (1H, d, J = 8.2 Hz), 7.16 (1H, d, J = 15.7 Hz), 6.34 (1H, d, J = 15.7 Hz), 4.88 (2H, overlapped with DHO, identified by COSY), 3.63 (2H, br t like), 3.32 (2H, d, J = 7.9 Hz), 3.15 (2H, q, J = 7.1), 1.94 (2H, pentet, J = 7.1), 1.53 (2H, pentet, J = 6.7 Hz), 1.42-1.31 (4H, m), 1.33 (3H, t, J = 7.1 Hz), 0.88 (3H, t, J = 7.0 Hz); 13C NMR (CD300) 5 163.4, 155.8, 138.1, 133.0, 132.0, 130.3, 125.1, 117.4, 112.8, 112.5, 44.5, 43.2, 41.1, 30.5, 28.0, 25.3, 25.2, 21.6, 12.4, 9.6.
Example 51 Preparation of N-Hydroxy-341-(2-isopropylamino-ethyl)-2-(3,3,3-trifluoro-propy1)-1H-benzoimidazol-5-y1Facrylamide (53) [0286] The titled compound (53) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 98.1%;
tR =
0.63 min. LC-MS m/z: 385 ([1v1+H]+).
Example 52 Preparation of 341-(2-Dimethyla mino-ethyl)-2- hex-3-eny1-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (54) [0287] The titled compound (54) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%, tR = 0.96 min. LCMS (ESI) m/z: 357 ([M+H]1). 1H NMR (CD30D) 8 7.87 (1H, d, J = 8.6 Hz), 7.80 (1H, d, J = 8.8 Hz), 7.72 (1H, d, J = 8.3 Hz), 7.49 (1H, d, J =
15.8 Hz), 6.44 (1H, d, J = 15.8 Hz), 5.44 (1H, m), 5.38 (1H, m), 4.84 (2H, t, J = 6.1 Hz), 3.61 (2H, t, J = 7.7 Hz), 3.20 (2H, t, J = 4.2 Hz) 2.97 (6H, s), 2.61 (4H, qt, J = 7.1 Hz), 1.93 (2H, qn, J = 7.7 Hz), 0.78 (3H, t, J = 7.5 Hz); 13C NMR (CD30D) 8 163.6, 160.0, 155.1, 138.1, 134.1, 133.1, 131.9, 131.6, 124.7, 123.9, 118.2, 117.2, 114.3, 113.1, 111.8, 53.2, 42.1, 38.8, 24.8, 23.3, 19.4, 12.4.
Example 53 Preparation of 341-(2-Amino-ethyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzoimidazol-y1]-N-hydroxy-acrylamide (55) SnC12.2H20 N e ga _v __ ( HOAc-Me0H (1:9) \
HN, HN,Boc Illal Boc INJe N
HCl/Me0H ( NH2OH/Na0Me ( NHOH
N
Via-1 H2N Vila-1 Step 1:
[0288] To a stirred solution of 344-(2-tert-Butoxycarbonylamino-ethylamino)-3-nitro-phenylFacrylic acid methyl ester (111a1, 65.2 mg, 0.178 mmol) and 3,5,5-trimetylhexanal (45 AL, 0.26 mmol) in a mixed solvent of Ac0H-Me0H (1:9 v/v, 2 mL) and DCM (1 mL) was added SnC12-2H20 (184 mg, 0.815 mmol). The resulting mixture was heated to C with stirring overnight. The solvent was removed under reduced pressure and the resultant residue was added saturated aqueous Na2CO3 and extracted with Et0Ac 5 (x3). The extracts gave the crude (Vial-1, 91 mg) with HPLC purity at 254 nm: 49.3%, tR = 3.02 min and 7.9%, tR = 1.97 min (de-Boc product). LCMS (ESI) m/z: 458 (IM
Hr) and 358 ([M + de-Boc product).
Step 2:
10 [0289] The above crude (Vial-1) was dissolved in Me0H (4 mL) and 6N HCI
(1 mL) and heated at 70 C for 30 min. The solution was evaporated to dryness and co-evaprote dwith PhMe (x2) and Me0H (x1). The residue (crude Vla-1, 81.9 mg) was spilt to two parts (43.4 mg, equal to 0.0945 mmol of Mat and 38.5 mg equal to 0.0839 mmol of !Hai).
Step 3:
[0290] The titled compound (55) was prepared according to the Step 4 described in Example 1, by using crude (Via-I, 38.5 mg). VIla-1 was obtained as TFA salt (2.3 mg, 4.7% from 111a1). HPLC purity at 254 nm: 92.7%, tR = 1.46 min. LCMS (ESI) m/z:
([M + H]+). 1H NMR (CD30D) 8 7.81 (1H, s), 7.70 (1H, d, J = 8.6 Hz), 7.65 (1H, d, J =
8.4 Hz), 7.59 (1H, d, J = 15.8 Hz), 6.47 (1H, br d, J = 14.6 Hz), 4.63 (2H,t, J = 5.4 Hz), 3.38 (2H, t, J = 6.5 Hz), 3.02 (1H, dd, J = 15.5, 6.5 Hz), 2.90 (1H, dd, J =
15.3, 8.6 Hz), 2.20 (1H, br s or m), 1.33 (1H, dd, J = 14.1, 3.4 Hz), 1.25 (1H, dd, J = 14.0, 6.6 Hz), 0.98 (3H, d, J = 6.2 Hz), 0.83 (9H, s).
Example 54 Preparation of 341-(2-Amino-ethyl)-2-(2-methoxy-nony1)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (56) [0291] The titled compound (56) was prepared according to the procedures described in Example 53, by using appropriate starting materials. HPLC purity at 254 nm: 91.8%, tR = 1.93 min. LCMS (ESI) m/z: 403 UM + Fin. 1H NMR (CD30D) 8 some , identified peaks: 7.81 (1H, s), 7.70 - 7.58 (3H, m), 6.46 (1H, br d, J =
14.4 Hz), 4.62 (2H, m), 3.69 (1H, br s or m), 3.38 (2H, t, J = 7.3 Hz), 1.67 (1H, m), 1.56 (1H, m), 1.50-1.20 (10H, m), 0.82 (3H, t, J = 6.2 Hz).
Example 55 Preparation of 342-Butyl-1-(2-dimethylamino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (57) [0292] The titled compound (57) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 100%, tR = 0.42 min. LC-MS m/z: 331 (WI H]+). 1H NMR (DMSO-d6) 5 0.97 (3H, t, J = 7.3 Hz), 1.49 (3H, m), 1.83 (2H, m), 3.09 (2H, t, J = 7.72 Hz), 3.54 (2H, t, J = 7.6 Hz), 4.74 (2H, t, J = 7.6 Hz), 6.57 (1H, d, J = 15.7 Hz), 7.62 (1H, d, J =
15.7 Hz), 7.71 (1H, d, J = 8.6 Hz), 7.93 (1H, d, J = 8.6 Hz), 7.97 (1H, s), 10.68 (2H, bs).
Example 56 Preparation of 342-Hexy1-1-(2-dimethylamino-ethyl)-1H-benzoimidazol-5-y1141-hydroxy-acrylamide (58) [0293] The titled compound (58) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 100%, tR = 0.42 min. LC-MS m/z: 359 (EM + Hr). 1H NMR (DMSO-d6) 8 0.89 (3H, t, J = 6.9 Hz), 1.28-1.54 (6H, m), 1.85 (2H, m), 2.92 (6H, s), 3.09 (2H, t, J =
7.6 Hz), 3.51 (2H, t, J = 7.8 Hz), 4.76 (2H, t, J = 7.8 Hz), 6.57 (1H, d, J = 15.8 Hz), 7.63 (1H, d, J =
15.8 Hz), 7.70 (1H, d, J = 8.6 Hz), 7.90 (1H, d, J = 8.6 Hz), 7.91 (1H, s), 10.68 (2H, bs).
Example 57 Preparation of 3-{1-(2-Diethylamino-ethyl)-242-(2,2-dimethyl-propionylamino)-ethyl]-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (61) [0294] The titled compound (61) was prepared according to the procedures =
described below, Steps 1 & 2 were performed as in Scheme I:
Step 3:
02 N v,,, H2N io HN
HN
AcOH, Me0H, r.N
rr 61-2 [0295] To a pre-stirred solution of 344-(2-diethylamino-ethylamino)-3-nitro-pheny1]-acrylic acid methyl ester (61-1, 280 mg, 1.0 mmol) in glacial acetic acid (5 mL), tin chloride was added (1.18 g, 10.0 mmol). The resulting solution was heated to 45 C for 17 hours and then cooled to room temperature. The solvent was removed under vacuum. Water (20 mL) and dichloromethane (20 mL) was added to the residue and stirred for 30 minutes. The organic layer was dried (MgSO4), filtered and concentrated to an oily residue. 100 mL diethyl ether was added and stirred for 4 hours.
The product 3-[3-amino-4-(2-diethylamino-ethylamino)-phenyl]-acrylic acid methyl ester was obtained in 54.9% yield (207.6 mg). LCMS m/z: 292 ([M+H]).
Step 4 H2N Fmoc. N
HN 1W-P 0"
EDC, HOBt.H20, H HN CO2Me z_Th.e0F1 DrolEAon temp. ; DCMp. HN 111V
W
r 0 H 0 61-2 614 r N OA
[0296] To a pre-stirred solution of 343-amino-4-(2-diethylamino-ethylamino)-phenyl]-acrylic acid methyl ester (61-2, 1.93 g, 6.65 mmol) and dichloromethane (13.3 mL) was added a cocktail solution of N-(3-dimethylaminopropy1)-N1-ethylcarbodiimide hydrochloride (2.55 g, 13.31 mmol), 1-hydroxybenzotriazole hydrate (2.04 g, 13.31 mmol), N,N-diisopropylethylamine (2.20 mL, 13.31 mmol) and dichloromethane (26.6 mL). After stirring for 0.5h, Fmoc-Gly-OH (61-3, 2.97 g, 9.98 mmol) was added.
When the starting material has fully reacted, ethyl acetate (100 mL) was added to dilute the mixture. The organic contents were washed with saturated sodium hydrogencarbonate (2 x 25 mL) and brine (2 x 25 mL), before drying in sodium sulphate. The mixture was then filtered and concentrated in vacuo. The product 3-[3-amino-4-(2-diethylamino-ethylamino)-phenyl]-acrylic acid methyl ester was obtained in 67.3% yield (2.54 g).
LCMS m/z: 571 ([M+H]).
Step 5 Fmoc,NO
HN CO2Me AcOH, 70 C Fmoc¨NH N 40 CO2Me HN
r1-4 I I 61-5 [0297] Glacial acetic acid (8.9 mL) was added into 313-amino-4-(2-diethylamino-ethylamino)-phenyl]-acrylic acid methyl ester (61-4, 2.54 g, 4.46 mmol) and the reaction mixture was stirred at 70 C for 14h. When the reaction has completed, the mixture was concentrated in vacuo. Saturated sodium hydrogencarbonate (20 mL) was added and dicholoromethane (3 x 20 mL) was used to extract the aqueous layer.
The combined organic contents were dried in sodium sulphate before being filtered and concentrated in vacuo. The product 3-{1-(2-dethylamino-ethyl)-2-[(9H-fluoren-9-ylmethoxycarbonylamino)-methyl]-1H-benzoimidazol-5-y1}-acrylic acid methyl ester (61-5) was obtained in 66.1 % (1.62 g). LCMS m/z: 553 ([M+H]).
Step 6 Fmoc¨NH N CO2Me H2N N io .02.
piperidine, DCM, rm temp 1N h [0298] To a pre-stirred solution of 3-{1-(2-dethylamino-ethyl)-2-[(9H-fluoren-ylmethoxycarbonylamino)-methy1]-1H-benzoimidazol-5-y1}-acrylic acid methyl ester (61-5, 1.62 g, 2.94 mmol) and dichloromethane (8.90 mL) was added piperidine (1.45 mL, 14.69 mmol). When the reaction has completed, the mixture was concentrated iin vacuo. The desired product was separated by reverse phase preparative HPLC.
After lyopholyzation, 0.52 g (53.6 %) of 342-aminomethy1-1-(2-diethylamino-ethyl)-1H-benzoimidazo1-5-y1]-acrylic acid methyl ester was obtained as powder. LCMS
rn/z: 331 ([M+H]+).
Step 7 H2N N CO2Me 2¨NH N .02.
I>, DIEA, DCM
r r61-6 61-7 [0299] To a pre-stirred solution of 3-[2-aminomethy1-1-(2-diethylamino-ethyl)-benzoimidazol-5-y1]-acrylic acid methyl ester (61-6, 0.10 g, 0.23 mmol), N,N-diisopropylethylamine (97 pL, 0.58 mmol) and dichloromethane (1.17 mL) was added 2,2-dimethyl-propionyl chloride (34.6 pL, 0.28 mmol) and the resulting reaction mixture was stirred at room temperature for 1 h. When the reaction has completed, ethyl acetate (20 mL) was added to dilute the mixture. The organic contents were washed with saturated sodium hydrogencarbonate (2 x 20 mL) and brine (2 x 20 mL), before drying in Na2SO4. The mixture was filtered and concentrated in vacuo. The product 3-{1-(2-diethylami no-ethyl)-2-[(2,2-di methyl-propionylamino)-methy1]-1H-benzoim idazol-5-yI}-acrylic acid methyl ester (61-7) was obtained in 76.6 % (74.1 mg). LCMS
m/z: 415 ([M+H]).
Step 8 N
CO2Me H N
NH
NH2OH.HCI, /Z¨N\ _______________________________ </N 010 OH
Na0Me, Me0Hir r - 78 C
I I 61-7 r 61 [0300] To a stirred solution of 3-{1-(2-diethylamino-ethyl)-24(2,2-dimethyl-propionylamino)-methyl]-1H-benzoimidazol-5-y1}-acrylic acid methyl ester (61-7, 73.8 mg, 0.18 mmol) and hydroxylamine hydrochloride (124 mg, 1.78 mmol) in Me0H
(0.3 mL) was added sodium methoxide (30% in methanol) (0.8 mL, 3.6 mmol) at ¨ 78 C.
The reaction mixture was then allowed to warm up slowly to room temperature.
The reaction was monitored by LC/MS and was completed in around 15 min. IN HCI was then added slowly into the reaction mixture at 0 C. The desired product was separated by reverse phase preparative HPLC. After lyopholyzation, 22.2 mg (24.3 %) of 3-{1-(2-diethylamino-ethyl)-2-[(2,2-dimethyl-propionylamino)-methyl]-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide was obtained as powder. HPLC purity: 99.5%, tR = 0.94min.
LCMS m/z: 416 ([M+Hr). 1H NMR (CD30D) 5 7.89 (s, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.55 (d, J= 15.8 Hz, 1H), 6.53 (d, J= 15.8 Hz, 1H), 4.98 (t, J=
7.3 Hz, 2H), 4.73 (s, 2H), 3.75 (t, J = 7.5 Hz, 2H), 3.42 (q, J = 7.2 Hz, 4H), 1.37 (t, J =
7.3 Hz, 6H), 1.22 (s, 9H); 13C NMR (CD30D) 8 182.5, 168.9, 162.2, 161.9, 154.8, 140.8, 137.9, 135.0, 133.9, 126.0, 119.3, 117.1, 112.9, 50.9, 40.5, 39.7, 36.7, 27.6, 9.1. =
Example 58 Preparation of N-{2-[1-(2-Diethylamino-ethyl)-5-(2-hydroxycarbamoyl-viny1)-1H-benzoimidazol-2-y11-ethyl}-3,3-dimethyl-butyramide (59) [0301] The titled compound (59) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm: 94.0%; tR = 0.99 min. LC-MS m/z: 444 DA +
Example 59 Preparation of N-[1-(2-Diethylamino-ethyl)-5-(2-hydroxycarbamoyl-viny1)-1H-benzoimidazol-2-ylmethyli-butyramide (62) [0302] The titled compound (62) was prepared according to the procedures 5 described in Example 57, by using appropriate starting materials. HPLC
purity at 254 nm: 85.1 %; tR = 0.58 min; LCMS m/z: 402 ([M + H]4). 1H NMR (CD30D) 8 7.88 ¨
7.56 (m, 2H), 7.73 (s, 1H), 7.60 (d, J = 15.8 Hz, 1H), 6.51 (d, J = 15.8 Hz, 1H), 4.99 ¨ 4.79 (m, masked peaks), 4.81 (s, 2H), 3.74 (t, J = 7.8 Hz, 2H), 3.46 ¨ 3.41 (m, 4H), 2.31 (t, J
= 7.4 Hz, 2H), 1.39 (t, J = 7.2 Hz, 6H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR
(CD300) 8 10 117.1, 165.9, 154.6, 140.9, 129.6, 128.4, 127.3, 125.9, 118.6, 112.8, 111.5, 50.7, 40.4, 38.4, 36.4, 19.9, 14.0, 9Ø
Example 60 Preparation of 342-(3,3-Dimethyl-buty1)-1-(2-ethylamino-ethyl)-1H-benzoimidazol-15 5-y1J-N-hydroxy-acrylamide (63) [0303] The titled compound (63) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.0 %;
tFt =
0.93 min; LCMS m/z: 359 ([M + Hr). 1H NMR (CD30D) 8 7.5 (d, J = 8.4 Hz, 1H), 7.75 ¨7.74 (m, 2H), 7.16 (d, J = 15.7 Hz, 1H), 6.31 (d, J = 15.7 Hz, 1H), 4.89 (brs, 2H), 3.72 20 (brs, 2H), 3.29 ¨ 3.18 (m, 4H), 1.90 ¨ 1.86 (m, 2H), 1.35 (t, J = 7.1 Hz, 3H), 1.09 (s, 9H); 13C NMR (CD30D) 5 165.7, 158.4, 140.4, 134.9, 134.5, 134.2, 126.2, 122.5, 119.2, 115.6, 113.4, 55.3, 44.0, 40.8, 40.7, 31.3, 29.3, 22.9.
Example 61 25 Preparation of 341-(2-Dimethylamino-ethyl)-2-(3,3-dimethyl-buty1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (64) [0304] The titled compound (64) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.0 %;
tR =
0.83 min; LCMS m/z: 359 ([M + 1H NMR (CD30D) 5 7.94 (d, J = 7.8 Hz, 1H), 7.81 30 (s, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 15.7 Hz, 1H), 6.64 (d, J
= 15.7 Hz, 1H), 4.93 (brs, 2H), 3.76 (brs, 2H), 3.22 (t, J = 7.7 Hz, 2H), 3.09 (s, 6H), 1.91 ¨
1.87 (m, 2H), 1.08 (s, 9H); 13C NMR (CD30D) 8 165.4, 158.4, 140.2, 134.5, 134.2, 133.2, 126.5, 118.8, 115.3, 113.9, 46.4, 45.1, 42.9, 40.6, 31.3, 29.2, 22.9, 11.4.
35 Example 62 Preparation of 341-(2-Dimethylamino-ethyl)-2-pentyl-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (65) [0305] The titled compound (65) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.5%; tR = 0.78 min. LCMS m/z: 345([M + H]). 1H NMR (DMSO-d6) 8 0.89 (3H, m), 1.38 (4H, m), 1.83 (2H, m), 2.93 (6H, s), 3.04 (2H, m), 3.50 (2H, t), 4.70 (2H, m), 6.55 (1H, d), 7.57 (1H, d), 7.61 (1H, m), 7.81 (2H, m), 10.42 (1H, bs).
Example 63 Preparation of 341-(2-Dimethylamino-ethyl)-2-(2,2,2-trifluoro-ethyl)-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (64) [0306] The titled compound (64) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 91.1%; tR = 0.68 min. LCMS m/z: 357 ([M+Fi]+).
Example 64 Preparation of 341-(2-Ethylamino-ethyl)-2-penty1-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (68) [0307] The titled compound (68) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.4%; tR = 0.87 min. LCMS m/z: 345([M+H])-Example 65 Preparation of N-Hydroxy-341-(2-isopropylamino-ethyl)-2-penty1-1H-benzoimidazol-5-y1]-acrylamide (71) [0308] The titled compound (71) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 97.4%; tR = 0.95 min. LCMS m/z: 359 (DM + Hr). 1H NMR (DMSO-d6) 8 0.89 (3H, m), 1.22 (6H, d), 1.38 (4H, m), 1.82 (2H, m), 2.99 (3H, m), 4.56 (2H, m), 6.51 (1H, d), 7.59 (2H, d), 7.64 (1H, m), 7.88 (1H, m), 8.74 (2H, bs).
Example 66 Preparation of 342-Hexy1-1-(2-methylamino-ethyl)-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (74) [0309] The titled compound (74) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 96.0%, tR = 1.12 min. LCMS m/z: 345 ([M+H]+). 1H NMR (CD30D) 8 7.76 (2H, s), 7.70 (1H, d, J = 8.6 Hz). 7.50 (1H, d, J = 15.7 Hz), 6.43 (1H, d, J = 15.7 Hz), 4.81 (2H, d, J = 5.7 Hz), 3.49 (2H, bs), 3.15 (2H, dt, J = 4.8 Hz), 2.71 (3H, s), 1.85 (2H, qn, J =
5.1 Hz), 1.46 (2H, m), 1.33 (4H, m), 0.85 (3H, t, J = 7.1 Hz); 13C NMR (CD300) 163.7, 157.8, 138.5, 132.7, 124.2, 117.6, 113.7, 111.2, 40.2, 32.2, 30.5, 28.0, 25.6, 25.1, 21.6, 12.3.
Example 67 Preparation of N-Hydroxy-341-(2-methylamino-ethyl)-2-penty1-1H-benzoimidazol-5-y1]-acrylamide (75) [0310] The titled compound (75) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 97.8%; tR = 0.80 min. LCMS m/z: 331 (EM + H]+). 1H NMR (DMSO-d6) 8 0.89 (3H, m), 1.38 (4H, m), 1.84 (2H, m), 2.51 (3H, s), 3.14 (2H, m), 3.38 (2H, t), 4.70 (2H, m), 6.57 (1H, d), 7.62 (1H, d), 7.73 (1H, m), 7.96 (2H, m), 9.13 (2H, s).
Example 68 Preparation of 3-(2-Buty1-1-pyrrolidin-3-y1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (69) 02N io 0 OMe 0 OMe 02N is OMe Boc HN
CI Et3N SnC12, Me0H/ AcOH
la Heat IEloc I3oc HCl/Me0H OMe /
NH2OH NHOH, Step1 [0311] To a solution of methyl trans-4-Chloro-3-nitrocinnamate (la, 4.8 g, 20 mmol) in triethyl amine (5.5 mL, 40 mmol) was added 3-Amino-pyrrolidine-1-carboxylic acid tert-butyl ester (11.2 g, 60 mmol), the resulting mixture was then heated to 100 C
for 8 hours, then another portion of methyl trans-4-Chloro-3-nitrocinnamate (4.8 g, 20 mmol) and triethyl amine (5.5 mL, 40 mmol) was added, the resulting mixture was allowed to stir overnight at 100 C, then reaction was quenched by adding 200 mL of DCM
and 80 mL of 1M HCI solution. After separation of DCM layer, the aqueous solution was extracted with DCM one more time, and combined with previous DCM solution, which was then washed with brine, dried over sodium sulfate, then filtered through silica gel short column, and rinsed with ethyl acetate and hexanes mixture (2:1) until the orange color band was completely rinsed down. After removal of solvent under reduced pressure, the residue 69-2 was obtained (around 80% of yield in most of cases) as orange solid, which is pure enough (95% purity from HPLC) for next step. LC-MS
m/z:
292 ([M-Boc +H]).
Step 2 [0312] To a solution of compound 69-2 (7.84 g, 20.0 mmol) in 100 mL of Me0H
and AcOH mixture (1:9) was added corresponding aldehyde (3.0 mL, 30.0 mmol) and tin chloride (22.6 g, 100 mmol), the resulting mixture was stirred at 42 C for 24 hrs. Then the mixture was diluted using ethyl acetate (300 mL) at room temperature, and was then quenched with sat. sodium carbonate (30 mL). The resulting mixture was stirred for additional 1 hour, then organic layer was decanted to another conic flask.
Solid left in reaction flask was suspension with another portion of ethyl acetate (300 mL), which was then decanted and combined with previous portion of ethyl acetate and was then filtered through silica gel short column and rinsed with ethyl acetate, after removal of filtrate under reduced pressure, the residue was pure enough for next step and also could be purified on column (hexanes:Et0Ac = 1:2) to give a pale-yellow solid 69-3 (3.8 g, 44%). LC-MS m/z: 456 (EM + H]+).
Step 3 [0313] To a flask charged with compound 69-3 (456 mg, 1 mmol) was added 1.25 M
HCI in Me0H (4 mL), the resulting mixture was then heated to reflux for 2 hours, which was then evaporated to dryness under reduced pressure to give compound 4 as HCI
salt, which is pure enough for next step without any purification. LC-MS m/z:
356 ([M +
Fi]).
Step 4 [0314] To a solution of above crude 69-4 (around 0.16 mmol) product in Me0H
(0.5 mL) was added a pre-prepared NH2OH stock solution (2.0 M, 2 mL). The resulting mixture was stirred at room temperature for 2 hrs. After quenching with TFA
(0.4 mL), the resulting mixture was subjected to HPLC purification to afford 25 mg of 3-(2-Buty1-1-pyrrolidin-3-y1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide. HPLC purity:
98%; LC-MS m/z: 329 ([M + H]+). 1H NMR (CD30D) 8 0.95 (3H, t, J = 7.2 Hz), 1.46 (2H, m), 1.77 (2H, m), 2.52-2.82 (2H, m), 3.10-3.17 (2H, m), 3.48 (1H, m), 3.80 (2H, m), 5.55 (1H, m), 6.48 (1H, d, J = 16.0 Hz), 7.58 (1H, d, J= 16.0 Hz), 7.67 (1H, d, J= 8.0 Hz), 7.78-7.92 (2H, m).
Example 69 Preparation of 3-(2-Buty1-1-piperldin-4-y1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (70) [0315] The titled compound (70) was prepared according to the procedures described in Example 78, by using appropriate starting materials. HPLC purity:
98%;
LCMS m/z: 343 ([M + Hr). 1H NMR (CD30D) 6 0.96 (3H, t, J= 7.2 Hz), 1.46 (2H, m), 1.79 (2H, m), 2.21 (2H, m), 2.82 (2H, m), 3.10-3.17 (2H, m), 3.26 (1H, m), 3.60 (2H, m), 4.96 (1H, m), 6.49 (1H, d, J= 15.8 Hz), 7.60 (1H, d, J= 15.8 Hz), 7.66 (1H, d, J=
8.0 Hz), 7.82 (1H, s) (1H, d, J= 8.0 Hz).
Example 70 Preparation of 3-(2-Hexy1-1-pyrrolidin-3-y1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (80) [0316] The titled compound (80) was prepared according to the procedures described in Example 68, by using appropriate starting materials. HPLC purity: 98%; LCMS
m/z:
357 ([M + H]+). 1H NMR (CD30D) 8 0.84 (3H, t, J = 7.2 Hz), 1.22-1.38 (4H, m), 1.44 (2H, m), 1.81 (2H, m), 2.52-2.82 (2H, m), 3.10-3.17 (2H, m), 3.48 (1H, m), 3.80 (2H, m), 5.56 (1H, m), 6.48 (1H, d, J= 15.8 Hz), 7.56 (1H, d, J = 15.8 Hz), 7.65 (1H, d, J=
9.2 Hz), 7.84 (1H, s), 7.90 (1H, d, J= 9.2 Hz).
Example 71 Preparation of 342-Buty1-1-(1-methyl-pyrrolidin-3-y1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (81) [0317] The titled compound (81) was prepared according to the procedures described in Example 68, by using 69-4 via reductive amination to introduce a methyl group.
HPLC purity: 98%; LCMS m/z: 343 ([M + H]). 1H NMR (CD300) 6 0.99 (3H, t, J =
7.2 Hz), 1.52 (2H, m), 1.83 (2H, m), 2.65-2.92 (2H, m), 3.09 (3H, s), 3.15-3.25 (2H, m), 3.58 (1H, br.), 3.90 (2H, m), 5.73 (1H, m), 6.51 (1H, d, J = 16.0 Hz), 7.58 (1H, d, J =
16.0 Hz), 7.69 (1H, d, J= 8.0 Hz), 7.88 (1H, s), 8.00 (1H, d, J= 9.2 Hz).
Example 72 Preparation of 3-(2-Hexy1-1-piperidin-3-y1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (82) [0318] The titled compound (82) was prepared according to the procedures described in Example 68, by using appropriate starting materials. HPLC purity: 97%; LCMS
m/z:
343 ([M + Hr). 1H NMR (CD30D) 6 0.99 (3H, t, J= 7.2 Hz), 1.52 (2H, m), 1.84 (2H, m), 2.04 (1H, m), 2.20 (2H, m), 2.61 (1H, m), 3.12-3.22 (2H, m), 3.49 (1H, m), 3.67 (1H, m), 3.78 (1H, t, J = 12.0 Hz), 4.98 (1H, m), 6.53 (1H, d, J = 15.8 Hz), 7.63 (1H, d, J =
15.8 Hz), 7.70 (1H, d, J = 9.2 Hz), 7.86 (1H, s), 8.06 (1H, d, J = 8.8 Hz).
Example 73 Preparation of 3-(2-Butyl-1-piperidin-3-y1-1H-benzoimidazol-5-0)-N-hydroxy-acrylamide (83) [0319] The titled compound (83) was prepared according to the procedures described in Example 68, by using appropriate starting materials. HPLC purity: 97%; LCMS
m/z:
371 ([M + H]). 1H NMR (CD30D) 8 0.88 (3H, t, J = 7.2 Hz), 1.22-1.42 (4H, m), 1.47 (2H, m), 1.84 (211, m), 2.04 (1H, m), 2.20 (2H, m), 2.62 (1H, m), 3.12-3.22 (2H, m), 3.48(111, m), 3.68 (1H, m), 3.78 (1H, t, J = 12.0 Hz), 5.01 (1H, m), 6.53 (1H, d, J= 15.8 Hz), 7.62 (1H, d, J = 15.8 Hz), 7.70 (1H, d, J = 9.2 Hz), 7.86 (111, s), 8.06 (1H, d, J =
8.8 Hz).
Example 74 Preparation of (E)-N-hydroxy-3-(1-(1-methylpiperidin-3-y1)-2-penty1-1H-benzo[d]imidazol-5-yOacrylamide (86) [0320] The titled compound (86) was prepared according to the procedures described in Example 71, by using appropriate starting materials.HPLC purity: 99.3 %, tR
=1.06 min; LCMS m/z: 371 ([M + H]). 1H NMR (CD30D) 8 8.18 (d, J = 7.9 Hz, 1H), 7.92 (s, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.61 (d, J = 15.7 Hz, 1H), 6.58 (d, J = 15.7 Hz, 1H), 5.21 (brs, 1H), 3.69 (brs, 2H), 3.69 ¨ 3.66 (m, 1H), 3.37 ¨ 3.27 (masked peaks), 3.03 (s, 3H), 2.66 (brs, 1H), 2.29 ¨ 2.22 (m, 3H), 1.94¨ 1.90 (m, 2H), 1.54 ¨ 0.94 (m, 4H), 0.96 (t, J = 7.1 Hz, 3H); 13C NMR (CD30D) 8165.6, 157.6, 139.9, 134.6, 134.1, 132.5, 126.3, 120.4, 115.5, 115.2, 54.9, 54.4, 53.3, 44.1, 32.4, 27.5, 27.3, 26.8, 23.2, 23.1, 14.2.
Example 75 Preparation of (E)-3-(2-hexy1-1-(1-(2-hydroxyethyl)piperidin-3-y1)-1H-benzo[d]imidazol-5-y1)-N-hydroxyacrylamide (90) [0321] The titled compound (90) was prepared according to the procedures described in Example 68, by using appropriate starting materials and alkylation of the piperidine with 2-bromoethanol. LCMS m/z: 415 ([M +H]).
Example 76 Preparation of N-Hydroxy-3-[1-(1-pentyl-piperidin-3-y1)-1H-benzoimidazol-5-y1]-acrylamide (94) [0322] The titled compound (94) was prepared according to the procedures described in Example 68, by using appropriate starting materials (formic acid for benzimdiazoel ring formation and reductive amination of the piperidine with pentanal). HPLC
purity:
95%; LC-MS rn/z: 357 ([M+H]). 1H NMR (CD30D) 8 9.04 (s, 1H), 7.94 (brs, 2H), 7.78 (d, 1H, J=8.2 Hz), 7.70 (d, 1H, J= 15.7 Hz), 6.57 (d, 1H, J= 15.9 Hz), 5.14 ¨
5.10 (m, 1H), 3.85(dd, 2H, J = 88.0, 9.0 Hz), 3.48 ¨ 3.13 (m, 4H), 2.43 ¨ 2.12 (m, 4H), 1.94 ¨10 1.80 (m, 2H), 1.39 ¨ 1.29 (m, 4H), 0.94 (t, 3H, J= 6.8 Hz).
Example 77 Preparation of N-Hydroxy-3-[1-(1-phenethyl-piperidin-3-y1)-1H-benzoimidazol-5-y1]-acrylamide (96) [0323] The titled compound (96) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 98.6%; LC-MS
rn/z: 391([M+H]). 1H NMR (CD30D) 6 8.93 (s, 1H), 7.95 (s, 1H), 7.91 (d, 1H, J
= 8.5 Hz), 7.76 (d, 1H, J = 8.5 Hz), 7.70 (d, 1H, J = 15.8 Hz), 7.35 ¨ 7.24 (m, 6H), 6.56 (d, 1H, J = 15.7 Hz), 5.10 (t, 1H, J = 11.4 Hz), 3.91 (dd, 2H), 3.55 ¨ 3.45 (m, 2H), 3.15 -3.11 (m, 2H), 2.46 ¨ 2.13 (m, 6H).
Example 78 Preparation of N-Hydroxy-3-{141-(3-phenyl-propyl)-piperidin-3-y1]-benzoimidazol-5-y1}-acrylamide (97) [0324] The titled compound (97) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 94.5%; LC-MS:
405 ([M+Hr) 1H NMR (CD30D) 8 8.68 (s, 1H), 7.94 (s, 1H), 7.80 (d, 1H, J = 8.4 Hz), 7.71 (d, 1H, J= 15.7 Hz), 7.69 (d, 1H, J= 8.2 Hz), 7.31 ¨7.17 (m, 6H), 6.54(d, 1H, J=
15.6 Hz), 3.71 (dd, 2H, J= 66 Hz, 10.9 Hz), 3.48 ¨ 3.40 (m, 1H), 3.13 ¨ 3.05 (m, 2H), 2.73 (t, 2H, J= 7.4 Hz), 2.38 ¨ 2.04 (m, 8H);
. Example 79 Preparation of 3-(141-(3,3-Dimethyl-butyl)-pyrrolidin-3-y1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (99) [0325] The titled compound (99) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 91.9%; tR
= 1.10 min. LC-MS rn/z: 357 ([MH]+). 1H NMR (DMSO-d6) 6 0.91 (9H, s), 1.52 (4H, m), 3.09 (1H, m), 3.29 (6H, m), 6.52 (1H, d), 7.43 (2H, m), 7.62 (1H, m), 7.80 (1H, m), 8.82 (1H, s), 10.25 (1H, bs).
Example 80 Preparation of 3-{142-(Ethyl-methyl-amino)-ethy1]-2-penty1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (79) [0326] The titled compound (79) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity: 99%; tR =
0.68 min.
LC-MS m/z: 359 ([M+H]). 1H NMR (DMSO-d6) 60.89 (3H, m), 1.23 (3H, m), 1.38 (4H, m), 1.84 (2H, m), 2.92 (3H, s), 3.10 (2H, m), 3.28 (2H, m), 3.52 (2H, m), 4.77 (2H, m), 6.58 (1H, d), 7.61 (1H, d), 7.71 (1H, m), 7.92 (2H, m), 10.48 (1H, bs).
Example 81 Preparation of 3-{2-Buty1-142-(ethyl-methyl-amino)-ethy1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (85) [0327] The titled compound (85) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity: 95.8%; tR
=1.04 min. LC-MS m/z: 345 ([M+H]). 1H NMR (DMSO-d6) 8 0.95 (3H, m), 1.25 (3H, m), 1.46 (2H, m), 1.81 (2H, m), 2.92 (3H, s), 3.13 (2H, m), 3.27 (2H, m), 3.54 (2H, m), 4.80 (2H, m), 6.60 (1H, d), 7.62 (1H, d), 7.75 (1H, m), 7.92 (2H, m), 10.59 (1H, bs).
Example 82 Preparation of 3-(2-Buty1-1-{2-[ethyl-(3-hydroxy-propy1)-amino]-ethyl}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (91) [0328] The titled compound (91) was prepared according to the procedures described =
in Example 1, by using appropriate starting materials. HPLC purity: 93.5%; tR=
0.50 min. LC-MS (m/z): 389 ([MH]-). 1F1 NMR (DMSO-d6) 8 0.94 (3H, m), 1.25 (311, m), 1.46 (2H, m), 1.83 (4H, m), 3.04 (2H, m), 3.31 (4H, m), 3.50 (4H, m), 4.72 (2H, m), 6.54 (1H, d), 7.61 (1H, m), 7.69 (1H, m), 7.80 (1H, m), 7.90 (1H, m), 10.20 (1H, bs).
Example 83 Preparation of 3-(1-{2-[Ethyl-(3-hydroxy-propy1)-amino]-ethyl}-2-pentyl-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (92) [0329] The titled compound (92) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity: 93.5%; tR
= 0.50 min. LC-MS (m/z): 389 ([M+H]4) 1H NMR (DMSO-d6) 60.94 (3H, m), 1.25 (3H, m), 1.46 (2H, m), 1.83 (4H, m), 3.04 (2H, m), 3.31 (4H, m), 3.50 (4H, m), 4.72 (2H, m), 6.54 (1H, d), 7.61 (1H, m), 7.69 (1H, m), 7.80 (1H, m), 7.90 (1H, m), 10.20 (1H, bs).
Example 84 Preparation of 3-{142-(Butyl-ethyl-amino)-ethy1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (95) [0330] The titled compound (95) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 99.9%; LC-MS
miz: 331([M+H]). 1H NMR (CD30D) 8 9.29 (s, 1H), 7.99 ¨ 7.95 (m, 2H), 7.82 (d, 1H, J
= 8.5 Hz), 7.56 (d, 1H, J = 15.6 Hz), 6.53 (d, 1H, J = 15.5 Hz), 5.0 ¨ 4.95 (m, 2H), 3.86 ¨ 3.78 (m, 2H), 3.42 (dd, 2H, J = 13.3, 7.1 Hz), 3.28 ¨ 3.26 (m, 2H), 1.74 ¨
1.71 (m, 2H), 1.43 (qt, 2H, J = 7.4, 3.8 Hz), 1.38 (t, 3H, J = 7.2 Hz), 1.00 (t, 3H, J
= 7.3 Hz).
Example 85 Preparation of 3-[2-(4-Cyano-butyl)-1-(2-diethylamino-ethyl)-1H-benzoimidazol-yli-N-hydroxy-acrylamide (101) [0331] The titled compound (101) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm:
99.9%.
LC-MS (ESI) m/z: 384 ([M+H]). 1H NMR (CD300) 6 7.78 (1H, s) 7.76 (1H, d, J =
8.5 Hz), 7.63 (1H, d, J = 16.9 Hz), 7.58 (1H, d. J = 5.1 Hz), 6.44 (1H, d, J =
15.3 Hz), 4.70 (2H, in water peak), 3.50 (2H, t, J = 7.6 Hz), 3.32 (4H, qt, J = 7.3 Hz), 3.07 (2H, t, J =
8.0 Hz), 2.50 (2H, t, J = 7.0 Hz), 1.99 (2H, q, J = 7.5 Hz), 1.78 (2H, q, J =
7.3 Hz), 1.29 (6H, t, J = 7.3 Hz).
Example 86 Preparation of 3-{142-(Butyl-isopropyl-amino)-ethyl]-1H-benzoimidazol-5-y1}-19-hydroxy-acrylamide (108) [0332] The titled compound (108) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 98.8%; tR
= 1.33 min. LC-MS mk: 345 ([M+Hr). 1H NMR (DMSO-d6) 8 0.90 (3H, m), 1.25 (6H, d), 1.35 (2H, m), 1.64 (2H, m), 3.09 (2H, m), 3.51 (1H, m), 3.73 (2H, m), 4.74 (2H, m), 6.52 (1H, d), 7.53 (2H, m), 7.64 (1H, m), 7.80 (1H, m), 8.62 (1H, m), 9.40 (1H, bs), 10.72 (1H, bs).
Example 87 Preparation of N-Hydroxy-3-{142-(isopropyl-pentyl-amino)-ethyl]-benzoimidazol-5-y1}-acrylamide (109) [0333] The titled compound (109) was prepared according to the procedures described in Example 76, by using appropriate starting materials. LC-MS m/z: 359 ([M+H]). 1H
NMR (DMSO-d6) 8 0.88 (3H, t), 1.25 (10H, m), 1.64 (2H, m), 3.12 (2H, m), 3.51 (1H, b), 3.60 (1H, b), 3.73 (1H, b), 4.74 (2H, t), 6.51 (1H, d), 7.59 (1H, s), 7.63 (1H, d), 7.80 (1H, d), 7.93 (1H, s), 8.65 (1H, s), 9.46 (1H, b) Example 88 Preparation of 342-(5-Cyano-penty1)-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (110) [0334] The titled compound (110) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm:
95.4%.
LC-MS (ESI) m/z: 347 ([M+H]). 1H NMR (CD30D) 8 7.96 (1H, d, J = 8.5 Hz), 7.90(1H, s) 7.81 (1H, d, J = 8.5 Hz), 7.59 (1H, d. J = 15.6 Hz), 6.55 (1H, d, J = 15.5 Hz), 4.96 (2H, t, J = 7.3 Hz), 3.69 (2H, t, J = 7.1 Hz), 3.44 (4H, qt, J = 7.2 Hz), 3.31 (2H, embedded in Me0D peak), 2.51 (2H, t, J = 6.9Hz), 2.05-1.98 (2H, m), 1.78 (2H, m, J =
7.4 Hz), 1.70 (2H, m, J = 6.4 Hz), 1.41(3H, t, J = 7.2 Hz);
Example 89 Preparation of 3-(1-{2-[(3,3-Dimethyl-butyl)-ethyl-amino]-ethyl}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (111) [0335] The titled compound (111) was prepared according to the procedures described in Example 76, by using appropriate starting materials. TFA salt. HPLC purity:
97.7%;
LC-MS m/z: 359 ([M+H]). 1H NMR (CD30D) 8 9.10 (s, 1H), 7.89 (d, 1H, J = 8.9 Hz), 7.88 (s, 1H), 7.74 (d, 1H, J = 8.6 Hz), 7.51 (d, 1H, J = 15.7 Hz), 6.46 (d, 1H, J = 15.7 Hz), 4.98 ¨ 4.93 (m, 2H), 3.77 ¨ 3.75 (m, 2H), 3.38 (dd, 2H, J = 13.3, 7.2 Hz), 3.22 ¨
3.18 (m, 2H), 1.60 ¨ 1.59 (m, 2H), 1.33 (t, 3H, J = 7.1 Hz), 0.91 (s, 9H);
[0336] HCI salt. 1H NMR (DMSO-d6) 8 9.90 (bs, 1H), 8.65 (s, 1H), 7.93 (s, 1H), 7.82 (d, . 1H, J = 8.5 Hz), 7.64 (d, 1H, J = 8.1 Hz), 7.61 (d, 1H, J = 15.6 Hz), 7.52 (d, 1H, J =
15.8 Hz), 4.76 ¨ 4.72 (t, 2H, J = 7.0), 3.65 ¨ 3.60 (m, 2H), 3.32 ¨ 3.24 (m, 2H), 3.17 ¨
3.08 (m, 2H), 1.52¨ 1.47 (m, 2H), 1.22 (t, 3H, J = 7.2 Hz), 0.87 (s, 9Hz).
Example 90 Preparation of 3-{1-12-(Ethyl-propyl-amino)-ethyl]-1H-benzoimidazo1-5-y1)-N-hydroxy-acrylamide (112) [0337] The titled compound (112) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 98.1%; LC-MS
m/z: 315 ([M+H]). 1H NMR (CD30D) 8 9.43 (s, 1H), 7.99 (d, 1H, J= 8.5 Hz), 7.93 (s, 1H), 7.82 (d, 1H, J= 8.5 Hz), 7.53 (d, 1H, J= 15.7 Hz), 6.50 (d, 1H, J= 15.5 Hz), 5.00 ¨ 4.96 (m, 2H), 3.78 (t, 2H, J= 6.1 Hz), 3.37 (dd, 2H, J= 14.2, 7.2 Hz), 3.22 ¨ 3.19 (m, 2H), 1.75 (qt, 2H, J= 7.5 Hz), 1.33 (t, 3H, J= 7.2 Hz), 0.99 (t, 3H, J= 7.3 Hz).
Example 91 Preparation of N-Hydroxy-3-(1-{2-[isopropyl-(2-methyl-penty1)-amino]-ethyl}-1H-benzoimidazol-5-y1)-acrylamide (113) [0338] The titled compound (113) was prepared according to the procedures described in Example 76, by using appropriate starting materials. LC-MS m/z: 373RM+H)1].
NMR (DMSO-d6) 8 0.86 ¨ 0.97 (7H, m), 1.14 ¨1.28 (12H, m), 4.70 (2H, b), 6.49 (1H, d), 7.58 ¨7.62 (2H, m), 7.73 (1H, d), 7.91 (1H, s), 8.48 (1H, s) Example 92 Preparation of 3-{142-(Ethyl-hexyl-amino)-ethyl]-2-methyl-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (116) [0339] The titled compound (116) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm:
98.2%, tR = 1.27 min. LC-MS (ESI) m/z: 373 ([M+Hr). 1H NMR (CD30D) 8 7.85 (1H, s), 7.78 (1H, d, J= 8.4 Hz), 7.70 (1H, d, J= 8.7 Hz), 7.15 (1H, d. J= 15.9 Hz), 6.53 (1H, d, J=
15.9 Hz), 4.81 (2H), 3.63 (2H, t, J = 7.7 Hz), 3.41 (2H, qt, J= 7.2 Hz), 3.29 (2H), 2.82 (3H, s), 1.74 (2H, m), 1.37 (11H, m), 0.93 (3H, t, J = 6.9 Hz).
Example 93 Preparation of 3-(1-[2-(Butyl-ethyl-am i no)-ethyl]-2-trifluoromethy1-1H-benzoi midazol-5-y1)-N-hydroxy-acrylamide (117) [0340] The titled compound (117) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm:
97.3%, tR = 1.50 min. LC-MS (ESI) m/z: 399 (1M+Hr). 1H NMR (CD30D) 8 7.95 (1H, s), 7.70 (2H, s), 7.62 (1H, d, J= 15.9 Hz), 6.46 (1H, d, J= 15.8 Hz), 5.24 (2H), 3.50 (2H, t, J=
8.8 Hz), 3.31 (2H, qt, J= 7.2 Hz), 3.17 (2H), 1.63 (2H, m), 1.35 (2H, qt, J =
7.5 Hz), 1.29 (3H, t, J = 7.2 Hz), 0.92 (3H, t, J = 7.4 Hz).
Example 94 Preparation of 3-{142-(Ethyl-hexyl-amino)-ethyl]-2-trifluoromethy1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (118) [0341] The titled compound (118) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm:
94.6%, tR = 2.07 min. LC-MS (ESI) m/z: 427 ([M+111+). 1H NMR (CD30D) 8 8.04 (1H, s), 7.80 (2H, s), 7.72 (1H, d, J = 15.8 Hz), 6.56 (1H, d, J = 15.6 Hz), 4.85 (2H), 3.61 (2H, t, J =
8.5 Hz), 3.42 (2H, qt, J = 7.2 Hz), 3.26 (2H), 1.75 (2H, m), 1.39 (9H, m, J =
7.5 Hz), 0.93 (3H, t, J = 7.0 Hz).
Example 95 Preparation of 341-(2-Dipropylamino-ethyl)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (120) [0342] The titled compound (120) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 100%. LC-MS
m/z: 331 ([M+H]). 1H NMR (DMSO-d6) 8 0.86 (6H, d), 1.64 (4H, m), 3.09 (4H, m), 3.60 (2H, m), 4.76 (2H, m), 6.53 (1H, d), 7.55 (2H, m), 7.65 (1H, m), 7.88 (1H, m), 8.75 (1H, m), 9.93 (1H, bs).
Example 96 Preparation of N-Hydroxy-3-(1-{24isopropyl-(3-methyl-butyl)-aminoFethyl}-1H-benzoimidazol-5-y1)-acrylamide (121) [0343] The titled compound (121) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 98.7%; tR
= 1.02 min. LC-MS (m/z): 358 ([M+H]). 1H NMR (DMSO-d6) 8 0.88 (6H, d), 1.28 (6H, m), 1.59 (3H, m), 3.10 (3H, m), 3.68 (2H, m), 4.71 (2H, m), 6.50 (1H, d), 7.50 (2H, m), 7.59 (1H, m), 7.63 (1H, m), 8.52 (1H, m), 9.50 (1H, bs), 10.70 (11-1, bs).
Example 97 Preparation of 3-(1-{2-[(3,3-Dimethyl-butyl)-methyl-aminoFethyl}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (122) [0344] The titled compound (122) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity at 254 nm:
97.8%;
tR = 0.93 min. LC-MS m/z: 345 ([M+H]). 1H NMR (DMSO-d6) 8 0.84 (9H, s), 1.52 (2H, m), 2.90 (3H, s), 3.17 (2H, m), 3.68 (2H, m), 4.80 (2H, m), 6.58 (1H, d), 7.59 (2H, m), 7.86 (1H, m), 7.90 (1H, m), 8.82 (1H, m), 10.10 (1H, bs).
Example 98 Preparation of 3-(1-{2-[(2-Ethyl-buty1)-methyl-amino]-ethy1}-1H-benzoimidazol-y1)-N-hydroxy-acrylamide (123) [0345] The titled compound (123) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity at 254 nm:
97.7%;
tR= 0.87 min. LC-MS m/z: 345 ([M+H]). 1H NMR (DMSO-d6) 5 0.81 (6H, m), 1.29 (4H, m), 1.69 (1H, m), 2.89 (3H, s), 3.08 (2H, m), 3.59 (2H, m), 4.77 (2H, m), 6.53 (1H, d), 7.52 (2H, m), 7.86 (1H, m), 7.94 (1H;rn), 8.80 (1H, m), 9.54 (1H, bs).
Example 99 Preparation of 3-{142-(3,3-Dimethyl-butylamino)-ethy1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (126) [0346] The titled compound (126) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 100%; tR
= 1.01 min. LC-MS m/z: 331 ([M-I+11+). 1H NMR (DMSO-d6) 8 0.88 (9H, s), 1.44 (2H, m), 2.92 (2H, m), 3.50 (2H, m), 4.66 (2H, m), 6.54 (1H, d), 7.58 (2H, m), 7.82 (1H, m), 7.90 (1H, m), 8.74 (1H, m).
Example 100 Preparation of N-Hydroxy-3-{1-12-(methyl-pent-4-enyl-amino)-ethy1]-1H-benzoimidazol-5-y1}-acrylamide (127) [0347] The titled compound (127) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 100%; tR
= 0.92 min. LC-MS m/z: 329 ([M+H]+). 1H NMR (DMSO-d6) 8 1.17 (2H, m), 2.06 (2H, m), 2.90 (3H, s), 3.10 (2H, m), 3.65 (2H, m), 4.80 (2H, m), 5.03 (2H, m), 5.75 (11-1, m), 6.57 (1H, d), 7.60 (1H, d), 7.69 (1H, m), 7.90 (1H, m), 7.97 (1H, m), 8.92 (1H, m), 10.29 (1H, bs).
Example 101 Preparation of 3-(1-{2-[(3,3-Dimethyl-buty1)-propyl-aminoFethyl}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (128) [0348] The titled compound (128) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 99.0%;
tR=1.18 min. LC-MS m/z: 373 ([M-I-Hr). 1H NMR (DMSO-d6) 60.88 (12H, m), 1.51 (2H, m), 1.64 (2H, m), 3.10 (4H, m), 3.63 (2H, m), 4.76 (2H, m), 6.54 (1H, d), 7.65 (2H, m), 7.80 (1H, m), 7.94 (1H, m), 8.83 (1H, m), 9.93 (1H, bs).
Example 102 Preparation of 3-{142-(3,3-Dimethyl-butylamino)-ethy1]-2-propy1-benzoimidazol-5-y1)-N-hydroxy-acrylamide (130) [0349] Step 1: Cyclization OMe OMe ______________________________________ - ______ N
HN
Zn, Me0H/AcOH
-Z O¨H
Formula (111b) 10 [0050] wherein X,Y, Z, R2, R3, Fe, R20, R21, R22, R23,R24, R25, K.-.26 and R27 are as defined in formula (I).
[0051] In an even more specific form of this embodiment R20, R21, R24, R25 are H, and R22 and R23 are methyl providing compounds of formula (111c).
N
R2-- 3Dt1 I 4 5 -2> NO¨H
7 ,9 N
Formula (111c) [0052] wherein X,Y, Z, R2, R3, R4, R20, R21, R22, R23, R24, R25, R26 and 11 are as defined in formula (I).
[0053] In each of the above embodiments of the invention R2 and R21 may represent a number of different variables. In one embodiment R2 and R21 are independently selected from the group consisting of H, alkyl, alkenyl and alkynyl. In another embodiment R2 and R21 are independently selected from the group consisting of H and alkyl. In a specific embodiment R2 and R21 are both H.
[0054] In each of the above embodiments of the invention R22 and R23 may represent a number of different variables. In one embodiment R22 and R23 are independently selected from the group consisting of H, alkyl, alkenyl and alkynyl. In another embodiment R22 and R23 are independently selected from the group consisting of H and alkyl. In a further embodiment R22 and R23 are independently selected from the group consisting of alkyl. In a most specific embodiment R22 and R23 are both methyl.
[0055] In each of the above embodiments of the invention R24 and R25 may represent a number of different variables. In one embodiment R24 and R25 are preferably independently selected from the group consisting of H, alkyl, alkenyl and alkynyl. In another embodiment R24 and R25 are independently selected from the group consisting of H and alkyl. In a specific embodiment R24 and R25 are both H.
[0056] In each of the above embodiments there are a number of values for R26 and R27. In one embodiment R26 and R27 are independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, alkoxyalkyl, and acyl. In another embodiment R26 and R27 are independently selected from the group consisting of: H, alkyl and acyl.
In a further embodiment R26 and R27 are independently selected from the group . consisting of H, methyl, ethyl, isopropyl, propyl, 2-ethyl-propyl, 3,3-dimethyl-propyl, butyl, isobutyl, 3,3-dimethyl-butyl, 2-ethyl-butyl, pentyl, 2-methyl, pentyl, pent-4-enyl, hexyl, heptyl, octyl, acetyl and 2-methoxy-ethyl.
[0057] In another embodiment R1 is a heterocycloalkyl group which may optionally be substituted.
[0058] In one form of this embodiment the heterocycloalkyl group is selected from the group consisting of:
N/
R28 "R28 [0059] wherein R28 is selected from the group consisting of H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, alkoxycarbonyl, alkylaminocarbonyl, arylacyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR5 and acyl, each of which may be optionally substituted.
[0060] In one embodiment R28 is selected from the group consisting of H, alkyl, alkenyl, arylalkyl and arylacyl. Specific values of R28 are H, methyl; ethyl;
propyl; 2-methyl-propyl, 2-2-dimethyl-propyl; isopropyl; 3,3,3-triflouro-propyl; butyl;
isobutyl; 3,3-, dimethyl-butyl; pentyl; 2,4,4-trimethyl-pentyl; penten-4-yl, hexyl;
heptyl, octyl, nonyl, 2-methoxy nonyl, benzyl, 2-phenyl-ethyl, 2-phenyl-acetyl, 3-phenyl-propyl, [0061] In another embodiment the heterocycloalkyl group is pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, and 1,4-oxathiapane. It is particularly preferred that R1 is selected from the group consisting of piperidine-3-yl, piperidine-4-y1 and pyrollidin-3-y.
[0062] In another embodiment R1 is a heteroaryl group.
[0063] In another embodiment R1 is a group selected from the group consisting of:
(32.4.N
N
(32.2 N N
N La?7- N N
NH
,CNH
N
NH
N
N
N N N
NH
N
N
[0064] In one specific embodiment R1 is a group of formula:
'Z'etNH2 [0065] In another specific embodiment R1 is a group of formula:
[0066] In another specific embodiment R1 is a group of formula:
[0067] In yet another specific embodiment R1 is a group of formula:
[0068] In another specific embodiment R1 is a group of formula:
N/
[0069] In another specific embodiment R1 is a group of formula:
N/
[0070] In another specific embodiment R1 is a group of formula:
[0071] In another specific embodiment R1 is a group of formula:
[0072] In another specific embodiment R1 is a group of formula:
Lh2,N
[0073] In one embodiment R2 is selected from the group consisting of H, alkyl, cycloalkyl, heteroalkyl, alkenyl, alkynyl, alkoxyalkyl and cycloalkylalkyl.
[0074] In one form of this embodiment R2 is alkyl. In one embodiment the alkyl is a C1-C10 alkyl. In anotherform of this embodiment the alkyl is a C,-C6 alkyl group. In another form of this embodiment R2 is selected from the group consisting of:
methyl;
ethyl; propyl; 2-methyl-propyl, 2-2-dimethyl-propyl; isopropyl; 3,3,3-triflouro-propyl;
butyl; isobutyl; 3,3-dimethyl-butyl; pentyl; 2,4,4-trimethyl-pentyl; hexyl;
heptyl, octyl, nonyl, and 2-methoxy nonyl.
[0075] In one form of this embodiment R2 is alkenyl. In one form of this embodiment the alkenyl is y a Ci-Cio alkeny. In another form of this embodiment the alkenyl is a C1-C6 alkenyl group. In another form of this embodiment R2 is selected from the group consisting of: ethenyl, prop-1-enyl, prop-2-enyl, but-l-enyl, but-2-enyl but-3-enyl, pent-1-enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl and hex-5-enyl.
[0076] In another embodiment R2 is selected from the group consisting of R11S(0)R13-, R11S(0)2R13-, R11c(o)N(R12)R13-, R11S02N(R12)R13-, R11N(R12)C(0)R13-, R11N(R12)S02R13-, and RN(R12)C(0)N(R12)R13-. In one form of this embodiment R2 is a group of the formula R11C(0)N(R12)R13-. In one form of this embodiment R13 is a Cr 06 alkyl. In a specific form of this embodiment R13 is methyl or ethyl. In one form of thsi embodiment R12 is H or C1-C6alkyl. A specific value for R12 is H. In one form of thsi embodiment R11 is 01-06 alkyl group. Specific values for R11 include t-butyl and propyl.
. Specific examples of groups of this type include: (CH3)3CCH2CONH(CH2)2-;
(CH3)3CCONH(CH2)2-; (CH3)3CCONH(CH2)- and CH3(CH2)2CONH(CH2)-=
[0077] Specific values of R2 are Selected from the group consisting of: H;
methyl;
ethoxymethyl; [Bicylco[2.2.1]2-ylmethyl; Adamantan-2-ylmethyl; 2-methansulfanyl-ethyl; 2,2,2-triflouro-ethyl; propyl; 2-2-dimethyl-propyl; isopropyl; 3,3,3-trifiouro-propyl;
butyl; isobutyl; 3,3-dimethyl-butyl; but-3-enyl; but-3-yny; pentyl; 2,4,4-trimethyl-pentyl;
Bicyclo[2.2.1]hept-5-en-2y1; hexyl; hex-3-enyl; octyl; non-3-enyl; non-6-enyl;
methoxy-nonyl, 2-phenyl-cyclopropyl; cyclohexyl; (CH3)3CCH2CONH(CH2)2-;
(CH3)3CCONH(CH2)2-; (CF13)3CCONH(CH2)- and CH3(0H2)2CONH(CH2)-=
[0078] In one embodiment X and Y may be the same or different and are selected from the group consisting of H, halogen, 01-04 alkyl, -CF3, -NO2, -C(0)R5, -SR6, -ON and NR7R8.
[0079] In one embodiment X is H;
[0080] In one embodiment Y is H;
[0081] In one embodiment X and Y (if present) are at the 4 and 7 positions of the aromatic ring.
[0082] In one embodiment R3 is H, C1-C6 alkyl, or acyl. In another embodiment R3 is H or C1-C4 alkyl. A specific value for R3 is H;
[0083] In one embodiment R4 is H or C1-C4 alkyl. A specific value for R4 is H;
[0084] In one embodiment R5 is C1-C4 alkyl, heteroalkyl, or acyl. A specific value for R5 is methyl;
[0085] In one embodiment R5 is C1-C4 alkyl, heteroalkyl or acyl. A specific value for R5 is 01-04 alkyl;
10086] In one embodinnentR7 and R5 are selected from the group consisting of H, C1-C6 alkyl, C4-C9cycloalkyl, C4-C9heterocycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl [0087] Many if not all of the variables discussed above may be optionally substituted.
If the variable is optionally substituted then in one embodiment the optional substituent is selected from the group consisting of: halogen, =0, =S, -CN, -NO2, -CF3, -0CF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, arylalkyloxy, -amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, aminoalkyl, alkoxyalky, -COOH, -COR5, -C(0)0R5, -SH, -SR5, -0R6and acyl;
[0088] In a further embodiment the optional substituents are selected from the group consisting of: halogen, =0, =S, -CN, -NO2, alkyl, alkenyl, heteroalkyl, haloalkyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkylamino, aminoalkyl, acylamino, phenoxy, alkoxyalkyl, benzyloxy, alkylsulfonyl, arylsulfonyl, aminosulfonyl, -C(0)0R5, COOH, SH, and acyl.
[0089] In one embodiment the Z moiety is at the 5 or 6 position. In a specific embodiment the Z moiety is at the 5 position. In one embodiment the Z moiety is a group of formula -CH=CH-. If the Z moiety is a group of this type it is preferably in the "E" configuration.
[0090] In addition to compounds of Formula (I), the embodiments disclosed are also directed to pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of such compounds, and pharmaceutically acceptable salts of such metabolites. Such compounds, salts, prodrugs and metabolites are at times collectively referred to herein as "HDAC inhibiting agents" or "HDAC inhibitors".
[0091] The invention also relates to pharmaceutical compositions including a compound of the invention with a pharmaceutically acceptable carrier, diluent or excipient.
[0092] In yet a further aspect the present invention provides a method of treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis including administration of a therapeutically effective 5 amount of a compound of formula (I). The embodiments disclosed also relate to pharmaceutical compositions each comprising a therapeutically effective amount of a HDAC inhibiting agent of the embodiments described with a pharmaceutically acceptable carrier or diluent for treating cellular proliferative ailments, e.g., inhibition of proliferation of malignant cancer cells, benign tumor cells or other proliferative cells.
[0093] In one embodiment the method includes administration of a compound of formula (la) or (lb) as described herein.
[0094] In one embodiment the disorder is selected from the group consisting of but not limited to cancer (e.g. breast cancer, colon cancer, prostate cancer, pancreatic cancer, leukemias, lymphomas, ovarian cancers, neuroblastomas, melanoma, inflammatory diseases/immune system disorders, angiofibroma, cardiovascular diseases (e.g. restenosis, arteriosclerosis), fibrotic diseases (e.g. liver fibrosis), diabetes, autoimmune -diseases, chronic and acute neurodegenerative disease like .
disruptions of nerval tissue, Huntington's disease and infectious diseases like fungal, bacterial and viral infections. In another embodiment the disorder is a proliferative disorder. In one embodiment the proliferative disorder is cancer. The cancer can include solid tumors or hematologic malignancies.
[0095] The invention also provides agents for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis including a compound of formula (1) as disclosed herein. In one embodiment the agent is an anti-cancer agent. In another embodiment the agent is an anti-angiogenesis agent.
[0096] In one embodiment the agent contains a compound of formula (la) or (lb).
[0097] The invention also relates to the use of compounds of formula (I) in the preparation of a medicament for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis. In one embodiment the disorder is a proliferative disorder. In a specific embodiment the disorder is a cancer.
[0098] The compounds of the present invention surprisingly show low toxicity, together with a potent anti-proliferative activity.
[0099] In yet a further embodiment the invention provides a method of treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase including administration of a therapeutically effective amount of a compound of formula (I).
[0100] In one embodiment the method includes administration of a compound of formula (la) or (lb) as described herein.
[0101] In one embodiment the disorder is selected from the group consisting of but not limited to Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesis, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Pick's disease, Intracerebral haemorrhage Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, macular myopic degeneration, Rubeotic glaucoma, Interstitial keratitis, Diabetic retinopathy, Peters anomaly retinal degeneration, Cellophane Retinopathy; Cogan's Dystrophy;
Corneal Dystrophy; Iris Neovascularization (Rubeosis); Neovascularization of the Cornea;
Retinopathy of Prematurity; Macular Edema; Macular Hole; Macular Pucker;
Marginal Blepharitis, Myopia, nonmalignant growth of the conjunctiva; Inflammatory diseases and/or Immune system disorders including Rheumatoid Arthritis (RA), Osteoarthritis, Juvenile chronic arthritis, Graft versus Host disease, Psoriasis, Asthma, Spondyloarthropathy, Crohn's Disease, inflammatory bowel disease, Colitis Ulcerosa, Alcoholic hepatitis, Diabetes, Sjoegrens's syndrome, Multiple Sclerosis, Ankylosing spondylitis, Membranous glomerulopathy, Discogenic pain, Systemic Lupus Erythematosus, allergic contact dermatitis; Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease, schizophrenia, depression and dementia; Cardiovascular Diseases including Heart failure, restenosis, cardiac hypertrophy and arteriosclerosis; Fibrotic diseases including liver fibrosis, lung fibrosis, cystic fibrosis and angiofibroma;
Infectious diseases including Fungal infections, such as Candida Albicans, Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis, and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
[0102] The invention also provides agents for the treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase including a compound of formula (I) as disclosed herein. In one embodiment the agent is an anti-cancer agent.
[0103] The invention also relates to the use of compounds of formula (I) in the preparation of a medicament for the treatment of a disorder, disease or condition that can be treated by the inhibition of histone deacetylase.
[0104] The invention also provides a method for inhibiting cell proliferation including administration of an effective amount of a compound according to formula (I).
[0105] In yet an even further aspect the invention provides a method of treatment of a neurodegenerative disorder in a patient including administration of a therapeutically effective amount of a compound of formula (I). In one embodiment the method includes administration of a compound of formula (la) or (lb) as described herein. In one embodiment the neurodegenerative disorder is Huntington's Disease.
[0106] The invention also provides agents for the treatment of neurodegenerative disorder including a compound of formula (I) as disclosed herein. In one embodiment the agent is preferably anti-Huntington's disease agent.
[0107] The invention also relates to the use of compounds of formula (I) in the preparation of a medicament for the treatment of a neurodegenerative disorder.
In one embodiment the neurodegenerative disorder is Huntington's Disease.
[0108] In yet an even further aspect the invention provides a method of treatment of an inflammatory disease and/or immune system disorder in a patient including administration of a therapeutically effective amount of a compound of formula (1). In one embodiment the method includes administration of a compound of formula (la) or (lb) as described herein. In one embodiment the inflammatory disease and/or immune system disorder is rheumatoid arthritis. In another embodiment the inflammatory disease and/or immune system disorder is Systemic Lupus Erythematosus.
[0109] The invention also provides agents for the treatment of inflammatory disease 5 and/or immune system disorder including a compound of formula (I) as disclosed herein.
[0110] The invention also provides agents for the treatment of eye disease mediated by HDAC inhibition including a compound of formula (I) as disclosed herein. In one 10 embodiment, the eye disease is macular degeneration. In another embodiment, the eye disease is glaucoma. In another embodiment, the eye disease is retinal degeneration.
[0111] The invention also relates to the use of compounds of formula (I) in the 15 preparation of a medicament for the treatment of inflammatory disease and/or immunesystem disorder. In one embodiment the inflammatory disease and/or immune system disorder is rheumatoid arthritis. In another embodiment the inflammatory disease and/or immune system disorder is Systemic Lupus Erythematosus.
[0111a] In accordance with an aspect of the present invention there is provided a compound of the formula (I):
X
R2 ___________________ < 0-R4 N
Formula I
wherein R1 is a group of formula:
_( CR20-R 21 )õ,-( cR22R2),-(CR24R25 )0_NR26R27;
R2 is selected from the group consisting of: alkyl and heteroalkyl, each of which may be optionally substituted with one or more optional substituents wherein 23a each optional substituent is selected from the group consisting of halogen, =0, -CN, alkenyl, alkynyl and alkoxy;
R3 is H;
X and Y are H;
R4 is H;
each R5 is independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
each R6 is independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl;
each of which may be optionally substituted;
each R20, R21, R22, R23, R24 and R25 is independently selected from the group consisting of: H, halogen, -ON, -NO2, -CF3, -0CF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy heteroaryloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, aminosulfonyl, arylsulfonyl, arylsulfinyl -COOH, -C(0)0R5, -COR5, -SH, -SR6, -0R6 and acyl, each of which may be optionally substituted;
or R2 and R21 when taken together may form a group of formula =0 or =S, and/or R22 and R23 when taken together may form a group of formula =0 or =S, and/or R24 and R25 when taken together may form a group of formula =0 or =S;
23b each R26 and R27 is independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR5, and acyl, each of which may be optionally substituted, or R26 and R27 when taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycloalkyl group;
m, n and o are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
Z is ¨CH=CH- and is attached at ring position 5;
or a pharmaceutically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0112] In this specification a number of terms are used which are well known to a skilled addressee. Nevertheless for the purposes of clarity a number of terms will be defined.
[0113] As used herein, the term unsubstituted means that there is no substituent or that the only substituents are hydrogen.
[0114] The term "optionally substituted" as used throughout the specification denotes that the group may or may not be further substituted or fused (so as to form a condensed polycyclic system), with one or more substituent groups. Preferably the substituent groups are one or more groups independently selected from the group consisting of halogen, =0, =S, -CN, -NO2, -CF3, -0CF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, arylalkenyl, heteroarylalkenyl, cycloalkylheteroalkyl, heterocycloalkyiheteroalkyl, arylheteroalkyl, heteroarylheteroalkyl, hydroxy, 23c sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR5, and acyl, each of which may be optionally substituted, or R26 and R27 when taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycloalkyl group;
m, n and o are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
or a pharmaceutically acceptable salt or prod rug thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0112] In this specification a number of terms are used which are well known to a skilled addressee. Nevertheless for the purposes of clarity a number of terms will be defined.
[0113] As used herein, the term unsubstituted means that there is no substituent or that the only substituents are hydrogen.
[0114] The term "optionally substituted" as used throughout the specification denotes that the group may or may not be further substituted or fused (so as to form a condensed polycyclic system), with one or more substituent groups. Preferably the substituent groups are one or more groups independently selected from the group consisting of halogen, =0, =S, -CN, -NO2, -CF3, -0CF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, arylalkenyl, heteroarylalkenyl, cycloalkylheteroalkyl, heterocycloalkyiheteroalkyl, arylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycycloalkyl, alkoxyheterocycloalkyl, alkoxyaryl, alkoxyheteroaryl, alkoxycarbonyl, alkylaminocarbonyl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, phenoxy, benzyloxy, heteroaryloxy, arylalkyloxy, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonylamino, sulfinylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, sulfinyl, alkylsulfinyl, arylsulfinyl, aminosulfinylaminoalkyl, -COOH, -COR5, -C(0)0R5, CONHR5, NHCOR5, NHCOOR5, NHCONHR5, C(=NOH)R5, -SH, -SR5, -0R5 and acyl.
[0115] "Alkyl" as a group or part of a group refers to a straight or branched aliphatic hydrocarbon group, preferably a C1¨C14 alkyl, more preferably C1-C10 alkyl, most preferably C1-C6 unless otherwise noted. Examples of suitable straight and branched C1-C6 alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl, hexyl, and the like.
[0116] "Alkylamino" includes both monoalkylamino and dialkylamino, unless specified. "Monoalkylamino" means a ¨NH-Alkyl group, in which alkyl is as defined above. "Dialkylamino" means a ¨N(alkyl)2 group, in which each alkyl may be the same or different and are each as defined herein for alkyl. The alkyl group is preferably a C1-C6 alkyl group.
[0117] "Alkylamino" includes both monoalkylamino and dialkylamino, unless specified. "Monoalkylamino" means a ¨NH-Alkyl group in which alkyl is as defined above. "Dialkylamino" means a ¨N(alkyl)2 group in which each alkyl may be the same or different and are each as defined herein for alkyl. The alkyl group is preferably a C6 alkyl group.
[0118] "Arylamino" includes both mono-arylamino and di-arylamino unless specified.
Mono-arylamino means a group of formula aryl NH-, in which aryl is as defined herein.
di-arylamino means a group of formula (ary12) N- where each aryl may be the same or different and are each as defined herein for aryl.
[0119] "Acyl" means an alkyl-CO- group in which the alkyl group is as described herein. Examples of acyl include acetyl and benzoyl. The alkyl group is preferably a Cr C6 alkyl group.
[0120] "Alkenyl" as a group or part of a group denotes an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched preferably having 2-14 carbon atoms, more preferably 2-12 carbon atoms, most preferably 2-6 carbon atoms, in the normal chain. The group may contain a 5 plurality of double bonds in the normal chain and the orientation about each is independently E or Z. Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl and nonenyl.
[0121] "Alkoxy" refers to an ¨0-alkyl group in which alkyl is defined herein.
10 Preferably the alkoxy is a C1-C6alkoxy. Examples include, but are not limited to, nnethoxy and ethoxy.
[0122] "Alkenyloxy" refers to an -0- alkenyl group in which alkenyl is as defined herein. Preferred alkenyloxy groups are C1-C6alkenyloxy groups.
[0123] "Alkynyloxy" refers to an ¨0-alkynyl group in which alkynyl is as defined herein. Preferred alkynyloxy groups are C1-C6alkynyloxy groups.
[0124] "Alkoxycarbonyl" refers to an ¨C(0)-0-alkyl group in which alkyl is as defined herein. The alkyl group is preferably a C1-C6 alkyl group. Examples include, but not limited to, methoxycarbonyl and ethoxycarbonyl.
[0125] "Akylsulfinyl" means a ¨S(0)-alkyl group in which alkyl is as defined above.
The alkyl group is preferably a C1-C6 alkyl group. Exemplary alkylsulfinyl groups include, but not limited to, methylsulfinyl and ethylsulfinyl.
[0126] "Alkylsulfonyl" refers to a ¨S(0)2-alkyl group in which alkyl is as defined above. The alkyl group is preferably a C1-C6 alkyl group. Examples include, but not limited to methylsulfonyl and ethylsulfonyl.
[0127] "Alkynyl as a group or part of a group means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched preferably having from 2-14 carbon atoms, more preferably 2-12 carbon atoms, more preferably 2-6 carbon atoms in the normal chain. Exemplary structures include, but are not limited to, ethynyl and propynyl.
[0128] "Alkylaminocarbonyl" refers to an alkylamino-carbonyl group in which alkylamino is as defined above.
[0129] "Cycloalkyl" refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle preferably containing from 3 to 9 carbons per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, unless otherwise specified.
It includes monocyclic systems such as cyclopropyl and cyclohexyl, bicyclic systems such as decalin, and polycyclic systems such as adamantane.
[0130] "Cycloalkenyl" means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and preferably having from 5-carbon atoms per ring. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl. The cycloalkenyl group may be substituted by one or more substituent groups.
[0131] The above discussion of alkyl and cycloalkyl substituents also applies to the alkyl portions of other substituents, such as without limitation, alkoxy, alkyl amines, alkyl ketones, arylalkyl, heteroarylalkyl, alkylsulfonyl and alkyl ester substituents and the like.
[0132] "Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.
[0133] "Halogen" represents chlorine, fluorine, bromine or iodine.
[0134] "Heterocycloalkyl" refers to a saturated or partially saturated monocycli, bicyclic, or polycyclic ring containing at least one heteroatom selected from nitrogen, sulfur, oxygen, preferably from 1 to 3 heteroatoms in at least one ring. Each ring is preferably from 3 to 10 membered, more preferably 4 to 7 membered. Examples of suitable heterocycloalkyl substituents include pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, and 1,4-oxathiapane.
[0135] "Heterocycloalkenyl" refers to a heterocycloalkyl as described above but containing at least one double bond.
[0136] "Heterocycloalkylalkyl" refers to a heterocycloalkyl-alkyl group in which the heterocycloalkyl and alkyl moieties are as previously described. Exemplary heterocycloalkylalkyl groups include (2-tetrahydrofuryl)methyl, (2-tetra hydrothiofura nyl)methyl.
[0137] "Heteroalkyl" refers to a straight- or branched-chain alkyl group preferably having from 2 to 14 atoms, more preferably 2 to 10 atoms in the chain, one or more of which is a heteroatom selected from S, 0, and N. Exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl ainines, alkyl sulfides, and the like.
[0138] "Aryl" as a group or part of a group denotes (i) an optionally substituted monocyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) preferably having from 5 to 12 atoms per ring. Examples of aryl groups include phenyl, naphthyl, and the like; (ii) an optionally substituted partially saturated bicyclic aromatic carbocyclic moiety in which a phenyl and a C5_7 cycloalkyl or C5_7 cycloalkenyl group are fused together to form a cyclic structure, such as tetrahydronaphthyl, indenyl or indanyl.
[0139] "Arylalkenyl" means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described. Exemplary arylalkenyl groups include phenylallyl.
[0140] "Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C1.-5 alkyl moiety.
Exemplary arylalkyl groups include benzyl, phenethyl and naphthelenemethyl.
[0141] "Arylacyl" means an aryl-acyl- group in which the aryl and acyl moieties are as previously described. In general the aryl moiety is attached to the alkyl portion of the acyl moiety, typically to the terminal carbon of the alkyl portion of the acyl moiety.
Preferred arylacyl groups contain a C1..5 alkyl moiety in the acyl moiety.
Exemplary arylacyl groups include 2-phenyl-acetyl.
[0142] "Heteroaryl" either alone or part of a group refers to groups containing an aomatic ring (preferably a 5 or 6 membererd aromatic ring) having one or more heteroatoms as ring atoms in the aromatic ring with the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include nitrogen, oxygen and sulphur.
Examples of hetreoaryl include thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, isoindolizine, xantholene, phenoxatine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1H-indazole, purine, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, cinnoline, carbazole, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, oxazole, isooxazole, furazane, phenoxazine, 2-,3- or4- pyridyl, 2-, 3-, 4-, 5-, or 8-quinolyl, 1-, 3-, 4-, or 5- isoquinoliny11-, 2-, or 3- indolyl, and 2-, or 3-thienyl.
[0143] "Heteroarylalkyl" means a heteroaryl-alkyl group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a lower alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.
[0144] "Lower alkyl" as a group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having 1 to 6 carbon atoms in the chain, more preferably 1 to 4 carbons such as methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n-butyl, isobutyl or tertiary-butyl).
[0145] In Formula (I), as well as in Formulae (la) ¨ (lb) defining sub-sets of compounds within Formula (I), there is shown a benzimidazole ring system.
Within this ring system, there are substitutable positions at the 4-,5-, 6-, and 7-ring positions. In each of Formulae (I), (la), and (lb), there is a requirement for attachment of an acidic moiety at one of the ring positions. This acidic moiety may be provided by but is not limited to groups containing, a hydroxamic acid or salt derivatives of such acid which when hydrolyzed would provide the acidic moiety. In some embodiments the acidic moiety may be attached to the ring position through an alkylene group such as ¨CH2-or ¨CH2CH2-, or an alkenylene group such as -CH=CH-. Preferred positions for attachment of the acidic moiety are the 5¨ and 6¨ring positions.
[0146] It is understood that included in the family of compounds of Formula (I) are isomeric forms including diastereoisomers, enantiomers, tautomers, and geometrical isomers in "E" or "Z" configurational isomer or a mixture of E and Z isomers.
It is also understood that some isomeric forms such as diastereomers, enantiomers, and geometrical isomers can be separated by physical and/or chemical methods and by those skilled in the art.
[0147] Some of the compounds of the disclosed embodiments may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and /or diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the subject matter described and claimed.
[0148] Additionally, Formula (1) is intended to cover, where applicable, solvated as well as unsolvated forms of the compounds. Thus, each formula includes compounds having the indicated structure, including the hydrated as well as the non-hydrated forms.
[0149] In addition to compounds of the Formula (I), the HDAC inhibiting agents of the various embodiments include pharmaceutically acceptable salts, prodrugs, and active metabolites of such compounds, and pharmaceutically acceptable salts of such metabolites.
[0150] The term "Pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the above-identified compounds, and include pharmaceutically acceptable acid addition salts and base addition salts.
Suitable pharmaceutically acceptable acid addition salts of compounds of Formula (1) may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, sulfuric, and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, mak, tartaric, citric, fumaric, maleic, alkyl sulfonic, arylsulfonic. Suitable pharmaceutically acceptable base addition salts of compounds of Formula (1) include metallic salts made from lithium, sodium, potassium, magnesium, calcium, aluminium, and zinc, and organic salts made from organic bases such as choline, diethanolamine, morpholine. Other examples of organic salts are:
ammonium salts, quatemary salts such as tetramethylammonium salt; amino acid addition salts such as salts with glycine and arginine. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Co., Easton, PA 1995. In the case of agents that are solids, it is understood by those skilled in the art that the inventive compounds, agents and salts may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulae.
[0151] "Prodrug" means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of formula (I). For example an ester prodrug of a compound of formula (I) containing a hydroxyl group . 30 may be convertible by hydrolysis in vivo to the parent molecule. Suitable esters of compounds of formula (I) containing a hydroxyl group, are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-f3-hydroxynaphthoates, gestisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates. As another example an ester prodrug of a compound of formula (1) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule. (Examples of ester prodrugs are those described by F. J. Leinweber, Drug Metab. Res.,18:379, 1987).
[0152] Preferred HDAC inhibiting agents include those having an IC50 value of 10 0.4 or less.
[0153] Specific compounds of the invention include the following:
341-(3-Dimethylamino-2,2-dimethyl-propy1)-2-( (2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-N
hydroxy-acrylamide <
341-(3-Dimethylamino-2,2-dimethyl-propy1)-2-isopropy1-1H-benzoimidazol-5-y1]-N-hydroxy--/ acrylamide 312-Buty1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide 3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-(2-io11 nnethylsulfanyl-ethyl)-1H-benzoimidazol-5-A-N-- ________________________________ hydroxy-acrylamide OH
3-[1-(3-Dimethylamino-2,2-dimethyl-propy1)-2-ethoxyrnethy1-1H-benzoimidazol-5-y1]-N-N hydroxy-acrylamide /N
3-[1-(3-Dimethylamino-2,2-dimethyl-propy1)-2-( N.
isobuty1-1H-benzoimidazol-5-y1]-N-hydroxy-N
a cryla m ide 3-[1-(2-Diethylamino-ethyl)-2-isobuty1-1H-( __ c" 40 benzoimidazol-5-y1]-N-hydroxy-acrylamide r-N) 342-Buty1-1-(2-diethylamino-ethyl)-1H-\ 10 N
benzoimidazol-5-y1FN-hydroxy-acrylamide r-N) 312-But-3-yny1-1-(3-dimethylamino-2,2-dimethyl-\ 40 propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-N
acrylamide H OH 342-But-3-eny1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-.
hydroxy-acrylamide N OH 3-[2-But-3-eny1-1-(2-diethylamino-ethyl)-1H-iobenzoimidazol-5-y1]-N-hydroxy-acrylamide r-N) 342-But-3-yny1-1-(2-diethylamino-ethyl)-1H-- ______ 10 0E1 benzoimidazol-5-y11-N-hydroxy-acrylamide r-N) HNcm 341-(3-Dimethylamino-2,2-d imethyl-propy1)-2-\ (3,3,3-trifluoro-propy1)-1H-benzoirnidazol-5-y1]-N-hydroxy-acrylamide HN
F 3-[1-(2-Diethylaminc-ethyl)-2-(3,3,3-trifluoro-F F o propyl)-1 H-benzoimidazol-5-y1]-N-hydroxy-N acrylamide õN H 341-(2-Diethylamino-ethyl)-2-ethoxymethy1-1 H-\ _____ o<
N
40 benzoimidazol-5-y1FN-hydroxy-acrylamide HN/ H 3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-0 methyl-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (6, 341-(2-Diethylamino-ethyl)-2-(2,2-dimethyl-NH
,CH propyI)-1 H-benzoimidazol-5-y1]-N-hydroxy-N
acrylamide r) N! N-Hydroxy-311-(3-isopropylamino-propy1)-2-(3,3, 3-trifluoro-propy1)-1 H-benzoimidazo1-5-y1]-N acrylamide o 3-[2-(2,2-Dimethyl-propyI)-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-N
acrylamide / NH
341-(2-Diisopropylamino-ethyl)-2-(2,2-dimethyl-propy1)-1H-benzoimidazol-5-A-N-hydroxy-N
acrylamide 341-(2-Diisopropylamino-ethyl)-2-isobuty1-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide 311-(3-Dimethylamino-2,2-dimethyl-propy1)-2-/ <
hex-3-eny1-1H-benzoimidazol-5-A-N-hydroxy-acrylamide 3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-io(2,4,4-trimethyl-penty1)-1H-benzoimidazol-5-y11-7& ( N-hydroxy-acrylamide /N
o 312-Cyclohexy1-1-(3-dimethylamino-2,2-(JRNN = dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-\N-- hydroxy-acrylamide 342-Bicyclo[2.2.1]hept-5-en-2-y1-1-(3-; dimethylamino-2,2-dimethyl-propyI)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide 341-(2-Diethylamino-ethyl)-2-hex-3-eny1-1 H-/ 40 benzoimidazol-5-y9-N-hydroxy-acrylamide rN) 341-(2-Diisopropylamino-ethyl)-2-hex-3-eny1-1 / ___ NN IP IHN benzoimidazol-5-y1FN-hydroxy-acrylamide N)"
342-Hex-3-eny1-1-(2-isopropylamino-ethyl)-1 N
= benzoimidazol-5-y1FN-hydroxy-acrylamide 342-Hex-3-eny1-1-(3-isopropylamino-propy1)-1 benzoimidazol-5-y1]-N-hydroxy-acrylamide 3-[1-(2-Ethylamino-ethyl)-2-hex-3-eny1-1H-/ NN benzoimidazol-5-y1]-N-hydroxy-acrylamide 3-[1-(2-Diethylamino-ethyl)-2-hexyl-1 H-benzoimidazol-5-yll-N-hydroxy-acrylamide N-Hydroxy-3-[1-(3-isopropylamino-propyI)-2-(2,4,4-trimethyl-penty1)-1H-benzoimidazol-5-y1]-N acrylamide 3-[2-(2,2-Dimethyl-propyI)-1-(3-isopropylamino-propyI)-1 H-benzoimidazol-5-y1FN-hydroxy-N
acrylamide ,11 1" 341-(2-Diisopropylamino-ethyl)-2-(3,3,3-trifluoro-propyI)-1 H-benzoimidazol-5-y1]-N-hydroxy-F 111 acrylamide F
N-Hydroxy-3[2-isobuty1-1 -(2-isopropylamino-K a r ethyl)-1 H-benzoimidazol-5-y1]-acrylamide N ''Illre-/ NH
342-(2,2-Dimethyl-propy1)-1 -(2-ethylamino-)( 0 ethyl)-1H-benzoimidazol-5-y11-N-hydroxy-. 'P
\-- , acrylamide 341 -(2-Ethylami no-ethyl)-2-isobuty1-1 H-K a TH benzoimidazol-5-y1]-N-hydroxy-acrylamide HN
) 341 -(2-Diisopropylamino-ethyl)-2-(2,4,4-( <
r HO trimethyl-pentyI)-1 H-benzoi midazol-5-yll-N-hydroxy-acrylamide )N)--.
N-Hydroxy-341-(2-isopropylamino-ethyl)-2-( < 10 : (2,4,4-trimethyl-pentyI)-1 H-benzoimidazol-5-y1J-N
)---- acrylamide N
3-[1-(2-Ethylamino-ethyl)-2-(2,4,4-trimethyl-. (I\ pentyI)-1 H-benzoimidazol-5-y1]-N-hydroxy-NH--- .1" acrylamide 341 -(2-Diethylamino-ethyl)-2-(2,4,4-trimethyl-(N 41 \ pentyI)-1 H-benzoimidazo1-5-y1]-N-hydroxy-/) H''' acrylamide 341 -(2-Diethylamino-ethyl)-2-propy1-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide , 1"7,y" 40 \ -,,,,, /'---312-Buty1-1-(2-diisopropylamino-ethyl)-1H-[.
= benzoimidazol-5-y1J-N-hydroxy-acrylamide HO
gp-(2-ethylamino-ethyl)-1 benzoimidazol-5-A-N-hydroxy-acrylamide H
f, 311 -(2-Diethylam ino-ethyl)-2-(2-methylsulfanyl-ethyl)-1H-benzoimidazol-5-y1FN-hydroxy-/ acrylamide o 3[2-Buty1-1-(2-isopropylamino-ethyl)-1 benzoimidazol-5-y1FN-hydroxy-acrylamide / NH
OF1 342-Buty1-1-(3-isopropylamino-propy1)-1H-\
benzoimidazol-5-y1]-N-hydroxy-acrylamide 341-(1-Benzyl-piperidin-4-y1)-2-buty1-1 H-\ 40 benzoimidazol-5-A-N-hydroxy-acrylamide 44, 342-But-3-eny1-1-(2-ethylamino-ethyl)-1 / 40 benzoimidazol-5-y1]-N-hydroxy-acrylamide rNH
3[2-Hexy1-1-(2-isopropylamino-ethyl)-1 H-\
benzoimidazol-5-A-N-hydroxy-acrylamide / NH
)(' 0 341-(2-Dimethylamino-ethyl)-2-(2,4,4-trimethyl-(pentyI)-1 H-benzoimidazol-5-y1]-N-hydroxy-rj acrylamide 341-(2-Ethylamino-ethyl)-2-hexyl-1 H-40 NIH benzoimidazol-5-y11-N-hydroxy-acrylamide N-Hydroxy-3-[1-(2-isopropylamino-ethyl)-2-' I \
(3,3,3-trifluoro-propyI)-1 H-benzoimidazol-5-y1]-N
acrylamide HN\
3-[1-(2-Dimethylamino-ethyl)-2-hex-3-eny1-1 H-/ __ <
ip benzoinnidazol-5-yll-N-hydroxy-acrylamide 3-[1-(2-Amino-ethy1)-2-(2,4,4-trimethyl-penty1)-< 40 OH 1 H-benzoimidazol-5-y1J-N-hydroxy-acrylamide (-7( 112,4 3-[1-(2-Amino-ethyl)-2-(2-methoxy-nony1)-1H-OH /
benzoimidazol-5-y1]-N-hydroxy-acrylamide Hp õAN 342-Buty1-1-(2-dimethylamino-ethyl)-1H-\ vi benzoimidazol-5-y1]-N-hydroxy-acrylamide o 311-(2-Dimethylamino-ethyl)-2-hexy1-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide N-{2-[1-(2-Diethylamino-ethyl)-5-(2-"" OH
hydroxycarbamoyl-vinyI)-1 H-benzoimidazol-2-ylj-ethyl)-3,3-dimethyl-butyramide o 3-{1-(2-Diethylamino-ethyl)-242-(2,2-dimethyl-HN¨\ propionylamino)-ethy1]-1 H-benzoimidazol-5-y1}-N
N-hydroxy-acrylamide \
3-{1 -(2-Diethylam ino-ethyl)-2-[(2, 2-dimethyl-r propionylamino)-methy1]-1 H-benzoimidazol-5-y1}-N-hydroxy-acrylamide rN) N-E1-(2-Diethylamino-ethyl)-5-(2-hydroxycarbamoyl-viny1)-1 H-benzoimidazol-2-N
ylmethyli-butyramide 3-[1-(2-ethylamino-ethyl) -2-(3,3-dimethyl-butyI)-____ (N
1 H-benzoimidazol-5-yli-N-hydroxy-acrylamide OH
NH
3-[2-(3,3-Dimethyl-butyI)-1-(2-Dimethylamino-)\ __ ethyl)-1 H-benzoimidazol-5-y1]-N-hydroxy-N
acrylamide ¨4\
341-(2-Dimethylamino-ethyl)-2-penty1-1 H-. 411 \ 0 benzoimidazol-5-y1]-N-hydroxy-acrylamide F ___________ F
3-[1-(2-Dimethylamino-ethyl)-2-(2,2,2-trifluoro-ethyl)-1H-benzoimidazol-5-yli-N-hydroxy-N
4100 \0 acrylamide HN-OH
=
N-Hydroxy-341-(5-methy1-1H-pyrazol-3-y1)-2-õ
( 10 : (2,4,4-trimethyl-penty1)-1H-benzoimidazol-5-y9-acrylamide 341-(2-Ethylamino-ethyl)-2-penty1-I H-2 isbenzoimidazol-5-y9-N-hydroxy-acrylamide HN\
342-Butyl-I -pyrrolidin-3-y1-1 H-benzoimidazol-5-ioyI)-N-hydroxy-acrylamide NH
3-(2-Buty1-1-piperidin-4-y1-1H-benzoimidazol-5-yI)-N-hydroxy-acrylamide N
N-Hydroxy-311-(2-isopropylamino-ethyl)-2-, / OH penty1-1H-benzoimidazol-5-y1Facrylamide HN
0 N-Hydroxy-341-(2-methylamino-ethyl)-2-non-, eny1-1H-benzoimidazol-5-y1]-acrylamide __________________ 401 _---NH
N-Hydroxy-341-(2-methylamino-ethyl)-2-non-6-10 eny1-1H-benzoinnidazol-5-y1]-acrylamide io[r H 342-Hexy1-1-(2-methylannino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide N-Hydroxy-3-[1-(2-methylamino-ethyl)-2-pentyl-/ __ <
ioOH
1H-benzoimidazol-5-A-acrylamide "N\
N-Hydroxy-3-[1-(2-methylamino-ethy1)-2-octyl-11101 1H-benzoimidazol-5-y1Facrylamide FIN \
341-(2-Amino-ethyl)-2-octy1-1H-benzoimidazol-TH 5-y11-N-hydroxy-acrylannide 3-{2-Buty1-142-(isopropyl-methyl-amino)-ethy1]-OH / <
1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide 3-{112-(Ethyl-methyl-amino)-ethy1]-2-penty1-1 r(H-ON
benzoimidazol-5-y1}-N-hydroxy-acrylamide r-N\
0,4 3-(2-Hexy1-1-pyrrolidin-3-y1-1H-benzoimidazol-5-yI)-N-hydroxy-acrylamide OH 3[2-Buty1-1-(1-methyl-pyrrolidin-3-y1)-1 H-a N '"W"' benzoimidazol-5-yli-N-hydroxy-acrylamide N\
OH
3-(2-Butyl-1 -piperidin-3-y1-1 H-benzoimidazol-5-a N
yI)-N-hydroxy-acrylamide 0.4 3-(2-Hexy1-1-piperidin-3-y1-1H-benzoimidazol-5-) yI)-N-hydroxy-acrylamide 0 3-(1-{2-[Ethyl-(2-methoxy-ethyl)-amino]-ethyl}-2-N
11101 N-0H penty1-1H-benzoimidazol-5-y1)-N-hydroxy-H
acrylamide 0 3-{2-Butyl-1 42-(ethyl-methyl-amino)-ethy1]-1H-N
H benzoimidazol-5-y1}-N-hydroxy-acrylamide r 0 N-Hydroxy-341-(1-methyl-piperidin-3-y1)-2-OH
r/1 401 penty1-1H-benzoimidazol-5-y1]-acrylamide 0 3-{142-(Ethyl-hexyl-amino)-ethy11-1 benzoimidazol-5-y1}-N-hydroxy-acrylamide 0 3-{142-(Ethyl-pentyl-amino)-ethy1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide o 3-{142-(Ethyl-heptyl-amino)-ethy1]-1H-"N N,OH
benzoimidazol-5-y1}-N-hydroxy-acrylamide jj-j-(E)-3-(2-hexy1-1-(1-(2-hydroxyethyl)piperidin-3-NH
\oH yl )- 1 H-benzo[d]imidazol-5-y1)-N-hydroxyacrylamide 3-(2-Buty1-1-{24ethyl-(3-hydroxy-propyl)-amino]-\NOH ethy11-1H-benzoimidazol-5-y1)-N-hydroxy-. acrylamide 3-(1-{2-[Ethyl-(3-hydroxy-propy1)-amino]-ethyll-/
/ ____ < S 2-penty1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide o (E)-N-hydroxy-3-(1 -(1 -phenethylpyrrolidin-3-y1)-1 H-benzo[d]imidazol-5-yl)acrylamide o =(E)-N-hydroxy-3-(1 -(1 -pentylpiperidin-3-y1)-1 N--\N benzo[d]imidazol-5-yl)acrylamide 3-{1-[2-(Butyl-ethyl-amino)-ethy1]-1H-benzoimidazol-5-yll-N-hydroxy-acrylarnide rrN) (E)-N-hydroxy-3-(1-(1-phenethylpiperidin-3-y1)-c,, 1 H-benzo[d]imidazol-5-ypacrylamide o = (E)-N-hydroxy-3-(1-(1-(3-phenylpropyppiperidin-Nc'H
H 3-y1)-1 H-benzo[d]imidazol-5-yl)acrylamide 41, (E)-N-hydroxy-3-(1-(1-(3-phenylpropyl)pyrrolidin-3-y1)-1 H-benzo[d]imidazol-5-yl)acrylamide o 3-{141-(3,3-Dimethyl-buty1)-pyrrolidin-3-y1]-1 H-N = voH
benzoimidazol-5-y1)-N-hydroxy-acrylamide =
0 (E)-3-(1-(2-(diethylamino)ethyl)-1H-N
benzo[djimidazol-5-y1)-N-hydroxyacrylamide rN) - ___________________ õõ 3-[2-(4-Cyano-butyl)-1-(2-diethylamino-ethyl)-\
C'El 1 H-benzoimidazol-5-y1FN-hydroxy-acrylamide o (E)-3-(1-(1-butylpiperidin-3-y1)-1 H-N
benzo[d]imidazol-5-y1)-N-hydroxyacrylamide NH
OH
0 (E)-N-hydroxy-3-(1-(1-(pent-4-enyl)piperidin-3-OH y1)-1 H-benzo[d]imidazol-5-yl)acrylamide (E)-3-(1-(1-(3,3-dimethylbutyl)piperidin-4-y1)-1H-benzo[d]imidazol-5-y1)-N-hydroxyacrylamide tr,ori 3-[1-(2-Diethylamino-ethy1)-2-propylamino-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide O (E)-N-hydroxy-3-(1 -(2-(isopropyl(propyl)amino)ethyl)-1 H-N benzo[d]imidazol-5-ypacrylamide Ny o 3-{142-(Butyl-isopropyl-amino)-ethy1]-1 benzoimidazol-5-y11-N-hydroxy-acrylamide 0 N-Hyd roxy-3-{1 -[2-(isopropyl-pentyl-amino)-OH
ethyI]-1 H-benzoimidazol-5-y1}-acrylamide \\r-N
3-[2-(5-Cyano-penty1)-1-(2-diethylamino-ethyl)-\ 1 H-benzoimidazol-5-y11-N-hydroxy-acrylamide 1:
0 3-(1-{2-[(3,3-Dimethyl-buty1)-ethyl-aminoFethyl}-401 ( H1 H-benzoimidazol-5-y1)-N-hydroxy-acrylamide 0 3-{1-[2-(Ethyl-propyl-am ino)-ethy1]-1 OH
110 benzoimidazol-5-y1}-N-hydroxy-acrylamide 0 N-Hyd roxy-3-(1 -{24isopropyl-(2-methyl-penty1)-OH
amino]-ethyl}-1 H-benzoimidazol-5-y1)-acrylamide o "\r¨N
(E)-N-hydroxy-3-(1-(2-(isopropy1(4,4,4-40, V trifluorobutypamino)ethyl)-1 H-benzo[d]imidazol-N 5-yl)acrylamide F F
3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-OH
1101 propylamino-1 H-benzoinnidazol-5-y1]-N-hydroxy-N acrylamide o 3-{142-(Ethyl-hexyl-amino)-ethy11-2-methyl-1H-i) OH benzoimidazol-5-y1}-N-hydroxy-acrylamide rN
o 3-{142-(Butyl-ethyl-amino)-ethy1]-2-F __ N trifluoromethy1-1H-benzoimidazol-5-y1}-N-NH
hydroxy-acrylamide FrJ
3-{142-(Ethyl-hexyl-amino)-ethy1]-2-F N OH
F __ trifluoromethy1-1H-benzoimidazol-5-y1}-N-FriN hydroxy-acrylamide rN
o (E)-3-(1-(2-(dibutylamino)ethyl)-2-propy1-1H-/,, benzo[d]imidazol-5-y1)-N-hydroxyacrylamide 0 341-(2-Dipropylamino-ethyl)-1H-benzoimidazol-OH
N
5-y1]-N-hydroxy-acrylamide o N-Hydroxy-3-(1-{2-psopropyl-(3-methyl-butyl)-amino]-ethyl}-1 H-benzoimidazol-5-y1)-acrylamide O 3-(1-{2-[(3,3-Dimethyl-buty1)-methyl-amino]-(OH
ethyl}-1 H-benzoimidazol-5-y1)-N-hydroxy-acrylamide N
O 3-(1-{2-[(2-Ethyl-butyl)-methyl-amino]-ethyl}-1 40/ ( H
\N benzoimidazo1-5-y1)-N-hydroxy-acrylamide (E)-3-(1-(2-(bis(3,3-dimethylbutyl)amino)ethyly N,,OH
1 H-benzo[d]imidazol-5-y1)-N-hydroxyacrylamide 0 (E)-3-(1-(2-(diisobutylamino)ethyl)-1H-NVOH benzo[d]imidazol-5-y1)-N-hydroxyacrylamide 0 3-{14243,3-Dimethyl-butylamino)-ethy1]-1 H-N
N/OH
benzoimidazol-5-y1}-N-hydroxy-acrylamide HN
0 N-Hydroxy-3-{1-[2-(methyl-pent-4-enyl-amino)-N SI N/OH
ethyl]-1H-benzoimidazol-5-y1}-acrylamide N
N
, 0 3-(1-{2-[(3,3-Dimethyl-buty1)-propyl-amino]-/) 40 õ, Nõ..õ...OH
N
ethyl}-1 H-benzoimidazol-5-y1)-N-hydroxy-acrylamide 0 3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-OH
\ 110 rr methylsulfanyl-1 H-benzoimidazol-5-y1]-N-N hydroxy-acrylamide N"----/ o 3-{142-(3,3-Dimethyl-butylamino)-ethy1]-2-õ.
propyl-1 H-benzoimidazo1-5-y1}-N-hydroxy-acrylamide \---- 0 34142-(3,3-Dimethyl-butylamino)-ethyl]-2-(2,2-dimethyl-propy1)-1 H-benzoimidazo1-5-y1]-N-7( hydroxy-acrylamide HN
k [1-{2-[Bis-(3,3-dimethyl-butyl)-amino]-ethyl)-2-7( < =
(2,2-dimethyl-propy1)-1H-benzoimidazol-5-A-N-. hydroxy-acrylamide 0 3-{1-[2-(2,2-Dimethyl-propylam ino)-ethyl]-1H-OH
benzoimidazol-511}-N-hydroxy-acrylamide 3-(1-{2-[(2,2-Dimethyl-propyI)-propyl-amino]-ethyll-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide 3-{1 42-(3,3-Dimethyl-butylamino)-ethyl]-2-ethyl-N OH
1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide NH
[0154] The compounds disclosed are hydroxamate compounds containing a hydroxamic acid type moiety in one of the substituents that may be inhibitors of deacetylases, including but not limited to inhibitors of histone deacetylases.
The 5 hydroxamate compounds may be suitable for prevention or treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis when used either alone or together with a pharmaceutically acceptable carrier, diluent or excipient. An example of such a disorder is cancer. .
[0155] Administration of compounds within Formula (I) to humans can be by any of the accepted modes for enteral administration such as oral or rectal, or by parenteral administration such as subcutaneous, intramuscular, intravenous and intradermal routes. Injection can be bolus or via constant or intermittent infusion. The active compound is typically included in a pharmaceutically acceptable carrier or diluent and in an amount sufficient to deliver to the patient a therapeutically effective dose. In various embodiments the inhibitor compound may be selectively toxic or more toxic to rapidly proliferating cells, e.g. cancerous tumors, than to normal cells.
[0156] As used herein the term 'cancer' is a general term intended to encompass the vast number of conditions that are characterised by uncontrolled abnormal growth of cells.
[0157] It is anticipated that the compounds of the invention will be useful in treating various cancers including but not limited to bone cancers including Ewing's sarcoma, osteosarcoma, chondrosarcoma and the like, brain and CNS tumours including acoustic neuronia, neuroblastomas, glioma and other brain tumours, spinal cord tumours, breast cancers, colorectal cancers, advanced colorectal adenocarcinomas, colon cancers, endocrine cancers including adenocortical carcinoma, pancreatic cancer, pituitary cancer, thyroid cancer, parathyroid cancer, thymus cancer, multiple endocrine neoplasma, gastrointestinal cancers including stomach cancer, esophageal cancer, small intestine cancer, Liver cancer, extra hepatic bile duct cancer, gastrointestinal carcinoid tumour, gall bladder cancer, genitourinary cancers including testicular cancer, penile cancer, prostate cancer, gynaecological cancers including cervical cancer, ovarian cancer, vaginal cancer, uterus/endometrium cancer, vulva cancer, gestational trophoblastic cancer, fallopian tube cancer, uterine sarcoma, head and neck cancers including oral cavity cancer, lip cancer, salivary gland cancer, larynx cancer, hypopharynx cancer, orthopharynx cancer, nasal cancer, paranasal cancer, nasopharynx cancer, leukemias including childhood leukemia, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, acute promyelocytic leukemia, plasma cell leukemia, myelomas, haematological disorders including myelodysplastic syndromes, myeloproliferative disorders, aplastic anemia, Fanconi anemia, Waldenstroms Macroglobulinemia, lung cancers including small cell lung cancer, non-small cell lung cancer, lymphomas including Hodgkin's disease, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, AIDS related Lymphoma, B-cell lymphoma, Burkitt's lymphomaõ eye cancers including retinoblastoma, intraocular melanoma, skin cancers including melanoma, non-melanoma skin cancer, merkel cell cancer, soft tissue sarcomas such as childhood soft tissue sarcoma, adult soft tissue sarcoma, Kaposi's sarcoma, urinary system cancers including kidney cancer, Wilms tumour, bladder cancer, urethral cancer, and transitional cell cancer.
[0158] Exemplary cancers that may be treated by the compounds of the present invention are breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer (e.g. renal cell carcinoma), gastric cancer, colon cancer, colon cancer, colorectal cancer and brain cancer.
[0159] Exemplary cancers that may be treated by compounds of the present inventions include but are not limited to B-cell lymphoma (e.g. Burkitt's lymphoma), leukemias (e.g. acute promyeiocytiC leukemia), cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma.
[0160] Exemplary cancers that may be treated by compounds of the present invention include solid tumors and hematologic malignancies. In another embodiment, preferred cancers that may be treated the compounds of the present invention are colon cancer, prostate cancer, hepatoma and ovarian cancer.
[0161] The compounds may also be used in the treatment of a disorder involving, relating to or, associated with dysregulation of histone deacetylase (HDAC).
[0162] There are a number of disorders that have been implicated by or known to be mediated at least in part by HDAC activity, where HDAC activity is known to play a role in triggering disease onset, or whose symptoms are known or have been shown to be alleviated by HDAC inhibitors. Disorders of this type that would be expected to be amenable to treatment with the compounds of the invention include the following but not limited to: Proliferative disorders (e.g. cancer); Neurodegenerative diseases including Huntington's Disease, Polyglutamine diseases, Parkinson's Disease, Alzheimer's Disease, Seizures, Striatonigral degeneration, Progressive supranuclear palsy, Torsion dystonia, Spasmodic torticollis and dyskinesis, Familial tremor, Gilles de la Tourette syndrome, Diffuse Lewy body disease, Pick's disease, Intracerebral haemorrhage Primary lateral sclerosis, Spinal muscular atrophy, Amyotrophic lateral sclerosis, Hypertrophic interstitial polyneuropathy, Retinitis pigmentosa, Hereditary optic atrophy, Hereditary spastic paraplegia, Progressive ataxia and Shy-Drager syndrome; Metabolic diseases including Type 2 diabetes; Degenerative Diseases of the Eye including Glaucoma, Age-related macular degeneration, macular myopic degeneration, Rubeotic glaucoma, Interstitial keratitis, Diabetic retinopathy, Peter's anomaly, retinal degeneration, Cellophane Retinopathy; Cogan's Dystrophy;
Corneal Dystrophy; Iris Neovascularization (Rubeosis); Neovascularization of the Cornea;
Retinopathy of Prematurity; Macular Edema; Macular Hole; Macular Pucker;
Marginal Blepharitis, Myopia, nonmalignant growth of the conjunctiva; Inflammatory diseases and/or Immune system disorders including Rheumatoid Arthritis (RA), Osteoarthritis, Juvenile chronic arthritis, Graft versus Host disease, Psoriasis, Asthma, Spondyloarthropathy, Crohn's Disease, inflammatory bowel disease, Colitis Ulcerosa, Alcoholic hepatitis, Diabetes, Sjoegrens's syndrome, Multiple Sclerosis, Ankylosing spondylitis, Membranous glomerulopathy, Discogenic pain, Systemic Lupus Erythematosus, allergic contact dermatitis; Disease involving angiogenesis including cancer, psoriasis, rheumatoid arthritis; Psychological disorders including bipolar disease, schizophrenia, depression and dementia; Cardiovascular Diseases including Heart failure, restenosis, cardiac hypertrophy and arteriosclerosis; Fibrotic diseases including liver fibrosis, lung fibrosis, cystic fibrosis and angiofibroma;
Infectious diseases including Fungal infections, such as Candida Albicans, Bacterial infections, Viral infections, such as Herpes Simplex, Protozoal infections, such as Malaria, Leishmania infection, Trypanosoma brucei infection, Toxoplasmosis and coccidiosis, and Haematopoietic disorders including thalassemia, anemia and sickle cell anemia.
[0163] In using the compounds of the invention they can be administered in any form or mode which makes the compound bioavailable. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the condition to be treated, the stage of the condition to be treated and other relevant circumstances. We refer the reader to Remingtons Pharmaceutical Sciences, 19th edition, Mack Publishing Co. (1995) for further information.
[0164] The compounds of the present invention can be administered alone or in the form of a pharmaceutical composition in combination with a pharmaceutically acceptable carrier, diluent or excipient. The compounds of the invention, while effective themselves, are typically formulated and administered in the form of their pharmaceutically acceptable salts as these forms are typically more stable, more easily crystallised and have increased solubility.
[0165]The compounds are, however, typically used in the form of pharmaceutical compositions which are formulated depending on the desired mode of administration.
As such in a further embodiment the present invention provides a pharmaceutical composition including a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent or excipient. The compositions are prepared in manners well known in the art.
[0166] The invention in other embodiments provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. In such a pack or kit can be found a container having a unit dosage of the agent (s). The kits can include a composition comprising an effective agent either as concentrates (including lyophilized compositions), which can be diluted further prior to use or they can be provided at the concentration of use, where the vials may include one or more dosages.
Conveniently, in the kits, single dosages can be provided in sterile vials so that the physician can employ the vials directly, where the vials will have the desired amount and concentration of agent(s). Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
[0167] The compounds of the invention may be used or administered in combination with one or more additional drug (s) that are chemotherapeutic drugs or HDAC
inhibitor drugs and/or procedures (e.g. surgery, radiotherapy) for the treatment of the disorder/diseases mentioned. The components can be administered in the same formulation or in separate formulations. If administered in separate formulations the compounds of the invention may be administered sequentially or simultaneously with the other drug (s).
[0168] In addition to being able to be administered in combination with one or more additional drugs that include chemotherapeutic drugs or HDAC inhibitor drugs the compounds of the invention may be used in a combination therapy. When this is done the compounds are typically administered in combination with each other. Thus one or more of the compounds of the invention may be administered either simultaneously (as ' a combined preparation) or sequentially in order to achieve a desired effect. This is especially desirable where the therapeutic profile of each compound is different such that the combined effect of the two drugs provides an improved therapeutic result [0169] Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), 5 and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0170] These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like.
It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the 15 like.
Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminium monostearate and gelatin.
[0171] If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
[0172] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile 25 solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
[0173] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with 30 at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium 35 carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[0174] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0175] The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
Examples of embedding compositions which can be used include polymeric substances and waxes.
[0176] If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
[0177] The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
[0178] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
[0179] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0180] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-s agar, and tragacanth, and mixtures thereof.
[0181] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[0182] Dosage forms for topical administration of a compound of this invention include powders, patches, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required.
[0183] The term "therapeutically effective amount" or "effective amount" is an amount sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations. An effective amount is typically sufficient to palliate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state. A therapeutically effective amount can be readily determined by an attending diagnostician by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective amount a number of factors are to be considered including but not limited to, the species of animal, its size, age and general health, the specific condition involved, the severity of the condition, the response of the patient to treatment, the particular compound administered, the mode of administration, the bioavailability of the preparation administered, the dose regime selected, the use of other medications and other relevant circumstances.
[0184] A preferred dosage will be a range from about 0.01 to 300 mg per kilogram of body weight per day. A more preferred dosage will be in the range from 0.1 to 100 mg per kilogram of body weight per day, more preferably from 0.2 to 80 mg per kilogram of body weight per day, even more preferably 0.2 to 50 mg per kilogram of body weight per day. A suitable dose can be administered in multiple sub-doses per day.
[0185] As discussed above, the compounds of the embodiments disclosed inhibit histone deacetylases. The enzymatic activity of a histone deacetylase can be measured using known methodologies [Yoshida M. et al, J. Biol. Chem., 265, (1990), J. Taunton et al, Science 1996 272: 408]. In certain embodiments, the histone deacetylase inhibitor interacts with and/or reduces the activity of more than one known histone deacetylase in the cell, which can either be from the same class of histone deacetylase or different class of histone deacetylase. In some other embodiments, the histone deacetylase inhibitor interacts and reduces the activity of predominantly one histone deacetylase, for example HDAC-1, HDAC-2, HDAC-3 or HDAC-8 which belongs to Class I HDAC enzymes [De Ruijter A.J.M. et al, Biochem. J., 370, (2003)]. HDACs can also target non-histone substrates to regulate a variety of biological functions implicated in disease pathogenesis. These non-histone substrates include Hsp90, a-tubulin, p53, NFkb and HIF1a [Drummond et al., Annu. Rev.
Pharmacol. Toxicol. 45:495 (2004)]. Certain preferred histone deacetylase inhibitors are those that interact with, and/or reduce the activity of a histone deacetylase which is involved in tumorigenesis, and these compounds may be useful for treating proliferative diseases. Examples of such cell proliferative diseases or conditions include cancer (include any metastases), psoriasis, and smooth muscle cell proliferative disorders such as restenosis. The inventive compounds may be particularly useful for treating tumors such as breast cancer, colon cancer, lung cancer, ovarian cancer, prostate cancer, head and/or neck cancer, or renal, gastric, pancreatic cancer and brain cancer as well as hematologic malignancies such as lymphomas and leukemias. In addition, the inventive compounds may be useful for treating a proliferative disease that is refractory to the treatment with other chemotherapeutics; and for treating hyperproliferative condition such as leukemias, psoriasis and restenosis. In other embodiments, compounds of this invention can be used to treat pre-cancer conditions or hyperplasia including familial adenomatous polyposis, colonic adenomatous polyps, myeloid dysplasia, endometrial dysplasia, endometrial hyperplasia with atypia, cervical dysplasia, vaginal intraepithelial neoplasia, benign prostatic hyperplasia, papillomas of the larynx, actinic and solar keratosis, seborrheic keratosis and keratoacanthoma.
[0186] Additionally compounds of the various embodiments disclosed herein may be useful for treating neurodegenerative diseases, and inflammatory diseases and/or immune system disorders.
[0187] In one embodiment the disorder is selected from the group consisting of cancer, inflammatory diseases and/or immune system disorders (e.g. rheumatoid arthritis, systemic lupus erythematosus), angiofibroma, cardiovascular diseases, fibrotic diseases, diabetes, autoimmune diseases, chronic and acute neurodegenerative disease like Huntington's disease, Parkinson's disease, disruptions of nerval tissue and infectious diseases like fungal, bacterial and viral infections. In another embodiment the disorder is a proliferative disorder.
[0188] The histone deacetylase inhibitors of the invention have significant antiproliferative effects and promote differentiation, cell cycle arrest in the G1 or G2 phase, and induce apoptosis.
SYNTHESIS OF DEACETYLASE INHIBITORS
[0189] The agents of the various embodiments may be prepared using the reaction routes and synthesis schemes as described below, employing the techniques available in the art using starting materials that are readily available. The preparation of particular compounds of the embodiments is described in detail in the following examples, but the artisan will recognize that the chemical reactions described may be readily adapted to prepare a number of other agents of the various embodiments. For example, the synthesis of non-exemplified compounds may be successfully performed by modifications apparent to those skilled in the art, e.g. by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions. A list of suitable protecting groups in organic synthesis can be found in T.W. Greene's Protective Groups in Organic Synthesis, Td Edition, John Wiley & Sons, 1999. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the various embodiments.
[0190] Reagents useful for synthesizing compounds may be obtained or prepared according to techniques known in the art.
[0191] In the examples described below, unless otherwise indicated, all temperatures in the following description are in degrees Celsius and all parts and percentages are by weight, unless indicated otherwise.
[0192] Various starting materials and other reagents were purchased from commercial suppliers, such as Aldrich Chemical Company or Lancaster Synthesis Ltd., and used without further purification, unless otherwise indicated.
Tetrahydrofuran (THE) and N,N-dimethylformamide (DMF) were purchased from Aldrich in SureSeal bottles and used as received. All solvents were purified by using standard methods in the art, unless otherwise indicated.
[0193] The reactions set forth below were performed under a positive pressure of 5 nitrogen, argon or with a drying tube, at ambient temperature (unless otherwise stated), in anhydrous solvents, and the reaction flasks are fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven-dried and/or heat-dried. Analytical thin-layer chromatography was performed on glass-backed silica gel 60 F 254 plates (E Merck (0.25 mm)) and eluted with the appropriate solvent ratios 10 (v/v). The reactions were assayed by TLC and terminated as judged by the consumption of starting material.
[0194] The TLC plates were visualized by UV absorption or with a p-anisaldehyde spray reagent or a phosphomolybdic acid reagent (Aldrich Chemical, 20wt% in ethanol) 15 which was activated with heat, or by staining in iodine chamber. Work-ups were typically done by doubling the reaction volume with the reaction solvent or extraction solvent and then washing with the indicated aqueous solutions using 25% by volume of the extraction volume (unless otherwise indicated). Product solutions were dried over anhydrous sodium sulfate prior to filtration, and evaporation of the solvents was under 20 reduced pressure on a rotary evaporator and noted as solvents removed in vacuo.
Flash column chromatography [Still et al, J. Org. Chem., 43, 2923 (1978)] was conducted using Silica gel 60 (Merck KGaA, 0.040-0.063 mm, 230-400 mesh ASTM) and a silica gel:crude material ratio of about 20:1 to 50:1, unless otherwise stated.
Hydrogenolysis was done at the pressure indicated or at ambient pressure.
[0195] NMR spectra were recorded on a Bruker AVANCE 400 spectrometer operating at 400 MHz for 11-I NMR and 100 MHz for 13C-NMR. NMR spectra are obtained as CDCI3 solutions (reported in ppm), using chloroform as the reference standard (7.26 ppm and 77.14 ppm) or CD3OD (3.3 and 49.3 ppm), or DMSO-d6 (2.50 and 39.5 ppm) or an internal tetramethylsilane standard (0.00 ppm) when appropriate.
Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, q =
quartet, m =
multiplet, br = broadened, dd = doublet of doublets, dt = doublet of triplets.
Coupling constants, when given, are reported in Hertz.
[0196] Mass spectra were obtained using LC/MS either in ESI or APCI. All melting points are uncorrected.
[0197] All final products had greater than 90% purity (by HPLC at wavelengths of 254 nm and/or 220 nm). Analytical HPLC conditions for purity check: Xterra RP18 3.5 gm 4.6 x 20mm IS column; 2.0 ml/min, gradient 5-65% B over 4 min, then 65-95%b over 1 min and 95%6 for additional 0.1 min; Solvent A: H20 with 0.1% TFA;
Solvent B:
acetonitrile with 0.1% TFA.
[0198] The following examples are intended to illustrate the embodiments disclosed and are not to be construed as being limitations thereto. Additional compounds, other than those described below, may be prepared using the following described reaction scheme or appropriate variations or modifications thereof.
SYNTHESIS
[0199] Scheme I and ll illustrates the procedure used for preparing compounds of formula lb, wherein X and Y are hydrogens, compounds (VII) of formula la can be prepared by analogous procedure, for example, by the choice of appropriate starting material. For example, in the case of Z is ¨CH=CH- and attached to C5-position in Formula lb, such compound(s) can be synthesized by analogous method illustrated in Scheme I and ll starting with a substituted cinnamic acid (e.g. trans-3-nitro-4-chloro-cinnamic acid), appropriate amine component (R1NF12), carboxylic acid component (R2CO2H, Scheme I) or aldehyde (R2CHO, Scheme II), and appropriate hydroxylamine or N-alkyl hydroxylamine (NHR3OH where R3 is defined as above in Formula la).
[0200] Specifically, the hydroxamate compounds Formula lb can be synthesized by the synthetic route shown in Scheme I. The reaction of trans-4-chloro-3-nitrocinnamic acid (I) with an amine R1NH2 in the present of a base (e.g. triethylamine) in an appropriate solvent (e.g. dioxane) gave (II). Treatment of (II) in methanol under acid catalysis (e.g. sulfuric acid) resulted in esterification providing (III).
Alternatively, the carboxylic acid (I) may be esterified to the methyl ester (la) and then the chloride was replaced by the appropriate amine component R1NH2 to give compound (III). The nitro group of (III) can be reduced by appropriate reducing agent (e.g. tin (II) chloride) and , the resulting phenylenediamine (IV) was coupled with an acid R2CO2H to give amide (V) which was subsequently cyclized in an appropriate solvent (e.g. acetic acid) to give benzimidazole (VI) (J. Med. Chem. 2001, 44, 1516-1529). The hydroxamate compounds (VI) were obtained from methyl ester (VI) by a known synthesis method (J.
Med. Chem., 2002, 45, 753-757).
Scheme I
02N la 02N
OH Base la OH Me0H 02N lb 0v pp.
CI IW dioxane WN H2SO4 H ii H iii Me0H o, RiNH2,/
H+ Base CI IW dioxane la SnCl2 H2N R2CO2H
AcOH/MedHN coupling reagent IV
n RV and/orO' .,R2 R' W
V
ItpLILs.... R44 40 , NH2OH.H.C1 R2 -\N pl N.OH
NaOCH3 R' VI vii [0201] Alternatively, as depicted in Scheme II, compound (VI) was prepared by reacting with an appropriate aldehyde component R2CHO in the presence of a reducing agent of nitro group (e.g. tin (II) chloride or zinc powder) in one-pot (Tetrahedron Letters, 2000, 41, 9871-9874). Formic acid was used to prepare compound (VI) when R2= H.
Scheme II
SnCl2 or Zn N
02N AcOH/Me0H N
R' WN Ilirvi H Ill HCO2H, SnCl2 __________________________________________ )1,- VI (R2 = H) Me0H
[0202] in both Schemes I & II, the benzimidazole ring may be constructed by a cyclization step involving either an aldehyde or a carboxylic acid. The following reaction steps 1-4 refer to the use of carboxylic acid for the cyclization of (IV) via (V) to form benzimidazole derivatives (VI), followed by the conversion of ester (VI) to the hydroxamate (VII). For one-pot cycylization of (III) to (VI), see the procedures under Example 1.
Step 1: Reduction of nitro group [0203] To a pre-stirred solution of starting material (III, 1.0 mmol) in 50 mL
of co-solvent (glacial acetic acid: methanol= 2:8), Tin chloride was added (5.0 mmol). The resulting solution was heated to 55 C overnight and then cooled to room temperature.
The solvent was removed and the mixture was neutralized with sodium bicarbonate to pH 8. The crude product was extracted with dichloromethane (20 mL) for three times.
The organic extracts were combined and washed with water (15 mL) twice and brine (15 mL) once and further dried over Na2SO4 for 1 hour. It was filtered and concentrated; the diamino product (IV) was purified by flash chromatography.
Step 2: Amide formation [0204] To a pre-stirred solution of carboxylic acid (1.1 mmol), diamino product (IV, 1.0 mmol) and PyBOP (1.1 mmol) in 10 mL of dried dichloromethane, was added DIEA
(3.0 mmol) via a syringe. The resulting mixture was stirred at room temperature for 4 hours. The amide product (V) was purified by silica gel column chromatography.
Step 3: Cyclization [0205] The amide product (V), obtained in Step 2, was treated with 5 mL of glacial acetic acid, the resulting solution was heated to 75 C for 24 hours. After cooling down to it, the solvent was removed under vacuum to give product (VI) near quantitatively.
Step 4: Hydroxamic acid formation [0206] To a stirred solution of ester (VI) and NH2OH=FICI (10 equiv.) in Me0H
(0.5 M) was added Na0Me solution (20 equiv.) at - 78 C. The reaction mixture was then allowed to warm up slowly to room temperature. The reaction was monitored by LC/MS
and was completed in around 15-60 min. IN HCI was then added slowly into the reaction mixture at 0 C. The desired product was separated by reverse-phase preparative HPLC and the fractions containing the desired product were freeze-dried.
The hydroxamate product (VI) was obtained as TEA salt (isolated yield varies between 40 - 70%).
[0207] Scheme III illustrates another alternative procedure used for preparing , compounds of formula lb, where X and Y are hydrogens and R2 is selected from the group R11S(0)R13-, R11S(0)2R13-, R11c(0)N(R12)R13_, R11S02N(R12)R13-, R11N(R12)c(0)R13_, R11N(Ri2)so2R13_, R11N(R12)C(0)N(R12)R13- and heteroalkyl.
For example, in the case of Z is -CH=CH- and attached to C5-position in Formula lb, such compound(s) (XIII) can be synthesized by analogous method illustrated in Schemes I &
starting with appropriate (III), appropriate Fmoc protected amino acids, appropriate acid chlorides or aldehydes, and hydroxylamine.
Scheme III
o o OMe SnC12/H+ H2N lei OMe I.
R1-N Me0H HN
i H III R1 IV , - -H 0 A Fmoc-HN-0-14 i 0 Fmoc-N n n OH 0 H2N 0 and/or 0 OMe __________________ N. 40 ', I
- HN Fmoc-HN n R1 Me0H/H+
OMe 20% Piperidine N
nN 4g _________ if/ _____ 1 40 OMe n H2N 1 Fmoc-HN rj Ri XI R1 x NaBH(OAc)3 R12-COCI [or R12-S02C1]
CH3COOH 0 Triethyl amine z 1 Iµl 0 OMe 0 z __ i 40 m -N1--i n FJ e i-NH 1 n r1 R12 R1 XII
R"12 Ri XiV [R12-S02] NH2OH.HCI
NH2OH.HCI
N
N Na0Me 0 a0Me 0 n 11101 1 )1\ii i <N OH
.
rN1-1 n ri RI 1 n=1, 2 n=1, 2 [0208] More specifically, for example, the hydroxamate compounds Formula lb, where X and Y are hydrogens, R2 is selected from the group R11S(0)R13-, R11S(0)2R13-, R"C(0)N(R12)R13-, Fe1s02N(R12)R13_, R11N(R12)C(0)R13-, R11N(R12)S02R13-, R11N(R12)C(0)N(R12)R13- and heteroalkyl; and Z is attached to C5-position, can be synthesized by the synthetic route shown in Scheme Ill. Appropriate intermediate (Ill) was reduced with tin chloride to the corresponding diamines (IV). The coupling reaction with appropriate Fmoc protected amino acids in the presence of PyBOP gave coupling product(s) (VIII) and/or (IX). Without further separation, (VIII) and/or (IX) were subjected to cyclization under acid conditions and yielded benzimdiazole (X).
The key intermediate (XI) can be obtained by treating (X) with 20% piperidine.
Treatment of (XI) with an appropriate acid chloride or an appropriate sulfonyl chloride gave (XII) and the target compounds (XIII) were obtained by using similar method described in Scheme I.
[0209] When (XI) was reacted with an appropriate aldehyde under reduction 5 conditions (NaBH(OAc)3 /CH3CO2H), (XIV) was obtained and can be transformed to corresponding hydroxamate derivatives (XV) by the same methods described above.
[0210] Scheme IV illustrates some reactions to further modify R1 side chain.
If the R1 side chain contained a protecting group such as Boc in compound (Vial), it could be 10 removed before converting to the final hydroxamic acid (Vila). The intermediate (Via) could be modified by acylation, reductive alkylation, alkylation or sulfonylation to form new analogs (VIlb, Vlic, Viid and Vile) through new intermediates (Vib, Vic, Vid and Vie). The above described methods were also applied to R1 = heterocycles, e.g., R1 =
N-Boc-piperidin-3-yl, N-Boc-piperidin-4-y1 and N-Boc-pyrrolidin-3-yl.
Scheme IV
o o 0 R2-N SI OMe H4*
--).- R2-<' N fa `- OMe NH OKHCI N 0 NH
2 ,... R2_</
N N W-P N OH
Vial H
NaOCH3 -.. Vla L.i Vila BOCN .Ri 1 HN..R11 H14..
N
OMe NH2OH.HCI R2_.N fa 0 R12CO2H or R2-<' 0 N NOH.
(Rump ______,...
N iqP H
v. L----. Vlb NaOCH3 H VIlb . ' Y. Ri 1 12 R N. u 0 it R
o o o OMe 0 R CHO R2--N liffl N id N,OH
R2- 1101 OMe NH2OH.HCI R2_.
ip. .
N
Reductive H Vic NaOCH3 H
L-1 via VlIc amination Ri2 NRi 1, ---....õ--HN,Ri 1 0.12 m rl 1'1' R11 N N-OH
R12X N NH2OH.HCI R2_<, 0 H
N
H Vld NaOCH3 (X = halide) R12____N, H I/11d R1 2._ pd, 0 '' \ 0 OMe N-OH
H
N
R12S0201 Vie NaOCH3 1:3 IfIle R124-N,Ril 8 R12_g-N-Ril II
[0211] Scheme V illustrates some alternative method to prepared (Via) and (Vic).
The primary amine (II1a2) was prepared either from (la) or via (Mai). The derivertization of the amino group (e.g., reductive amination) could be performed either from (111a2) or (VIa2). The products, i.e., (111a2-1) and (VIa2-1), could be further derivertized (e.g., reductive amination of the secondary amine).
Scheme V
H2N''-'NHBoc 02N
02N io o, ________ HN H+ 02N
CI H 111a1 HN
la NHBoc HNH2 111 a2 H2N, ¨ NH2 02N n R2CHO or HCO2H R24 al 1 R12CH0 __ R241 SCI2 or Zn N 11W
HN
11182 V1a2 reductive amination Vla2-1 reductive amination R2CHO or HCO2H R12 SnCl2 or Zn N
(y"
02N = 0.- 0 fa 2N
N
HN HN IWP
Vla2-2 111a2-1 \¨N
R1`2,..¨ NH
[0212] The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the subject matter hereof. They should not be considered as limiting the scope of the disclosure, but merely as being illustrative and representative thereof.
Preparation of intermediates III
[0213] Compound (III) was prepared either from (I) via (II) or from (I) via (la) (Scheme I and V). The following are examples of (III).
Intermediate 1 3-[4-(2-Dimethylamino-ethylamino)-3-nitro-phenyn-acrylic acid methyl ester [0214] A mixture of 3-(4-chloro-3-nitro-phenyl)acrylic acid methyl ester (la, 0.658 g, 2.72 mmol), N,N-dimethylethylenediamine (0.90 mL, 8.20 mmol) and triethylamine (1.2 mL, 8.6 mmol) in dioxane (20 mL) was heated at 80 C for 5h. The solution was evaporated and the residue was added DCM and aqueous Na2CO3. The DCM (x3) , extracts were concentrated and the residue was added Et0Ac-hexane. The resulting red solid was filtered to give the titled compound (0.672 g, 84.2%). HPLC
purity at 254 nm: 99.2%, tR = 1.59 min. LCMS (ESI) m/z: 294 ([M Fi]). 1H NMR (CDCI3 CD30D) 8 8.21 (1H, d, J = 2.1 Hz), 7.56 (1H, dd, J = 9.0, 2.1 Hz), 7.48 (1H, d, J =
16.0 Hz), 6.81 (1H, d, J = 9.0 Hz), 6.20 (1H, d, J = 15.9 Hz), 3.70 (3H, s), 3.34 (2H, t, J =
6.5 Hz), 2.56 68 =
(2H, t, J = 6.4 Hz), 2.23 (6H, s); 13C NMR (CDCI3 + CD30D) 8 167.3, 145.4, 142.6, 134.0, 131.1, 127.1, 121.3, 114.8, 114.0, 56.7, 51.1, 44.6,40.1.
Intermediate 2 344-(2-Diethylamino-ethylamino)-3-nitro-phenylFacrylic acid methyl ester.
[0215] Yellow solid. LCMS (ESI) m/z: 322 ([M + HIP). 1H NMR (CDCI3) 8 8.73 (1H, t-like, J = 4.3 Hz), 8.32 (1H, d, J = 2.0 Hz), 7.62 (1H, dd, J = 9.2, 2.0 Hz), 7.58 (1H, d, J
= 15.9 Hz), 6.85 (1H, d, J = 9.0 Hz), 6.29 (1H, d, J = 15.9 Hz), 3.80 (3H, s), 3.35 (2H, td, J = 5.4, 6.0 Hz), 2.77 (2H, t, J = 6.2 Hz), 2.59 (4H, q, J = 7.1 Hz), 1.07 (6H, t, J = 7.1 Hz).
Intermediate 3 344-(2-Ethylamino-ethylamino)-3-nitro-phenylFacrylic acid methyl ester [0216] Red solid. LCMS (ESI) m/z: 294 ([kl H]). 1H NMR (DMSO-d6) 58.49 (1H, t, J = 6.1 Hz), 8.35 (1H, d, J = 2.0 Hz), 7.96 (1H, dd, J = 9.1, 1.9 Hz), 7.62 (1H, d, J =
16.0 Hz), 7.20 (1H, d, J = 9.1 Hz), 6.52 (1H, d, J = 16.0 Hz), 3.75 (2H, td, J
= 6.5, 6.2 Hz), 3.70 (3H, s), 3.08 (2H, t, J = 6.5 Hz), 2.93 (4H, q, J = 7.2 Hz), 1.17 (6H, t, J = 7.2 Hz).
Intermediate 4 344-(2-lsopropylamino-ethylamino)-3-nitro-phenylFacrylic acid methyl ester [0217] Red solid. LCMS (ESI) m/z: 308 ([M H]+). 1H NMR (DMSO-d6) 8 8.58 (1H, t, J = 5.6 Hz), 8.33 (1H, d, J = 2.0 Hz), 7.94 (1H, dd, J = 9.1, 1.9 Hz), 7.60 (1H, d, J =
16.0 Hz), 7.14 (1H, d, J = 9.2 Hz), 6.49 (1H, d, J = 16.0 Hz), 3.70 (3H, s), 3.56 (2H, masked by water peak, identified by COSY), 3.10 (1H, septet, J = 6.4 Hz), 2.94 (2H, t, J = 6.2 Hz), 1.10 (6H, d, J = 6.4 Hz).
Intermediate 5 344-(3-Dimethylamino-2,2-dimethyl-propylamino)-3-nitro-phenylFacrylic acid methyl ester.
[0218] Red solid. LCMS (ESI) m/z: 336 ([M + Hr.). 1H NMR (CDCI3) 8 9.73 (1H, br s or t), 8.33 (1H, d, J = 2.0 Hz), 7.60 (1H, dd, J = 8.9, 2.0 Hz), 7.59 (1H, d, J = 16.1 Hz), 6.88 (1H, d, J = 9.1 Hz), 6.28 (1H, d, J = 15.9 Hz), 3.80 (3H, s), 3.21 (2H, d, J = 4.6 Hz), 2.36 (2H, s), 2.34 (6H, s), 1.04 (6H, s).
Intermediate 6 3-[4-(2-Diisopropylamino-ethylamino)-3-nitro-phenyl]acrylic acid methyl ester [0219] Yellow solid. LCMS (ESI) m/z: 350 UM + Hr). 1H NMR (CDCI3) 8 8.76 (1H, t-like, J = 4.3 Hz), 8.32 (1H, d, J = 2.0 Hz), 7.61 (1H, dd, J = 8.3, 2.7 Hz), 7.58 (1H, d, J
= 15.8 Hz), 6.85 (1H, d, J = 9.0 Hz), 6.29 (1H, d, J = 15.9 Hz), 3.79 (3H, s), 3.31 (2H, td, J = 5.3, 6.1 Hz), 3.08 (2H, septet, J = 6.6 Hz), 2.84 (2H, t, J = 6.2 Hz), 1.07 (12H, d, J = 6.6 Hz).
Intermediate 7 3-[4-(2-Methylamino-ethylamino)-3-nitro-phenyl]-acrylic acid methyl ester [0220] Red solid. LCMS (ESI) m/z: 280 ([M + H]4). 1H NMR (CDCI3) 8 8.54 (1H, t-like, J = 4.2 Hz), 8.33 (1H, d, J = 2.1 Hz), 7.63 (1H, dd, J = 9.0, 2.2 Hz). 7.59 (1H, d, J =
16.0 Hz), 6.90 (1H, d, J = 9.0 Hz), 6.31 (1H, d, J = 15.9 Hz), 3.80 (3H, s), 3.45 (2H, td, J = 5.8, 5.6 Hz), 2.96 (2H, t, J = 6.2 Hz), 2.50 (3H, s).
Intermediate 8 314-(2-tert-Butoxycarbonylamino-ethylamino)-3-nitro-pheny1]-acrylic acid methyl ester (111a1) Step 1:
[0221] A suspension of trans-4-chloro-3-nitrocinnamic acid (1, 5.057 g, 22.22 mmol) in Me0H (40 mL) and DCM (20 mL) was stirred and cooled in a dry-ice/acetone bath.
SOCl2 (1.0 mL, 13.8 mmol) was added to the above mixture. Dry-ice bath was removed, then the mixture was warmed to room temperature and stirred at 40 C
till the reaction completed. The solution was evaporated to dryness to a pale yellow solid (5.364 g, 99.9%). HPLC purity at 254 nm: 99.5%; tR = 2.96 min. LCMS (ESI) m/z:
and 212 (very weak signal, [M+H-Me0H]+).
Step 2:
[0222] A mixture of 3-(4-chloro-3-nitro-phenyl)acrylic acid methyl ester (la, 0.243 g, 1.00 mmol), N-Boc-ethylenediamine (0.316 mL, 2.0 mmol) and triethylamine (0.50 mL, 3.59 mmoL) in dioxane (7 mL) was heated at 80 C for about 80 h. The solution was evaporated and the residue was added Me0H. The resulting solid was filtered and washed with Me0H. 344-(2-tert-Butoxycarbonylamino-ethylamino)-3-nitro-pheny1]-, acrylic acid methyl ester (111a1) was obtained as bright yellow solid (9.193 g, 52.6%).
HPLC purity at 254 nm: 96.0-98.1%; tR = 3.27 min. LCMS (ESI) m/z: 366 (DM +
HIE), 310 (M+H-56), 266 (M+H-Boc). 1H NMR (CDCI3) 68.41 (1H, br t like, NHAr), 8.31 (1H, d, J = 1.8 Hz), 7.63 (1H, dd, J = 9.0, 1.7 Hz), 7.57 (1H, d, J = 16.0 Hz), 6.98 (1H, d, J =
8.9 Hz), 6.30 (1H, d, J = 15.9 Hz), 3.80 (3H, s), 3.52 (2H, m), 3.45 (2H, m), 1.45 (9H, s); 13C NMR (CDCI3) 8 166.9, 155.7, 145.8, 142.3, 134.1, 131.5, 127.1, 121.8, 115.4, 113.9, 79.5, 51.2, 42.7, 39.1, 27.9.
Intermediate 9 5 3-(4-(2-Amino-ethylamino)4-nitro-phenylFacrylic acid methyl ester (111a2) [0223] Method 1:
Remove Boc protecting group from (111a1) under acidic condition: 1) HCl/Me0H;
2) TFA/DCM.
[0224] Method 2:
10 To the ester (la, 2.47 g, 10.2 mmol) in dioxane (102 mL, 0.1 M) was added ethylenediamine (Merck. Product no. 8.00947, 2.04 mL, 30.6 mmol) followed by triethylamine (2.8 mL, 20.47 mmol). The resulting mixture was heated to 90 C
and stirred for 20 hours. The completion of reaction was confirmed by using HPLC
(where the product 111a2 tR = 1.6 min, starting material la tR = 3.1 min). Upon completion, 15 solvent was removed and the crude was dissolved in DCM. The solution was washed with water, brine, dried over Na2SO4 and filtered. The filtrate after removal of the solvent gave the titled compound 111a2. Yield =98 %, LCMS m/z: 266 ([M+H]).
Example 1 20 Preparation of 311 -(3-Dimethylamino-2,2-dimethyl-propy1)-2-(2,2-dimethyl-propy1)-1H-benzoimidazol-5-A-N-hydroxy-acrylamide (1) [0225] The titled compound (1) was prepared according to Scheme 1 and 11, by using appropriate starting materials.
Step 1:
25 [0226]
To a pre-stirred solution of trans-4-chloro-3-nitrocinnamic acid (1, 11g, 48 ' mmol) in dioxane (200 mL) was added triethylamine (20 mL, 126 mmol), followed by 3-dimethylamino-2,2-dimethyl-propylamine (20 mL, 143 mmol). The reaction mixture was allowed to stir at 100 C for 1-2 days till all starting material was fully converted. Then, the solvent was removed under vacuum followed by the addition of H20 (250 mL) to 30 dissolve the residue. Conc. HCI was added till pH 1 with orange precipitation. The suspension was filtered and residue was washed with H20 several times to obtain (11) as orange solid (13 g, 84%). LCMS (ESI) m/z: 322 ([M+H]).
Step 2:
[0227] Compound (11,13 g, 40.5 mmol) was dissolved in Me0H (250 mL) followed by the addition of conc. H2SO4(5 mL). The reaction mixture was allowed to stir at 80 C for 18 h. Solvent was removed under vacuum and H20 (250 mL) was added to dissolve the residue. Na2CO3 was added till pH 8-9, subsequently, Me0H was added and stirred for 1 hour. Then, the suspension was filtered under vacuo and the residue was washed with H20 several times to obtain ester (III) as orange solid (10 g, 74%). LCMS
(ESI) m/z: 336 ([M+H]).
Step 3:
[0228] To a stirred solution of ester (III, 1 equiv) and SnC12=2H20 (5 equiv) in AcOH
and Me0H (0.2 M, 1:9 mixture) was added 3,3-dimethyl butyraldehyde (1.5 equiv). The resulting mixture was heated to 45 C with stirring. The progress of the reaction was monitor by LC/MS. When the reaction was completed, solvent was removed under reduced pressure at 30-35 C. To the resulting residue, 20 mL of water and 20 mL of ethyl acetate were added at room temperature, the pH value of the mixture was carefully adjusted to 9-10 by addition of conc. NH3=H20. The mixture was stirred for half an hour, followed by centrifuge if necessary to separate the organic layer. The organic layer was collected. The aqueous phase and residue (oily-solid precipitate) were extracted another 3 times more with ethyl acetate as described above. The combined organic contents were dried over sodium sulphate, filtered and evaporated to dryness. The resulting oily residue was purified by flash column chromatography (isolated yield of cyclized product (VI) varies between 50-90%). LCMS (ESI) m/z: 386 ([M+H]).
Step 4:
[0229] To a stirred solution of ester (VI) and NH2OH.HCI (10 equiv.) in Me0H
(0.5M) was added Na0Me (20 equiv.) at ¨ 78 C. The reaction mixture was then allowed to warm up slowly to room temperature. The reaction was monitored by LC/MS and was completed in around 15 min. 1N HCI was then added slowly into the reaction mixture at 0 C. The desired product was separated by prep-HPLC and the fractions containing the desired product were freeze-dried. Product (VII) was obtained as di-TFA
salt (isolated yield varies between 40 ¨ 70%). HPLC purity at 254 nm: 100%, tR =
0.78 min.
LCMS (ESI) m/z: 387 ([M+H]). 1H NMR (DMSO-d6) 8 0.99 (15H, s), 2.91 (6H, s), 2.92 (2H, s), 3.32 (2H, bs), 4.30 (2H, s), 6.49 (1H, d, J = 15.8 Hz), 7.56 (1H, d, J = 9.0 Hz), 7.61 (1H, d, J = 15.76 Hz), 7.83 (1H, d, J = 9.0 Hz), 7.85 (1H, s), 9.22 (1H, bs), 10.72 (1H, bs); 13C NMR (DMSO-d6) 8 162.6, 154.2, 138.0, 135.3 (br), 134.7, 131.5, 122.8, 119.2, 115.2, 114.0,66.5, 51.1, 46.7, 38.4, 38.3, 33.6, 29.1, 22.8.
Example 2 Preparation of 3-[1-(3-Dimethylamino-2,2-dimethyl-propy1)-2-isopropyl-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (2) [0230] The titled compound (2) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm:
100%, tR
= 0.54 min. LCMS (ES!) miz: 359 ([M+H]+). 1H NMR (DMSO-d6) 6 1.05 (6H, s), 1.40 (6H, d, J = 6.36 Hz), 2.92 (6H, s), 3.36 (2H, s), 3.58 (1H, m, J = 6.4 Hz), 4.44 (2H, s), 6.55 (1H, d, J = 15.8 Hz), 7.63 (1H, d, J = 15.8 Hz), 7.66 (1H, d, J = 8.7 Hz), 7.95 (1H, d, J = 8.7 Hz), 7.90 (1H, s), 9.71 (1H, bs), 10.80 (1H, bs).
Example 3 Preparation of 3-[2-Butyl-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide (3) [0231] The titled compound (3) was prepared according to the procedures described in Example 1, by using appropriate starting materials. Yield: 74 mg as TFA
salt. HPLC
purity at 254 nm: 99.0%, tR = 0.89 min. LCMS (ES!) m/z: 373 ([M + 1H
NMR
(CD30D) 8 7.99 (1H, d, J = 8.8 Hz), 7.84 (1H, s), 7.72 (1H, d, J = 8.7 Hz), 7.55 (1H, d, J
= 15.8 Hz), 6.53 (1H, d, J = 15.7 Hz), 4.55 (2H, s), 3.43 (2H, s), 3.24 (2H, overlapped with CD2HOD), 3.00 (6H, s), 1.90 (2H, pentet, J = 7.2 Hz), 1.49 (2H, m), 1.21 (6H, s), 0.98 (3H, t, J = 7.3 Hz); 13C NMR (CD30D) 5 165.5 (br), 158.2, 139.8, 135.3, 135.1, 132.4, 126.4, 120.6 (br), 115.6, 114.3, 68.7, 53.5, 47.8 (Mex2), 39.5, 29.9, 27.2, 23.6 (Mex2), 23.3, 13.9.
Example 4 Preparation of 341-(3-D imethylamino-2,2-di methyl-propyI)-2-(2-methylsu Ifanyl-ethyl)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (4) [0232] The titled compound (4) was prepared according to the procedures described in Example 1, by using appropriate starting materials. Yield: 17 mg as TFA
salt. HPLC
purity at 254 nm: 96.2%, tR = 0.75 min. LCMS (ES!) miz: 391 UM + 1H
NMR
(CD30D) 8 8.02 (1H, d, J = 8.3 Hz), 7.92 (1H, s), 7.80 (1H, d, J = 8.7 Hz), 7.69 (1H, d, J
= 15.8 Hz), 6.60 (1H, d, J = 15.8 Hz), 4.49 (2H, s), 3.50 (2H, t, J = 7.2 Hz), 3.37 (21-I, s), 3.03 (2H, t, J = 7.2 Hz), 2.95 (6H, s), 2.18 (3H, s), 1.25 (6H, s); 13C NMR
(CD30D) 8 163.7, 154.6, 138.2, 133.9, 132.8, 132.5, 124.1, 118.2, 113.3, 113.2, 66.7, 51.5, 45.9 (Mex2), 37.6, 29.9, 26.2, 21.7 (Mex2), 13.7.
Example 5 Preparation of 3-[1-(3-Dimethylamino-2,2-dimethyl-propy1)-2-isobutyl-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide (6) [0233] The titled compound (6) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm:
96.2%, tR
= 0.82 min. LCMS (ESI) m/z: 373 ([M+H]+). 1H NMR (DMSO-d6): 8 10.80 (1H, s), 9.47 (1H, s), 7.93 (1H, s), 7.90 (1H, d, J=6.6 Hz), 7.64 (1H, d, J= 7.4 Hz), 7.62 (1H, d, J=
15.5 Hz), 6.54 (1H, d, J= 15.8 Hz), 4.39 (2H, s), 3.33 (2H, s), 2.97 (2H, d, J
= 7.26 Hz), 2.92 (6H, s), 2.35 (1H, qn), 1.09 (6H; s), 0.97 (6H, d, J = 6.6 Hz).
Example 6 Preparation of 341-(2-Diethylamino-ethyl)-2-isobuty1-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (7) [0234] The titled compound (7) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm:
99.0%, tR
= 0.56 min. LCMS (ESI) m/z: 359 ([M+H]). 1H NMR (DMSO-d6): 8 10.81 (1H, s), 10.13 (1H, s), 7.90 (1H, s), 7.81 (1H, d, J= 8.5 Hz), 7.66 (1H, d, J= 8.6 Hz), 7.61 (1H, d, J=
15.8 Hz), 6.53 (1H, d, J= 15.8 Hz), 4.72 (2H, t, J = 7.8 Hz), 3.30 (2H, d), 2.93 (2H, d, J
= 7.2 Hz), 2.27 (1H, m), 1.24 (6H, t, J = 7.2 Hz), 0.97 (6H, d, J= 6.6 Hz) 13C
NMR
(DMSO-d6) 8 162.7, 158.5, 158.2, 155.2, 138.4, 133.9, 131.0, 123.0, 118.6, 116.0, 111.6, 48.8, 46.8, 34.1, 27.1, 22.2, 8.5.
Example 7 Preparation of 342-Buty1-1-(2-diethylamino-ethyl)-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (8) [0235] The titled compound (8) was prepared according to the procedures described in Example 1, by using appropriate starting materials. Yield: 61 mg (20% in two steps) as TFA salt. HPLC purity at 254 nm: 98.1%, tR = 0.59 min. LCMS (ESI) m/z: 359 (EM +
Hr). 1H NMR (CD30D) 67.89 (1H, d, J = 8.6 Hz), 7.80 (1H, s), 7.71 (1H, d, J =
8.5 Hz), 7.45 (1H, d, J = 15.7 Hz), 6.44 (1H, d, J = 15.7 Hz), 4.90 (2H, overlapped with DHO, identified by COSY), 3.64 (2H, t-like, J = 7.6 Hz), 3.39 (4H, q, J = 7.6 Hz), 3.21 (2H, t, J
= 7.9 Hz), 1.89 (2H, pentet, J = 7.5 Hz), 1.52 (2H, m), 1.35 (6H, t, J. = 7.2 Hz), 1.00 (3H, t, J = 7.3 Hz); 13C NMR (CD30D) 8 163.6, 155.7, 138.1, 132.8, 132.1, 131.9, 124.6, 118.0, 113.2, 111.7, 48.3, 46.8 (2C), 38.6, 27.5, 24.7, 21.4, 12.0, 7.0 (2C) Example 8 Preparation of 342-But-3-yny1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (9) [0236] The titled compound (9) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm:
98.3 %;
tR = 0.52 min; LCMS (ESI) rn/z: 369 ([K4 +Fi]). 1H NMR (DMSO-d6) 8 9.49 (brs, 1H), 7.88 ¨ 7.85 (m, 2H), 7.63 ¨ 7.59 (m, 2H), 6.52 (d, J = 15.79 Hz, 1H), 4.37 (s, 1H), 3.33 (s, 2H), 3.26 (t, J = 7.24 Hz, 2H), 2.92 (s, 6H), 2.88 (t, J = 2.54 Hz, 1H), 2.81 (dt, J =
2.48, 7.70 Hz, 2H), 1.09 (s, 6H); 13C NMR (DMSO-d6) 5 162.8, 155.3, 138.4, 138.0, 135.9, 130.5, 122.3, 118.4, 117.8, 116.4, 114.9, 112.9, 111.9, 82.8, 72.3, 66.9, 50.9, 46.7, 25.8, 22.8, 16.2.
Example 9 Preparation of 342-But-3-eny1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (10) [0237] The titled compound (10) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99 %; tR = 0.80 min; LCMS (ESI) rn/z: 371 ([M + H].). 1H NMR (CD30D) 8 7.95 (d, J = 8.8 Hz, 1H), 7.85 (s, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 15.8 Hz, 1H), 6.54 (d, J = 15.8 Hz, 1H), 5.94 ¨ 5.84 (m, 1H), 5.10 (dd, J = 1.4, 17.1 Hz, 1H), 5.03 (dd, J =
1.1, 10.2 Hz, 1H), 4.51 (s, 2H), 3.40 (s, 2H), 3.32 (t, J = 7.6 Hz, 2H), 2.99 (s, 6H), 2.66 (q, J = 7.5 Hz, 2H), 1.19 (s, 6H); 13C NMR (CD30D) 8 165.7, 157.6, 140.2, 136.3, 135.9, 134.7, 134.5, 125.9, 120.2, 117.9, 115.2, 103.6, 68.8, 53.4, 39.6, 32.0, 27.2, 23.7.
Example 10 Preparation of 342-But-3-eny1-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (11) [0238] The titled compound (11) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.4 CYO tR =
0.52 min; LCMS (ESI) m/z: 357 ([M+H]+1). 1H NMR (CD30D) 5 7.94 (d, J = 8.7 Hz, 1H), 7.81 (s, 1H), 7.73 (d, J = 8.3 Hz, 1H), 7.50 (d, J = 15.87 Hz, 1H), 6.46 (d, 1= 15.8 Hz, 1H), 5.96 ¨ 5.86 (m, 1H), 5.13 (dd, J = 1.4, 17.1 Hz, 1H), 5.05 (dd, J = 1.1, 10.2 Hz, 1H), 4.93 (t, J = 7.9 Hz, 2H), 3.62 ¨ 3.58 (m, 2H), 3.38 ¨ 3.31 (m, 6H), 2.65 (q, J = 7.6 Hz, 2H), 1.35 ¨ 1.32 (m, 6H); 13C NMR (CD30D) 8 165.8, 157.0, 140.5, 136.6, 135.9, 134.6, 134.2, 126.1, 119.5, 117.7, 116.0, 113.3, 50.4, 40.4, 31.7, 26.7, 9.1.
Example 11 Preparation of 3-[2-But-3-yny1-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-y1]-N-' hydroxy-acrylamide (12) [0239] The titled compound (12) was prepared according to the procedures 5 described in Example 1, by using appropriate starting materials. HPLC:
99.6 %; tiR =
0.37 min; LCMS (ESI) m/z: 355 ([M+H]). 1H NMR (CD300) 8 7.82 (d, J = 8.7 Hz, 1H), 7.68 (s, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 15.8 Hz, 1H), 6.31 (d, J
= 15.8 Hz, 1H), 4.87 ¨ 4.79 (masked peaks), 3.54 ¨ 3.50 (m, 2H), 3.37 (t, J = 7.1 Hz, 2H), 3.24 (q, J = 7.2 Hz, 4H), 2.73 (dt, J = 2.4, 6.0 Hz, 2H), 2.30 (t, J = 2.5 Hz, 1H), 1.21 (t, J = 7.2 10 Hz, 6H); 13C NMR (CD30D) 8 165.9, 156.1, 140.9, 138.1, 135.2, 133.4, 125.6, 118.8, 117.0, 112.8, 82.4, 72.1, 50.6, 40.2, 26.7, 26.4, 17.3, 9.1.
Example 12 Preparation of 341-(3-Dimethylamino-2,2-dimethyl-propy1)-2-(3,3,3-trifluoro-15 propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (13) [0240] The titled compound (13) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 96.5 %; tR = 0.80 min; LCMS (ESI) m/z: 413 ([M+H]).
20 Example 13 Preparation of 341-(2-Diethylamino-ethyl)-2-(3,3,3-trifluoro-propy1)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (14) [0241] The titled compound (14) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity:
96.4%; tR
25 = 1.37 min; LCMS (ESI) m/z: 399 ([M+H]). 1H NMR (DMSO-d6) 8 1.25 (6H, t), 2.96 (2H, m), 3.31 (6H, m), 3.44 (2H, m), 4.72 (2H, m), 6.51 (1H, m), 7.51 (2H, m), 7.65 (1H, m), 7.83 (1H, m), 10.45 (1H, bs) .
Example 14 30 Preparation of 341-(2-Diethylamino-ethyl)-2-ethoxymethy1-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (15) , [0242] The titled compound (15) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity:
98.1%; tR
= 0.48 min; LCMS (ESI) m/z: 361([M+H]).
Example 15 Preparation of 341-(3-Dimethylamino-2,2-dimethyl-propy1)-2-methy1-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (16) [0243] The titled compound (16) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity:
99.5%; tR
= 0.30 min; LCMS (ESI) m/z: 331 ([M+H]). 1H NMR (DMSO-d6) 8 1.13 (6H, s), 2.78 (2H, m), 2.89 (6H, s), 3.33 (2H, m), 4.42 (3H, s), 6.57 (1H, m), 7.57-7.69 (2H, m), 7.95 (2H, m), 9.68 (1H, bs), 10.81 (1H, bs) Example 16 Preparation of 3-[1-(2-Diethylamino-ethyl)-2-(2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (17) [0244] The titled compound (17) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%, tR = 0.95 min. LCMS (ESI) m/z: 373 ([M+Hr). 1H NMR (CD30D) 8 7.85 (2H, t, J = 8.3 Hz), 7.75 (1H, d, J = 8.8 Hz), 7.61 (1H, d, J = 15.8 Hz), 6.51 (1H, d, J =
15.8 Hz), 4.93 (2H, t, J = 6.1 Hz), 3.54 (2H, t, J = 8.1 Hz), 3.31 (4H, qt, J
= 7.3 Hz), 3.10 (2H, s), 1.27 (6H, t, J = 7.3 Hz), 1.06 (9H, s); 13C NMR (CD30D) 8 163.7, 153.3, 138.3, 133.1, 131.9, 124.5, 118.3, 117.1, 113.5, 111.8, 48.1, 39.1, 37.5, 32.9, 27.8, 7.1.
Example 17 Preparation of N-Hydroxy-3-[1-(3-isopropylamino-propy1)-2-(3,3,3-trifluoro-propy1)-1H-benzoimidazol-5-y11-acrylamide (18) [0245] The titled compound (18) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity:
96.8%; tR
= 0.72 min. LCMS (ESI) m/z: 399 ([M+H]). 1H NMR (DMSO-d6) 8 1.18 (6H, d), 2.07 (2H, m), 2.95 (4H, m), 3.27 (3H, m), 4.43 (2H, m), 6.52 (1H, m), 7.55 (2H, m), 7.61 (1H, m), 7.84 (1H, m), 8.65 (2H, bs).
Example 18 Preparation of 342-(2,2-Dimethyl-propy1)-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (19) [0246] The titled compound (19) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.1%, tR = 0.86 min. LCMS (ESI) m/z: 359 ([M+H]+). 1H NMR (CD30D) 8 7.86 (1H, d, J = 8.6 Hz), 7.78 (1H, s), 7.73 (1H, d, J = 8.5 Hz), 7.44 (1H, d, J =
15.8 Hz), 6.45 (1H, d, J = 15.4 Hz), 4.83 (2H, t, J = 6.42 Hz), 3.52 (2H, t, J = 6.6 Hz), 3.36 (1H, 77 =
qt, J = 6.5 Hz), 3.13 (2H, s), 1.26 (6H, d, J = 6.2 Hz), 1.04 (9H, s); 13C NMR
(CD30D) 161.2, 153.4, 138.3, 133.0, 124.4, 113.6, 112.0, 51.1, 41.8, 41.1, 37.3, 33.1,27.8, 17.2.
Example 19 Preparation of 341-(2-Diisopropylamino-ethyl)-2-(2,2-dimethyl-propyl)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (20) [0247] The titled compound (20) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 96.8%, tR = 0.94 min. LCMS (ESI) rn/z: 400 ([M+1-11+). 1H NMR (CD30D) 8 7.86 (1H, s), 7.80 (1H, d, J = 8.7 Hz), 7.76 (1H, d, J = 8.6 Hz), 7.62 (1H, d, J =
15.8 Hz), 6.52 (1H, d, J = 16.0 Hz), 4.96 (2H, t, J = 5.2 Hz), 3.84 (2H, m), 3.53 (2H, t, J = 8.3 Hz), 3.06 (2H, s), 1.38 (12H, d, J = 6.5 Hz), 1.05 (9H, s); 13C NMR (CD30D) 8 160.2, 153.1, 138.2, 133.2, 131.9, 124.6, 113.5, 111.8, 54.9, 423.0, 40.5, 37.7, 33.0, 27.8, 16.3.
Example 20 Preparation of 3-[1-(2-Dilsopropylamino-ethyl)-2-isobuty1-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (21) [0248] The titled compound (21) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 95.3%, tR = 0.76 min. LCMS (ESI) m/z: 387 aM+Hr). 1H NMR (CD30D) 8 7.85 (1H, s), 7.71 (2H, s), 7.66 (1H, d, J = 15.8 Hz), 6.51 (1H, d, J= 15.8 Hz), 4.75 (2H, t, J
= 7.2 Hz), 3.86 (2H, t, J = 6.5 Hz), 3.50 (2H, t, J = 8.6 Hz), 2.98 (2H, d, J
= 7.4 Hz), 2.26 (1H, m) 1.41 (12H, d, J = 6.3 Hz), 1.06 (6H, d, J = 6.6 Hz).
Example 21 Preparation of 3-[1-(3-Dimethylami no-2,2-d i methyl-propy1)-2-hex-3-eny1-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (22) [0249] The titled compound (22) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%; tR = 1.24 min; LCMS (ESI) m/z: 399 ([M+Hr). 1H NMR (CD30D) 8 8.22 (d, J = 8.7 Hz, 1H), 8.11 (s, 1H), 7.96 (d, J = 8.6 Hz, 1H), 7.81 (d, J = 15.8 Hz, 1H), 6.68 (d, J = 15.8 Hz, 1H), 5.69 ¨ 5.59 (m, 2H), 4.79 (s, 2H), 3.66 (s, 2H), 3.55 (t, J = 7.3 Hz, 2H), 3.24 (s, 6H), 2.91 (q, J = 6.8 Hz, 2H), 2.21 ¨2.11 (m, 2H), 1.44 (s, 6H), 1.02 (t, J =
7.5 Hz, 3H); 13C NMR (CD30D) 8 165.7, 157.9, 140.2, 135.8, 134.6, 134.5, 126.1, 125.9, 120.1, 115.2, 114.6, 68.7, 533, 47.9, 39.6, 27.6, 25.9, 23.7, 21.4, 14.4.
Example 22 Preparation of 3-0-(3-Dimethylamino-2,2-dimethyl-propy1)-2-(2,4,4-trimethyl-pentyl)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (23) [0250] The titled compound (23) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.6%; tR = 1.61 min; LCMS (ESI) m/z: 429 ([M+H]). 1H NMR (CD30D) 8 8.19 (d, J = 8.8 Hz, 1H), 8.08 (s, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 15.7 Hz, 1H), 6.75 (d, J = 15.8 Hz, 1H), 4.79 (s, 2H), 3.62 (s, 2H), 3.35 ¨ 3.29 (m, 1H), 3.23 (s, 6H), 2.52 (brs, 2H), 1.50¨ 1.45 (m, 2H), 1.36 (d, J = 3.8 Hz, 6H), 1.12 (d, J = 5.5 Hz, 3H), 1.02 (s, 6H); 13C NMR (CD300) 8 165.6, 157.4, 139.9, 135.2, 135.1, 132.9, 126.4, 120.6, 115.7, 114.6, 68.6, 53.3, 51.4, 47.9, 39.7, 36.3, 31.9, 31.3, 30.2, 23.8, 22.3.
Example 23 Preparation of 342-Cyclohexy1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (24) [0251] The titled compound (24) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%; tR = 0.96 min; LCMS (ESI) m/z: 399([M+Hr). 1F1 NMR (CD300): 8 8.21 (d, J = 8.8 Hz, 1H), 8.06 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.83 (d, J = 15.8 Hz, 1H), 6.76 (d, J = 15.8 Hz, 1H), 4.79 (s, 2H), 3.65 (s, 2H), 3.60 ¨ 3.51 (m, 1H), 3.22 (s, 6H), 3.29 ¨
3.26 (m, 2H), 2.12 ¨ 2.09 (m, 2H), 2.03 ¨ 1.92 (m, 3H), 1.78 ¨ 1.59 (m, 3H), 1.41 (s, 6H); 13C NMR (CD30D) 8 165.7, 161.3, 140.1, 135.4, 134.8, 134.0, 126.1, 120.3, 119.6, 116.7, 115.5, 114.9, 68.7, 53.1, 47.9, 39.2, 37.0, 32.4, 26.5, 26.3, 23.6.
Example 24 Preparation of 342-Bicyclo[2.2.1]hept-5-en-2-y1-1-(3-dimethylamino-2,2-dimethyl-propy1)-1H-benzoimidazol-5-ylj-N-hydroxy-acrylamide (25) [0252] The titled compound (25) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%; tR = 0.91 min; LCMS (ESI) m/z: 409 ([M+H]+).
Example 25 Preparation of 3-[1-(2-Diethylamino-ethyl)-2-hex-3-eny1-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (26) [0253] The titled compound (26) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.9%;
tR
1.14 min; LCMS (ESI) m/z: 385 ([M+H]). 1H NMR (CD30D) 87.95 (d, J = 8.6 Hz, 1H), 7.87 (s, 1H), 7.77 (d, J = 8.5 Hz, 1H), 7.52 (d, J = 15.8 Hz, 1H), 6.50 (d, J
= 15.8 Hz, 1H), 5.57 - 5.44 (m, 2H), 3.72 - 3.68 (m, 2H), 3.44 (q, J = 7.2 Hz, 4H), 3.35 -3.30 (masked peaks), 2.73 (q, J = 7.1 Hz, 2H), 2.07 - 1.99 (m, 2H), 1.41 (t, J =
7.2 Hz, 6H), 0.88 (t, J = 7.5 Hz, 3H); 13C NMR (CD30D) 6 165.6, 157.2, 140.2, 135.9, 134.8, 134.6, 134.2, 126.4, 126.1, 119.8, 115.6, 113.5, 50.4, 40.5, 26.9, 25.4, 21.4, 14.4, 8.9.
Example 26 Preparation of 341 -(2-Diisopropylamino-ethyl)-2-hex-3-eny1-1 H-benzoimidazol-yli-N-hydroxy-acrylamide (27) [0254] The titled compound (27) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.9%;
tR =
1.22 min; LCMS (ESI) m/z: 413 ([M+H]). 1H NMR (CD30D) 8 7.94- 7.89 (m, 2H), 7.78 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 15.8 Hz, 1H), 6.50 (d, J = 15.8 Hz, 1H), 5.63 -5.44 (m, 2H), 3.99 - 3.91 (m, 2H), 3.69 - 3.64 (m, 2H), 3.36 - 3.26 (masked peaks), 2.72 (q, J = 7.2 Hz, 2H), 2.08 - 2.01 (m, 2H), 1.50 (d, J = 6.5 Hz, 12H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR (CD30D) 8 165.6, 157.0, 140.2, 135.9, 135.4, 134.5, 134.3, 126.6, 126.3,126.2, 119.8, 115.8, 113.3, 56.9, 45.3, 41.9, 27.2, 25.5, 21.4, 18.2, 14.4.
Example 27 Preparation of 342-Hex-3-eny1-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (28) [0255] The titled compound (28) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%; = 1.12 min; LCMS (ESI) m/z: 371 (EM+Hl+). 1H NMR (CD30D) 68.00 (d, J = 9.1 Hz, 1H), 7.77 - 7.75 (m, 2H), 7.17 (d, J = 15.7 Hz, 1H), 6.34 (d, J =
15.7 Hz, 1H), 5.57 - 5.42 (m, 2H), 4.92 (t, J = 5.9 Hz, 2H), 3.72 (t, J = 5.7 Hz, 2H), 3.54 - 3.48 (m, 1H), 3.39 (t, J = 7.5 Hz, 2H), 2.72 (q, J = 7.3 Hz, 2H), 2.06 - 1.99 (m, 2H), 1.39 (d, J = 6.5 Hz, 6H),0.87 (t, J = 7.5 Hz, 3H).
Example 28 Preparation of 341-(2-Ethylamino-ethyl)-2-hex-3-eny1-1H-benzoimidazol-5-y1FN-, hydroxy-acrylamide (29) [0256] The titled compound (29) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%; tR = 1.23 min; LCMS (ESI) m/z: 385 ([M+H]+). 1H NMR (CD300) 6 7.94 (d, J = 8.6 Hz, 1H), 7.89 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 15.8 Hz, 1H), 6.55 (d, J = 15.7 Hz, 1H), 5.57 - 5.42 (m, 2H), 4.62 (t, J = 7.5 Hz, 2H), 3.42 -3.33 (m, 1H), 3.32 ¨ 3.30 (masked peaks), 3.28 ¨ 3.24 (m, 2H), 2.71 (q, J = 7.2 Hz, 2H), 2.33 (brs, 2H), 2.03 ¨ 1.94 (m, 2H), 1.36 (d, J = 6.5 Hz, 6H), 0.84 (t, J = 7.5 Hz, 3H);
(CD30D) 6 165.6, 156.3, 139.9, 136.8, 136.2, 135.2, 133.8, 132.8, 126.7, 125.8, 120.4, 114.6, 114.1, 52.2, 43.5, 42.9, 27.2, 26.5, 25.5, 21.4, 19.2, 14.4.
Example 29 Preparation of 342-Hex-3-eny1-1-(3-isopropylamino-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (30) [0257] The titled compound (30) was prepared according to the procedures 10 described in Example 1, by using appropriate starting materials. HPLC
purity at 254 nm: 99.9%; tR = 1.04 min; LCMS (ESI) m/z: 357([M+H]+). 1H NMR (CD30D) 8 7.93 (d, J
= 8.4 Hz, 1H), 7.77 ¨ 7.73 (m, 2H), 7.23 (d, J= 15.7 Hz, 1H), 6.34(d, J = 15.7 Hz, 1H), 5.57 ¨ 5.42 (m, 2H), 4.87 (masked peaks), 3.68 (brs, 2H), 3.35 ¨ 3.30 (masked peaks), 3.22 ¨ 3.17 (m, 2H), 2.72 (q, J = 7.1 Hz, 2H), 1.35 (t, J = 7.2 Hz, 3H), 0.88 (t, J = 7.6 15 Hz, 3H); 13C NMR (CD30D) 5 165.6, 157.3, 140.5, 135.8, 134.9, 134.6, 134.2, 126.2, 126.1, 118.7, 115.9, 113.7, 113.6, 46.5, 45.0, 42.7, 26.4, 25.4, 21.4, 14.4, 11.4.
Example 30 Preparation of 3-[1-(2-Diethylam i no-ethyl)-2-hexy1-1H-benzoimidazol-5-y1]-N-20 hydroxy-acrylamide (31) [0258] The titled compound (31) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 100%, tR = 1.31 min. LC-MS m/z: 387 ([M+H]+). 1H NMR (DMSO-d6) 8 0.88 (3H, t, J = 7.0 Hz), 1.26 (6H, t, J = 7.2 Hz), 1.34 (4H, m), 1.44 (2H, m), 1.85 (2H, m), 3.12 25 (2H, t, J = 7.7 Hz), 3.31 (4H, m), 3.52 (2H, t, J = 7.7 Hz), 4.81 (2H, t, J = 7.7 Hz), 6.59 (1H, d, J = 15.8 Hz), 7.63 (1H, d, J = 15.8 Hz), 7.73 (1H, d, J = 8.8 Hz), 7.93 (1H, d, J =
8.8 Hz), 7.94 (1H, s) Example 31 30 Preparation of 3-[1-(3-isopropylamino-propy1)-2-(2,4,4-trimethyl-penty1)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (32) [0259] The titled compound (32) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: HPLC: 97.5%, tR = 1.68 min. LC-MS m/z: 415 ([M+H]+). 1H NMR (DMSO-d6) 5 0.89 35 (9H, s), 0.98 (3H, d, J = 6.6 Hz), 1.23 (6H, d, J = 6.5 Hz), 2.08-2.29 (4H, m), 2.27 (1H, m), 2.98-3.12 (4H, m), 3.29 (1H, m), 4.53 (2H, t, J = 7.4 Hz), 6.60 (1H, d, J
= 15.8 Hz), 7.65 (1H, d, J = 15.8 Hz), 7.75 (1H, d, J = 9.0 Hz), 7.96 (1H, d, J = 9.0 Hz), 7.98 (1H, s), 8.75 (2H, bs).
Example 32 Preparation of 342-(2,2-Dimethyl-propy1)-1-(3-isopropylamino-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (33) [0260] The titled compound (33) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99%, tR = 1.01 min. LC-MS m/z: 375 ([M+Hr). 1H NMR (DMSO-d6) 80.98 (9H, s), 1.24 (6H, bs), 2.17 (2H, bs), 3.14 (4H, m), 3.28 (1H, bs), 4.53 (2H, bs), 6.65 (1H, d, J =
15.5 Hz), 7.65 (1H, d, J = 15.5 Hz), 7.81 (1H, d, J = 7.4 Hz), 8.02 (1H, s), 8.03 (1H, d, J
= 7.4 Hz), 8.85 (2H, bs).
Example 33 Preparation of 3-[1-(2-Diisopropylamino-ethyl)-2-(3,3,3-trifluoro-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (34) [0261] The titled compound (34) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 97.5%;
tR =
0.93 min. LCMS (ESI) m/z: 427 ([M+H]). 1H NMR (DMSO-d6) 81.35 (12H, m), 2.94 (2H, m), 3.24 (2H, m), 3.45 (2H, t), 3.80 (211, m), 4.68 (2H, t), 6.48 (1H, m), 7.55 (3H, m), 7.85 (1H, m), 9.48 (1H, bs).
Example 34 Preparation of N-Hydroxy-342-isobuty1-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-y1]-acrylamide (35) [0262] The titled compound (35) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.3%, tR = 0.51 min. LCMS (ESI) m/z: 345 ([M-I-H]). 1H NMR (CD30D) 8 7.78 (1H, d, J = 8.7 Hz), 7.76 (1H, s), 7.68 (1H, d, J = 8.6 Hz), 7.46 (1H, d, J =
15.8 Hz), 6.42 (1H, d, J = 15.9 Hz), 4.70 (2H, t, J = 7.4 Hz), 3.48 (2H, t, J = 6.9 Hz), 3.37 (1H, m), 3.01 (2H, d, J = 7.4 Hz), 2.21 (1H, m), 1.27 (6H, d, J = 6.5 Hz), 1.00 (6H, d, J = 6.6 Hz);
13C NMR (CD30D) 5 160.3, 155.3, 138.5, 134.1, 131.5, 124.2, 113.9, 111.4, 51.1, 42.0, 40.3, 33.4, 27.3, 20.6, 17.2.
Example 35 Preparation of 342-(2,2-Dimethyl-propy1)-1-(2-ethylamino-ethyl)-benzoimidazol-5-*N-hydroxy-acrylamide (36) [0263] The titled compound (36) was prepared according to the procedures described in Example 1, by using appropriate starting materials. Yield: 74%.
HPLC
purity at 254 nm: 99.9%, tR = 0.71 min. LCMS (ESI) m/z: 345 ([M+H]+). 1H NMR
(CD30D) 5 7.81 (1H, d, J = 8.6 Hz), 7.75 (1H, s), 7.69 (1H, d, J = 8.5 Hz), 7.36 (1H, d, J
= 15.7 Hz), 6.40 (1H, d, J = 15.3 Hz), 4.81 (2H, t, J = 6.4 Hz), 3.51 (2H, t, J = 6.3 Hz), 3.10 (2H, s), 3.06 (2H, qt, J = 7.3 Hz), 1.23 (3H, t, J = 7.2 Hz), 1.04 (9H, s); 13C NMR
(CD30D) 5 161.0, 153.3, 138.5, 132.7, 132.2, 124.2, 117.5, 113.9, 111.9, 44.2, 43.0, 41.0, 37.4, 33.0, 27.9, 9.5.
Example 36 Preparation of 3-[1-(2-Ethylami no-ethyl)-2-isobuty1-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide (37) [0264] The titled compound (37) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%, tR = 0.40 min. LCMS (ESI) m/z: 331 ([M+1-1]+). 1H NMR (CD30D) 6 7.81 (1H, d, J = 8.6 Hz), 7.73 (1H, s), 7.67 (1H, d, J = 8.2 Hz), 7.34 (1H, d, J =
15.7 Hz), 6.36 (1H, d, J = 15.7 Hz), 4.74 (2H, t, J= 6.7 Hz), 3.54 (2H, t, J= 6.5 Hz), 3.10 (211, d, J = 7.4 Hz), 3.06 (2H, d, J = 9.5 Hz), 2.21 (1H, m), 1.23 (3H, t, J = 7.3 Hz), 1.04 (6H, d, J = 6.6 Hz); 13C NMR (CD30D) 8 163.7, 161.1, 154.8, 138.6, 133.2, 132.6, 132.4, 124.2, 117.2, 113.9, 111.6, 44.4, 43.0, 40.5, 33.4, 27.3, 20.6, 9.5.
Example 37 Preparation of 341-(2-Diisopropylamino-ethyl)-2-(2,4,4-trimethyl-penty1)-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (38) [0265] The titled compound (38) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.0 %;
tR
1.62 min; LCMS (ESI) m/z: 443 ([M4-Hr). 1H NMR (CD30D) 6 7.96 ¨ 7.94 (m, 2H), 7.82 (d, J = 8.7 Hz, 1H), 7.55 (d, J = 15.8 Hz, 1H), 6.54 (d, J = 15.8 Hz, 1H), 5.13 ¨
5.06 (masked peaks), 4.01 ¨ 3.92 (m, 2H), 3.71 ¨ 3.67 (m, 2H), 3.33 ¨ 3,24 (masked peaks), 3.18 ¨ 3.12 (m, 1H), 2.38 ¨ 2.36 (m, 1H), 1.52 (s, 6H), 1.51 (s, 6H), 1.41 ¨ 1.40 (m, 2H), 1.09 (d, J = 6.6 Hz, 3H), 0.94 (s, 9H); 13C NMR (CD30D) 8 165.5, 156.5, 140.1, 134.8, 134.7, 134.0, 126.5, 120.0, 114.6, 113.6, 56.9, 51.7, 45.2, 42.0, 35.9, 31.9, 30.6, 30.2, 22.6, 18.3.
Example 38 Preparation of N-Hydroxy-311-(2-isopropylamino-ethyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzoimidazol-5-yl]-acrylamide (39) [0266] The titled compound (39) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 97.9 %; tR = 1.49 min; LCMS (ESI) m/z: 401 ([M+H]+). 1H NMR (CD30D) 8 7.98 (d, J = 8.7 Hz, 1H), 7.79 - 7.76 (m, 2H), 7.24 (d, J = 15.7 Hz, 1H), 6.39 (d, J =
15.7 Hz, , 1H), 4.97 - 4.89 (masked peaks), 3.70 - 3.66 (m, 2H), 3.53 - 3.47 (m, 1H), 3.34 - 3.28 (masked peaks), 3.22 - 3.15 (m, 1H), 2.31 - 2.29 (m, 1H), 1.39- 1.38(m, 9H), 1.07(d, J = 6.6 Hz, 3H), 0.9 (s, 9H); 13C NMR (CD30D) 8 165.5, 156.9, 140.5, 134.7, 134.4, 126.3, 118.9, 115.9, 113.8, 53.2, 51..5, 44.2, 42.8, 35.7, 31.9, 30.9, 30.2, 29.6, 19.1, 18.8.
Example 39 Preparation of 341-(2-Ethylamino-ethyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzoimidazol-5111-N-hydroxy-acrylamide (40) [0267] The titled compound (40) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 100.0%; tR = 1.57 min; LCMS (ESI) miz: 387 ([M+H]+). 1H NMR (CD30D) 8 7.96 (d, J = 8.6 Hz, 1H), 7.79 (s, 1H), 7.78 - 7.75 (d, J = 8.7 Hz, 1H), 7.23 (d, J =
15.7 Hz, 1H), 6.37 (d, J = 15.7 Hz, 1H), 4.96 - 4.89 (masked peaks), 3.70 - 3.68 (m, 2H), 3.36 - 3.28 (masked peaks), 3.26 - 3.14 (m, 3H), 2.31 - 2.30 (m, 1H), 1.40 - 1.32 (m, 5H), 1.07(d, J = 6.6 Hz, 3H), 0.92 (s, 9H); 13C NMR (CD30D) 8 165.6, 156.9, 140.6, 134.9, 134.5, 134.2, 126.2, 118.7, 116.0, 113.7, 51.6, 46.5, 45.0, 42.7, 35.8, 31.9, 30.8, 30.2, 22.6, 11.4.
Example 40 Preparation of 3-E1 -(2-D iethylam ino-ethyl)-2-(2,4,4-trimethyl-penty1)-1 H-benzoim idazol-5-yll-N-hydroxy-acrylam i de (41) [0268] The titled compound (41) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 85.6%, tR = 1.55 min. LC-MS m/z: 415 ([M+H]). 1H NMR (CD30D) a 7.91 (d, 2H, ,J
= 6.0 Hz), 7.80 (br, d, 1H, J = 8.9 Hz), 7.68 (d, 2H, J = 15.8 Hz), 6.58 (d, 1H, J = 15.8 Hz), 4.96 (br, q, 2H), 3.64 (br, q, 2H), 3.43 (q, 4H, J = 7.3 Hz), 1.40 (t, 8H), 1.09 (br, d, 4H, J = 6.6 Hz), 0.94 (br, s, 10H); 13C NMR (CD30D) 8 156.8, 140.4, 135.8, 134.4, 134.3, 126.1, 115.8, 113.2, 119.7, 119.2, 51.6, 50.3, 40.3, 35.8, 31.9, 22.6, 9Ø
Example 41 Preparation of 341-(2-Diethylamino-ethyl)-2-propy1-1H-benzoimidazol-5-yll-N-hydroxy-acrylamide (42) [0269] The titled compound (42) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254nm:
99.0%, tR = 0.68 min. LC-MS (ESI) miz: 345 ([M+H]). 1H NMR (CD30D) 8 8.15 (d, 2H, J= 8.7 Hz), 7.68 (d, 1H, J = 15.8 Hz), 6.63 (d, 1H, J = 15.8 Hz), 5.08 (br, t, 2H), 3.70 (br, t, 2H), 3.44 (br, m, 4H), 3.35 (t, 2H), 2.03 (br, m, 2H), 1.44 (t, 6H, J
= 7.2 Hz), 1.20 (t, 3H); 13C NMR (CD30D) 8 165.5,157.4, 139.8, 135.5, 133.5, 132.3, 120.7, 120.7, 114.5, 114.3, 40.8, 28.5, 21.0, 13.9, 9.1.
Example 42 Preparation of 3-[1-(2-Diethylamino-ethyl)-2-(2-methylsulfanyl-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (45) [0270] The titled compound (45) was prepared according to the procedures described in Example 1, by using appropriate starting materials. Yield:17 mg (in two steps) as TFA salt. HPLC purity at 254 nm: 80%, tR = 0.50 min. LCMS (ESI) miz:
+ Hr). 1H NMR (CD300) 8 7.79 (1H, s), 7.77 (1H, d), 7.66 (1H, d, J = 8.6 Hz), 7.54 (1H, d, J = '15.8 Hz), 6.44 (1H, d, J = 15.8 Hz), 4.83 (2H, masked by DHO, identified by COSY), 3.57 (2H, m), 3.41 (2H, t, J = 7.1 Hz), 3.32 (4H), 3.01 (2H, t, J = 7.1 Hz), 2.89 (3H, s), 1.30 ¨1.25 (9H, overlapped t).
Example 43 Preparation of 342-Buty1-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (46) [0271] The titled compound (46) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.4%; tR = 1.56 min. LCMS m/z: 345 ([M+Hr). 1H NMR (DMSO-d6) 60.95 (3H, t), 1.22 (6H, m), 1.42 (2H, m), 1.80 (2H, m), 3.13 (2H, m), 3.41 (3H, t), 4.69 (2H, t), 6.58 (1H, m), 7.56 (1H, m), 7.73 (1H, m), 7.90 (2H, m), 9.14 (2H, bs).
Preapration of the freebase of the titled compound:
[0272] To a pre-stirred solution of the methyl ester (1 eq) in dried methanol, NH2OH.HCI (12 eq.) was added. The mixture was stirred in ice-water bath for about 10 min, followed by adding sodium methoxide solution (20 eq.). HPLC showed the reaction completed after 20 min, less than 1% of the acid was observed.
[0273] The above crude was treated with 1M of HCI until all the precipitate was dissolved (pH around 1-2). The pH value was carefully adjusted to around 7-8 using NaOH or NaHCO3, the precipitate which was formed was collected by filtration.
The solid was washed with water once. The above solid was suspended in methanol and 5 water again and was treated with 6N HCI until all dissolved, the pH value was carefully adjusted to around 7-8 using NaOH and NaHCO3. The precipitate, which was formed, was again collected by filtration; the freebase compound was obtained by drying in vacuo, the yield was around 80%-85%.
10 Preapration of the hydrochloric acid salt of the titled compound:
[0274] The above freebase compound was suspended in methanol and water and was treated with 6N HCI (2.8 eq.). The solution became clear. After removing the methanol on a Rotary Evaporator, the hydrochloric acid salt was obtained by freeze-drying. It was further recrystallized from methanol (HPLC purity at 254 nm: >
99%).
Example 44 Preparation of 342-Butyl-1-(3-isopropylamino-propy1)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (47) [0275] The titled compound (47) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.2%; tR = 1.72 min. LCMS (ESI) m/z: 359 ([MH]+). 1H NMR (DMSO-d6) 8 0.95 (3H, t), 1.22 (6H, m), 1.45 (2H, m), 1.82 (2H, m), 2.14 (2H, m), 3.17 (4H, m), 3.28 (1H, m), 4.52 (2H, t), 6.62 (1H, m), 7.57 (1H, m), 7.72 (1H, m), 7.89 (2H, m), 8.80 (2H, bs).
=
Example 45 Preparation of 341-(1-Benzyl-piperidin-4-y1)-2-butyl-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (48) [0276] The titled compound (48) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 96.7%, tR = 1.35 min. LC-MS m/z: 433 ([M+H]). 1H NMR (DMSO-d6) 6 0.94 (3H, s), 1.41 (2H, m), 1.77 (2H, m), 2.19 (2H, m), 2.99-3.10 (2H, m), 3.24 (4H, m), 3.68 (2H, m), 4.38 (2H, s), 5.01 (1H, m), 6.65 (1H, d, J = 15.8 Hz), 7.47-7.49 (3H, m), 7.61 (1H, d, J = 15.8 Hz), 7.69 (3H, m), 7.97 (1H, s), 8.60 (1H, d, J = 8.8 Hz), 10.35 (2H, s), 11.95 (1H, s).
Example 46 Preparation of 342-B utyl-1-(2-ethylam no-ethyl)-1H-benzoimidazol-5-yll-N-hydroxy-acrylamide (44) [0277] The titled compound (44) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm:
98%;
LC-MS m/z: 331 ([M+H]). 1H NMR (DMSO-d6) 6 10.88 (br s, 1H), 9.12 (br s, 2H), 7.93 (s, 1H), 7.87 (d, 1H, J = 8.4 Hz), 7.71 (d, 1H, J = 8.3 Hz), 7.62 (d, 1H, J =
15.7 Hz), 6.59 (d, 1H, J = 15.6 Hz), 4.67 (t-like, 2H), 3.42 (br s, 2H), 3.08 (q, 2H, J
= 7.7 Hz, Pr-CH2), 3.05 (br s, 2H), 1.81 (m, 2H), 1.45 (m, 2H), 1.18 (t, 3H, J = 7.1 Hz), 0.95(t, 3H, J
= 7.0 Hz); 130 NMR (DMSO-d6) 5 162.6, 156.2, 138.0, 135.0, 133.5, 131.6, 123.5, 119.2, 114.8, 112.1, 44.5, 42.4, 40.6, 28.2, 25.2, 21.7, 13.5, 10.8.
Example 47 Preparation of 342-But-3-eny1-1-(2-ethylamino-ethyl)-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (49) [0278] The titled compound (49) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.0 %;
tR =-1.61 min; LCMS m/z: 329 ([M+H]). 1H NMR (CD30D) 8 7.85 (d, J = 8.5 Hz, 1H), 7.78 (s, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.38 (d, J = 15.7 Hz, 1H), 6.40 (d, J =
15.5 Hz, 1H), 6.02 ¨ 5.92 (m, 1H), 5.19 (dd, J = 17.1, 1.3 Hz, 1H), 5.12 (dd, J = 10.2, 0.9 Hz, 1H), 4.80 (t, J = 6.4 Hz, 2H), 3.62 (t, J = 6.2 Hz, 2H), 3.22 ¨ 3.16 (m, 2H), 2.71 (q, J = 7.2 Hz, 2H), 1.35 (t, J = 7.2 Hz, 3H); 130 NMR (CD30D) 8 178.3, 157.1, 140.7, 136.5, 133.9, 125.9, 118.8, 117.6, 116.2, 113.2, 101.5, 67.6, 46.4, 44.9, 42.4, 31.6, 26.7, 20.7, 11.4.
Example 48 Preparation of 342-Hexy1-1-(2-isopropylamino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (50) [0279] The titled compound (50) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 94.4%, tR = 1.32 min. LCMS (ESI) m/z: 373 ([M+H]). 1H NMR (CD30D) 5 7.80 (1H, d, J = 8.5 Hz), 7.74 (1H, s), 7.64 (1H, d, J = 9.0 Hz), 7.50 (1H, d, J =
13. 6 Hz), 6.42 (1H, d, J = 15.8 Hz), 4.65 (2H, d, J = 6.6 Hz), 3.48 (2H, d, J = 6.6 Hz), 3.38 (1H, qt, J = 6.5 Hz), 3.13 (2H, t, J = 5.9 Hz) 1.82 (2H, t, J = 6.7 Hz), 1.44 (2H, t, J = 7.0 Hz) 1.29 (7H, m) 0.84 (6H, d, J = 7.0 Hz).
Example 49 Preparation of 3-[1-(2-Dimethylamino-ethyl)-2-(2,4,4-trimethyl-penty1)--1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (51) [0280] The titled compound (51) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 100%, tR = 1.49 min. LC-MS m/z: 331 ([M+H]). 1H NMR (DMSO-d6) 60.85 (9H, s), 1.03 (2H, d, J = 6.4 Hz), 1.34 (2H, m), 2.27 (1H, m), 3.00 (6H, s), 3.24-3.27 (4H, m), 4.79 (3H, m), 6.53 (1H, d, J = 15.72 Hz), 7.62 (1H, d, J = 15.7 Hz), 7.75 (1H, d, J = 8.4 Hz), 7.86 (1H, s), 7.87 (1H, d, J = 8.4 Hz).
Example 50 Preparation of 341-(2-Ethylamino-ethyl)-2-hexy1-1H-benzoimidazol-5-y13-N-hydroxy-acrylamide (52) [0281] The titled compound (52) was prepared according to the procedures described in Example 1, by using appropriate starting materials. The modified or detailed procedures were described as below.
Step 3:
[0282] To a stirred solution of 344-(2-ethylamino-ethylamino)-3-nitro-phenylFacrylic acid methyl ester (8.174 g, 27.87 mmol) and heptaldehyde (4.85 g, 42.47 mmol, 1.52 eq) in AcOH and Me0H (1:9 v/v, 300mL) was added SnC122H20 (31.45 g, 139.4 mmol, 5 eq) in portions. The resulting mixture was heated to 40 C with stirring.
The progress of the reaction was monitor by LC/MS. When the reaction was completed, solvent was removed under reduced pressure below 40 C. The resultant residue was diluted with Et0Ac (50 mL) then basified (pH >10) with saturated aqueous Na2CO3 and extracted with dichloromethane (x3). Filtration may be needed to remove the white precipitates or suspension derived from Tin in order to get clearly separated layers. The organic extracts were combined, dried (Na2SO4), filtered, and evaporated to dryness.
The resulting oily residue was purified by flash column chromatography (silica, 4)67 x 65 mm, solvent Me0H/DCM gradient from 0 to 10%). 341-(2-ethylamino-ethyl)-2-hexyl-1H-benzoimidazol-5-y11-acrylic acid methyl ester was obtained as yellow solid (4.445 g, 44.6%). HPLC purity at 254 nm: 98.8%, tR = 1.71 min. LCMS (ESI) m/z: 358 (RA +
Hr).
1H NMR (CDCI3) 8 7.88 (1H, d, J = 1.2 Hz), 7.83 (1H, d, J = 16.0 Hz), 7.43 (1H, dd, J =
8.4, 1.4 Hz), 7.33 (1H, d, J = 8.4 Hz), 6.43 (1H, d, J = 15.9 Hz), 4.22 (1H, t, J = 6.6 Hz), 3.80 (3H, s), 3.01 (2H, t, J = 6.6 Hz), 2.89 (2H, t, J = 7.9 Hz), 2.65 (2H, q, J = 7.1 Hz), 1.91 (2H, pentet, J = 7.8 Hz), 1.46 (2H, m), 1.35 (4H, m), 1.07 (3H, t, J =
7.1 Hz), 0.90 (3H, t, J = 7.0 Hz). The solid could be recrystallized from Hexanes-ether to give a white or pale yellow solid with HPLC purity at 254 nm: 99.2%.
[0283] In another experiment starting with 2.725 g of 3-[4-(2-ethylamino-ethylamino)-3-nitro-pheny1]-acrylic acid methyl ester, the titled compound was obtained in 52.8%
yield (1.753 g).
Step 4:
[0284] To a solution of 341-(2-ethylamino-ethyl)-2-hexy1-1H-benzoimidazol-5-y1]-acrylic acid methyl ester (4.428 g, 12.39 mmol) and NH201-11-1C1 (8.66 g, 124.7 mmol) in dry Me0H (50 mL) which was stirred and cooled in a dry-ice acetone bath, added Na0Me solution in Me0H (25%, 4.37 M, 55 mL, 240 mmol). The reaction mixture was then stirred at room temperature. The progress of reaction was monitored by LC/MS
(usually reaction completed within 30-90 min) and quenched by adding 6N HCI
(40 mL). The mixture (HPLC purity at 254 nm = 94.6%) was added Milli-Q water, adjusted pH -8 by 1N NaOH and evaporated to remove the organic solvent. The resultant residue was washed with Milli-Q water (x3) and re-dissolved in Me0H-DCM, the solution was filtered and diluted with Milli-Q water. The suspension was evaporated to remove the organic solvent and the resultant residue was washed with Milli-Q
water (x2). The free base of the titled compound was obtained (HPLC purity at 254 nm =
98%). The free base could be recrystallized from Me0H-Ethyl acetate to give a white or pale yellow solid.
Step 5: hydrochloric acid salt formation.
[0285] The above freebase was dissolved in Me0H and excess 6N HCI (final pH
<2) and the clear solution was evaporated to dryness and then diluted with Me0H, co-evaporated with PhMe (x1) and Et0Ac (x2). The solid was recrystallized from Me0H-Et0Ac to give a white or pale yellow solid (3.298 g, 61.7%). HPLC purity at 254 nm:
98.4-99.6%, tR = 1.23 min. LCMS (ESI) m/z: 359 ([M + H]+). 1H NMR (CD30D) 5 9.33 (residual NH), 8.03 (1H, d, J = 8.3 Hz), 7.77 (1H, s), 7.73 (1H, d, J = 8.2 Hz), 7.16 (1H, d, J = 15.7 Hz), 6.34 (1H, d, J = 15.7 Hz), 4.88 (2H, overlapped with DHO, identified by COSY), 3.63 (2H, br t like), 3.32 (2H, d, J = 7.9 Hz), 3.15 (2H, q, J = 7.1), 1.94 (2H, pentet, J = 7.1), 1.53 (2H, pentet, J = 6.7 Hz), 1.42-1.31 (4H, m), 1.33 (3H, t, J = 7.1 Hz), 0.88 (3H, t, J = 7.0 Hz); 13C NMR (CD300) 5 163.4, 155.8, 138.1, 133.0, 132.0, 130.3, 125.1, 117.4, 112.8, 112.5, 44.5, 43.2, 41.1, 30.5, 28.0, 25.3, 25.2, 21.6, 12.4, 9.6.
Example 51 Preparation of N-Hydroxy-341-(2-isopropylamino-ethyl)-2-(3,3,3-trifluoro-propy1)-1H-benzoimidazol-5-y1Facrylamide (53) [0286] The titled compound (53) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 98.1%;
tR =
0.63 min. LC-MS m/z: 385 ([1v1+H]+).
Example 52 Preparation of 341-(2-Dimethyla mino-ethyl)-2- hex-3-eny1-1 H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (54) [0287] The titled compound (54) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 99.9%, tR = 0.96 min. LCMS (ESI) m/z: 357 ([M+H]1). 1H NMR (CD30D) 8 7.87 (1H, d, J = 8.6 Hz), 7.80 (1H, d, J = 8.8 Hz), 7.72 (1H, d, J = 8.3 Hz), 7.49 (1H, d, J =
15.8 Hz), 6.44 (1H, d, J = 15.8 Hz), 5.44 (1H, m), 5.38 (1H, m), 4.84 (2H, t, J = 6.1 Hz), 3.61 (2H, t, J = 7.7 Hz), 3.20 (2H, t, J = 4.2 Hz) 2.97 (6H, s), 2.61 (4H, qt, J = 7.1 Hz), 1.93 (2H, qn, J = 7.7 Hz), 0.78 (3H, t, J = 7.5 Hz); 13C NMR (CD30D) 8 163.6, 160.0, 155.1, 138.1, 134.1, 133.1, 131.9, 131.6, 124.7, 123.9, 118.2, 117.2, 114.3, 113.1, 111.8, 53.2, 42.1, 38.8, 24.8, 23.3, 19.4, 12.4.
Example 53 Preparation of 341-(2-Amino-ethyl)-2-(2,4,4-trimethyl-pentyl)-1H-benzoimidazol-y1]-N-hydroxy-acrylamide (55) SnC12.2H20 N e ga _v __ ( HOAc-Me0H (1:9) \
HN, HN,Boc Illal Boc INJe N
HCl/Me0H ( NH2OH/Na0Me ( NHOH
N
Via-1 H2N Vila-1 Step 1:
[0288] To a stirred solution of 344-(2-tert-Butoxycarbonylamino-ethylamino)-3-nitro-phenylFacrylic acid methyl ester (111a1, 65.2 mg, 0.178 mmol) and 3,5,5-trimetylhexanal (45 AL, 0.26 mmol) in a mixed solvent of Ac0H-Me0H (1:9 v/v, 2 mL) and DCM (1 mL) was added SnC12-2H20 (184 mg, 0.815 mmol). The resulting mixture was heated to C with stirring overnight. The solvent was removed under reduced pressure and the resultant residue was added saturated aqueous Na2CO3 and extracted with Et0Ac 5 (x3). The extracts gave the crude (Vial-1, 91 mg) with HPLC purity at 254 nm: 49.3%, tR = 3.02 min and 7.9%, tR = 1.97 min (de-Boc product). LCMS (ESI) m/z: 458 (IM
Hr) and 358 ([M + de-Boc product).
Step 2:
10 [0289] The above crude (Vial-1) was dissolved in Me0H (4 mL) and 6N HCI
(1 mL) and heated at 70 C for 30 min. The solution was evaporated to dryness and co-evaprote dwith PhMe (x2) and Me0H (x1). The residue (crude Vla-1, 81.9 mg) was spilt to two parts (43.4 mg, equal to 0.0945 mmol of Mat and 38.5 mg equal to 0.0839 mmol of !Hai).
Step 3:
[0290] The titled compound (55) was prepared according to the Step 4 described in Example 1, by using crude (Via-I, 38.5 mg). VIla-1 was obtained as TFA salt (2.3 mg, 4.7% from 111a1). HPLC purity at 254 nm: 92.7%, tR = 1.46 min. LCMS (ESI) m/z:
([M + H]+). 1H NMR (CD30D) 8 7.81 (1H, s), 7.70 (1H, d, J = 8.6 Hz), 7.65 (1H, d, J =
8.4 Hz), 7.59 (1H, d, J = 15.8 Hz), 6.47 (1H, br d, J = 14.6 Hz), 4.63 (2H,t, J = 5.4 Hz), 3.38 (2H, t, J = 6.5 Hz), 3.02 (1H, dd, J = 15.5, 6.5 Hz), 2.90 (1H, dd, J =
15.3, 8.6 Hz), 2.20 (1H, br s or m), 1.33 (1H, dd, J = 14.1, 3.4 Hz), 1.25 (1H, dd, J = 14.0, 6.6 Hz), 0.98 (3H, d, J = 6.2 Hz), 0.83 (9H, s).
Example 54 Preparation of 341-(2-Amino-ethyl)-2-(2-methoxy-nony1)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (56) [0291] The titled compound (56) was prepared according to the procedures described in Example 53, by using appropriate starting materials. HPLC purity at 254 nm: 91.8%, tR = 1.93 min. LCMS (ESI) m/z: 403 UM + Fin. 1H NMR (CD30D) 8 some , identified peaks: 7.81 (1H, s), 7.70 - 7.58 (3H, m), 6.46 (1H, br d, J =
14.4 Hz), 4.62 (2H, m), 3.69 (1H, br s or m), 3.38 (2H, t, J = 7.3 Hz), 1.67 (1H, m), 1.56 (1H, m), 1.50-1.20 (10H, m), 0.82 (3H, t, J = 6.2 Hz).
Example 55 Preparation of 342-Butyl-1-(2-dimethylamino-ethyl)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (57) [0292] The titled compound (57) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 100%, tR = 0.42 min. LC-MS m/z: 331 (WI H]+). 1H NMR (DMSO-d6) 5 0.97 (3H, t, J = 7.3 Hz), 1.49 (3H, m), 1.83 (2H, m), 3.09 (2H, t, J = 7.72 Hz), 3.54 (2H, t, J = 7.6 Hz), 4.74 (2H, t, J = 7.6 Hz), 6.57 (1H, d, J = 15.7 Hz), 7.62 (1H, d, J =
15.7 Hz), 7.71 (1H, d, J = 8.6 Hz), 7.93 (1H, d, J = 8.6 Hz), 7.97 (1H, s), 10.68 (2H, bs).
Example 56 Preparation of 342-Hexy1-1-(2-dimethylamino-ethyl)-1H-benzoimidazol-5-y1141-hydroxy-acrylamide (58) [0293] The titled compound (58) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 100%, tR = 0.42 min. LC-MS m/z: 359 (EM + Hr). 1H NMR (DMSO-d6) 8 0.89 (3H, t, J = 6.9 Hz), 1.28-1.54 (6H, m), 1.85 (2H, m), 2.92 (6H, s), 3.09 (2H, t, J =
7.6 Hz), 3.51 (2H, t, J = 7.8 Hz), 4.76 (2H, t, J = 7.8 Hz), 6.57 (1H, d, J = 15.8 Hz), 7.63 (1H, d, J =
15.8 Hz), 7.70 (1H, d, J = 8.6 Hz), 7.90 (1H, d, J = 8.6 Hz), 7.91 (1H, s), 10.68 (2H, bs).
Example 57 Preparation of 3-{1-(2-Diethylamino-ethyl)-242-(2,2-dimethyl-propionylamino)-ethyl]-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (61) [0294] The titled compound (61) was prepared according to the procedures =
described below, Steps 1 & 2 were performed as in Scheme I:
Step 3:
02 N v,,, H2N io HN
HN
AcOH, Me0H, r.N
rr 61-2 [0295] To a pre-stirred solution of 344-(2-diethylamino-ethylamino)-3-nitro-pheny1]-acrylic acid methyl ester (61-1, 280 mg, 1.0 mmol) in glacial acetic acid (5 mL), tin chloride was added (1.18 g, 10.0 mmol). The resulting solution was heated to 45 C for 17 hours and then cooled to room temperature. The solvent was removed under vacuum. Water (20 mL) and dichloromethane (20 mL) was added to the residue and stirred for 30 minutes. The organic layer was dried (MgSO4), filtered and concentrated to an oily residue. 100 mL diethyl ether was added and stirred for 4 hours.
The product 3-[3-amino-4-(2-diethylamino-ethylamino)-phenyl]-acrylic acid methyl ester was obtained in 54.9% yield (207.6 mg). LCMS m/z: 292 ([M+H]).
Step 4 H2N Fmoc. N
HN 1W-P 0"
EDC, HOBt.H20, H HN CO2Me z_Th.e0F1 DrolEAon temp. ; DCMp. HN 111V
W
r 0 H 0 61-2 614 r N OA
[0296] To a pre-stirred solution of 343-amino-4-(2-diethylamino-ethylamino)-phenyl]-acrylic acid methyl ester (61-2, 1.93 g, 6.65 mmol) and dichloromethane (13.3 mL) was added a cocktail solution of N-(3-dimethylaminopropy1)-N1-ethylcarbodiimide hydrochloride (2.55 g, 13.31 mmol), 1-hydroxybenzotriazole hydrate (2.04 g, 13.31 mmol), N,N-diisopropylethylamine (2.20 mL, 13.31 mmol) and dichloromethane (26.6 mL). After stirring for 0.5h, Fmoc-Gly-OH (61-3, 2.97 g, 9.98 mmol) was added.
When the starting material has fully reacted, ethyl acetate (100 mL) was added to dilute the mixture. The organic contents were washed with saturated sodium hydrogencarbonate (2 x 25 mL) and brine (2 x 25 mL), before drying in sodium sulphate. The mixture was then filtered and concentrated in vacuo. The product 3-[3-amino-4-(2-diethylamino-ethylamino)-phenyl]-acrylic acid methyl ester was obtained in 67.3% yield (2.54 g).
LCMS m/z: 571 ([M+H]).
Step 5 Fmoc,NO
HN CO2Me AcOH, 70 C Fmoc¨NH N 40 CO2Me HN
r1-4 I I 61-5 [0297] Glacial acetic acid (8.9 mL) was added into 313-amino-4-(2-diethylamino-ethylamino)-phenyl]-acrylic acid methyl ester (61-4, 2.54 g, 4.46 mmol) and the reaction mixture was stirred at 70 C for 14h. When the reaction has completed, the mixture was concentrated in vacuo. Saturated sodium hydrogencarbonate (20 mL) was added and dicholoromethane (3 x 20 mL) was used to extract the aqueous layer.
The combined organic contents were dried in sodium sulphate before being filtered and concentrated in vacuo. The product 3-{1-(2-dethylamino-ethyl)-2-[(9H-fluoren-9-ylmethoxycarbonylamino)-methyl]-1H-benzoimidazol-5-y1}-acrylic acid methyl ester (61-5) was obtained in 66.1 % (1.62 g). LCMS m/z: 553 ([M+H]).
Step 6 Fmoc¨NH N CO2Me H2N N io .02.
piperidine, DCM, rm temp 1N h [0298] To a pre-stirred solution of 3-{1-(2-dethylamino-ethyl)-2-[(9H-fluoren-ylmethoxycarbonylamino)-methy1]-1H-benzoimidazol-5-y1}-acrylic acid methyl ester (61-5, 1.62 g, 2.94 mmol) and dichloromethane (8.90 mL) was added piperidine (1.45 mL, 14.69 mmol). When the reaction has completed, the mixture was concentrated iin vacuo. The desired product was separated by reverse phase preparative HPLC.
After lyopholyzation, 0.52 g (53.6 %) of 342-aminomethy1-1-(2-diethylamino-ethyl)-1H-benzoimidazo1-5-y1]-acrylic acid methyl ester was obtained as powder. LCMS
rn/z: 331 ([M+H]+).
Step 7 H2N N CO2Me 2¨NH N .02.
I>, DIEA, DCM
r r61-6 61-7 [0299] To a pre-stirred solution of 3-[2-aminomethy1-1-(2-diethylamino-ethyl)-benzoimidazol-5-y1]-acrylic acid methyl ester (61-6, 0.10 g, 0.23 mmol), N,N-diisopropylethylamine (97 pL, 0.58 mmol) and dichloromethane (1.17 mL) was added 2,2-dimethyl-propionyl chloride (34.6 pL, 0.28 mmol) and the resulting reaction mixture was stirred at room temperature for 1 h. When the reaction has completed, ethyl acetate (20 mL) was added to dilute the mixture. The organic contents were washed with saturated sodium hydrogencarbonate (2 x 20 mL) and brine (2 x 20 mL), before drying in Na2SO4. The mixture was filtered and concentrated in vacuo. The product 3-{1-(2-diethylami no-ethyl)-2-[(2,2-di methyl-propionylamino)-methy1]-1H-benzoim idazol-5-yI}-acrylic acid methyl ester (61-7) was obtained in 76.6 % (74.1 mg). LCMS
m/z: 415 ([M+H]).
Step 8 N
CO2Me H N
NH
NH2OH.HCI, /Z¨N\ _______________________________ </N 010 OH
Na0Me, Me0Hir r - 78 C
I I 61-7 r 61 [0300] To a stirred solution of 3-{1-(2-diethylamino-ethyl)-24(2,2-dimethyl-propionylamino)-methyl]-1H-benzoimidazol-5-y1}-acrylic acid methyl ester (61-7, 73.8 mg, 0.18 mmol) and hydroxylamine hydrochloride (124 mg, 1.78 mmol) in Me0H
(0.3 mL) was added sodium methoxide (30% in methanol) (0.8 mL, 3.6 mmol) at ¨ 78 C.
The reaction mixture was then allowed to warm up slowly to room temperature.
The reaction was monitored by LC/MS and was completed in around 15 min. IN HCI was then added slowly into the reaction mixture at 0 C. The desired product was separated by reverse phase preparative HPLC. After lyopholyzation, 22.2 mg (24.3 %) of 3-{1-(2-diethylamino-ethyl)-2-[(2,2-dimethyl-propionylamino)-methyl]-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide was obtained as powder. HPLC purity: 99.5%, tR = 0.94min.
LCMS m/z: 416 ([M+Hr). 1H NMR (CD30D) 5 7.89 (s, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.55 (d, J= 15.8 Hz, 1H), 6.53 (d, J= 15.8 Hz, 1H), 4.98 (t, J=
7.3 Hz, 2H), 4.73 (s, 2H), 3.75 (t, J = 7.5 Hz, 2H), 3.42 (q, J = 7.2 Hz, 4H), 1.37 (t, J =
7.3 Hz, 6H), 1.22 (s, 9H); 13C NMR (CD30D) 8 182.5, 168.9, 162.2, 161.9, 154.8, 140.8, 137.9, 135.0, 133.9, 126.0, 119.3, 117.1, 112.9, 50.9, 40.5, 39.7, 36.7, 27.6, 9.1. =
Example 58 Preparation of N-{2-[1-(2-Diethylamino-ethyl)-5-(2-hydroxycarbamoyl-viny1)-1H-benzoimidazol-2-y11-ethyl}-3,3-dimethyl-butyramide (59) [0301] The titled compound (59) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm: 94.0%; tR = 0.99 min. LC-MS m/z: 444 DA +
Example 59 Preparation of N-[1-(2-Diethylamino-ethyl)-5-(2-hydroxycarbamoyl-viny1)-1H-benzoimidazol-2-ylmethyli-butyramide (62) [0302] The titled compound (62) was prepared according to the procedures 5 described in Example 57, by using appropriate starting materials. HPLC
purity at 254 nm: 85.1 %; tR = 0.58 min; LCMS m/z: 402 ([M + H]4). 1H NMR (CD30D) 8 7.88 ¨
7.56 (m, 2H), 7.73 (s, 1H), 7.60 (d, J = 15.8 Hz, 1H), 6.51 (d, J = 15.8 Hz, 1H), 4.99 ¨ 4.79 (m, masked peaks), 4.81 (s, 2H), 3.74 (t, J = 7.8 Hz, 2H), 3.46 ¨ 3.41 (m, 4H), 2.31 (t, J
= 7.4 Hz, 2H), 1.39 (t, J = 7.2 Hz, 6H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR
(CD300) 8 10 117.1, 165.9, 154.6, 140.9, 129.6, 128.4, 127.3, 125.9, 118.6, 112.8, 111.5, 50.7, 40.4, 38.4, 36.4, 19.9, 14.0, 9Ø
Example 60 Preparation of 342-(3,3-Dimethyl-buty1)-1-(2-ethylamino-ethyl)-1H-benzoimidazol-15 5-y1J-N-hydroxy-acrylamide (63) [0303] The titled compound (63) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.0 %;
tFt =
0.93 min; LCMS m/z: 359 ([M + Hr). 1H NMR (CD30D) 8 7.5 (d, J = 8.4 Hz, 1H), 7.75 ¨7.74 (m, 2H), 7.16 (d, J = 15.7 Hz, 1H), 6.31 (d, J = 15.7 Hz, 1H), 4.89 (brs, 2H), 3.72 20 (brs, 2H), 3.29 ¨ 3.18 (m, 4H), 1.90 ¨ 1.86 (m, 2H), 1.35 (t, J = 7.1 Hz, 3H), 1.09 (s, 9H); 13C NMR (CD30D) 5 165.7, 158.4, 140.4, 134.9, 134.5, 134.2, 126.2, 122.5, 119.2, 115.6, 113.4, 55.3, 44.0, 40.8, 40.7, 31.3, 29.3, 22.9.
Example 61 25 Preparation of 341-(2-Dimethylamino-ethyl)-2-(3,3-dimethyl-buty1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (64) [0304] The titled compound (64) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC: 99.0 %;
tR =
0.83 min; LCMS m/z: 359 ([M + 1H NMR (CD30D) 5 7.94 (d, J = 7.8 Hz, 1H), 7.81 30 (s, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 15.7 Hz, 1H), 6.64 (d, J
= 15.7 Hz, 1H), 4.93 (brs, 2H), 3.76 (brs, 2H), 3.22 (t, J = 7.7 Hz, 2H), 3.09 (s, 6H), 1.91 ¨
1.87 (m, 2H), 1.08 (s, 9H); 13C NMR (CD30D) 8 165.4, 158.4, 140.2, 134.5, 134.2, 133.2, 126.5, 118.8, 115.3, 113.9, 46.4, 45.1, 42.9, 40.6, 31.3, 29.2, 22.9, 11.4.
35 Example 62 Preparation of 341-(2-Dimethylamino-ethyl)-2-pentyl-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (65) [0305] The titled compound (65) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.5%; tR = 0.78 min. LCMS m/z: 345([M + H]). 1H NMR (DMSO-d6) 8 0.89 (3H, m), 1.38 (4H, m), 1.83 (2H, m), 2.93 (6H, s), 3.04 (2H, m), 3.50 (2H, t), 4.70 (2H, m), 6.55 (1H, d), 7.57 (1H, d), 7.61 (1H, m), 7.81 (2H, m), 10.42 (1H, bs).
Example 63 Preparation of 341-(2-Dimethylamino-ethyl)-2-(2,2,2-trifluoro-ethyl)-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (64) [0306] The titled compound (64) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 91.1%; tR = 0.68 min. LCMS m/z: 357 ([M+Fi]+).
Example 64 Preparation of 341-(2-Ethylamino-ethyl)-2-penty1-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (68) [0307] The titled compound (68) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 98.4%; tR = 0.87 min. LCMS m/z: 345([M+H])-Example 65 Preparation of N-Hydroxy-341-(2-isopropylamino-ethyl)-2-penty1-1H-benzoimidazol-5-y1]-acrylamide (71) [0308] The titled compound (71) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 97.4%; tR = 0.95 min. LCMS m/z: 359 (DM + Hr). 1H NMR (DMSO-d6) 8 0.89 (3H, m), 1.22 (6H, d), 1.38 (4H, m), 1.82 (2H, m), 2.99 (3H, m), 4.56 (2H, m), 6.51 (1H, d), 7.59 (2H, d), 7.64 (1H, m), 7.88 (1H, m), 8.74 (2H, bs).
Example 66 Preparation of 342-Hexy1-1-(2-methylamino-ethyl)-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (74) [0309] The titled compound (74) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 96.0%, tR = 1.12 min. LCMS m/z: 345 ([M+H]+). 1H NMR (CD30D) 8 7.76 (2H, s), 7.70 (1H, d, J = 8.6 Hz). 7.50 (1H, d, J = 15.7 Hz), 6.43 (1H, d, J = 15.7 Hz), 4.81 (2H, d, J = 5.7 Hz), 3.49 (2H, bs), 3.15 (2H, dt, J = 4.8 Hz), 2.71 (3H, s), 1.85 (2H, qn, J =
5.1 Hz), 1.46 (2H, m), 1.33 (4H, m), 0.85 (3H, t, J = 7.1 Hz); 13C NMR (CD300) 163.7, 157.8, 138.5, 132.7, 124.2, 117.6, 113.7, 111.2, 40.2, 32.2, 30.5, 28.0, 25.6, 25.1, 21.6, 12.3.
Example 67 Preparation of N-Hydroxy-341-(2-methylamino-ethyl)-2-penty1-1H-benzoimidazol-5-y1]-acrylamide (75) [0310] The titled compound (75) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity at 254 nm: 97.8%; tR = 0.80 min. LCMS m/z: 331 (EM + H]+). 1H NMR (DMSO-d6) 8 0.89 (3H, m), 1.38 (4H, m), 1.84 (2H, m), 2.51 (3H, s), 3.14 (2H, m), 3.38 (2H, t), 4.70 (2H, m), 6.57 (1H, d), 7.62 (1H, d), 7.73 (1H, m), 7.96 (2H, m), 9.13 (2H, s).
Example 68 Preparation of 3-(2-Buty1-1-pyrrolidin-3-y1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (69) 02N io 0 OMe 0 OMe 02N is OMe Boc HN
CI Et3N SnC12, Me0H/ AcOH
la Heat IEloc I3oc HCl/Me0H OMe /
NH2OH NHOH, Step1 [0311] To a solution of methyl trans-4-Chloro-3-nitrocinnamate (la, 4.8 g, 20 mmol) in triethyl amine (5.5 mL, 40 mmol) was added 3-Amino-pyrrolidine-1-carboxylic acid tert-butyl ester (11.2 g, 60 mmol), the resulting mixture was then heated to 100 C
for 8 hours, then another portion of methyl trans-4-Chloro-3-nitrocinnamate (4.8 g, 20 mmol) and triethyl amine (5.5 mL, 40 mmol) was added, the resulting mixture was allowed to stir overnight at 100 C, then reaction was quenched by adding 200 mL of DCM
and 80 mL of 1M HCI solution. After separation of DCM layer, the aqueous solution was extracted with DCM one more time, and combined with previous DCM solution, which was then washed with brine, dried over sodium sulfate, then filtered through silica gel short column, and rinsed with ethyl acetate and hexanes mixture (2:1) until the orange color band was completely rinsed down. After removal of solvent under reduced pressure, the residue 69-2 was obtained (around 80% of yield in most of cases) as orange solid, which is pure enough (95% purity from HPLC) for next step. LC-MS
m/z:
292 ([M-Boc +H]).
Step 2 [0312] To a solution of compound 69-2 (7.84 g, 20.0 mmol) in 100 mL of Me0H
and AcOH mixture (1:9) was added corresponding aldehyde (3.0 mL, 30.0 mmol) and tin chloride (22.6 g, 100 mmol), the resulting mixture was stirred at 42 C for 24 hrs. Then the mixture was diluted using ethyl acetate (300 mL) at room temperature, and was then quenched with sat. sodium carbonate (30 mL). The resulting mixture was stirred for additional 1 hour, then organic layer was decanted to another conic flask.
Solid left in reaction flask was suspension with another portion of ethyl acetate (300 mL), which was then decanted and combined with previous portion of ethyl acetate and was then filtered through silica gel short column and rinsed with ethyl acetate, after removal of filtrate under reduced pressure, the residue was pure enough for next step and also could be purified on column (hexanes:Et0Ac = 1:2) to give a pale-yellow solid 69-3 (3.8 g, 44%). LC-MS m/z: 456 (EM + H]+).
Step 3 [0313] To a flask charged with compound 69-3 (456 mg, 1 mmol) was added 1.25 M
HCI in Me0H (4 mL), the resulting mixture was then heated to reflux for 2 hours, which was then evaporated to dryness under reduced pressure to give compound 4 as HCI
salt, which is pure enough for next step without any purification. LC-MS m/z:
356 ([M +
Fi]).
Step 4 [0314] To a solution of above crude 69-4 (around 0.16 mmol) product in Me0H
(0.5 mL) was added a pre-prepared NH2OH stock solution (2.0 M, 2 mL). The resulting mixture was stirred at room temperature for 2 hrs. After quenching with TFA
(0.4 mL), the resulting mixture was subjected to HPLC purification to afford 25 mg of 3-(2-Buty1-1-pyrrolidin-3-y1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide. HPLC purity:
98%; LC-MS m/z: 329 ([M + H]+). 1H NMR (CD30D) 8 0.95 (3H, t, J = 7.2 Hz), 1.46 (2H, m), 1.77 (2H, m), 2.52-2.82 (2H, m), 3.10-3.17 (2H, m), 3.48 (1H, m), 3.80 (2H, m), 5.55 (1H, m), 6.48 (1H, d, J = 16.0 Hz), 7.58 (1H, d, J= 16.0 Hz), 7.67 (1H, d, J= 8.0 Hz), 7.78-7.92 (2H, m).
Example 69 Preparation of 3-(2-Buty1-1-piperldin-4-y1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (70) [0315] The titled compound (70) was prepared according to the procedures described in Example 78, by using appropriate starting materials. HPLC purity:
98%;
LCMS m/z: 343 ([M + Hr). 1H NMR (CD30D) 6 0.96 (3H, t, J= 7.2 Hz), 1.46 (2H, m), 1.79 (2H, m), 2.21 (2H, m), 2.82 (2H, m), 3.10-3.17 (2H, m), 3.26 (1H, m), 3.60 (2H, m), 4.96 (1H, m), 6.49 (1H, d, J= 15.8 Hz), 7.60 (1H, d, J= 15.8 Hz), 7.66 (1H, d, J=
8.0 Hz), 7.82 (1H, s) (1H, d, J= 8.0 Hz).
Example 70 Preparation of 3-(2-Hexy1-1-pyrrolidin-3-y1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (80) [0316] The titled compound (80) was prepared according to the procedures described in Example 68, by using appropriate starting materials. HPLC purity: 98%; LCMS
m/z:
357 ([M + H]+). 1H NMR (CD30D) 8 0.84 (3H, t, J = 7.2 Hz), 1.22-1.38 (4H, m), 1.44 (2H, m), 1.81 (2H, m), 2.52-2.82 (2H, m), 3.10-3.17 (2H, m), 3.48 (1H, m), 3.80 (2H, m), 5.56 (1H, m), 6.48 (1H, d, J= 15.8 Hz), 7.56 (1H, d, J = 15.8 Hz), 7.65 (1H, d, J=
9.2 Hz), 7.84 (1H, s), 7.90 (1H, d, J= 9.2 Hz).
Example 71 Preparation of 342-Buty1-1-(1-methyl-pyrrolidin-3-y1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide (81) [0317] The titled compound (81) was prepared according to the procedures described in Example 68, by using 69-4 via reductive amination to introduce a methyl group.
HPLC purity: 98%; LCMS m/z: 343 ([M + H]). 1H NMR (CD300) 6 0.99 (3H, t, J =
7.2 Hz), 1.52 (2H, m), 1.83 (2H, m), 2.65-2.92 (2H, m), 3.09 (3H, s), 3.15-3.25 (2H, m), 3.58 (1H, br.), 3.90 (2H, m), 5.73 (1H, m), 6.51 (1H, d, J = 16.0 Hz), 7.58 (1H, d, J =
16.0 Hz), 7.69 (1H, d, J= 8.0 Hz), 7.88 (1H, s), 8.00 (1H, d, J= 9.2 Hz).
Example 72 Preparation of 3-(2-Hexy1-1-piperidin-3-y1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (82) [0318] The titled compound (82) was prepared according to the procedures described in Example 68, by using appropriate starting materials. HPLC purity: 97%; LCMS
m/z:
343 ([M + Hr). 1H NMR (CD30D) 6 0.99 (3H, t, J= 7.2 Hz), 1.52 (2H, m), 1.84 (2H, m), 2.04 (1H, m), 2.20 (2H, m), 2.61 (1H, m), 3.12-3.22 (2H, m), 3.49 (1H, m), 3.67 (1H, m), 3.78 (1H, t, J = 12.0 Hz), 4.98 (1H, m), 6.53 (1H, d, J = 15.8 Hz), 7.63 (1H, d, J =
15.8 Hz), 7.70 (1H, d, J = 9.2 Hz), 7.86 (1H, s), 8.06 (1H, d, J = 8.8 Hz).
Example 73 Preparation of 3-(2-Butyl-1-piperidin-3-y1-1H-benzoimidazol-5-0)-N-hydroxy-acrylamide (83) [0319] The titled compound (83) was prepared according to the procedures described in Example 68, by using appropriate starting materials. HPLC purity: 97%; LCMS
m/z:
371 ([M + H]). 1H NMR (CD30D) 8 0.88 (3H, t, J = 7.2 Hz), 1.22-1.42 (4H, m), 1.47 (2H, m), 1.84 (211, m), 2.04 (1H, m), 2.20 (2H, m), 2.62 (1H, m), 3.12-3.22 (2H, m), 3.48(111, m), 3.68 (1H, m), 3.78 (1H, t, J = 12.0 Hz), 5.01 (1H, m), 6.53 (1H, d, J= 15.8 Hz), 7.62 (1H, d, J = 15.8 Hz), 7.70 (1H, d, J = 9.2 Hz), 7.86 (111, s), 8.06 (1H, d, J =
8.8 Hz).
Example 74 Preparation of (E)-N-hydroxy-3-(1-(1-methylpiperidin-3-y1)-2-penty1-1H-benzo[d]imidazol-5-yOacrylamide (86) [0320] The titled compound (86) was prepared according to the procedures described in Example 71, by using appropriate starting materials.HPLC purity: 99.3 %, tR
=1.06 min; LCMS m/z: 371 ([M + H]). 1H NMR (CD30D) 8 8.18 (d, J = 7.9 Hz, 1H), 7.92 (s, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.61 (d, J = 15.7 Hz, 1H), 6.58 (d, J = 15.7 Hz, 1H), 5.21 (brs, 1H), 3.69 (brs, 2H), 3.69 ¨ 3.66 (m, 1H), 3.37 ¨ 3.27 (masked peaks), 3.03 (s, 3H), 2.66 (brs, 1H), 2.29 ¨ 2.22 (m, 3H), 1.94¨ 1.90 (m, 2H), 1.54 ¨ 0.94 (m, 4H), 0.96 (t, J = 7.1 Hz, 3H); 13C NMR (CD30D) 8165.6, 157.6, 139.9, 134.6, 134.1, 132.5, 126.3, 120.4, 115.5, 115.2, 54.9, 54.4, 53.3, 44.1, 32.4, 27.5, 27.3, 26.8, 23.2, 23.1, 14.2.
Example 75 Preparation of (E)-3-(2-hexy1-1-(1-(2-hydroxyethyl)piperidin-3-y1)-1H-benzo[d]imidazol-5-y1)-N-hydroxyacrylamide (90) [0321] The titled compound (90) was prepared according to the procedures described in Example 68, by using appropriate starting materials and alkylation of the piperidine with 2-bromoethanol. LCMS m/z: 415 ([M +H]).
Example 76 Preparation of N-Hydroxy-3-[1-(1-pentyl-piperidin-3-y1)-1H-benzoimidazol-5-y1]-acrylamide (94) [0322] The titled compound (94) was prepared according to the procedures described in Example 68, by using appropriate starting materials (formic acid for benzimdiazoel ring formation and reductive amination of the piperidine with pentanal). HPLC
purity:
95%; LC-MS rn/z: 357 ([M+H]). 1H NMR (CD30D) 8 9.04 (s, 1H), 7.94 (brs, 2H), 7.78 (d, 1H, J=8.2 Hz), 7.70 (d, 1H, J= 15.7 Hz), 6.57 (d, 1H, J= 15.9 Hz), 5.14 ¨
5.10 (m, 1H), 3.85(dd, 2H, J = 88.0, 9.0 Hz), 3.48 ¨ 3.13 (m, 4H), 2.43 ¨ 2.12 (m, 4H), 1.94 ¨10 1.80 (m, 2H), 1.39 ¨ 1.29 (m, 4H), 0.94 (t, 3H, J= 6.8 Hz).
Example 77 Preparation of N-Hydroxy-3-[1-(1-phenethyl-piperidin-3-y1)-1H-benzoimidazol-5-y1]-acrylamide (96) [0323] The titled compound (96) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 98.6%; LC-MS
rn/z: 391([M+H]). 1H NMR (CD30D) 6 8.93 (s, 1H), 7.95 (s, 1H), 7.91 (d, 1H, J
= 8.5 Hz), 7.76 (d, 1H, J = 8.5 Hz), 7.70 (d, 1H, J = 15.8 Hz), 7.35 ¨ 7.24 (m, 6H), 6.56 (d, 1H, J = 15.7 Hz), 5.10 (t, 1H, J = 11.4 Hz), 3.91 (dd, 2H), 3.55 ¨ 3.45 (m, 2H), 3.15 -3.11 (m, 2H), 2.46 ¨ 2.13 (m, 6H).
Example 78 Preparation of N-Hydroxy-3-{141-(3-phenyl-propyl)-piperidin-3-y1]-benzoimidazol-5-y1}-acrylamide (97) [0324] The titled compound (97) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 94.5%; LC-MS:
405 ([M+Hr) 1H NMR (CD30D) 8 8.68 (s, 1H), 7.94 (s, 1H), 7.80 (d, 1H, J = 8.4 Hz), 7.71 (d, 1H, J= 15.7 Hz), 7.69 (d, 1H, J= 8.2 Hz), 7.31 ¨7.17 (m, 6H), 6.54(d, 1H, J=
15.6 Hz), 3.71 (dd, 2H, J= 66 Hz, 10.9 Hz), 3.48 ¨ 3.40 (m, 1H), 3.13 ¨ 3.05 (m, 2H), 2.73 (t, 2H, J= 7.4 Hz), 2.38 ¨ 2.04 (m, 8H);
. Example 79 Preparation of 3-(141-(3,3-Dimethyl-butyl)-pyrrolidin-3-y1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (99) [0325] The titled compound (99) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 91.9%; tR
= 1.10 min. LC-MS rn/z: 357 ([MH]+). 1H NMR (DMSO-d6) 6 0.91 (9H, s), 1.52 (4H, m), 3.09 (1H, m), 3.29 (6H, m), 6.52 (1H, d), 7.43 (2H, m), 7.62 (1H, m), 7.80 (1H, m), 8.82 (1H, s), 10.25 (1H, bs).
Example 80 Preparation of 3-{142-(Ethyl-methyl-amino)-ethy1]-2-penty1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (79) [0326] The titled compound (79) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity: 99%; tR =
0.68 min.
LC-MS m/z: 359 ([M+H]). 1H NMR (DMSO-d6) 60.89 (3H, m), 1.23 (3H, m), 1.38 (4H, m), 1.84 (2H, m), 2.92 (3H, s), 3.10 (2H, m), 3.28 (2H, m), 3.52 (2H, m), 4.77 (2H, m), 6.58 (1H, d), 7.61 (1H, d), 7.71 (1H, m), 7.92 (2H, m), 10.48 (1H, bs).
Example 81 Preparation of 3-{2-Buty1-142-(ethyl-methyl-amino)-ethy1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (85) [0327] The titled compound (85) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity: 95.8%; tR
=1.04 min. LC-MS m/z: 345 ([M+H]). 1H NMR (DMSO-d6) 8 0.95 (3H, m), 1.25 (3H, m), 1.46 (2H, m), 1.81 (2H, m), 2.92 (3H, s), 3.13 (2H, m), 3.27 (2H, m), 3.54 (2H, m), 4.80 (2H, m), 6.60 (1H, d), 7.62 (1H, d), 7.75 (1H, m), 7.92 (2H, m), 10.59 (1H, bs).
Example 82 Preparation of 3-(2-Buty1-1-{2-[ethyl-(3-hydroxy-propy1)-amino]-ethyl}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (91) [0328] The titled compound (91) was prepared according to the procedures described =
in Example 1, by using appropriate starting materials. HPLC purity: 93.5%; tR=
0.50 min. LC-MS (m/z): 389 ([MH]-). 1F1 NMR (DMSO-d6) 8 0.94 (3H, m), 1.25 (311, m), 1.46 (2H, m), 1.83 (4H, m), 3.04 (2H, m), 3.31 (4H, m), 3.50 (4H, m), 4.72 (2H, m), 6.54 (1H, d), 7.61 (1H, m), 7.69 (1H, m), 7.80 (1H, m), 7.90 (1H, m), 10.20 (1H, bs).
Example 83 Preparation of 3-(1-{2-[Ethyl-(3-hydroxy-propy1)-amino]-ethyl}-2-pentyl-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (92) [0329] The titled compound (92) was prepared according to the procedures described in Example 1, by using appropriate starting materials. HPLC purity: 93.5%; tR
= 0.50 min. LC-MS (m/z): 389 ([M+H]4) 1H NMR (DMSO-d6) 60.94 (3H, m), 1.25 (3H, m), 1.46 (2H, m), 1.83 (4H, m), 3.04 (2H, m), 3.31 (4H, m), 3.50 (4H, m), 4.72 (2H, m), 6.54 (1H, d), 7.61 (1H, m), 7.69 (1H, m), 7.80 (1H, m), 7.90 (1H, m), 10.20 (1H, bs).
Example 84 Preparation of 3-{142-(Butyl-ethyl-amino)-ethy1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (95) [0330] The titled compound (95) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 99.9%; LC-MS
miz: 331([M+H]). 1H NMR (CD30D) 8 9.29 (s, 1H), 7.99 ¨ 7.95 (m, 2H), 7.82 (d, 1H, J
= 8.5 Hz), 7.56 (d, 1H, J = 15.6 Hz), 6.53 (d, 1H, J = 15.5 Hz), 5.0 ¨ 4.95 (m, 2H), 3.86 ¨ 3.78 (m, 2H), 3.42 (dd, 2H, J = 13.3, 7.1 Hz), 3.28 ¨ 3.26 (m, 2H), 1.74 ¨
1.71 (m, 2H), 1.43 (qt, 2H, J = 7.4, 3.8 Hz), 1.38 (t, 3H, J = 7.2 Hz), 1.00 (t, 3H, J
= 7.3 Hz).
Example 85 Preparation of 3-[2-(4-Cyano-butyl)-1-(2-diethylamino-ethyl)-1H-benzoimidazol-yli-N-hydroxy-acrylamide (101) [0331] The titled compound (101) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm:
99.9%.
LC-MS (ESI) m/z: 384 ([M+H]). 1H NMR (CD300) 6 7.78 (1H, s) 7.76 (1H, d, J =
8.5 Hz), 7.63 (1H, d, J = 16.9 Hz), 7.58 (1H, d. J = 5.1 Hz), 6.44 (1H, d, J =
15.3 Hz), 4.70 (2H, in water peak), 3.50 (2H, t, J = 7.6 Hz), 3.32 (4H, qt, J = 7.3 Hz), 3.07 (2H, t, J =
8.0 Hz), 2.50 (2H, t, J = 7.0 Hz), 1.99 (2H, q, J = 7.5 Hz), 1.78 (2H, q, J =
7.3 Hz), 1.29 (6H, t, J = 7.3 Hz).
Example 86 Preparation of 3-{142-(Butyl-isopropyl-amino)-ethyl]-1H-benzoimidazol-5-y1}-19-hydroxy-acrylamide (108) [0332] The titled compound (108) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 98.8%; tR
= 1.33 min. LC-MS mk: 345 ([M+Hr). 1H NMR (DMSO-d6) 8 0.90 (3H, m), 1.25 (6H, d), 1.35 (2H, m), 1.64 (2H, m), 3.09 (2H, m), 3.51 (1H, m), 3.73 (2H, m), 4.74 (2H, m), 6.52 (1H, d), 7.53 (2H, m), 7.64 (1H, m), 7.80 (1H, m), 8.62 (1H, m), 9.40 (1H, bs), 10.72 (1H, bs).
Example 87 Preparation of N-Hydroxy-3-{142-(isopropyl-pentyl-amino)-ethyl]-benzoimidazol-5-y1}-acrylamide (109) [0333] The titled compound (109) was prepared according to the procedures described in Example 76, by using appropriate starting materials. LC-MS m/z: 359 ([M+H]). 1H
NMR (DMSO-d6) 8 0.88 (3H, t), 1.25 (10H, m), 1.64 (2H, m), 3.12 (2H, m), 3.51 (1H, b), 3.60 (1H, b), 3.73 (1H, b), 4.74 (2H, t), 6.51 (1H, d), 7.59 (1H, s), 7.63 (1H, d), 7.80 (1H, d), 7.93 (1H, s), 8.65 (1H, s), 9.46 (1H, b) Example 88 Preparation of 342-(5-Cyano-penty1)-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (110) [0334] The titled compound (110) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm:
95.4%.
LC-MS (ESI) m/z: 347 ([M+H]). 1H NMR (CD30D) 8 7.96 (1H, d, J = 8.5 Hz), 7.90(1H, s) 7.81 (1H, d, J = 8.5 Hz), 7.59 (1H, d. J = 15.6 Hz), 6.55 (1H, d, J = 15.5 Hz), 4.96 (2H, t, J = 7.3 Hz), 3.69 (2H, t, J = 7.1 Hz), 3.44 (4H, qt, J = 7.2 Hz), 3.31 (2H, embedded in Me0D peak), 2.51 (2H, t, J = 6.9Hz), 2.05-1.98 (2H, m), 1.78 (2H, m, J =
7.4 Hz), 1.70 (2H, m, J = 6.4 Hz), 1.41(3H, t, J = 7.2 Hz);
Example 89 Preparation of 3-(1-{2-[(3,3-Dimethyl-butyl)-ethyl-amino]-ethyl}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (111) [0335] The titled compound (111) was prepared according to the procedures described in Example 76, by using appropriate starting materials. TFA salt. HPLC purity:
97.7%;
LC-MS m/z: 359 ([M+H]). 1H NMR (CD30D) 8 9.10 (s, 1H), 7.89 (d, 1H, J = 8.9 Hz), 7.88 (s, 1H), 7.74 (d, 1H, J = 8.6 Hz), 7.51 (d, 1H, J = 15.7 Hz), 6.46 (d, 1H, J = 15.7 Hz), 4.98 ¨ 4.93 (m, 2H), 3.77 ¨ 3.75 (m, 2H), 3.38 (dd, 2H, J = 13.3, 7.2 Hz), 3.22 ¨
3.18 (m, 2H), 1.60 ¨ 1.59 (m, 2H), 1.33 (t, 3H, J = 7.1 Hz), 0.91 (s, 9H);
[0336] HCI salt. 1H NMR (DMSO-d6) 8 9.90 (bs, 1H), 8.65 (s, 1H), 7.93 (s, 1H), 7.82 (d, . 1H, J = 8.5 Hz), 7.64 (d, 1H, J = 8.1 Hz), 7.61 (d, 1H, J = 15.6 Hz), 7.52 (d, 1H, J =
15.8 Hz), 4.76 ¨ 4.72 (t, 2H, J = 7.0), 3.65 ¨ 3.60 (m, 2H), 3.32 ¨ 3.24 (m, 2H), 3.17 ¨
3.08 (m, 2H), 1.52¨ 1.47 (m, 2H), 1.22 (t, 3H, J = 7.2 Hz), 0.87 (s, 9Hz).
Example 90 Preparation of 3-{1-12-(Ethyl-propyl-amino)-ethyl]-1H-benzoimidazo1-5-y1)-N-hydroxy-acrylamide (112) [0337] The titled compound (112) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 98.1%; LC-MS
m/z: 315 ([M+H]). 1H NMR (CD30D) 8 9.43 (s, 1H), 7.99 (d, 1H, J= 8.5 Hz), 7.93 (s, 1H), 7.82 (d, 1H, J= 8.5 Hz), 7.53 (d, 1H, J= 15.7 Hz), 6.50 (d, 1H, J= 15.5 Hz), 5.00 ¨ 4.96 (m, 2H), 3.78 (t, 2H, J= 6.1 Hz), 3.37 (dd, 2H, J= 14.2, 7.2 Hz), 3.22 ¨ 3.19 (m, 2H), 1.75 (qt, 2H, J= 7.5 Hz), 1.33 (t, 3H, J= 7.2 Hz), 0.99 (t, 3H, J= 7.3 Hz).
Example 91 Preparation of N-Hydroxy-3-(1-{2-[isopropyl-(2-methyl-penty1)-amino]-ethyl}-1H-benzoimidazol-5-y1)-acrylamide (113) [0338] The titled compound (113) was prepared according to the procedures described in Example 76, by using appropriate starting materials. LC-MS m/z: 373RM+H)1].
NMR (DMSO-d6) 8 0.86 ¨ 0.97 (7H, m), 1.14 ¨1.28 (12H, m), 4.70 (2H, b), 6.49 (1H, d), 7.58 ¨7.62 (2H, m), 7.73 (1H, d), 7.91 (1H, s), 8.48 (1H, s) Example 92 Preparation of 3-{142-(Ethyl-hexyl-amino)-ethyl]-2-methyl-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (116) [0339] The titled compound (116) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm:
98.2%, tR = 1.27 min. LC-MS (ESI) m/z: 373 ([M+Hr). 1H NMR (CD30D) 8 7.85 (1H, s), 7.78 (1H, d, J= 8.4 Hz), 7.70 (1H, d, J= 8.7 Hz), 7.15 (1H, d. J= 15.9 Hz), 6.53 (1H, d, J=
15.9 Hz), 4.81 (2H), 3.63 (2H, t, J = 7.7 Hz), 3.41 (2H, qt, J= 7.2 Hz), 3.29 (2H), 2.82 (3H, s), 1.74 (2H, m), 1.37 (11H, m), 0.93 (3H, t, J = 6.9 Hz).
Example 93 Preparation of 3-(1-[2-(Butyl-ethyl-am i no)-ethyl]-2-trifluoromethy1-1H-benzoi midazol-5-y1)-N-hydroxy-acrylamide (117) [0340] The titled compound (117) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm:
97.3%, tR = 1.50 min. LC-MS (ESI) m/z: 399 (1M+Hr). 1H NMR (CD30D) 8 7.95 (1H, s), 7.70 (2H, s), 7.62 (1H, d, J= 15.9 Hz), 6.46 (1H, d, J= 15.8 Hz), 5.24 (2H), 3.50 (2H, t, J=
8.8 Hz), 3.31 (2H, qt, J= 7.2 Hz), 3.17 (2H), 1.63 (2H, m), 1.35 (2H, qt, J =
7.5 Hz), 1.29 (3H, t, J = 7.2 Hz), 0.92 (3H, t, J = 7.4 Hz).
Example 94 Preparation of 3-{142-(Ethyl-hexyl-amino)-ethyl]-2-trifluoromethy1-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (118) [0341] The titled compound (118) was prepared according to the procedures described in Example 57, by using appropriate starting materials. HPLC purity at 254 nm:
94.6%, tR = 2.07 min. LC-MS (ESI) m/z: 427 ([M+111+). 1H NMR (CD30D) 8 8.04 (1H, s), 7.80 (2H, s), 7.72 (1H, d, J = 15.8 Hz), 6.56 (1H, d, J = 15.6 Hz), 4.85 (2H), 3.61 (2H, t, J =
8.5 Hz), 3.42 (2H, qt, J = 7.2 Hz), 3.26 (2H), 1.75 (2H, m), 1.39 (9H, m, J =
7.5 Hz), 0.93 (3H, t, J = 7.0 Hz).
Example 95 Preparation of 341-(2-Dipropylamino-ethyl)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide (120) [0342] The titled compound (120) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 100%. LC-MS
m/z: 331 ([M+H]). 1H NMR (DMSO-d6) 8 0.86 (6H, d), 1.64 (4H, m), 3.09 (4H, m), 3.60 (2H, m), 4.76 (2H, m), 6.53 (1H, d), 7.55 (2H, m), 7.65 (1H, m), 7.88 (1H, m), 8.75 (1H, m), 9.93 (1H, bs).
Example 96 Preparation of N-Hydroxy-3-(1-{24isopropyl-(3-methyl-butyl)-aminoFethyl}-1H-benzoimidazol-5-y1)-acrylamide (121) [0343] The titled compound (121) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 98.7%; tR
= 1.02 min. LC-MS (m/z): 358 ([M+H]). 1H NMR (DMSO-d6) 8 0.88 (6H, d), 1.28 (6H, m), 1.59 (3H, m), 3.10 (3H, m), 3.68 (2H, m), 4.71 (2H, m), 6.50 (1H, d), 7.50 (2H, m), 7.59 (1H, m), 7.63 (1H, m), 8.52 (1H, m), 9.50 (1H, bs), 10.70 (11-1, bs).
Example 97 Preparation of 3-(1-{2-[(3,3-Dimethyl-butyl)-methyl-aminoFethyl}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (122) [0344] The titled compound (122) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity at 254 nm:
97.8%;
tR = 0.93 min. LC-MS m/z: 345 ([M+H]). 1H NMR (DMSO-d6) 8 0.84 (9H, s), 1.52 (2H, m), 2.90 (3H, s), 3.17 (2H, m), 3.68 (2H, m), 4.80 (2H, m), 6.58 (1H, d), 7.59 (2H, m), 7.86 (1H, m), 7.90 (1H, m), 8.82 (1H, m), 10.10 (1H, bs).
Example 98 Preparation of 3-(1-{2-[(2-Ethyl-buty1)-methyl-amino]-ethy1}-1H-benzoimidazol-y1)-N-hydroxy-acrylamide (123) [0345] The titled compound (123) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity at 254 nm:
97.7%;
tR= 0.87 min. LC-MS m/z: 345 ([M+H]). 1H NMR (DMSO-d6) 5 0.81 (6H, m), 1.29 (4H, m), 1.69 (1H, m), 2.89 (3H, s), 3.08 (2H, m), 3.59 (2H, m), 4.77 (2H, m), 6.53 (1H, d), 7.52 (2H, m), 7.86 (1H, m), 7.94 (1H;rn), 8.80 (1H, m), 9.54 (1H, bs).
Example 99 Preparation of 3-{142-(3,3-Dimethyl-butylamino)-ethy1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (126) [0346] The titled compound (126) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 100%; tR
= 1.01 min. LC-MS m/z: 331 ([M-I+11+). 1H NMR (DMSO-d6) 8 0.88 (9H, s), 1.44 (2H, m), 2.92 (2H, m), 3.50 (2H, m), 4.66 (2H, m), 6.54 (1H, d), 7.58 (2H, m), 7.82 (1H, m), 7.90 (1H, m), 8.74 (1H, m).
Example 100 Preparation of N-Hydroxy-3-{1-12-(methyl-pent-4-enyl-amino)-ethy1]-1H-benzoimidazol-5-y1}-acrylamide (127) [0347] The titled compound (127) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 100%; tR
= 0.92 min. LC-MS m/z: 329 ([M+H]+). 1H NMR (DMSO-d6) 8 1.17 (2H, m), 2.06 (2H, m), 2.90 (3H, s), 3.10 (2H, m), 3.65 (2H, m), 4.80 (2H, m), 5.03 (2H, m), 5.75 (11-1, m), 6.57 (1H, d), 7.60 (1H, d), 7.69 (1H, m), 7.90 (1H, m), 7.97 (1H, m), 8.92 (1H, m), 10.29 (1H, bs).
Example 101 Preparation of 3-(1-{2-[(3,3-Dimethyl-buty1)-propyl-aminoFethyl}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (128) [0348] The titled compound (128) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 99.0%;
tR=1.18 min. LC-MS m/z: 373 ([M-I-Hr). 1H NMR (DMSO-d6) 60.88 (12H, m), 1.51 (2H, m), 1.64 (2H, m), 3.10 (4H, m), 3.63 (2H, m), 4.76 (2H, m), 6.54 (1H, d), 7.65 (2H, m), 7.80 (1H, m), 7.94 (1H, m), 8.83 (1H, m), 9.93 (1H, bs).
Example 102 Preparation of 3-{142-(3,3-Dimethyl-butylamino)-ethy1]-2-propy1-benzoimidazol-5-y1)-N-hydroxy-acrylamide (130) [0349] Step 1: Cyclization OMe OMe ______________________________________ - ______ N
HN
Zn, Me0H/AcOH
50 C
[0350] To the starting material (111a2, 3.34 g, 12.6 mmol) in 20% AcOH in Me0H
(33 mL, 0.2 M) was added butyraldehyde (1.7 mL, 18.9 mmol) followed by zinc powder =
(4.12 g, 63 mmol). The resulting mixture was heat up to 50 C and stirred at this temperature for 30 minutes. The completion of reaction was monitored by HPLC
and LCMS. The solvent was then evaporated to dryness and the crude was dissolved with ethyl acetate, subsequently saturated aqueous sodium carbonate was added till pH = 9 and the mixture was centrifuged spin at 9000 rpm for 10 min. The liquid was decanted and solid was rinsed with ethyl acetate (sonicated). The liquid was extracted with ethyl acetate and then purifed by flash chromatography (silica, 3% Me0H in DCM) to give 3-[1-(2-Amino-ethyl)-2-propyl-1H-benzoimidazol-5-A-acrylic acid methyl ester.
Yield = 25 c/o, LC-MS m/z: 288 ([M+H]).
[0351] Step 2: Reductive-amination 0 </N so ___________________________________________________ OMe ;4 OMe / (14 NaCNBH3, AcOH/ Me0H ,y¨NH
[0352] To 341-(2-Amino-ethyl)-2-propy1-1H-benzoimidazol-5-y1]-acrylic acid methyl ester (1.2 g, 4.2 mmol) in Me0H (40 mL) was added 3,3-Dimethyl-butyraldehyde (0.524 mL, 4.2 mmol). The resulting mixture was stirred at it for 2 hours prior to the addition of acetic acid (2 mL) and sodium cyanoborohydride (0.395 g, 6.3 mmol) and the reaction was stirred at it for another 30 minutes. Solvent was removed and the residual was dissolved in DCM upon which was washed with aqueous sodium bicarbonate, water and brine. The combined organic layer, after workup, was purfied by flash chromatography (silica, 4% Me0H in DCM). LC-MS m/z: 372 ([M+H]).
[0353] Step 3: hydroxannic acid formation.
The titled compound (130) was prepared according to the procedures described in Example 1 (Step 4), by using appropriate starting materials.
TFA salt of 130: HPLC purity: 99.9%; LC-MS m/z: 373 ([M+H]). 1H NMR (CD30D) 8 7.89 (d, 1H, J = 8.6 Hz), 7.81 (s, 1H), 7.76 (d, 1H, J = 8.6 Hz), 7.44 (d, 1H, J = 15.7 Hz), 6.44 (d, 1H, J= 15.7 Hz), 4.81 (t, 2H, J = 7.0 Hz), 3.65 (t, 2H, J= 6.4 Hz), 3.23 ¨
3.19 (m, 2H), 3.16 ¨ 3.12 (m, 2H), 2.01 ¨1.94 (m, 2H), 1.65 ¨ 1.61 (m, 2H), 1.16 (t, 3H, 7.3 Hz), 0.96 (s, 9H).
HCI salt of 130: HPLC purity: 98.1 %; LC-MS m/z: 373 ([M+H]). 1H NMR (CD30D) 8.06 (d, 1H, J = 8.3 Hz), 7.90 (s, 1H), 7.88 (d, 1H, J = 8.4 Hz), 7.59 (d, 1H, J = 15.8 Hz), 6.56 (d, 1H, J= 15.8 Hz), 4.91 ¨ 4.81 (m, 2Hz), 3.60 ¨ 3.66 (m, 2H), 3.31 ¨ 3.35 (m, 2H), 3.17 ¨ 3.13 (m, 2H), 2.05¨ 1.97 (m, 2H), 1.70¨ 1.66 (m, 2H), 1.20 (t, 3H, J=
7.3 Hz), 0.98 (s, 9 H).
Example 103 Preparation of 34142-(3,3-Dimethyl-butylamino)-ethyl]-2-(2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (131) [0354] The titled compound (131) was prepared according to the procedures described in Example 102, by using appropriate starting materials. HPLC purity: 92%; LC-MS
m/z: 401([M+H]4). 1H NMR (CD30D) 8 7.89 (s, 1H), 7.85 (d, 1H, J= 8.5 Hz), 7.77 (d, 1H, J= 8.7 Hz), 7.63 (d, 1H, J= 15.8 Hz), 6.55 (d, 1H, J= 15.7 Hz), 4.91-4.81 (m, 2H), 3.58 (t, 2H, J = 6.5 Hz), 3.13-3.08 (m, 4H), 1.63-1.58 (m, 2H), 1.13 (s, 9H), 0.96 (s, 9H).
Example 104 Preparation of 341-{2-[Bis-(3,3-dimethyl-butyl)-amino]-ethyl}-2-(2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (132) [0355] The titled compound (132) was prepared according to the procedures described in Example 102, by using appropriate starting materials. HPLC purity: 96%; LC-MS
nn/z: 485([M+H]). 1H NMR (CD30D) 8 7.93 (s, 1H), 7.88 (d, 1H, J= 8.5 Hz), 7.80 (d, 1H, J=8.7 Hz), 7.72(d, 1H, J= 15.8 Hz), 6.59 (d, 1H, J= 15.8 Hz), 5.00 (t, 2H, J=6.5 Hz), 3.67 (t, 2H, J = 7.5 Hz), 3.13 ¨ 3.08 (m, 2H), 1.68 ¨ 1.64 (m, 4H), 1.14 (s, 9H), 0.96 (s, 18H).
Example 105 Preparation of 3-{142-(2,2-Dimethyl-propylamino)-ethy1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (133) [0356] The titled compound (133) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 99.9%; LC-MS
m/z: 317([M+H]). 1H NMR (CD30D) 8 8.82 (s, 1H), 7.94 (s, 1H), 7.83 (d, 1H, J =
8.5 Hz), 7.75 (d, 1H, J = 8.7 Hz), 7.66 (d, 1H, J = 15.8 Hz), 6.53 (d, 1H, J =
15.8 Hz), 4.92 ¨ 4.78 (m, 2H), 3.64 (t, 2H, J = 7.0 Hz), 2.98 (s, 2H), 1.09 (s, 9H).
Example 106 Preparation of 3-(1-{2-[(2,2-D imethyl-propy1)-propyl-amino]-ethy1}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (134) [0357] The titled compound (134) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 99.9%;
LCMS
m/z: 359 ([M+H]). 1H NMR (CD30D) 8 9.07 (s, 1H), 7.95 (s, 1H), 7.92 (d, 1H, J
= 8.7 Hz), 7.78 (d, 1H, J= 8.4 Hz), 7.66 (d, 1H, J= 15.8 Hz), 6.56 (d, 1H, J= 15.8 Hz), 4.99 ¨ 4.97 (m, 2H), 3.74 (t, 2H = 7.0 Hz), 3.32 ¨ 3.20 (m, 4H), 1.85¨ 1.82 (m, 2H), 1.03 (s, 9H), 0.92 (t, 3H, J = 7.1 Hz).
Example 107 Preparation of 3-{142-(3,3-Dimethyl-butylamino)-ethy1]-2-ethyl-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (135) [0358] The titled compound (135) was prepared according to the procedures described in Example 102, by using appropriate starting materials. HPLC purity: 94.3%;
LCMS
m/z: 359 ([M+H]). 1H NMR (CD30D) 6 7.69 (d, 1H, J = 8.0 Hz), 7.54 (s, 1H), 7.53 (d, 1H, J = 9.8 Hz), 6.89 (d, 1H, J = 16.1 Hz), 6.08 (d, 1H, J = 15.7 Hz), 4.80 ¨
4.70 (m, 2H), 3.55 ¨ 3.45 (m, 2H), 3.20 ¨ 3.19 (m, 2H), 2.95 ¨ 2.90 (m, 2H), 1.56¨ 1.52 (m, 2H), 1.42 (t, 3H, 7.4 Hz), 0.81 (s, 9H).
Example 108 Preparation of 341-(2-Diethylamino-ethyl)-2-propylamino-1H-benzoimidazol-5-y1)-, N-hydroxy-acrylamide (105) [0359] The titled compound (105) was made according to the following synthetic scheme.
F \rN
rjiN NE 1'W \ __ \ H2N
rHy = and h)r DCC \ N NH2OH N RN¨<'\ 14-OH
w HN-14 (00 riN
r'5 r"?
[0360] HPLC purity: 100%. 11-1-NMR (DMSO-d6) 8 0.97 (3H, t, J = 7.32 Hz), 1.22 (6H, m), 1.68 (2H, m), 3.09-3.60 (10H, m), 6.47 (1H, d, J = 15.80 Hz), 7.52-7.64 (4H, m), 9.03 (2H, bs), 10.10 (1H, s), 10.81 (1H, s) Example 109 Preparation of 341-(3-Dimethylamino-2,2-dimethyl-propy1)-2-propylamino-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (115) [0361] The titled compound (115) was made by using method analogous to compound (105).HPLC purity: 97%.111-NMR (DMSO-d6) 8 0.97 (3H, t, J = 7.28), 1.15 (6H, s), 1.69 (2H, m, J = 7.28 Hz), 2.89 (6H, s), 3.28 (2H, s), 3.42 (2H, m), 4.15 (2H, s), 6.47 (2H, d, J = 15.80), 7.49-7.75 (4H, m), 8.94 (1H, bs), 9.42 (1H, bs), 10.81 (1H, bs), 13.44 (1H, bs).
[0362] The following compounds are representative examples prepared by methods disclosed or analogous to those disclosed in above Examples 1-109:
Cmpd rniz Structure NAME
No [M+H]
341-(3-Dimethylamino-( 2,2-dimethyl-propyI)-2-(2,2-dimethyl-propyI)-1H-benzoimidazol-5-/ yfl-N-hydroxy-=
acrylamide Cmpd m/z Structure NAME
No [M+H]
. 3-[1-(3-Dimethylamino-.4 '' 2,2-dimethyl-propy1)-2-N
359 isopropyl-1H-benzoimidazol-5-y1]-N-/ hydroxy-acrylamide , _ . 342-Buty1-1-(3-\_ r'. H dimethylamino-2,2-3 i 373 dimethyl-propy1)-1H-benzoimidazol-5-A-N-hydroxy-acrylamide _ 3-[1-(3-Dimethylamino-.
\ 2,2-dimethyl-propy1)-2-,,,OH
H
(2-methylsulfanyl-c ¨ ethyl)-1H-benzoimidazol-5-yli-N-I
hydroxy-acrylamide OH
3-[1-(3-Dimethylamino-40 ' . 2,2-dimethyl-propy1)-2-375 ethoxymethy1-1H-benzoimidazol-5-yl]-N-- hydroxy-acrylamide %
O 3-[1-(3-Dimethylamino-( =Ntc.....
2,2-dimethyl-propy1)-2-N
373 isobuty1-1H-benzoimidazol-5-y1]-N-%-- hydroxy-acrylamide , . .
3-[1 -(2-Diethylamino-( ethyl)-2-isobuty1-1H-359 benzoimidazol-5-A-N-rN) hydroxy-acrylamide Cmpd m/z Structure NAME
No [M+H]
-' 342-Buty1-1-(2-\ .`"
\ .
diethylamino-ethy1)-1H-N
359 benzoimidazol-5-y1]-N-ri r-N) hydroxy-acrylamide .
342-But-3-yny1-1-(3- -.õ dimethylamino-2,2-¨ \ 0 ' vi' 9 .
,..,\-----\\N ----/ 369 dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide . 342-But-3-eny1-1-(3-\ 10 ' g' dimethylamino-2,2-10 .
\----\,_.¨ 371 dimethyl-propy1)-1H-benzoimidazol-5-y11-N-/ hydroxy-acrylamide _ a µ
3-[2-But-3-eny1-1-(2-.- ,AH
\ 0 ri diethylamino-ethyl)-1H-.
357 benzoimidazol-5-yI]-N-hydroxy-acrylamide r-) _ 342-But-3-yny1-1-(2-¨ \ 0 ' n' diethylamino-ethyl)-1H-N
hydroxy-acrylamide 355 benzoimidazol-5-y1FN-r) OH 3-[1-(3-Dimethylamino-.
F I \ io . 2,2-dimethyl-propy1)-2-(3,3,3-trifluoro-propy1)-N
1H-benzoimidazol-5-y1]-N-hydroxy-/ acrylamide Cmpd m/z Structure NAME
No [WM+
/ H
HN 3-[1-(2-Diethylamino-' I \ 0 ethyl)-2-(3,3,3-trifluoro-14 N 399 propyI)-1H-benzoimidazol-5-A-N-hydroxy-acrylamide _ _ ,," 3-[1-(2-Diethylamino-.
\___._ io ethyl)-2-ethoxymethyl-.
15 N 361 1H-benzoimidazol-5-\--. yI]-N-hydroxy-acrylamide õõ"i 3-0 -(3-Dimethylamino-0 . 2,2-dimethyl-propyI)-2-331 methyl-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide 3-[1-(2-Diethylamino-. )c < 0 NH
,c,õ ethyl)-2-(2,2-dimethyl-373 propy1)-1H-benzoimidazol-5-y1]-N-r) hydroxy-acrylamide . .
. (.,.
/ N-Hydroxy-3-[1-(3-isopropylamino-propyl)-NI 11 2-(3,3,3-trifluoro-F)cr'N\ propy1)-1H-benzoimidazol-5-y11-):-- acrylamide _ - 342-(2,2-Dimethyl-)( 0 Li propyI)-1-(2-isopropylannino-ethyl) N
, 3 1H-benzoirnidazol-5-/ NH y1]-11-hydroxy-acrylamide I
Cmpd . miz Structure NAME
No [M+H]
_ 3-[1-(2-.
40 r Diisopropylamino-ethyl)-2-(2,2-dimethyl-N
propyI)-1H-)n' benzoimidazol-5-y1]-N-, hydroxy-acrylamide . _ 3-[1-(2-( io 1: Diisopropylamino-N
387 ethyl)-2-isobuty1-1H-) benzoimidazol-5-y1]-N-n" hydroxy-acrylamide -_ O
3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-z NN io OH
399 hex-3-eny1-1H-.--- benzoimidazol-5-y1]-N-/ hydroxy-acrylamide 3-[1-(3-Dimethylamino-2,2-dimethyl-propy1)-2-429 (2,4,4-trimethyl-penty1)-i -- \----\_- 1H-benzoimidazol-5-/ yll-N-hydroxy-acrylamide O
_ 342-Cyclohexy1-1-(3-_ 399 dimethylamino-2,2-dimethyl-propyI)-1H-V-\-- benzoimidazol-5-yli-N-hydroxy-acrylamide 342-Bicyclo[2.2.1]hept-5-en-2-y1-1-(3-4, /N
"
. 0 1".
409 dimethylamino-2,2-\---\_.- dimethyl-propyI)-1H-/ benzoimidazol-5-y1]-N-hydroxy-acrylamide Cmpd m/z Structure NAME
No [WM+
3-[1-(2-Diethylamino-/ ''. 10 NE, ethyl)-2-hex-3-eny1-1H-26 ( 385 benzoimidazol-5-y1FN-hydroxy-acrylamide r.) _ .
. 341-(2-,,N, =' Ni:
<
/ Diisopropylamino-27 413 ethyl)-2-hex-3-eny1-1H-benzoimidazol-5-ylj-N-N)-- hydroxy-acrylamide . 342-Hex-3-eny1-1-(2-isopropylamino-ethyl)-/ <N S NH
1.
CH
N 371 1H-benzoimidazol-5-yli-N-hydroxy-acrylamide 342-Hex-3-eny1-1-(3-isopropylam ino-propy1)-29 / : SI .
1. 385 1H-benzoimidazol-5-( y1FN-hydroxy-H
acrylamide . . 3-[1-(2-Ethylamino-N
/ 110 ' NH
I
. 357 ethyl)-2-hex-3-eny1-1H-( Cvi benzoimidazol-5-y1FN-\,...- hydroxy-acrylamide _ .
7---- . 341-(2-Diethylamino-_ \ .
ti' ethyl)-2-hexy1-1H-.
387 benzoimidazol-5-y11-N-hydroxy-acrylamide ) . .
N-Hydroxy-341-(3-.
isopropylamino-propyI)-< 16"2-(2,4,4-trimethyl-pentyI)-1H-benzoimidazol-5-y1]-acrylamide 34242,2-Dimethyl-propyI)-143-isopropylamino-propy1)-1H-benzoimidazol-5-yI]-N-hydroxy-N
acrylamide _ Diisopropylamino-ethyl)-243,3,3-tritluoro-F F)4. 427 propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide o N-Hydroxy-342-( r 35 isobutyl-142-345 isopropylamino-ethyl)-1H-benzoimidazol-5-yll-acrylamide o 3-[2-(2,2-Dimethyl-NH propyI)-1-(2-36 345 ethylamino-ethyl)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide 34142-Ethylamino-ethyl)-2-isobuty1-1H-37 331 benzoimidazol-5-y1J-N-.
hydroxy-acrylamide 3-[1-(2-. , Diisopropylamino-H
/ NN * IN ethyl)-2-(2,4,4-38 \ 443 trimethyl-penty1)-1H-N benzoimidazol-5-y1]-N-hydroxy-acrylamide N-Hydroxy-3-[1 -(2-isopropylamino-ethyl) \ 01 NH
/ N N
401 2-(2,4,4-trimethyl-C¨H
N \ _ r penty1)-1H-benzoimidazol-5-A-acrylamide 3-[1-(2-Ethylamino-N
ethyl)-2-(2,4,4-387 trimethyl-pentyI)-1H-CNH--, HNH/ benzoimidazol-5-y1]-N-hydroxy-acrylamide 3-[1-(2-Diethylamino-N
/
ethyl)-2-(2,4,4-41 .
415 trimethyl-penty1)-1 H-HN.õ
91 benzoimidazol-5-A-N-hydroxy-acrylamide , 3-[1-(2-Diethylamino-r'l ethyl)-2-propy1-1H-/-,¨/N 11 \ Nõõ benzoimidazol-5-y1]-N-7---N\
hydroxy-acrylamide ¨)N>¨ 3-12-Buty1-1-(2-43 \ 387 diisopropylamino-ethyl)-1H-/ \ < 0 0 benzoimidazol-5-A-N-NEI hydroxy-acrylamide ,,,, .-.-.-.
7----NI 342-Buty1-1-(2-ethylamino-ethyl)-1 H-44 / \ < 40 331 benzoimidazol-5-A-N-"" 0 hydroxy-acrylamide ..
_ , 3-[1-(2-Diethylamino-\ethyl)-2-(2-. B¨\ .1 0 ./ 11 H
N
methylsulfanyl-ethyl)-ri 377 1H-benzoimidazol-5-r) yll-N-hydroxy-acrylamide _ = 342-Buty1-1-(2-\ ,..
\ N 10 n isopropylamino-ethyl)-345 1H-benzoimidazol-5-3 yI]-N-hydroxy-/ NH acrylamide ...
3-[2-Buty1-1-(3-\ , ..., ..,,Ø
\ 0 H isopropylamino-propyI)-_.-- 359 1H-benzoimidazol-5-y1]-N-hydroxy-.
----c acrylamide . .
\ r 3-[1-(1-Benzyl-\ 10 ' N piperidin-4-y1)-2-butyl-6 433 1H-benzoimidazo1-5-y1]-N-hydroxy-Oacrylamide .
342-But-3-eny1-1-(2-/ <NN 0 C'" ethylamino-ethyl)-1H-49 // 329 benzoimidazol-5-yli-N-hydroxy-acrylamide i----_ \ . 342-Hexy1-1-(2-\
NH
111 isopropylamino-ethyl)-N
\_.,.. 373 1H-benzoimidazol-5-y1]-N-hydroxy-/ NH acrylamide . 3-[1-(2-Dimethylamino-ethyl)-2-(2,4,4-
[0350] To the starting material (111a2, 3.34 g, 12.6 mmol) in 20% AcOH in Me0H
(33 mL, 0.2 M) was added butyraldehyde (1.7 mL, 18.9 mmol) followed by zinc powder =
(4.12 g, 63 mmol). The resulting mixture was heat up to 50 C and stirred at this temperature for 30 minutes. The completion of reaction was monitored by HPLC
and LCMS. The solvent was then evaporated to dryness and the crude was dissolved with ethyl acetate, subsequently saturated aqueous sodium carbonate was added till pH = 9 and the mixture was centrifuged spin at 9000 rpm for 10 min. The liquid was decanted and solid was rinsed with ethyl acetate (sonicated). The liquid was extracted with ethyl acetate and then purifed by flash chromatography (silica, 3% Me0H in DCM) to give 3-[1-(2-Amino-ethyl)-2-propyl-1H-benzoimidazol-5-A-acrylic acid methyl ester.
Yield = 25 c/o, LC-MS m/z: 288 ([M+H]).
[0351] Step 2: Reductive-amination 0 </N so ___________________________________________________ OMe ;4 OMe / (14 NaCNBH3, AcOH/ Me0H ,y¨NH
[0352] To 341-(2-Amino-ethyl)-2-propy1-1H-benzoimidazol-5-y1]-acrylic acid methyl ester (1.2 g, 4.2 mmol) in Me0H (40 mL) was added 3,3-Dimethyl-butyraldehyde (0.524 mL, 4.2 mmol). The resulting mixture was stirred at it for 2 hours prior to the addition of acetic acid (2 mL) and sodium cyanoborohydride (0.395 g, 6.3 mmol) and the reaction was stirred at it for another 30 minutes. Solvent was removed and the residual was dissolved in DCM upon which was washed with aqueous sodium bicarbonate, water and brine. The combined organic layer, after workup, was purfied by flash chromatography (silica, 4% Me0H in DCM). LC-MS m/z: 372 ([M+H]).
[0353] Step 3: hydroxannic acid formation.
The titled compound (130) was prepared according to the procedures described in Example 1 (Step 4), by using appropriate starting materials.
TFA salt of 130: HPLC purity: 99.9%; LC-MS m/z: 373 ([M+H]). 1H NMR (CD30D) 8 7.89 (d, 1H, J = 8.6 Hz), 7.81 (s, 1H), 7.76 (d, 1H, J = 8.6 Hz), 7.44 (d, 1H, J = 15.7 Hz), 6.44 (d, 1H, J= 15.7 Hz), 4.81 (t, 2H, J = 7.0 Hz), 3.65 (t, 2H, J= 6.4 Hz), 3.23 ¨
3.19 (m, 2H), 3.16 ¨ 3.12 (m, 2H), 2.01 ¨1.94 (m, 2H), 1.65 ¨ 1.61 (m, 2H), 1.16 (t, 3H, 7.3 Hz), 0.96 (s, 9H).
HCI salt of 130: HPLC purity: 98.1 %; LC-MS m/z: 373 ([M+H]). 1H NMR (CD30D) 8.06 (d, 1H, J = 8.3 Hz), 7.90 (s, 1H), 7.88 (d, 1H, J = 8.4 Hz), 7.59 (d, 1H, J = 15.8 Hz), 6.56 (d, 1H, J= 15.8 Hz), 4.91 ¨ 4.81 (m, 2Hz), 3.60 ¨ 3.66 (m, 2H), 3.31 ¨ 3.35 (m, 2H), 3.17 ¨ 3.13 (m, 2H), 2.05¨ 1.97 (m, 2H), 1.70¨ 1.66 (m, 2H), 1.20 (t, 3H, J=
7.3 Hz), 0.98 (s, 9 H).
Example 103 Preparation of 34142-(3,3-Dimethyl-butylamino)-ethyl]-2-(2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (131) [0354] The titled compound (131) was prepared according to the procedures described in Example 102, by using appropriate starting materials. HPLC purity: 92%; LC-MS
m/z: 401([M+H]4). 1H NMR (CD30D) 8 7.89 (s, 1H), 7.85 (d, 1H, J= 8.5 Hz), 7.77 (d, 1H, J= 8.7 Hz), 7.63 (d, 1H, J= 15.8 Hz), 6.55 (d, 1H, J= 15.7 Hz), 4.91-4.81 (m, 2H), 3.58 (t, 2H, J = 6.5 Hz), 3.13-3.08 (m, 4H), 1.63-1.58 (m, 2H), 1.13 (s, 9H), 0.96 (s, 9H).
Example 104 Preparation of 341-{2-[Bis-(3,3-dimethyl-butyl)-amino]-ethyl}-2-(2,2-dimethyl-propy1)-1H-benzoimidazol-5-y1FN-hydroxy-acrylamide (132) [0355] The titled compound (132) was prepared according to the procedures described in Example 102, by using appropriate starting materials. HPLC purity: 96%; LC-MS
nn/z: 485([M+H]). 1H NMR (CD30D) 8 7.93 (s, 1H), 7.88 (d, 1H, J= 8.5 Hz), 7.80 (d, 1H, J=8.7 Hz), 7.72(d, 1H, J= 15.8 Hz), 6.59 (d, 1H, J= 15.8 Hz), 5.00 (t, 2H, J=6.5 Hz), 3.67 (t, 2H, J = 7.5 Hz), 3.13 ¨ 3.08 (m, 2H), 1.68 ¨ 1.64 (m, 4H), 1.14 (s, 9H), 0.96 (s, 18H).
Example 105 Preparation of 3-{142-(2,2-Dimethyl-propylamino)-ethy1]-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (133) [0356] The titled compound (133) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 99.9%; LC-MS
m/z: 317([M+H]). 1H NMR (CD30D) 8 8.82 (s, 1H), 7.94 (s, 1H), 7.83 (d, 1H, J =
8.5 Hz), 7.75 (d, 1H, J = 8.7 Hz), 7.66 (d, 1H, J = 15.8 Hz), 6.53 (d, 1H, J =
15.8 Hz), 4.92 ¨ 4.78 (m, 2H), 3.64 (t, 2H, J = 7.0 Hz), 2.98 (s, 2H), 1.09 (s, 9H).
Example 106 Preparation of 3-(1-{2-[(2,2-D imethyl-propy1)-propyl-amino]-ethy1}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide (134) [0357] The titled compound (134) was prepared according to the procedures described in Example 76, by using appropriate starting materials. HPLC purity: 99.9%;
LCMS
m/z: 359 ([M+H]). 1H NMR (CD30D) 8 9.07 (s, 1H), 7.95 (s, 1H), 7.92 (d, 1H, J
= 8.7 Hz), 7.78 (d, 1H, J= 8.4 Hz), 7.66 (d, 1H, J= 15.8 Hz), 6.56 (d, 1H, J= 15.8 Hz), 4.99 ¨ 4.97 (m, 2H), 3.74 (t, 2H = 7.0 Hz), 3.32 ¨ 3.20 (m, 4H), 1.85¨ 1.82 (m, 2H), 1.03 (s, 9H), 0.92 (t, 3H, J = 7.1 Hz).
Example 107 Preparation of 3-{142-(3,3-Dimethyl-butylamino)-ethy1]-2-ethyl-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide (135) [0358] The titled compound (135) was prepared according to the procedures described in Example 102, by using appropriate starting materials. HPLC purity: 94.3%;
LCMS
m/z: 359 ([M+H]). 1H NMR (CD30D) 6 7.69 (d, 1H, J = 8.0 Hz), 7.54 (s, 1H), 7.53 (d, 1H, J = 9.8 Hz), 6.89 (d, 1H, J = 16.1 Hz), 6.08 (d, 1H, J = 15.7 Hz), 4.80 ¨
4.70 (m, 2H), 3.55 ¨ 3.45 (m, 2H), 3.20 ¨ 3.19 (m, 2H), 2.95 ¨ 2.90 (m, 2H), 1.56¨ 1.52 (m, 2H), 1.42 (t, 3H, 7.4 Hz), 0.81 (s, 9H).
Example 108 Preparation of 341-(2-Diethylamino-ethyl)-2-propylamino-1H-benzoimidazol-5-y1)-, N-hydroxy-acrylamide (105) [0359] The titled compound (105) was made according to the following synthetic scheme.
F \rN
rjiN NE 1'W \ __ \ H2N
rHy = and h)r DCC \ N NH2OH N RN¨<'\ 14-OH
w HN-14 (00 riN
r'5 r"?
[0360] HPLC purity: 100%. 11-1-NMR (DMSO-d6) 8 0.97 (3H, t, J = 7.32 Hz), 1.22 (6H, m), 1.68 (2H, m), 3.09-3.60 (10H, m), 6.47 (1H, d, J = 15.80 Hz), 7.52-7.64 (4H, m), 9.03 (2H, bs), 10.10 (1H, s), 10.81 (1H, s) Example 109 Preparation of 341-(3-Dimethylamino-2,2-dimethyl-propy1)-2-propylamino-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide (115) [0361] The titled compound (115) was made by using method analogous to compound (105).HPLC purity: 97%.111-NMR (DMSO-d6) 8 0.97 (3H, t, J = 7.28), 1.15 (6H, s), 1.69 (2H, m, J = 7.28 Hz), 2.89 (6H, s), 3.28 (2H, s), 3.42 (2H, m), 4.15 (2H, s), 6.47 (2H, d, J = 15.80), 7.49-7.75 (4H, m), 8.94 (1H, bs), 9.42 (1H, bs), 10.81 (1H, bs), 13.44 (1H, bs).
[0362] The following compounds are representative examples prepared by methods disclosed or analogous to those disclosed in above Examples 1-109:
Cmpd rniz Structure NAME
No [M+H]
341-(3-Dimethylamino-( 2,2-dimethyl-propyI)-2-(2,2-dimethyl-propyI)-1H-benzoimidazol-5-/ yfl-N-hydroxy-=
acrylamide Cmpd m/z Structure NAME
No [M+H]
. 3-[1-(3-Dimethylamino-.4 '' 2,2-dimethyl-propy1)-2-N
359 isopropyl-1H-benzoimidazol-5-y1]-N-/ hydroxy-acrylamide , _ . 342-Buty1-1-(3-\_ r'. H dimethylamino-2,2-3 i 373 dimethyl-propy1)-1H-benzoimidazol-5-A-N-hydroxy-acrylamide _ 3-[1-(3-Dimethylamino-.
\ 2,2-dimethyl-propy1)-2-,,,OH
H
(2-methylsulfanyl-c ¨ ethyl)-1H-benzoimidazol-5-yli-N-I
hydroxy-acrylamide OH
3-[1-(3-Dimethylamino-40 ' . 2,2-dimethyl-propy1)-2-375 ethoxymethy1-1H-benzoimidazol-5-yl]-N-- hydroxy-acrylamide %
O 3-[1-(3-Dimethylamino-( =Ntc.....
2,2-dimethyl-propy1)-2-N
373 isobuty1-1H-benzoimidazol-5-y1]-N-%-- hydroxy-acrylamide , . .
3-[1 -(2-Diethylamino-( ethyl)-2-isobuty1-1H-359 benzoimidazol-5-A-N-rN) hydroxy-acrylamide Cmpd m/z Structure NAME
No [M+H]
-' 342-Buty1-1-(2-\ .`"
\ .
diethylamino-ethy1)-1H-N
359 benzoimidazol-5-y1]-N-ri r-N) hydroxy-acrylamide .
342-But-3-yny1-1-(3- -.õ dimethylamino-2,2-¨ \ 0 ' vi' 9 .
,..,\-----\\N ----/ 369 dimethyl-propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide . 342-But-3-eny1-1-(3-\ 10 ' g' dimethylamino-2,2-10 .
\----\,_.¨ 371 dimethyl-propy1)-1H-benzoimidazol-5-y11-N-/ hydroxy-acrylamide _ a µ
3-[2-But-3-eny1-1-(2-.- ,AH
\ 0 ri diethylamino-ethyl)-1H-.
357 benzoimidazol-5-yI]-N-hydroxy-acrylamide r-) _ 342-But-3-yny1-1-(2-¨ \ 0 ' n' diethylamino-ethyl)-1H-N
hydroxy-acrylamide 355 benzoimidazol-5-y1FN-r) OH 3-[1-(3-Dimethylamino-.
F I \ io . 2,2-dimethyl-propy1)-2-(3,3,3-trifluoro-propy1)-N
1H-benzoimidazol-5-y1]-N-hydroxy-/ acrylamide Cmpd m/z Structure NAME
No [WM+
/ H
HN 3-[1-(2-Diethylamino-' I \ 0 ethyl)-2-(3,3,3-trifluoro-14 N 399 propyI)-1H-benzoimidazol-5-A-N-hydroxy-acrylamide _ _ ,," 3-[1-(2-Diethylamino-.
\___._ io ethyl)-2-ethoxymethyl-.
15 N 361 1H-benzoimidazol-5-\--. yI]-N-hydroxy-acrylamide õõ"i 3-0 -(3-Dimethylamino-0 . 2,2-dimethyl-propyI)-2-331 methyl-1H-benzoimidazol-5-yli-N-hydroxy-acrylamide 3-[1-(2-Diethylamino-. )c < 0 NH
,c,õ ethyl)-2-(2,2-dimethyl-373 propy1)-1H-benzoimidazol-5-y1]-N-r) hydroxy-acrylamide . .
. (.,.
/ N-Hydroxy-3-[1-(3-isopropylamino-propyl)-NI 11 2-(3,3,3-trifluoro-F)cr'N\ propy1)-1H-benzoimidazol-5-y11-):-- acrylamide _ - 342-(2,2-Dimethyl-)( 0 Li propyI)-1-(2-isopropylannino-ethyl) N
, 3 1H-benzoirnidazol-5-/ NH y1]-11-hydroxy-acrylamide I
Cmpd . miz Structure NAME
No [M+H]
_ 3-[1-(2-.
40 r Diisopropylamino-ethyl)-2-(2,2-dimethyl-N
propyI)-1H-)n' benzoimidazol-5-y1]-N-, hydroxy-acrylamide . _ 3-[1-(2-( io 1: Diisopropylamino-N
387 ethyl)-2-isobuty1-1H-) benzoimidazol-5-y1]-N-n" hydroxy-acrylamide -_ O
3-[1-(3-Dimethylamino-2,2-dimethyl-propyI)-2-z NN io OH
399 hex-3-eny1-1H-.--- benzoimidazol-5-y1]-N-/ hydroxy-acrylamide 3-[1-(3-Dimethylamino-2,2-dimethyl-propy1)-2-429 (2,4,4-trimethyl-penty1)-i -- \----\_- 1H-benzoimidazol-5-/ yll-N-hydroxy-acrylamide O
_ 342-Cyclohexy1-1-(3-_ 399 dimethylamino-2,2-dimethyl-propyI)-1H-V-\-- benzoimidazol-5-yli-N-hydroxy-acrylamide 342-Bicyclo[2.2.1]hept-5-en-2-y1-1-(3-4, /N
"
. 0 1".
409 dimethylamino-2,2-\---\_.- dimethyl-propyI)-1H-/ benzoimidazol-5-y1]-N-hydroxy-acrylamide Cmpd m/z Structure NAME
No [WM+
3-[1-(2-Diethylamino-/ ''. 10 NE, ethyl)-2-hex-3-eny1-1H-26 ( 385 benzoimidazol-5-y1FN-hydroxy-acrylamide r.) _ .
. 341-(2-,,N, =' Ni:
<
/ Diisopropylamino-27 413 ethyl)-2-hex-3-eny1-1H-benzoimidazol-5-ylj-N-N)-- hydroxy-acrylamide . 342-Hex-3-eny1-1-(2-isopropylamino-ethyl)-/ <N S NH
1.
CH
N 371 1H-benzoimidazol-5-yli-N-hydroxy-acrylamide 342-Hex-3-eny1-1-(3-isopropylam ino-propy1)-29 / : SI .
1. 385 1H-benzoimidazol-5-( y1FN-hydroxy-H
acrylamide . . 3-[1-(2-Ethylamino-N
/ 110 ' NH
I
. 357 ethyl)-2-hex-3-eny1-1H-( Cvi benzoimidazol-5-y1FN-\,...- hydroxy-acrylamide _ .
7---- . 341-(2-Diethylamino-_ \ .
ti' ethyl)-2-hexy1-1H-.
387 benzoimidazol-5-y11-N-hydroxy-acrylamide ) . .
N-Hydroxy-341-(3-.
isopropylamino-propyI)-< 16"2-(2,4,4-trimethyl-pentyI)-1H-benzoimidazol-5-y1]-acrylamide 34242,2-Dimethyl-propyI)-143-isopropylamino-propy1)-1H-benzoimidazol-5-yI]-N-hydroxy-N
acrylamide _ Diisopropylamino-ethyl)-243,3,3-tritluoro-F F)4. 427 propy1)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide o N-Hydroxy-342-( r 35 isobutyl-142-345 isopropylamino-ethyl)-1H-benzoimidazol-5-yll-acrylamide o 3-[2-(2,2-Dimethyl-NH propyI)-1-(2-36 345 ethylamino-ethyl)-1H-benzoimidazol-5-y11-N-hydroxy-acrylamide 34142-Ethylamino-ethyl)-2-isobuty1-1H-37 331 benzoimidazol-5-y1J-N-.
hydroxy-acrylamide 3-[1-(2-. , Diisopropylamino-H
/ NN * IN ethyl)-2-(2,4,4-38 \ 443 trimethyl-penty1)-1H-N benzoimidazol-5-y1]-N-hydroxy-acrylamide N-Hydroxy-3-[1 -(2-isopropylamino-ethyl) \ 01 NH
/ N N
401 2-(2,4,4-trimethyl-C¨H
N \ _ r penty1)-1H-benzoimidazol-5-A-acrylamide 3-[1-(2-Ethylamino-N
ethyl)-2-(2,4,4-387 trimethyl-pentyI)-1H-CNH--, HNH/ benzoimidazol-5-y1]-N-hydroxy-acrylamide 3-[1-(2-Diethylamino-N
/
ethyl)-2-(2,4,4-41 .
415 trimethyl-penty1)-1 H-HN.õ
91 benzoimidazol-5-A-N-hydroxy-acrylamide , 3-[1-(2-Diethylamino-r'l ethyl)-2-propy1-1H-/-,¨/N 11 \ Nõõ benzoimidazol-5-y1]-N-7---N\
hydroxy-acrylamide ¨)N>¨ 3-12-Buty1-1-(2-43 \ 387 diisopropylamino-ethyl)-1H-/ \ < 0 0 benzoimidazol-5-A-N-NEI hydroxy-acrylamide ,,,, .-.-.-.
7----NI 342-Buty1-1-(2-ethylamino-ethyl)-1 H-44 / \ < 40 331 benzoimidazol-5-A-N-"" 0 hydroxy-acrylamide ..
_ , 3-[1-(2-Diethylamino-\ethyl)-2-(2-. B¨\ .1 0 ./ 11 H
N
methylsulfanyl-ethyl)-ri 377 1H-benzoimidazol-5-r) yll-N-hydroxy-acrylamide _ = 342-Buty1-1-(2-\ ,..
\ N 10 n isopropylamino-ethyl)-345 1H-benzoimidazol-5-3 yI]-N-hydroxy-/ NH acrylamide ...
3-[2-Buty1-1-(3-\ , ..., ..,,Ø
\ 0 H isopropylamino-propyI)-_.-- 359 1H-benzoimidazol-5-y1]-N-hydroxy-.
----c acrylamide . .
\ r 3-[1-(1-Benzyl-\ 10 ' N piperidin-4-y1)-2-butyl-6 433 1H-benzoimidazo1-5-y1]-N-hydroxy-Oacrylamide .
342-But-3-eny1-1-(2-/ <NN 0 C'" ethylamino-ethyl)-1H-49 // 329 benzoimidazol-5-yli-N-hydroxy-acrylamide i----_ \ . 342-Hexy1-1-(2-\
NH
111 isopropylamino-ethyl)-N
\_.,.. 373 1H-benzoimidazol-5-y1]-N-hydroxy-/ NH acrylamide . 3-[1-(2-Dimethylamino-ethyl)-2-(2,4,4-
51 )(¨( la NH
b. 387 N
trimethyl-penty1)-1H-rj benzoimidazo1-5-y1]-11----"\ hydroxy-acrylamide \ 0 341-(2-Ethylamino-\¨\ 0I. 359 ethyl)-2-hexy1-1H-
b. 387 N
trimethyl-penty1)-1H-rj benzoimidazo1-5-y1]-11----"\ hydroxy-acrylamide \ 0 341-(2-Ethylamino-\¨\ 0I. 359 ethyl)-2-hexy1-1H-
52 N benzoimidazol-5-yli-N-\ hydroxy-acrylamide N.,....-NH
N-Hydroxy-3-[1-(2-I- I 40 ,...
H isopropylamino-ethyl) \ 2-(3,3,3-trifluoro-
N-Hydroxy-3-[1-(2-I- I 40 ,...
H isopropylamino-ethyl) \ 2-(3,3,3-trifluoro-
53 . 385 propyI)-1H-H N\ _ r benzoimidazol-5-y1]-acrylamide 3-[1-(2-Dimethylamino-
54 1õ
Iti fa ...., OH
/
1r 357 ethyl)-2-hex-3-eny1-1H-benzoimidazol-5-y1]-N-) hydroxy-acrylamide _--\
.
3-[1-(2-Amino-ethyl)-2-"40 ' 'OH (2,4,4-trimethyl-penty1)-
Iti fa ...., OH
/
1r 357 ethyl)-2-hex-3-eny1-1H-benzoimidazol-5-y1]-N-) hydroxy-acrylamide _--\
.
3-[1-(2-Amino-ethyl)-2-"40 ' 'OH (2,4,4-trimethyl-penty1)-
55 c< __ < 359 1H-benzoimidazol-5-y1]-11-hydroxy-acrylamide 3-[1-(2-Amino-ethyl)-2-<,"ti...,,OH
/
(2-methoxy-nonyI)-1H-
/
(2-methoxy-nonyI)-1H-
56 / N Willi 403 benzoimidazol-5-yli-N-, /
/ ,ip hydroxy-acrylamide ___________________________________________________________________ _ . 342-Buty1-1-(2-\
dimethylamino-ethyl)-
/ ,ip hydroxy-acrylamide ___________________________________________________________________ _ . 342-Buty1-1-(2-\
dimethylamino-ethyl)-
57 N
331 1H-benzoimidazol-5-y1FN-hydroxy-acrylamide ___________________________________________________________________ _ \ a 311-(2-Dimethylamino-\ .
N /
, ethyl)-2-hexy1-1H-
331 1H-benzoimidazol-5-y1FN-hydroxy-acrylamide ___________________________________________________________________ _ \ a 311-(2-Dimethylamino-\ .
N /
, ethyl)-2-hexy1-1H-
58 359 benzoimidazol-5-A-N-hydroxy-acrylamide _ __________________________________________________________________ N-{241 -(2-, ( . Diethylamino-ethyl)-5-HN \ ,0H
a (2-hydroxycarbamoyl-N
a (2-hydroxycarbamoyl-N
59 444 viny1)-1H-benzoimidazol-2-A-/ ethy1}-3,3-dimethyl-butyramide , _ 3-{1-(2-Diethylamino-Y. ethyl)-242-(2,2-\IT(OH
dimethyl-N
430 propionylamino)-ethyly \ 1H-benzoimidazol-5-õN\
/ yI}-N-hydroxy-acrylamide 3-{1-(2-Diethylamino-07,,_, s ethyl)-2-[(2,2-dimethyl-/ 0 ' L
H
N propionylamino)-methyl)-1H-r-N) benzoimidazol-5-y1}-N-hydroxy-acrylamide _ N-0-(2-Diethylamino-Ml N
i ethyl)-5-(2-OH hyd roxycarbamoyl-viny1)-1H-r) benzoimidazol-2-ylmethy1}-butyramide _ . 341-(2-ethylamino-___\\ \ _<7 0 NH
i" 359 ethyl) -2-(3,3-dimethyl-63 N buty1)-1H-\ benzoimidazol-5-y11-N-H hydroxy-acrylamide 3-[2-(3,3-Dimethyl-butyl)-1-(2-)F\ 40 10:1 Dimethylamino-ethyl) 1H-benzoimidazol-5-y1FN-hydroxy-,\
acrylamide 3-[1-(2-Dimethylamino-65 345 ethyl)-2-penty1-1H-.
..-0. benzoimidazol-5-y1FN---õ, \ hydroxy-acrylamide _ ' 3-[1-(2-Dimethylamino-F F
ethyl)-2-(2,212-trifluoro-ethyl)-1H-benzoimidazol-5-y1W-, ..
----N
\ hydroxy-acrylamide _ N-Hydroxy-3-[1-(5-methy1-1H-pyrazol-3-67 <N. SLi 396 yI)-2-(2,4,4-trimethyl-/c( penty1)-1H-7,11/ benzoimidazol-5-y11-acrylamide , 341 -(2-Ethylamino-,A.
F7 < 10 ti ethyl)-2-penty1-1H-345 benzoimidazol-5-y1]-N-hydroxy-acrylamide .) . 0 3-(2-Butyl-1 -pyrrolidin-0 \ (-ad 69 __---.<, 329 3-y1-1H-benzoimidazol-NH 5-yI)-N-hydroxy-acrylamide 0 3-(2-Butyl-1 -piperidin-70 __,, N 'S\ '-rcµH 343 4-y1-1H-benzoimidazol-5-yI)-N-hydroxy-IIN acrylamide . _ N-Hydroxy-3-[1-(2-/¨ 'Ic isopropylamino-ethyl) / 2-penty1-1H-benzoimidazol-5-y1]-, r acrylamide \ N-Hydroxy-3-[1-(2-\
= methylamino-ethyl)-2-.
72 . 385 non-3-eny1-1H-I.
N benzoimidazol-5-yli-rj acrylamide NH
/ N-Hydroxy-3-[1-(2-: 385 methylamino-ethyl)-2-non-6-eny1-1H-benzoimidazol-5-yll-acrylamide ri \ . 342-Hexy1-1-(2-N /CM
345 methylamino-ethyI)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide --4,-, . N-Hydroxy-341 -(2-7 40 ' ' methylamino-ethyl)-2-75 / 331 penty1-1H-benzoimidazol-5-y1]-'IN\ acrylamide N-Hydroxy-3-[1-(2-0 Nr. methylamino-ethyl)-2-octy1-1H-benzoimidazol-5-y1]-\ HN \
acrylamide 3-[1-(2-Amino-ethy1)-2-_________________________ 40 r . octyl-1H-359 benzoimidazol-5-yli-N-H2N hydroxy-acrylamide \
3-12-Butyl-I-[2-N
40 ' ' , /--/ <c (isopropyl-methyl-/ 359 amino)-ethy1]-1H--N\ benzoimidazol-5-y1}-N-hydroxy-acrylamide 341424Ethyl-methyl--/ <
;,, 0 N- aminoyethy1]-2-pentyl-79 _/
359 1 H-benzoimidazol-5-y1}-N-hydroxy-r-N\ acry1amide .
.
342-(2-1-pyrrolidin-_ O.
; 6 357 . 3-y1-1 H-benzoimidazol-80 0, 5-yI)-N-hydroxy-acrylamide ' H
3-[2-Butyl-1-(1-methyl--tr , 40 O" pyrrolidin-3-yI)-1H-81 343 benzoimidazol-5-y1FN-:I> hydroxy-acrylamide N\ , .
.
342-Hexy1-1-piperidin-_ ,.,--'3"
a N 'IIIIV- H
371 3-y1-1 H-benzoimidazol-5-yI)-N-hydroxy-a acrylamide _ .
0 342-Butyl-I -piperidin-_ _,.0H
.....õ,õ...............õ......,.,<N -...... 0, 3-y1-1 H-benzoimidazol-83 N 343 5-yI)-N-hydroxy-acrylamide dil - _ _ 0 3-(1-{2-[Ethyl-(2-N
/ <
/ le '- NOH
H
/ N methoxy-ethyl)-amino]-ethy1}-2-penty1-1H-/
84 403 benzoimidazol-5-y1)-N-N hydroxy-acrylamide r co H
0 3-{2-Butyl-1I 424ethyl-N si ,,, N,OH
methyl-aminoyethyli-/ N I H-benzoimidazol-5-yI}-N-hydroxy-N
r \ acrylamide _________________________________________________________________ _ 0 N-Hydroxy-3-[1-(1-NõOH
methyl-piperidin-3-y1)-H
' N 2-penty1-1H-benzoimidazol-5-y11-a acrylamide . 0 - 3-{142-(Ethy)-hexyl-N
N -., N,OH
, H amino)-ethy1]-1H-benzoimidazol-5-A-N-87 359 hydroxy-acrylamide N
[if , _ 0 3-{142-(Ethyl-pentyl-N
N N_OH
H aminoyethy1]-1H-benzoimidazol-5-y1}-N-345 hydroxy-acrylamide N
j---1¨
-_ 0 3-{142-(Ethyl-heptyl-N
H arnino)-ethy1]-1 H-N
benzoimidazol-5-y1}-N-89 373 hydroxy-acrylamide N
\ 0 3-{2-Hexy1-141 -(2-\=hydroxy-ethyl)-N
\ =1 0 -,,, 1=61HH
piperidin-3-y1]-1H-90 415 benzoimidazol-5-yll-N-al . .
hydroxy-acrylamide ZOH
.126 0 3-(2-Butyl-1 42-[ethyl-(3-hydroxy-propy1)-OH amino]-ethyl}-1H-91 r----1 389 benzoimidazol-5-y1)-N-N \ hydroxy-acrylamide rff /
HO
_ -_ . 3-(142-[Ethyl-(3-- hydroxy-propy1)-/
403 amino]-ethyI}-2-pentyl-1H-benzoimidazol-5-yI)-N-hydroxy-acrylamide _ 0 1(0.
(E)-N-hydroxy-3-(1-(1---- c --,, phenethylpyrrolidin-3-yI)-1H-benzo[d]imidazol-5-ypacrylamide ill _ _ 0 (E)-N-hydroxy-3-(1-(1-_ N pentylpiperidin-3-yI)-1H-benzo[dlimidazol-5-N ypacrylamide -iii 0 34142-(Butyl-ethyl-N
amino)-ethyl]-1H-benzoimidazol-5-y1}-N-N hydroxy-acrylamide , -U
N opN,...AH
(E)-N-hydroxy-3-(1-(1-phenethylpiperidin-3-N
96 391 y1)-1 H-benzo[d]imidazol-5-N
ypacrylamide =0 .
(E)-N-hydroxy-3-(1-(1 -OH
(3-N phenylpropyl)piperidin-97 405 3-y1)-1 H-benzo[d]imidazol-5-N
41, yl)acrylamide ---õ, õAi, lei N (E)-N-hydroxy-3-(1-(1-(3---N 391 phenylpropyl)pyrrolidin-3-y1)-1 H-benzo[d]imidazol-5-ypacrylamide II _ 3-{141-(3,3-Dimethyl-N buty1)-pyrrolidin-3-y1F
3 357 1 H-benzoimidazol-5-N y1}-N-hydroxy-acrylamide OH (E)-3-(1-(2-(diethylamino)ethyl)-N
303 1 H-benzo[d]imidazol-5-y1)-N-N hydroxyacrylamide r) 3-[2-(4-Cyano-butyI)-1 N- \
(2-diethylamino-ethyl)-384 1H-benzoimidazol-5-y11-N-hydroxy-N
r acrylamide u la NH
111 (E)-3-(1-(1-N
butylpiperidin-3-yI)-1H-, benzo[d]imidazol-5-y1)-N-hydroxyacrylamide N
N
OH (E)-N-hydroxy-3-(1-(1-(pent-4-enyl)piperidin-N
di 355 3-yI)-1H-benzo[d]imidazol-5-\---\-- yl)acrylamide =-õ ,...., 0 ri OH (E)-3-(1-(1-(3,3-o 371 dimethylbutyl)piperidin-4-y1)-1H-N
benzo[d]imidazol-5-y1)------\ N-hydroxyacrylamide .
\
0 '4c" 3-[1-(2-Diethylamino-ethyl)-2-propylamino-N
360 1H-benzoimidazol-5-yll-N-hydroxy-r) acrylamide u ,l OH (E)-N-hydroxy-3-(1-(2-ei (isopropyl(propyl)amino N
331 )ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide _ 0 N....AH
3-{142-(Butyl--.., ' N H isopropyl-amino)-ethyl]-108 345 1H-benzoimidazol-5-\-----N___ yI)-N-hydroxy-ff acrylamide ' OH N-Hydroxy-3-{1-(2-' 0 r, (isopropyl-pentyl-N , 359 amino)-ethy1]-1H-benzoimidazol-5-y1)-\ acrylamide _ \ 342-(5-Cyano-penty1)-.
\ 1-(2-diethylamino-110 \K 0 r 398 ethyl)-1H-ri benzoimidazol-5-yli-N-r) hydroxy-acrylamide _ 0 ......õ.0H 40 3- 1- 2- 3 3-Dimeth ( { R 1-, Y ' N butyl)-ethyl-amino]-359 ethyl)-1H-benzoimidazol-5-y1)-N-N\
--------r / hydroxy-acrylamide _ 0 N 110 3-{142-(Ethyl-propyl-N amino)-ethyl]-1H-benzoimidazo1-5-y1)-N-hydroxy-acrylamide N
-1--- ) OH
i 0 N
\ N-Hydroxy-3-(1-{2-N
, 373 [isopropyl-(2-methyl-113pentyl)-amino]-ethyl}-r-N 1H-benzoimidazol-5-y1)-acrylamide . (E)-N-hydroxy-3-(1-(2-i 40 Nc'H
\N (isopropy1(4,4,4-trifluorobutyl)amino)eth 114 ><1 \ \ (iN 399 y1)-1H-benzo[d]imidazol-5-)-- yl)acrylamide .
\3-[1-(3-Dimethylamino- , <i) 40 ...,, N,,, OH
2,2-dimethyl-propyI)-2-N
((_____. 374 propylamino-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide N-/ -U
2; -,...... NH.OH
N 3-{142-(Ethyl-hexyl-rj aminoyethy1]-2-methyl-1H-benzoimidazol-5-r 373 y1}-N-hydroxy-acrylamide U
F F le NH
1,H 3-{142-(Butyl-ethyl-FriN amino)-ethyl]-2-117399 trifluoromethy1-1H-r,N
/ benzoimidazol-5-y1}-N-hydroxy-acrylamide .
F 24 0 ,...., ,OH
F
Frici 3-{142-(Ethyl-hexyl-amino)-ethy1]-2-rN 427 trifluoromethy1-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide U
/ io -..., N...,,,ON
(E)-3-(1-(2-(dibutylamino)ethyl)-2-119 401 propy1-1H-) benzo[d]innidazol-5-y1)-_ N-hydroxyacrylamide - U r OH
N 0 N,/' 3-[1-(2-Dipropylamino-ethyl)-1H-331 benzoimidazol-5-A-N------\_¨N hydroxy-acrylamide . 0 N-Hydroxy-3-(1-{2-/ 40, rii....
[isopropyl-(3-methyl-359 butylyaminoj-ethyl)-1H-benzoimidazol-5-yl)-acrylamide _ 0 3-(1-{2-[(3,3-Dimethyl-<iN 401 rrAH buty1)-methyl-aminol-345 ethy11-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide _ 0 3-(1-{2-[(2-Ethyl-butyl)-methyl-amino]-ethyl}-123N 345 1H-benzoimidazol-5-yI)-N-hydroxy-acrylamide (E)-3-(1-(2-(bis(3,3-<, " 40 'c'l dimethylbutyl)amino)et 415 hyl)-1H-\/---\____. benzo[d]innidazol-5-y1)-VN-hydroxyacrylamide o (E)-3-(1-(2-40 Nc'H
(diisobutylamino)ethyl)-N
359 1H-benzo[d]imidazol-5-y1)-N-hydroxyacrylamide U
N N 40 Nõ,,,, 3-{1-[2-(3,3-Dimethyl-331 butylaminoyethy1]-1H-benzoimidazol-5-y1}-N-HN
hydroxy-acrylamide .
' Ni' N-Hydroxy-3-{142-N (methyl-pent-4-enyl-127 329 amino)-ethyI]-1H-,N
benzoimidazol-5-y1}-acrylamide 3-(1-{2-[(3,3-Dimethyl-ti butyI)-propyl-aminol-373 ethy1}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide 3-0-(3-Dimethylamino-,, .."..,OH
\ lel Vi N 2,2-dimethyl-propyI)-2-129 363 methylsulfany1-1H-benzoimidazol-5-y1FN-N------- hydroxy-acrylamide 1 _ .
/ 7;\ lei N OH 3-{1-[2-(3,3-Dimethyl-N butylamino)-ethylj-2-373 propyl-1H-FIN benzoimidazol-5-y1}-N-hydroxy-acrylamide . 3-[1-[2-(3,3-Dimethyl-NriAilko, ....', ....AH
7( * butylaminoyethy1]-2-/ 401 (2,2-dimethyl-propyI)-1H-benzoimidazol-5-\---- yI]-N-hydroxy-acrylamide . 311-{2-[Bis-(3,3-N NAgib...
< * dimethyl-butyI)-amino]-/
Ni 485 ethy11-242,2-dimethyl-propy1)-1H-- benzoimidazol-5-y1FN-hydroxy-acrylamide u 2, 014 le ....., r 3-0 -[2(2,2-Dimethyl-N
317 propylamino)-ethy1]-1H-benzoimidazol-5-y1}-N-HN hydroxy-acrylamide 4 .
2, =,..., 14 ......õOH 341424(2,2-Dimethyl-N propyI)-propyl-amino]-359 ethy11-1H-benzoimidazol-5-y1)-N-4----N hydroxy-acrylamide . .F4 3-{14243,3-Dimethyl-/ -1 0 butylaminoyethy1]-2-N
359 ethy1-1H-benzoimidazol-5-y1}-N-ifNH
hydroxy-acrylamide _ BIOLOGICAL TESTING AND ENZYME ASSAYS
Recombinant GST-HDAC1 Protein expression and purification [0363] Human cDNA library was prepared using cultured SW620 cells.
Amplification of human HDAC1 coding region from this cDNA library was cloned separately into the baculovirus expression pDEST20 vector (GATEWAY Cloning Technology, Invitrogen Pte Ltd). The pDEST20-HDAC1 construct was confirmed by DNA sequencing.
Recombinant baculovirus was prepared using the Bac-To-Bac method following the manufacturer's instruction (lnvitrogen Pte Ltd). Baculovirus titer was determined by plaque assay to be about 108 PFU/ml.
[0364] Expression of GST-HDAC1 was done by infecting SF9 cells (Invitrogen Pte Ltd) with pDEST20-HDAC1 baculovirus at M01=1 for 48 h. Soluble cell lysate was incubated with pre-equilibrated Glutathione Sepharose 4B beads (Amersham) at 4 C
for 2 h. The beads were washed with PBS buffer for 3 times. The GST-HDAC1 protein was eluted by elution buffer containing 50 mM Tris, pH8.0, 150mM NaCI, 1%
Triton X-100 and 10mM or 20mM reduced Glutathione. The purified GST-HDAC1 protein was dialyzed with HDAC storage buffer containing 10mM Tris, pH7.5, 100mM NaC1 and 3mM MgC12. 20% Glycerol was added to purified GST-HDAC1 protein before storage at -80 C.
In vitro HDAC assay for determination of IC50 values [0365] The assay has been carried out in 96 well format and the BIOMOL
fluorescent-based HDAC activity assay has been applied. The reaction composed of assay buffer, containing 25 mM Tris pH 7.5, 137 mM NaCl, 2.7 mM KCI, 1 mM
MgCl2, 1 mg/ml BSA, tested compounds, an appropriate concentration of HDAC1 enzyme, 500 uM Flur de lys generic substrate for HDAC1 enzyme and subsequently was incubated at room temperature for 2 h. Flur de lys Developer was added and the reaction was incubated for 10 min. Briefly, deacetylation of the substrate sensitizes it to the developer, which then generates a fluorophore. The fluorophore is excited with 360 nm light and the emitted light (460 nm) is detected on a fluorometric plate reader (Tecan Ultra Microplate detection system, Tecan Group Ltd.).
[0366] The analytical software, Prism 3.0 (GraphPad Software Inc) has been used to generate IC50 from a series of data.
[0367] The HDAC enzyme inhibition results of representative compounds are shown in Table 1 (unit is micromolar).
[0368] Table 1. HDAC1 enzyme activity IC 50 (unit is micromolar).
Compound..,, No No Compound Compound No IC50 (invi) IC50 (uM) IC50 (PM) 1 0.042 46 0.049 - 91 ' 0.060 2 0.38 47 0.21 92 0.050 _ 3 0.15 48 0.43 93 - 0.23 4 0.12 49 0.11 94 0.064 0.17 50 0.036 95 0.052 _.
6 0.18 51 0.066 96 0.080 _ 7 0.091 52 0.025 97 0.10 8 0.052 53 0.10 98 0.32 _ 9 0.21 54 0.048 99 0.12 0.14 55 0.037 100 . 0.19 11 0.070 56 0.029 101 ' 0.08 12 0.064 57 0.090 102 0.54 13 0.42 58 0.030 103 0.10 .._ 14 '0.077 59 0.077 104 0.41 0.085 60 0.10 105 - 0.13 _ 17 0.13 61 0.070 107 0.074 19 0.064 62 - 0.054 108 - 0= .043 0.26 63 0.051 109 . 0.048 21 0.38 64 0.10 110 - 0= .044 22 0.064 65 0.078 111 0.029 _ _ 23 0.045 66 0.34 112 0.12 24 0.51 68 0.034 113 0.016 0.23 70 0.068 . 114 ' 0= .063 26 0.040 71 0.040 116 0.10 27 0.23 72 0.017 117 0.19 28 0.021 73 0.026 118 0.48 29 0.13 74 0.028 119 0.18 0.021 75 0.050 120 0.11 _ 31 0.045 76 0.018 121 0.079 32 - 0.060 77 0.026 122 0.037 33 0.23 78 0.044 123 0.027 34 0.88 79 0.040 124 0.085 _ 0.082 . 80 0.040 125 - 0.16 _ _ 36 0.096 81 0.12 126 0.042 37 0.091 82 = 0.10 127 0.078 = 38 0.56 83 0.19 128 0.031 39 0.024 84 0.063 129 0.77 40 0.027 85 0.11 130 = 0= .036 41 0.062 86 0.16 131 = 0= .066 42 0.15 - 8= 7 0.10 133 0.072 = 43 = 0.33 - 8= 8 0.047 134 0.22 ¨4-4 0.054 89 0.080 135 0.074 45 0.053 90 0.51 Cell-based proliferation assay for determination of G150 values [0369] Human colon cancer cell lines (Co10205, HCT116), Ovarian cancer cell line [0370] The cell activity results of representative compounds are shown in Table 2 and 3. The data indicated that the compounds of this invention are active in the [0371] Table 2. Cellular or Growth Inhibition Activity in Co1o205 cells (unit is micromolar) Compound Compound Compound G150 (I1M) GIN (IA) GI50 (0) No No No _ 1 0.50 46 0.48 - 91 2.40 _ .
2 2.12 47 3.6 92 1.82 _ .
3 2.22 48 0.78 93 2.14 _ . .
4 2.62 - 49 . 1.75 - 94 0.60 _ .
2.58 50 0.17 - 95 0.57 . .
6 , 2.69 51 0.26 '96 0.70 7 0.81 52 0.21 97 0.67 . .
8 0.56 53 1.05 - 99 1.89 9 - 1.87 - 54 0.46 '100 2.25 _.
1.77 55 0.91 '101 2.44 11 '0.48 56 0.90 102 ' 2.08 .
12 0.51 57 0.65 103 0.48 ' 13 - 5.5 58 0.38 ' 104 1.99 14 - 0.63 59 2.28 105 1.77 .
- 1.50 60 2.48 107 0.63 _ 17 - 1.19 ' 61 1.32 ' 108 0.44 _ 19 '0.53 62 2.60 109 0.49 '2.66 63 0.54 ' 110 1.74 _ 21 '2.51 64 0.73 111 0.21 _ 22 ' 0.75 65 0.56 112 0.88 _ 23 '0.19 66 8.8 113 0.61 _ 24 2.99 68 0.52 114 0.72 _ 2.38 70 7.0 116 0.70 26 '0.37 71 0.24 117 1.80 _ 27 '1.42 72 0.16 118 1.88 _ 28 0.18 73 0.23 119 0.77 _ 29 ' 1.92 74 0.55 120 0.49 _ 0.31 75 1.20 - 121 0.49 _ 31 0.42 76 0.29 122 0.15 _ 32 0.74 77 0.67 123 0.15 _ 33 2.11 78 0.54 - 124 0.54 _ _ 34 4.4 79 0.45 125 0.68 _ 35 0.66 80 1.37 126 0.42 _ 36 0.86 81 1.00 127 0.34 _ 37 1.09 82 1.23 128 0.14 _ 38 1.94 83 4.9 129 3.9 _ .
39 0.23 84 1.03 130 0.15 _ 40 0.16 85 1.52 -131 0.33 .
41 0.92 86 2.08 133 . 0.56 42 0.98 ' 87 ' 1.07 134 2.30 43 1.86 88 0.55 -135 0.26 _ 44 0.87 89 0.87 _ 45 0.54 90 8.1 [0372] Table 3. Cellular or Growth Inhibition Activity in Various Cancer Cell Lines Cell lines Compound' HCT116 A2780 PC3 HEP3B
1 ' ++ +++ +++ ++
7 + + ++ Not tested 8 ++ ++ +++ +
22 + +++ +++ Not tested 23 ++ +++ +++ Not tested 30 - ++ +++ +++ Not tested 40 +++ +44 +++ Not tested 44 + ++ +++ Not tested 46 +++ +++ +++ ++
50 +++ . +++ +++ Not tested 52 +++ +++ +++ Not tested 58 +++ +++ +++ +++
71 +++ +++ +++ Not tested - 111 Not tested Not testediNot tested +++
_ 130 +++ +++ +++ Not tested ("+++" for G150 < 0.5 M, "++" for G150 between 0.5 and 1.0 M," +" for GI50 between 1.0 JIM to 5.0 NI) Histone H3 acetylation assay [0373] A hallmark of histone deacetylase (HDAC) inhibition is the increase in the acetylation level of histones. Histone acetylation, including H3, H4 and H2A
can be detected by immuno-blotting (western-blot). Co10205 cells, approximately 5 x105 cells, were seeded in the previously described medium, cultivated for 24 h and subsequently treated with HDAC inhibitory agents and a positive control at 10 I.JM final concentration.
After 24 h, cells were harvested and lysed according to the instruction from Sigma Mammalian Cell Lysis Kit. The protein concentration was quantified using BCA
method (Sigma Pte Ltd). The protein lysate was separated using 4-12% bis-tris SDS-PAGE gel membrane was probed using primary antibody specific for acetylated histone H3 (Upstate Pte Ltd). The detection antibody, goat anti rabbit antibody conjugated with HRP was used according to the manufacturing instruction (Pierce Pte Ltd).
After removing the detection antibody from the membrane, an enhanced chemiluminescent removing the substrate, the membrane was exposed to an X-ray film (Kodak) for 1 sec ¨20 mins. The X-ray film was developed using the X-ray film processor. The density of each band observed on the developed film could be qualitatively analyzed using UVP
Bioimaging software (UVP, Inc, Upland, CA). The values were then normalized against protein.
[0374] The results of immuno-blotting assay using acetylated histone H3 antibody are shown in Table 4 for representative compounds of this invention.
[0375] Table 4 Histone Histone Histone Acetylation Acetylation Acetylation activities activities activities Compound (Histone-3) Compound (Histone-3) Compound (Histone-3) 1 Active 30 Active 49 Active 2 Active 32 Active 50 Active 3 Active 35 Active 52 Active 7 Active 36 Active 55 Active 8 Active 37 Active 58 Active 11 Active 39 Active 63 Active 12 Active - 40 Active 65 Active 14 Active - 41 Active 68 Active 17 Active 42 Active 71 Active 19 Active 44 Active 74 Active 22 Active 45 Active 130 Active 26 Active 46 Active 28 Active 48 Active [0376] These data demonstrate that compounds of this invention inhibit histone deacetylases, thereby resulting in the accumulation of acetylated histones such as H3.
Measurement of Microsomal stability [0377] Metabolic stability measurements in the in vitro using liver microsomes aids in the prediction of the in vivo hepatic clearance and the compound stability towards phase I biotransformation reactions mediated by P450 isozymes.
[0378] Pooled human liver microsome (HLM was purchased from BD Gentest (BD
BioSciences). The incubations consisted of test compound (5 pM) or control compound (Verapamil), NADPH-generating system solution A (25 mM NADP+, 66 mM glucose-6-phosphate, 66 mM MgC12 in H20), NADPH-generating system solution B (40 Wm( ,15 glucose-6-phosphate dehydrogenase in 5 mM sodium citrate) and 1.0 mg/ml microsomal protein, respectively, in 100 mM potassium phosphate buffer (pH
7.4).
Samples are incubated for 0, 5, 15, 30, 45, 60min. Reaction is terminated with ice-cold 80% acetonitrile and 20% DMSO. Samples are subsequently centrifuged at 4 C for min at 2,000 rpm. 100 pL of the supernatant is transferred to the LC-MS Plate for analysis. Before quantitative analysis, the compound is tuned in LC/MS machine to get the optimized MS condition. Liquid chromatography is performed on a Luna C18 column (Phenomenex U.S.A, Torrance, CA) (2x5Omm, 5 pM). % remaining of compound (by area) of each time point is calculated with respect to time 0.
Plot %remaining against time (min) to obtain the curve and use the Prism software to obtain the t112. These are demonstrated in table 5.
[0379] Table 5.
Compound No T1/2 (min) Compound No T1/2 (min) 1 >30 52 >30 2 >30 58 >30 8 >30 63 >30 11 >30 68 >30 12 >30 71 >30 14 >30 74 >30 19 >30 78 >30 35 >30 80 >30 40 >30 88 >30 44 >30 108 >30 46 >30 130 >30 [0380] The measured in vitro 11/2 >30 mins for the above compounds signifies that the contribution towards the clearance of the compound due to metabolism is expected to be low in the in vivo situation and thus help in yielding longer half-life and increased exposure of the compounds.
[0381] The above results demonstrated the compounds of formula (I) were metabolically stable in human liver microsme assay. Together with the appropriate physicochemical properties, e.g., molecular weight, logP and high solubility, the above compounds could exhibit adequate pharmacological exposure and effect to the body when administrated intravenously or especially orally.
In vivo Pharmacokinetic (PK) studies [0382] Compound is dissolved in appropriate solution (saline or DMA and Cremaphor in saline) at 1 mg/ml for intravenous (IV) administration, or in 0.5% methyl cellulose, 0.1% Tween 80 in water at 5 mg/ml for oral administration. Mice are randomized according to body weight, grouped three per time point. Mice are administered single IV dose (10 mg/kg) via tail vein, or single oral dose (50 mg/kg) via gavage.
At pre-defined time points (predose, 5 or 10, 30min, 1, 2, 4, 8, and 24h), one group of mice is sacrificed by overdose CO2 and blood samples are collected by cardiac puncture. The blood samples are centrifuged immediately for 10 min at 3000 rpm to separate plasma, and plasma is kept frozen at ¨80 C until analysis by LC/MS/MS. Before sample analysis, the method is developed for LC/MS/MS assay. The method is validated for signal-response of the calibration standards, auto-sampler stability for ¨15 hours intra-day and inter-day calibration curve using eight calibration standards excluding the blank plasma. QC samples at three different concentrations in triplicates were prepared to determine the accuracy and precision. The extracted QC samples were compared to unextracted samples to determine the extraction efficiency of the analyte.
LLOQ was determined by using triplicate samples of 1ng/mL and 2ng/mL to obtain accuracy and precision at the low end. Samples are analysed using the validated method.
Data are analyzed by the non-compartmental model using WinNolin 4.0 software (Pharsight, Mountain View, CA, USA). The mean values for the plasma compound concentration-time profiles are used in mouse PK study.
[0383] The PK parameter AUG 0-last providing the information on the overall exposure of the drug in vivo is one of the key PK/PD parameters that helps in predicting the efficacy of a anticancer compound. The higher the AUC value, the better will be the efficacy of the compound. Pharmacokinetic data of selected compounds in Table were shown in Table 6 below.
[0384] Table 6. Representative pharmacokinetic data [compounds were in hydrochloric acid salt form (2HCI), dosed at 50 mg/kg, p.o.]
Compound AUCo-last (ng.h/m1) [0385] The data in Table 6 further demonstrated that compounds with high metabolic stability as shown by representative compounds in Table 5 together with the appropriate physicochemical properties, e.g., molecular weight, logP, and high solubility, were able to yield adequate pharmacological exposure and effect in the animal when administrated orally.
In vivo antineoplastic (or anti-tumor) effect of HDAC inhibiting agents:
[0386] The efficacy of the compounds of the invention can then be determined using in vivo animal xenograft studies. The animal xenograft model is one of the most commonly used in vivo cancer models.
[0387] In these studies Female athymic nude mice (Harlan), 12-14 weeks of age would be implanted subcutaneously in the flank with 5 x 106 cells of HCT116 human colon tumor cells, or with 5 x 106 cells of A2780 human ovarian tumor cells, or with 5 x 106 cells of PC3 prostate cancer cells. When the tumor reaches the size 100 mm3, the xenograft nude mice would be paired-match into various treatment groups. The selected HDAC inhibitors would be dissolved in appropriate vehicles and administered to xenograft nude mice intraperitoneally or orally daily for 21 days. The dosing volume will be 0.01m1/g body weight. Paclitaxol, used as positive control, will be prepared for intravenous administration in an appropriate vehicle. The dosing volume for Paclitaxol will be 0.01 ml/g body weight. Tumor volume will be calculated every second day or twice-a-week of post injection using the formula: Volume (mm3) = (w2 x 1)/2, where w =
width and I = length in mm of an HCT116, or A2780, or PC3 tumor. Compounds of this invention that are tested would show significant reduction in tumor volume relative to controls treated with vehicle only. Acetylated histone relative to vehicle treated control group when measured shall be accumulated. The result will therefore indicate that compounds of this invention are efficacious in treating a proliferative disease such as cancer.
[0388] The details of specific embodiments described in this invention are not to be construed as limitations. Various equivalents and modifications may be made without departing from the essence and scope of this invention, and it is understood that such equivalent embodiments are part of this invention.
dimethyl-N
430 propionylamino)-ethyly \ 1H-benzoimidazol-5-õN\
/ yI}-N-hydroxy-acrylamide 3-{1-(2-Diethylamino-07,,_, s ethyl)-2-[(2,2-dimethyl-/ 0 ' L
H
N propionylamino)-methyl)-1H-r-N) benzoimidazol-5-y1}-N-hydroxy-acrylamide _ N-0-(2-Diethylamino-Ml N
i ethyl)-5-(2-OH hyd roxycarbamoyl-viny1)-1H-r) benzoimidazol-2-ylmethy1}-butyramide _ . 341-(2-ethylamino-___\\ \ _<7 0 NH
i" 359 ethyl) -2-(3,3-dimethyl-63 N buty1)-1H-\ benzoimidazol-5-y11-N-H hydroxy-acrylamide 3-[2-(3,3-Dimethyl-butyl)-1-(2-)F\ 40 10:1 Dimethylamino-ethyl) 1H-benzoimidazol-5-y1FN-hydroxy-,\
acrylamide 3-[1-(2-Dimethylamino-65 345 ethyl)-2-penty1-1H-.
..-0. benzoimidazol-5-y1FN---õ, \ hydroxy-acrylamide _ ' 3-[1-(2-Dimethylamino-F F
ethyl)-2-(2,212-trifluoro-ethyl)-1H-benzoimidazol-5-y1W-, ..
----N
\ hydroxy-acrylamide _ N-Hydroxy-3-[1-(5-methy1-1H-pyrazol-3-67 <N. SLi 396 yI)-2-(2,4,4-trimethyl-/c( penty1)-1H-7,11/ benzoimidazol-5-y11-acrylamide , 341 -(2-Ethylamino-,A.
F7 < 10 ti ethyl)-2-penty1-1H-345 benzoimidazol-5-y1]-N-hydroxy-acrylamide .) . 0 3-(2-Butyl-1 -pyrrolidin-0 \ (-ad 69 __---.<, 329 3-y1-1H-benzoimidazol-NH 5-yI)-N-hydroxy-acrylamide 0 3-(2-Butyl-1 -piperidin-70 __,, N 'S\ '-rcµH 343 4-y1-1H-benzoimidazol-5-yI)-N-hydroxy-IIN acrylamide . _ N-Hydroxy-3-[1-(2-/¨ 'Ic isopropylamino-ethyl) / 2-penty1-1H-benzoimidazol-5-y1]-, r acrylamide \ N-Hydroxy-3-[1-(2-\
= methylamino-ethyl)-2-.
72 . 385 non-3-eny1-1H-I.
N benzoimidazol-5-yli-rj acrylamide NH
/ N-Hydroxy-3-[1-(2-: 385 methylamino-ethyl)-2-non-6-eny1-1H-benzoimidazol-5-yll-acrylamide ri \ . 342-Hexy1-1-(2-N /CM
345 methylamino-ethyI)-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide --4,-, . N-Hydroxy-341 -(2-7 40 ' ' methylamino-ethyl)-2-75 / 331 penty1-1H-benzoimidazol-5-y1]-'IN\ acrylamide N-Hydroxy-3-[1-(2-0 Nr. methylamino-ethyl)-2-octy1-1H-benzoimidazol-5-y1]-\ HN \
acrylamide 3-[1-(2-Amino-ethy1)-2-_________________________ 40 r . octyl-1H-359 benzoimidazol-5-yli-N-H2N hydroxy-acrylamide \
3-12-Butyl-I-[2-N
40 ' ' , /--/ <c (isopropyl-methyl-/ 359 amino)-ethy1]-1H--N\ benzoimidazol-5-y1}-N-hydroxy-acrylamide 341424Ethyl-methyl--/ <
;,, 0 N- aminoyethy1]-2-pentyl-79 _/
359 1 H-benzoimidazol-5-y1}-N-hydroxy-r-N\ acry1amide .
.
342-(2-1-pyrrolidin-_ O.
; 6 357 . 3-y1-1 H-benzoimidazol-80 0, 5-yI)-N-hydroxy-acrylamide ' H
3-[2-Butyl-1-(1-methyl--tr , 40 O" pyrrolidin-3-yI)-1H-81 343 benzoimidazol-5-y1FN-:I> hydroxy-acrylamide N\ , .
.
342-Hexy1-1-piperidin-_ ,.,--'3"
a N 'IIIIV- H
371 3-y1-1 H-benzoimidazol-5-yI)-N-hydroxy-a acrylamide _ .
0 342-Butyl-I -piperidin-_ _,.0H
.....õ,õ...............õ......,.,<N -...... 0, 3-y1-1 H-benzoimidazol-83 N 343 5-yI)-N-hydroxy-acrylamide dil - _ _ 0 3-(1-{2-[Ethyl-(2-N
/ <
/ le '- NOH
H
/ N methoxy-ethyl)-amino]-ethy1}-2-penty1-1H-/
84 403 benzoimidazol-5-y1)-N-N hydroxy-acrylamide r co H
0 3-{2-Butyl-1I 424ethyl-N si ,,, N,OH
methyl-aminoyethyli-/ N I H-benzoimidazol-5-yI}-N-hydroxy-N
r \ acrylamide _________________________________________________________________ _ 0 N-Hydroxy-3-[1-(1-NõOH
methyl-piperidin-3-y1)-H
' N 2-penty1-1H-benzoimidazol-5-y11-a acrylamide . 0 - 3-{142-(Ethy)-hexyl-N
N -., N,OH
, H amino)-ethy1]-1H-benzoimidazol-5-A-N-87 359 hydroxy-acrylamide N
[if , _ 0 3-{142-(Ethyl-pentyl-N
N N_OH
H aminoyethy1]-1H-benzoimidazol-5-y1}-N-345 hydroxy-acrylamide N
j---1¨
-_ 0 3-{142-(Ethyl-heptyl-N
H arnino)-ethy1]-1 H-N
benzoimidazol-5-y1}-N-89 373 hydroxy-acrylamide N
\ 0 3-{2-Hexy1-141 -(2-\=hydroxy-ethyl)-N
\ =1 0 -,,, 1=61HH
piperidin-3-y1]-1H-90 415 benzoimidazol-5-yll-N-al . .
hydroxy-acrylamide ZOH
.126 0 3-(2-Butyl-1 42-[ethyl-(3-hydroxy-propy1)-OH amino]-ethyl}-1H-91 r----1 389 benzoimidazol-5-y1)-N-N \ hydroxy-acrylamide rff /
HO
_ -_ . 3-(142-[Ethyl-(3-- hydroxy-propy1)-/
403 amino]-ethyI}-2-pentyl-1H-benzoimidazol-5-yI)-N-hydroxy-acrylamide _ 0 1(0.
(E)-N-hydroxy-3-(1-(1---- c --,, phenethylpyrrolidin-3-yI)-1H-benzo[d]imidazol-5-ypacrylamide ill _ _ 0 (E)-N-hydroxy-3-(1-(1-_ N pentylpiperidin-3-yI)-1H-benzo[dlimidazol-5-N ypacrylamide -iii 0 34142-(Butyl-ethyl-N
amino)-ethyl]-1H-benzoimidazol-5-y1}-N-N hydroxy-acrylamide , -U
N opN,...AH
(E)-N-hydroxy-3-(1-(1-phenethylpiperidin-3-N
96 391 y1)-1 H-benzo[d]imidazol-5-N
ypacrylamide =0 .
(E)-N-hydroxy-3-(1-(1 -OH
(3-N phenylpropyl)piperidin-97 405 3-y1)-1 H-benzo[d]imidazol-5-N
41, yl)acrylamide ---õ, õAi, lei N (E)-N-hydroxy-3-(1-(1-(3---N 391 phenylpropyl)pyrrolidin-3-y1)-1 H-benzo[d]imidazol-5-ypacrylamide II _ 3-{141-(3,3-Dimethyl-N buty1)-pyrrolidin-3-y1F
3 357 1 H-benzoimidazol-5-N y1}-N-hydroxy-acrylamide OH (E)-3-(1-(2-(diethylamino)ethyl)-N
303 1 H-benzo[d]imidazol-5-y1)-N-N hydroxyacrylamide r) 3-[2-(4-Cyano-butyI)-1 N- \
(2-diethylamino-ethyl)-384 1H-benzoimidazol-5-y11-N-hydroxy-N
r acrylamide u la NH
111 (E)-3-(1-(1-N
butylpiperidin-3-yI)-1H-, benzo[d]imidazol-5-y1)-N-hydroxyacrylamide N
N
OH (E)-N-hydroxy-3-(1-(1-(pent-4-enyl)piperidin-N
di 355 3-yI)-1H-benzo[d]imidazol-5-\---\-- yl)acrylamide =-õ ,...., 0 ri OH (E)-3-(1-(1-(3,3-o 371 dimethylbutyl)piperidin-4-y1)-1H-N
benzo[d]imidazol-5-y1)------\ N-hydroxyacrylamide .
\
0 '4c" 3-[1-(2-Diethylamino-ethyl)-2-propylamino-N
360 1H-benzoimidazol-5-yll-N-hydroxy-r) acrylamide u ,l OH (E)-N-hydroxy-3-(1-(2-ei (isopropyl(propyl)amino N
331 )ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide _ 0 N....AH
3-{142-(Butyl--.., ' N H isopropyl-amino)-ethyl]-108 345 1H-benzoimidazol-5-\-----N___ yI)-N-hydroxy-ff acrylamide ' OH N-Hydroxy-3-{1-(2-' 0 r, (isopropyl-pentyl-N , 359 amino)-ethy1]-1H-benzoimidazol-5-y1)-\ acrylamide _ \ 342-(5-Cyano-penty1)-.
\ 1-(2-diethylamino-110 \K 0 r 398 ethyl)-1H-ri benzoimidazol-5-yli-N-r) hydroxy-acrylamide _ 0 ......õ.0H 40 3- 1- 2- 3 3-Dimeth ( { R 1-, Y ' N butyl)-ethyl-amino]-359 ethyl)-1H-benzoimidazol-5-y1)-N-N\
--------r / hydroxy-acrylamide _ 0 N 110 3-{142-(Ethyl-propyl-N amino)-ethyl]-1H-benzoimidazo1-5-y1)-N-hydroxy-acrylamide N
-1--- ) OH
i 0 N
\ N-Hydroxy-3-(1-{2-N
, 373 [isopropyl-(2-methyl-113pentyl)-amino]-ethyl}-r-N 1H-benzoimidazol-5-y1)-acrylamide . (E)-N-hydroxy-3-(1-(2-i 40 Nc'H
\N (isopropy1(4,4,4-trifluorobutyl)amino)eth 114 ><1 \ \ (iN 399 y1)-1H-benzo[d]imidazol-5-)-- yl)acrylamide .
\3-[1-(3-Dimethylamino- , <i) 40 ...,, N,,, OH
2,2-dimethyl-propyI)-2-N
((_____. 374 propylamino-1H-benzoimidazol-5-y1]-N-hydroxy-acrylamide N-/ -U
2; -,...... NH.OH
N 3-{142-(Ethyl-hexyl-rj aminoyethy1]-2-methyl-1H-benzoimidazol-5-r 373 y1}-N-hydroxy-acrylamide U
F F le NH
1,H 3-{142-(Butyl-ethyl-FriN amino)-ethyl]-2-117399 trifluoromethy1-1H-r,N
/ benzoimidazol-5-y1}-N-hydroxy-acrylamide .
F 24 0 ,...., ,OH
F
Frici 3-{142-(Ethyl-hexyl-amino)-ethy1]-2-rN 427 trifluoromethy1-1H-benzoimidazol-5-y1}-N-hydroxy-acrylamide U
/ io -..., N...,,,ON
(E)-3-(1-(2-(dibutylamino)ethyl)-2-119 401 propy1-1H-) benzo[d]innidazol-5-y1)-_ N-hydroxyacrylamide - U r OH
N 0 N,/' 3-[1-(2-Dipropylamino-ethyl)-1H-331 benzoimidazol-5-A-N------\_¨N hydroxy-acrylamide . 0 N-Hydroxy-3-(1-{2-/ 40, rii....
[isopropyl-(3-methyl-359 butylyaminoj-ethyl)-1H-benzoimidazol-5-yl)-acrylamide _ 0 3-(1-{2-[(3,3-Dimethyl-<iN 401 rrAH buty1)-methyl-aminol-345 ethy11-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide _ 0 3-(1-{2-[(2-Ethyl-butyl)-methyl-amino]-ethyl}-123N 345 1H-benzoimidazol-5-yI)-N-hydroxy-acrylamide (E)-3-(1-(2-(bis(3,3-<, " 40 'c'l dimethylbutyl)amino)et 415 hyl)-1H-\/---\____. benzo[d]innidazol-5-y1)-VN-hydroxyacrylamide o (E)-3-(1-(2-40 Nc'H
(diisobutylamino)ethyl)-N
359 1H-benzo[d]imidazol-5-y1)-N-hydroxyacrylamide U
N N 40 Nõ,,,, 3-{1-[2-(3,3-Dimethyl-331 butylaminoyethy1]-1H-benzoimidazol-5-y1}-N-HN
hydroxy-acrylamide .
' Ni' N-Hydroxy-3-{142-N (methyl-pent-4-enyl-127 329 amino)-ethyI]-1H-,N
benzoimidazol-5-y1}-acrylamide 3-(1-{2-[(3,3-Dimethyl-ti butyI)-propyl-aminol-373 ethy1}-1H-benzoimidazol-5-y1)-N-hydroxy-acrylamide 3-0-(3-Dimethylamino-,, .."..,OH
\ lel Vi N 2,2-dimethyl-propyI)-2-129 363 methylsulfany1-1H-benzoimidazol-5-y1FN-N------- hydroxy-acrylamide 1 _ .
/ 7;\ lei N OH 3-{1-[2-(3,3-Dimethyl-N butylamino)-ethylj-2-373 propyl-1H-FIN benzoimidazol-5-y1}-N-hydroxy-acrylamide . 3-[1-[2-(3,3-Dimethyl-NriAilko, ....', ....AH
7( * butylaminoyethy1]-2-/ 401 (2,2-dimethyl-propyI)-1H-benzoimidazol-5-\---- yI]-N-hydroxy-acrylamide . 311-{2-[Bis-(3,3-N NAgib...
< * dimethyl-butyI)-amino]-/
Ni 485 ethy11-242,2-dimethyl-propy1)-1H-- benzoimidazol-5-y1FN-hydroxy-acrylamide u 2, 014 le ....., r 3-0 -[2(2,2-Dimethyl-N
317 propylamino)-ethy1]-1H-benzoimidazol-5-y1}-N-HN hydroxy-acrylamide 4 .
2, =,..., 14 ......õOH 341424(2,2-Dimethyl-N propyI)-propyl-amino]-359 ethy11-1H-benzoimidazol-5-y1)-N-4----N hydroxy-acrylamide . .F4 3-{14243,3-Dimethyl-/ -1 0 butylaminoyethy1]-2-N
359 ethy1-1H-benzoimidazol-5-y1}-N-ifNH
hydroxy-acrylamide _ BIOLOGICAL TESTING AND ENZYME ASSAYS
Recombinant GST-HDAC1 Protein expression and purification [0363] Human cDNA library was prepared using cultured SW620 cells.
Amplification of human HDAC1 coding region from this cDNA library was cloned separately into the baculovirus expression pDEST20 vector (GATEWAY Cloning Technology, Invitrogen Pte Ltd). The pDEST20-HDAC1 construct was confirmed by DNA sequencing.
Recombinant baculovirus was prepared using the Bac-To-Bac method following the manufacturer's instruction (lnvitrogen Pte Ltd). Baculovirus titer was determined by plaque assay to be about 108 PFU/ml.
[0364] Expression of GST-HDAC1 was done by infecting SF9 cells (Invitrogen Pte Ltd) with pDEST20-HDAC1 baculovirus at M01=1 for 48 h. Soluble cell lysate was incubated with pre-equilibrated Glutathione Sepharose 4B beads (Amersham) at 4 C
for 2 h. The beads were washed with PBS buffer for 3 times. The GST-HDAC1 protein was eluted by elution buffer containing 50 mM Tris, pH8.0, 150mM NaCI, 1%
Triton X-100 and 10mM or 20mM reduced Glutathione. The purified GST-HDAC1 protein was dialyzed with HDAC storage buffer containing 10mM Tris, pH7.5, 100mM NaC1 and 3mM MgC12. 20% Glycerol was added to purified GST-HDAC1 protein before storage at -80 C.
In vitro HDAC assay for determination of IC50 values [0365] The assay has been carried out in 96 well format and the BIOMOL
fluorescent-based HDAC activity assay has been applied. The reaction composed of assay buffer, containing 25 mM Tris pH 7.5, 137 mM NaCl, 2.7 mM KCI, 1 mM
MgCl2, 1 mg/ml BSA, tested compounds, an appropriate concentration of HDAC1 enzyme, 500 uM Flur de lys generic substrate for HDAC1 enzyme and subsequently was incubated at room temperature for 2 h. Flur de lys Developer was added and the reaction was incubated for 10 min. Briefly, deacetylation of the substrate sensitizes it to the developer, which then generates a fluorophore. The fluorophore is excited with 360 nm light and the emitted light (460 nm) is detected on a fluorometric plate reader (Tecan Ultra Microplate detection system, Tecan Group Ltd.).
[0366] The analytical software, Prism 3.0 (GraphPad Software Inc) has been used to generate IC50 from a series of data.
[0367] The HDAC enzyme inhibition results of representative compounds are shown in Table 1 (unit is micromolar).
[0368] Table 1. HDAC1 enzyme activity IC 50 (unit is micromolar).
Compound..,, No No Compound Compound No IC50 (invi) IC50 (uM) IC50 (PM) 1 0.042 46 0.049 - 91 ' 0.060 2 0.38 47 0.21 92 0.050 _ 3 0.15 48 0.43 93 - 0.23 4 0.12 49 0.11 94 0.064 0.17 50 0.036 95 0.052 _.
6 0.18 51 0.066 96 0.080 _ 7 0.091 52 0.025 97 0.10 8 0.052 53 0.10 98 0.32 _ 9 0.21 54 0.048 99 0.12 0.14 55 0.037 100 . 0.19 11 0.070 56 0.029 101 ' 0.08 12 0.064 57 0.090 102 0.54 13 0.42 58 0.030 103 0.10 .._ 14 '0.077 59 0.077 104 0.41 0.085 60 0.10 105 - 0.13 _ 17 0.13 61 0.070 107 0.074 19 0.064 62 - 0.054 108 - 0= .043 0.26 63 0.051 109 . 0.048 21 0.38 64 0.10 110 - 0= .044 22 0.064 65 0.078 111 0.029 _ _ 23 0.045 66 0.34 112 0.12 24 0.51 68 0.034 113 0.016 0.23 70 0.068 . 114 ' 0= .063 26 0.040 71 0.040 116 0.10 27 0.23 72 0.017 117 0.19 28 0.021 73 0.026 118 0.48 29 0.13 74 0.028 119 0.18 0.021 75 0.050 120 0.11 _ 31 0.045 76 0.018 121 0.079 32 - 0.060 77 0.026 122 0.037 33 0.23 78 0.044 123 0.027 34 0.88 79 0.040 124 0.085 _ 0.082 . 80 0.040 125 - 0.16 _ _ 36 0.096 81 0.12 126 0.042 37 0.091 82 = 0.10 127 0.078 = 38 0.56 83 0.19 128 0.031 39 0.024 84 0.063 129 0.77 40 0.027 85 0.11 130 = 0= .036 41 0.062 86 0.16 131 = 0= .066 42 0.15 - 8= 7 0.10 133 0.072 = 43 = 0.33 - 8= 8 0.047 134 0.22 ¨4-4 0.054 89 0.080 135 0.074 45 0.053 90 0.51 Cell-based proliferation assay for determination of G150 values [0369] Human colon cancer cell lines (Co10205, HCT116), Ovarian cancer cell line [0370] The cell activity results of representative compounds are shown in Table 2 and 3. The data indicated that the compounds of this invention are active in the [0371] Table 2. Cellular or Growth Inhibition Activity in Co1o205 cells (unit is micromolar) Compound Compound Compound G150 (I1M) GIN (IA) GI50 (0) No No No _ 1 0.50 46 0.48 - 91 2.40 _ .
2 2.12 47 3.6 92 1.82 _ .
3 2.22 48 0.78 93 2.14 _ . .
4 2.62 - 49 . 1.75 - 94 0.60 _ .
2.58 50 0.17 - 95 0.57 . .
6 , 2.69 51 0.26 '96 0.70 7 0.81 52 0.21 97 0.67 . .
8 0.56 53 1.05 - 99 1.89 9 - 1.87 - 54 0.46 '100 2.25 _.
1.77 55 0.91 '101 2.44 11 '0.48 56 0.90 102 ' 2.08 .
12 0.51 57 0.65 103 0.48 ' 13 - 5.5 58 0.38 ' 104 1.99 14 - 0.63 59 2.28 105 1.77 .
- 1.50 60 2.48 107 0.63 _ 17 - 1.19 ' 61 1.32 ' 108 0.44 _ 19 '0.53 62 2.60 109 0.49 '2.66 63 0.54 ' 110 1.74 _ 21 '2.51 64 0.73 111 0.21 _ 22 ' 0.75 65 0.56 112 0.88 _ 23 '0.19 66 8.8 113 0.61 _ 24 2.99 68 0.52 114 0.72 _ 2.38 70 7.0 116 0.70 26 '0.37 71 0.24 117 1.80 _ 27 '1.42 72 0.16 118 1.88 _ 28 0.18 73 0.23 119 0.77 _ 29 ' 1.92 74 0.55 120 0.49 _ 0.31 75 1.20 - 121 0.49 _ 31 0.42 76 0.29 122 0.15 _ 32 0.74 77 0.67 123 0.15 _ 33 2.11 78 0.54 - 124 0.54 _ _ 34 4.4 79 0.45 125 0.68 _ 35 0.66 80 1.37 126 0.42 _ 36 0.86 81 1.00 127 0.34 _ 37 1.09 82 1.23 128 0.14 _ 38 1.94 83 4.9 129 3.9 _ .
39 0.23 84 1.03 130 0.15 _ 40 0.16 85 1.52 -131 0.33 .
41 0.92 86 2.08 133 . 0.56 42 0.98 ' 87 ' 1.07 134 2.30 43 1.86 88 0.55 -135 0.26 _ 44 0.87 89 0.87 _ 45 0.54 90 8.1 [0372] Table 3. Cellular or Growth Inhibition Activity in Various Cancer Cell Lines Cell lines Compound' HCT116 A2780 PC3 HEP3B
1 ' ++ +++ +++ ++
7 + + ++ Not tested 8 ++ ++ +++ +
22 + +++ +++ Not tested 23 ++ +++ +++ Not tested 30 - ++ +++ +++ Not tested 40 +++ +44 +++ Not tested 44 + ++ +++ Not tested 46 +++ +++ +++ ++
50 +++ . +++ +++ Not tested 52 +++ +++ +++ Not tested 58 +++ +++ +++ +++
71 +++ +++ +++ Not tested - 111 Not tested Not testediNot tested +++
_ 130 +++ +++ +++ Not tested ("+++" for G150 < 0.5 M, "++" for G150 between 0.5 and 1.0 M," +" for GI50 between 1.0 JIM to 5.0 NI) Histone H3 acetylation assay [0373] A hallmark of histone deacetylase (HDAC) inhibition is the increase in the acetylation level of histones. Histone acetylation, including H3, H4 and H2A
can be detected by immuno-blotting (western-blot). Co10205 cells, approximately 5 x105 cells, were seeded in the previously described medium, cultivated for 24 h and subsequently treated with HDAC inhibitory agents and a positive control at 10 I.JM final concentration.
After 24 h, cells were harvested and lysed according to the instruction from Sigma Mammalian Cell Lysis Kit. The protein concentration was quantified using BCA
method (Sigma Pte Ltd). The protein lysate was separated using 4-12% bis-tris SDS-PAGE gel membrane was probed using primary antibody specific for acetylated histone H3 (Upstate Pte Ltd). The detection antibody, goat anti rabbit antibody conjugated with HRP was used according to the manufacturing instruction (Pierce Pte Ltd).
After removing the detection antibody from the membrane, an enhanced chemiluminescent removing the substrate, the membrane was exposed to an X-ray film (Kodak) for 1 sec ¨20 mins. The X-ray film was developed using the X-ray film processor. The density of each band observed on the developed film could be qualitatively analyzed using UVP
Bioimaging software (UVP, Inc, Upland, CA). The values were then normalized against protein.
[0374] The results of immuno-blotting assay using acetylated histone H3 antibody are shown in Table 4 for representative compounds of this invention.
[0375] Table 4 Histone Histone Histone Acetylation Acetylation Acetylation activities activities activities Compound (Histone-3) Compound (Histone-3) Compound (Histone-3) 1 Active 30 Active 49 Active 2 Active 32 Active 50 Active 3 Active 35 Active 52 Active 7 Active 36 Active 55 Active 8 Active 37 Active 58 Active 11 Active 39 Active 63 Active 12 Active - 40 Active 65 Active 14 Active - 41 Active 68 Active 17 Active 42 Active 71 Active 19 Active 44 Active 74 Active 22 Active 45 Active 130 Active 26 Active 46 Active 28 Active 48 Active [0376] These data demonstrate that compounds of this invention inhibit histone deacetylases, thereby resulting in the accumulation of acetylated histones such as H3.
Measurement of Microsomal stability [0377] Metabolic stability measurements in the in vitro using liver microsomes aids in the prediction of the in vivo hepatic clearance and the compound stability towards phase I biotransformation reactions mediated by P450 isozymes.
[0378] Pooled human liver microsome (HLM was purchased from BD Gentest (BD
BioSciences). The incubations consisted of test compound (5 pM) or control compound (Verapamil), NADPH-generating system solution A (25 mM NADP+, 66 mM glucose-6-phosphate, 66 mM MgC12 in H20), NADPH-generating system solution B (40 Wm( ,15 glucose-6-phosphate dehydrogenase in 5 mM sodium citrate) and 1.0 mg/ml microsomal protein, respectively, in 100 mM potassium phosphate buffer (pH
7.4).
Samples are incubated for 0, 5, 15, 30, 45, 60min. Reaction is terminated with ice-cold 80% acetonitrile and 20% DMSO. Samples are subsequently centrifuged at 4 C for min at 2,000 rpm. 100 pL of the supernatant is transferred to the LC-MS Plate for analysis. Before quantitative analysis, the compound is tuned in LC/MS machine to get the optimized MS condition. Liquid chromatography is performed on a Luna C18 column (Phenomenex U.S.A, Torrance, CA) (2x5Omm, 5 pM). % remaining of compound (by area) of each time point is calculated with respect to time 0.
Plot %remaining against time (min) to obtain the curve and use the Prism software to obtain the t112. These are demonstrated in table 5.
[0379] Table 5.
Compound No T1/2 (min) Compound No T1/2 (min) 1 >30 52 >30 2 >30 58 >30 8 >30 63 >30 11 >30 68 >30 12 >30 71 >30 14 >30 74 >30 19 >30 78 >30 35 >30 80 >30 40 >30 88 >30 44 >30 108 >30 46 >30 130 >30 [0380] The measured in vitro 11/2 >30 mins for the above compounds signifies that the contribution towards the clearance of the compound due to metabolism is expected to be low in the in vivo situation and thus help in yielding longer half-life and increased exposure of the compounds.
[0381] The above results demonstrated the compounds of formula (I) were metabolically stable in human liver microsme assay. Together with the appropriate physicochemical properties, e.g., molecular weight, logP and high solubility, the above compounds could exhibit adequate pharmacological exposure and effect to the body when administrated intravenously or especially orally.
In vivo Pharmacokinetic (PK) studies [0382] Compound is dissolved in appropriate solution (saline or DMA and Cremaphor in saline) at 1 mg/ml for intravenous (IV) administration, or in 0.5% methyl cellulose, 0.1% Tween 80 in water at 5 mg/ml for oral administration. Mice are randomized according to body weight, grouped three per time point. Mice are administered single IV dose (10 mg/kg) via tail vein, or single oral dose (50 mg/kg) via gavage.
At pre-defined time points (predose, 5 or 10, 30min, 1, 2, 4, 8, and 24h), one group of mice is sacrificed by overdose CO2 and blood samples are collected by cardiac puncture. The blood samples are centrifuged immediately for 10 min at 3000 rpm to separate plasma, and plasma is kept frozen at ¨80 C until analysis by LC/MS/MS. Before sample analysis, the method is developed for LC/MS/MS assay. The method is validated for signal-response of the calibration standards, auto-sampler stability for ¨15 hours intra-day and inter-day calibration curve using eight calibration standards excluding the blank plasma. QC samples at three different concentrations in triplicates were prepared to determine the accuracy and precision. The extracted QC samples were compared to unextracted samples to determine the extraction efficiency of the analyte.
LLOQ was determined by using triplicate samples of 1ng/mL and 2ng/mL to obtain accuracy and precision at the low end. Samples are analysed using the validated method.
Data are analyzed by the non-compartmental model using WinNolin 4.0 software (Pharsight, Mountain View, CA, USA). The mean values for the plasma compound concentration-time profiles are used in mouse PK study.
[0383] The PK parameter AUG 0-last providing the information on the overall exposure of the drug in vivo is one of the key PK/PD parameters that helps in predicting the efficacy of a anticancer compound. The higher the AUC value, the better will be the efficacy of the compound. Pharmacokinetic data of selected compounds in Table were shown in Table 6 below.
[0384] Table 6. Representative pharmacokinetic data [compounds were in hydrochloric acid salt form (2HCI), dosed at 50 mg/kg, p.o.]
Compound AUCo-last (ng.h/m1) [0385] The data in Table 6 further demonstrated that compounds with high metabolic stability as shown by representative compounds in Table 5 together with the appropriate physicochemical properties, e.g., molecular weight, logP, and high solubility, were able to yield adequate pharmacological exposure and effect in the animal when administrated orally.
In vivo antineoplastic (or anti-tumor) effect of HDAC inhibiting agents:
[0386] The efficacy of the compounds of the invention can then be determined using in vivo animal xenograft studies. The animal xenograft model is one of the most commonly used in vivo cancer models.
[0387] In these studies Female athymic nude mice (Harlan), 12-14 weeks of age would be implanted subcutaneously in the flank with 5 x 106 cells of HCT116 human colon tumor cells, or with 5 x 106 cells of A2780 human ovarian tumor cells, or with 5 x 106 cells of PC3 prostate cancer cells. When the tumor reaches the size 100 mm3, the xenograft nude mice would be paired-match into various treatment groups. The selected HDAC inhibitors would be dissolved in appropriate vehicles and administered to xenograft nude mice intraperitoneally or orally daily for 21 days. The dosing volume will be 0.01m1/g body weight. Paclitaxol, used as positive control, will be prepared for intravenous administration in an appropriate vehicle. The dosing volume for Paclitaxol will be 0.01 ml/g body weight. Tumor volume will be calculated every second day or twice-a-week of post injection using the formula: Volume (mm3) = (w2 x 1)/2, where w =
width and I = length in mm of an HCT116, or A2780, or PC3 tumor. Compounds of this invention that are tested would show significant reduction in tumor volume relative to controls treated with vehicle only. Acetylated histone relative to vehicle treated control group when measured shall be accumulated. The result will therefore indicate that compounds of this invention are efficacious in treating a proliferative disease such as cancer.
[0388] The details of specific embodiments described in this invention are not to be construed as limitations. Various equivalents and modifications may be made without departing from the essence and scope of this invention, and it is understood that such equivalent embodiments are part of this invention.
Claims (51)
1. A compound of the formula (I):
wherein R1 is a group of formula:
-(CR20R21 )m-( CR22R23)n-(CR24R25)o-NR26R27;
R2 is selected from the group consisting of: alkyl and heteroalkyl, each of which may be optionally substituted with one or more optional substituents wherein each optional substituent is selected from the group consisting of halogen, =O, -CN, alkenyl, alkynyl and alkoxy;
R3 is H;
X and Y are H;
R4 is H;
each R5 is independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
each R6 is independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted;
each R20, R21, R22, R23, R24 and R25 is independently selected from the group consisting of: H, halogen, -CN, -NO2, -CF3, -OCF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy heteroaryloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, aminosulfonyl, arylsulfonyl, arylsulfinyl -COOH, -C(0)0R5, -COR5, -SH, -SR6, -OR6 and acyl, each of which may be optionally substituted; or R20 and R21 when taken together may form a group of formula =O or =S, and/or R22 and R23 when taken together may form a group of formula =O or =S, and/or R24 and R25 when taken together may form a group of formula =O or =S;
each R26 and R27 is independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, aIkenyloxy, alkynyloxy, cycloaIkylkoxy, heterocycloaIkyloxy, aryloxy, arylaIkyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR5, and acyl, each of which may be optionally substituted, or R26 and R27 when taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycloalkyl group;
m, n and o are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
Z is ¨CH=CH- and is attached at ring position 5;
or a pharmaceutically acceptable salt thereof.
wherein R1 is a group of formula:
-(CR20R21 )m-( CR22R23)n-(CR24R25)o-NR26R27;
R2 is selected from the group consisting of: alkyl and heteroalkyl, each of which may be optionally substituted with one or more optional substituents wherein each optional substituent is selected from the group consisting of halogen, =O, -CN, alkenyl, alkynyl and alkoxy;
R3 is H;
X and Y are H;
R4 is H;
each R5 is independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl, each of which may be optionally substituted;
each R6 is independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted;
each R20, R21, R22, R23, R24 and R25 is independently selected from the group consisting of: H, halogen, -CN, -NO2, -CF3, -OCF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkylkoxy, heterocycloalkyloxy, aryloxy, arylalkyloxy, phenoxy, benzyloxy heteroaryloxy, amino, alkylamino, acylamino, aminoalkyl, arylamino, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, aminosulfonyl, arylsulfonyl, arylsulfinyl -COOH, -C(0)0R5, -COR5, -SH, -SR6, -OR6 and acyl, each of which may be optionally substituted; or R20 and R21 when taken together may form a group of formula =O or =S, and/or R22 and R23 when taken together may form a group of formula =O or =S, and/or R24 and R25 when taken together may form a group of formula =O or =S;
each R26 and R27 is independently selected from the group consisting of: H, halogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, arylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, aIkenyloxy, alkynyloxy, cycloaIkylkoxy, heterocycloaIkyloxy, aryloxy, arylaIkyloxy, heteroaryloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, phenoxy, benzyloxy, COOH, alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR5, and acyl, each of which may be optionally substituted, or R26 and R27 when taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycloalkyl group;
m, n and o are integers independently selected from the group consisting of 0, 1, 2, 3 and 4;
Z is ¨CH=CH- and is attached at ring position 5;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein the sum of m+n+o is 2 or 3.
3. A compound according to any one of claims 1 to 2 wherein R1 is selected from the group consisting of:
_(CR20R21)2-NR26R27;
-(CR22R23)2-NR26R27;
-(CR24R25)2-NR26R27;
-(CR20R21)-(CR22R23)-NR26R27;
-(CR20R21)(CR24R25)-NR26R27;
-(CR22R23)-(CR24R25)-NR26R27;
-(CR20R21)3-NR26R27;
-(CR22R23)3-NR26R27;
-(CR24R25)3-NR26R27;
-(CR20R21)2-(CR22R23)-NR26R27;
-(CR20R21)2-(CR24R25)-NR26R27;
-(CR20R21)-(CR22R23)2-NR26R27;
-(CR22R23)2-(CR24R25)-NR26R27;
-(CR20R21)-(CR24R25)2-NR26R27;
-(CR22R23)-(CR24R25)2-NR26R27; and -(CR20R21)-(CR22R23)-(CR24R25)-NR26R27.
_(CR20R21)2-NR26R27;
-(CR22R23)2-NR26R27;
-(CR24R25)2-NR26R27;
-(CR20R21)-(CR22R23)-NR26R27;
-(CR20R21)(CR24R25)-NR26R27;
-(CR22R23)-(CR24R25)-NR26R27;
-(CR20R21)3-NR26R27;
-(CR22R23)3-NR26R27;
-(CR24R25)3-NR26R27;
-(CR20R21)2-(CR22R23)-NR26R27;
-(CR20R21)2-(CR24R25)-NR26R27;
-(CR20R21)-(CR22R23)2-NR26R27;
-(CR22R23)2-(CR24R25)-NR26R27;
-(CR20R21)-(CR24R25)2-NR26R27;
-(CR22R23)-(CR24R25)2-NR26R27; and -(CR20R21)-(CR22R23)-(CR24R25)-NR26R27.
4. A compound according to any one of claims 1 to 3 wherein the compound has the formula:
5. A compound according to any one of claims 1 to 4 wherein R20, R21, R22, R23, R24 and R25 are independently selected from the group consisting of H, alkyl, alkenyl and alkynyl.
6. A compound according to any one of claims 1 to 5 wherein R20, R21, R22, R23, R24 and R25 are independently selected from the group consisting of H and alkyl.
7. A compound according to any one of claims 1 to 6 wherein R20 and R21 are H.
8. A compound according to any one of claims 1 to 7 wherein R22 and R23 are methyl.
9. A compound according to any one of claims 1 to 8 wherein R24 and R25 are H.
10. A compound according to any one of claims 1 to 9 wherein R26 and R27 are independently selected from the group consisting of: H, alkyl, alkenyl, alkynyl, alkoxyalkyl, and acyl.
1 1. A compound according to any one of claims 1 to 10 wherein R26 and R27 are independently selected from the group consisting of: H, alkyl and acyl.
12. A compound according to any one of claims 1 to 10 wherein R26 and R27 are independently selected from the group consisting of H, methyl, ethyl, isopropyl, propyl, butyl, isobutyl, pentyl, hexyl, heptyl, acetyl and 2-methoxy-ethyl.
13. A compound according to claim 1 wherein R1 is a group of formula:
14. A
compound according to claim 1 wherein R1 is selected from the group consisting of:
compound according to claim 1 wherein R1 is selected from the group consisting of:
15. A compound according to claim 1 wherein R1 is a group of formula:
16. A compound according to claim 1 wherein R1 is a group of formula:
17. A compound according to claim 1 wherein R1 is a group of formula:
18. A compound according to claim 1 wherein R1 is a group of formula:
19. A compound according to claim 1 wherein R1 is a group of formula:
20. A compound according to claim 1 wherein R1 is a group of formula:
21. A compound according to claim 1 wherein R1 is a group of formula:
22. A compound according to claim 1 wherein R1 is a group of formula:
23. A compound according to claim 1 wherein R1 is a group of formula:
24. A compound according to any one of claims 1 to 23wherein R2 is alkyl.
25. A compound according to claim 1 wherein R2 is selected from the group consisting of:
methyl; ethoxymethyl; 2,2,2-triflouro-ethyl; propyl; 2-2-dimethyl-propyl;
isopropyl; 3,3,3-triflouro-propyl; butyl; isobutyl; 3,3-dimethyl-butyl; but-3-enyl; but-3-yny;
pentyl; 2,4,4-trimethyl-pentyl; hexyl; hex-3-enyl; octyl; non-3-enyl; non-6-enyl; 2-methoxy-nonyl, (CH3)3CCH2CONH(CH2)2-; (CH3)3CCONH(CH2)2-; (CH3)3CCONH(CH2)-and CH3(CH2)2CONH(CH2)--
methyl; ethoxymethyl; 2,2,2-triflouro-ethyl; propyl; 2-2-dimethyl-propyl;
isopropyl; 3,3,3-triflouro-propyl; butyl; isobutyl; 3,3-dimethyl-butyl; but-3-enyl; but-3-yny;
pentyl; 2,4,4-trimethyl-pentyl; hexyl; hex-3-enyl; octyl; non-3-enyl; non-6-enyl; 2-methoxy-nonyl, (CH3)3CCH2CONH(CH2)2-; (CH3)3CCONH(CH2)2-; (CH3)3CCONH(CH2)-and CH3(CH2)2CONH(CH2)--
26. A compound according to any one of claims 1 to 25 wherein the optional substituent is selected from the group consisting of: halogen, =O, =S, -CN, -NO2, -CF3, -OCF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkoxyheteroaryl, alkenyloxy, aIkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, heteroaryloxy, arylalkyl, heteroarylalkyl, arylalkyloxy, -amino, alkylamino, acylamino, aminoalkyl, arylamino, sulfonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, aminoalkyl, alkoxyalkyl, -COOH, -COR5, -C(O)OR5, -SH, -SR5, -OR6 and acyl.
27. The compound of claim 1 wherein the compound is selected from the group consisting of 3-[1-(3-Dimethylamino-2,2-dimethyl-propyl)-2- (2,2-dimethyl-propyI)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide and pharmaceutically acceptable salts thereof.
28. A pharmaceutical composition including a compound according to any one of claims 1 to 27 and a pharmaceutically acceptable diluent, excipient or carrier.
29. Use of a compound according to any one of claims 1 to 27 in the preparation of a medicament for the treatment of a disorder caused by, associated with or accompanied by disruptions of cell proliferation and/or angiogenesis.
30. A use according to claim 28 wherein the disorder is a proliferative disorder.
31. A use according to claim 30 wherein the proliferative disorder is cancer.
32. A use according to claim 31 wherein the cancer is colon cancer, prostate cancer, hepatoma and ovarian cancer.
33. Use of a compound according to any one of claims 1 to 27 or a pharmaceutical composition according to claim 28 to modify deacetylase activity.
34. A use according to claim 33 wherein the deacetylase activity is histone deacetylase activity.
35. A use according to claim 34 wherein the deacetylase activity is class I
histone deacetylase activity.
histone deacetylase activity.
36. A use according to claim 34 or 35 wherein the histone deacetylase is HDAC1.
37. Use of a compound according to any one of claims 1 to 27 in the preparation of a medicament for the treatment of a disorder that can be treated by the inhibition of histone deacetylase in a patient.
38. A use according to claim 37 wherein the disorder is a Proliferative disorder.
39. The use of a compound according to any one of claims 1 to 27 in the manufacture of a medicament for the treatment of cancer.
40. A use according to claim 39 wherein the cancer is a hematologic malignancy.
41. A use according to claim 40 wherein the hematologic malignancies are selected from a group consisting of B-cell lymphoma, T-cell lymphoma and leukemia.
42. A use according to claim 41 wherein the cancer is a solid tumor.
43. A use according to claim 42 wherein the solid tumor is selected from the group consisting of breast cancer, lung cancer, ovarian cancer, prostate cancer, head and neck cancer, renal cancer, gastric cancer, colon cancer, pancreatic cancer and brain cancer.
44. A use according to claim 39 wherein the cancer is selected from the group consisting of colon cancer, prostate cancer, hepatoma and ovarian cancer.
45. Use of a compound according to any one of claims 1 to 27 in the preparation of a medicament for the treatment of a proliferative disorder.
46. A compound having the structure:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
47. A pharmaceutical composition which comprises a pharmaceutically acceptable diluent, excipient, or carrier and a compound having the structure:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
48. A compound for use as a medicament, the compound having the structure:
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
49. The compound for use of claim 48, for use in the treatment of cancer.
50. The compound for use of claim 49, wherein the cancer is colon cancer, prostate cancer, hepatoma, or ovarian cancer.
51. The compound for use of claim 49, wherein the cancer is a hematologic malignancy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71482705P | 2005-09-08 | 2005-09-08 | |
US60/714,827 | 2005-09-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2540459A1 CA2540459A1 (en) | 2007-03-08 |
CA2540459C true CA2540459C (en) | 2014-02-18 |
Family
ID=37871987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2540459A Expired - Fee Related CA2540459C (en) | 2005-09-08 | 2006-03-21 | Benzimidazole compounds and uses in treating proliferative disorders |
Country Status (7)
Country | Link |
---|---|
CN (1) | CN101287712B (en) |
AR (1) | AR105930A2 (en) |
AU (1) | AU2006201177B2 (en) |
CA (1) | CA2540459C (en) |
ES (1) | ES2367811T3 (en) |
SI (1) | SI1937650T1 (en) |
ZA (1) | ZA200803017B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR108257A1 (en) * | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | POLYMORPHIC FORMS OF 3- [2-BUTIL-1- (2-DIETILAMINO-ETIL) -1H-BENCIMIDAZOL-5-IL] -N-HYDROXY-ACRYLAMIDE AND USES OF THE SAME |
WO2018157742A1 (en) * | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | Crystalline form of salt of sb-939, preparation method therefor, and use |
WO2019149262A1 (en) * | 2018-02-05 | 2019-08-08 | 苏州科睿思制药有限公司 | Crystal form of sb-939, preparation method and use thereof |
CN114656449A (en) * | 2022-02-28 | 2022-06-24 | 董金付 | Silibinin derivative containing carbamic acid structure and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ545864A (en) * | 2003-09-22 | 2009-12-24 | S Bio Pte Ltd | Benzimidazole derivates: preparation and pharmaceutical applications |
WO2005066151A2 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
-
2006
- 2006-03-21 AU AU2006201177A patent/AU2006201177B2/en not_active Ceased
- 2006-03-21 CA CA2540459A patent/CA2540459C/en not_active Expired - Fee Related
- 2006-08-01 CN CN2006800383271A patent/CN101287712B/en not_active Expired - Fee Related
- 2006-08-01 SI SI200631069T patent/SI1937650T1/en unknown
- 2006-08-01 ZA ZA200803017A patent/ZA200803017B/en unknown
- 2006-08-01 ES ES06769700T patent/ES2367811T3/en active Active
-
2016
- 2016-09-05 AR ARP160102717A patent/AR105930A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2540459A1 (en) | 2007-03-08 |
AR105930A2 (en) | 2017-11-22 |
ES2367811T3 (en) | 2011-11-08 |
AU2006201177B2 (en) | 2012-06-14 |
AU2006201177A1 (en) | 2007-03-22 |
SI1937650T1 (en) | 2011-09-30 |
ZA200803017B (en) | 2009-10-28 |
CN101287712A (en) | 2008-10-15 |
CN101287712B (en) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8143282B2 (en) | Heterocyclic compounds | |
CA2602328C (en) | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications | |
CA2539766C (en) | Benzimidazole derivates: preparation and pharmaceutical applications | |
AU715175B2 (en) | Selective B3 adrenergic agonists | |
WO2006101456A1 (en) | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors | |
CA2970500C (en) | Piperidine derivatives as hdac1/2 inhibitors | |
AU2005286717A1 (en) | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | |
EP2131840B1 (en) | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent | |
WO2007058626A1 (en) | Indazole compounds | |
CA2540459C (en) | Benzimidazole compounds and uses in treating proliferative disorders | |
WO2006101454A1 (en) | Benzothiophene derivatives: preparation and pharmaceutical applications | |
NZ519977A (en) | Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action | |
PL218430B1 (en) | Novel prodrugs of 1-methyl-2(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(n-2-pyridil-n-2-hydroxycarbonylethyl)-amide, production and use thereof as medicaments | |
WO2006079478A1 (en) | 2-phenylquinoxalines as inhibitors for mpp1 | |
US20230391753A1 (en) | Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof and use thereof | |
EP2064211B1 (en) | Imidazo[1,2-a]pyridine hydroxymate compounds that are inhibitors of histone deacetylase | |
AU2021334987A1 (en) | Inhibitors of Pseudomonas aeruginosa virulence factor LasB | |
WO2016107541A1 (en) | Pyrrole amide compound, preparation method therefor, and use thereof | |
AU2006220413A1 (en) | Compounds | |
AU3011500A (en) | Selective bita3 adrenergic agonists | |
JPH1081671A (en) | New peptide compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20220321 |